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Abstract 
West Nile virus (WNV) is a mosquito-borne flavivirus, originally isolated in Uganda in 1937, and 
responsible for sporadic outbreaks in Africa, Europe and Asia. In 1999 WNV was introduced into the 
USA starting in New York City, and has since become endemic in North America leading to 
thousands of cases annually. In Australia, a closely related strain of West Nile virus called Kunjin 
virus (WNVKUN) is endemic to the country. Despite the antigenic similarity between the two strains, 
WNVKUN does not cause an overt disease and is not linked to any human outbreaks. However, in 2011 
a more virulent strain of WNV initially found in New South Wales (WNVNSW2011) caused a large 
equine outbreak in south-eastern Australia, illustrating the national as well as global impact of WNV 
disease.  
 
This thesis investigates the role of interferon-stimulated genes (ISGs) in control of WNV in vitro and 
in vivo using an engineered WNVNSW2011 library that encodes artificial microRNAs (amiRs) targeting 
over one hundred mouse ISGs. Three in vitro passages of the virus library in mouse embryonic 
fibroblasts resulted in selection and enrichment of WNVNSW2011 encoding IFITM3-amiR, implying 
that IFITM3 was a dominant factor restricting WNV titres in vitro. This finding fits with the known 
role of IFITM3 in restricting various virus infections, including WNV. Peripheral infection of mice 
with the virus library led to a strong selection and enrichment in spleens and/or brains of viruses 
encoding amiRs targeting various ISGs, in particular ATF3-amiR. The ATF3-amiR WNV was the 
most enriched WNV in spleens and brains from several mice, and is a novel finding, as the 
transcription factor ATF3 was not previously known to have an antiviral function.  
 
To verify the role of identified ISGs in restricting WNV infection, recombinant WNVNSW2011 viruses 
encoding corresponding individual amiRs were generated and examined in vitro and in vivo. Infection 
with IFITM3-amiR-encoding WNV showed that depletion of IFITM3 in infected cells led to secretion 
of virions with increased infectivity. This implied that the most critical factor for virus replication in a 
cell culture environment was to increase infectivity. Furthermore, the IFITM3-amiR WNV exhibited 
increased replication in vitro and elevated virulence in mice. Moreover, the recombinant virus 
targeting ATF3 exhibited enhanced replication in vitro and virulence. Taken together, these data 
identify host factors that define WNV pathogenicity, and validate the artificial microRNA virus 
library approach as a unique tool to examine virus-host interactions in cells and in animal models.  
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Chapter 1:  Literature review 
1.1 Flaviviridae 
 
Flaviviridae is a family of small-enveloped viruses with positive sense RNA genomes, which 
consists of four genera: Flavivirus, Pestivirus, Hepacivirus and Pegivirus [1]. The family is 
named after yellow fever virus, as flavus refers to yellow in Latin. Although phylogenetic 
analysis has shown that members in within flaviviridae family have similar genomic organization, 
replication strategy and physicochemical properties, they are genetically and biologically 
different [2]. All members within the family encode at least two to four structural proteins 
together with seven to eight non-structural protein genes flanked by 5′ and 3′ untranslated regions 
(UTRs). In addition, the genera Hepacivirus, Pegivirus and Pestivirus share a closer degree of 
similarity [3]. A Phylogenetic tree based on conserved amino acid sequences in RNA-dependent 
RNA polymerase (RdRP) region of members in the Flaviviridae family was generated. To 
generate the phylogenetic tree, partial gene sequences from representative isolates of each species 
and related unclassified viruses were aligned using MUltiple Sequence Comparison by Log- 
Expectation (MUSCLE) software and confirmed by the presence of aligned motifs [4]. 
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Figure 1.1 Phylogenetic tree of conserved amino acids of the RdRP in the Flaviviridae family. 
The scale bar depicts the evolutionary distance in numbers of substitutions per amino acid site. 
(Adapted from Ictvonline) 
 
1.2 Flaviviruses 
The flavivirus genus consists of over 73 unique arthropod-borne viruses, some of which cause high 
morbidity and mortality. Flaviviruses are generally mosquito-borne or tick-borne and insect-specific 
flaviviruses, although some can be maintained in a vertebrate only transmission, without a known 
vector [5-7]. Mosquito-borne and tick-borne flaviviruses present the most public health concern. 
Mosquito-borne flaviviruses include Murray valley encephalitis virus (MVEV), St. Louis 
encephalitis virus (SLEV), yellow fever virus (YFV), dengue virus (DENV) serotypes 1–4, 
Japanese encephalitis virus (JEV), Zika virus (ZIKV) and West Nile virus (WNV) whereas tick-
borne encephalitis virus is the most prominent flavivirus spread by ticks [1]. Most flavivirus 
infections are reported in tropical and temperate regions where climatic conditions allow arthropods 
to thrive and favour flavivirus replicative lifecycles in arthropods [8, 9]. Emergence of new 
flaviviruses in areas where they were not known as endemic has been attributed to urbanisation, 
tourism, travel and improved surveillance programs [10, 11]. Furthermore, there is an increasing 
threat of emergence of highly virulent strains from previously less virulent strains [12].  
Flaviviruses are classified based on nucleotide sequence, antigenicity, pathogenicity, geographical 
distribution and ecological association [13]. Members of the flavivirus genus are positive-sense 
RNA viruses, which belong to nine serological complexes, with the JEV serological clade as the 
largest. Flaviviruses within JEV clade are maintained in a Culex mosquito-bird cycle and cause 
neurological infections. These include JEV, WNV, MVEV and (SLEV), Kunjin (WNVKUN), Alfuy, 
Koutango (KOU), Cacipacore (CPC), and Yaounde (YAO) viruses [14, 15]. MVEV and WNVKUN 
are the most endemic flaviviruses within Australia [16, 17]. JEV is closely related to MVEV and is 
a common human pathogen in Torres Strait Islands and Cape York with increasing threat of JEV 
infection on the Australian mainland [18-21]. Although other flaviviruses such as Kokobera 
(KOKV), Alfuy (ALFV), Stratford (STRV) and Edge Hill (EHV) have been identified in Australia; 
only KOKV is known to cause virus infection in humans [22-25]. Flaviviruses related to Yellow 
fever virus are spread by Aedes mosquitoes and cause systemic infections by feeding on humans, 
simians and other mammalian species. These include YFV, ZIKV and DENV [26].  
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1.3  West Nile Virus as a health concern 
West Nile virus was first isolated from a febrile female patient in 1937 in Uganda [27]. Since then, 
this particular strain has been linked to mild outbreaks in Africa and some parts of Europe [28]. In 
addition, a more virulent strain was reported in the United States of America (USA) in 1999. This 
WNV strain was named West Nile virus New York 99 (WNVNY99) strain and has since become 
endemic in America leading to thousands of cases annually [29]. By 2011, close to 1.8 million 
people had been infected, with up to 360,000 illnesses and close to 1,300 deaths reported [30]. 
According to the Centres for Disease Control and Prevention (CDC), 2387 cases and 243 deaths 
were reported in 2012, 2374 cases and 114 deaths in 2013 and 1935 cases and 71 deaths in 2014 
[31]. Furthermore, since 2010, WNVNY99 has caused outbreaks of febrile and neurological disease 
in Europe with close to 500 cases per year. This strain poses a huge threat to Australia because 
Australian birds and mosquitoes are capable of facilitating WNVNY99 replication and transmission 
[32]. 
Although WNVNY99 is antigenically closely related to Australia’s endemic WNVKUN, WNVKUN is 
avirulent [33]. WNVKUN is named after an Australian aboriginal clan that inhabited areas around the 
Mitchell River in far north Queensland [34]. Until 2011, WNVKUN was a known non-threatening 
endemic strain in the Northern Territory and Kimberly region of Western Australia, with a few 
isolations in North Queensland and patients presenting with mild illness and no encephalitic signs 
[35]. However in 2011, an unprecedented WNV outbreak was reported in New South Wales, 
Australia, causing equine neurological disease, with no reported human cases [36]. This strain was 
named WNVNSW2011 and was shown to have emerged from benign WNVKUN strain [12, 37]. In 
addition, surveillance of recent deadly WNV outbreaks in United States of America and Europe 
suggest that virulent WNV strains could have emerged from known benign strains [12, 38]. 
Collectively, these incidents highlight the vulnerability of Australia and world at large to future 
deadly WNV outbreaks. 
Despite major past outbreaks, future threats and increased resurgence of WNV that pose a huge 
public health concern, there are neither vaccines nor antivirals available to combat flavivirus 
infection. This reinforces the need for comprehensive research in understanding how WNV causes 
infection and how the host immune system antagonises WNV lifecycle to limit virus spread. 
Understanding WNV-host interaction will eventually identify and elucidate WNV therapeutic 
targets for generating vaccine and antivirals. In this thesis, the aim was to identify and understand 
host factors that control WNVNSW2011 replication both in vivo and in vitro. Identified host factors 
were further characterised by mechanistic studies to understand their role in WNV replication. 
Findings described herein further elucidate the role of host factors in WNV infection as well as how 
 5 
West Nile virus causes infections in the host. 
1.4 West Nile virus strains and lineages 
According to phylogenetic analyses, WNV is divided into five distinctive genetically related 
lineages, namely lineages 1, 2, 3, 4 and 5. Lineage 1 is subdivided into 1a, 1b and 1c clades, lineage 
1a consists of viruses causing encephalitis and meningitis, including strains isolated from north-
eastern USA, Europe, Israel, Africa, India, Russia, and Australia. [39-41]. The WNV strains in 
clade 1b and Clade 1c are mainly isolated from Australia and India respectively [42]. Recent WNV 
surveillance studies in birds, mosquitoes and human populations have attributed huge human 
outbreaks in southern Europe to lineage 2 WNV. Lineage 2 WNV strains are considered as less 
virulent than lineage 1 WNV strains and are commonly isolated only in sub-Saharan Africa and 
Madagascar [40-44]. Therefore, the recent isolation of lineage 2 WNV strains in Europe suggests 
migration of WNV reservoir birds from sub-Saharan Africa and Madagascar to Europe [45, 46]. 
Lineage 3, 4 and 5 WNV strains are associated with symptomatic human cases in Austria, Russia 
and India respectively [39, 47-50].  
1.5 West Nile virus Life cycle and Pathogenesis 
WNV life cycle is primarily maintained in a Culex mosquito-bird transmission cycle but often 
infects and causes disease in humans and horses [51, 52]. Humans and horses are considered dead-
end hosts, as they do not develop sufficient viraemia to transmit the virus [53, 54]. During a blood 
meal, WNV-infected mosquitoes transfer the virus to the dermis and to some extent directly into the 
blood stream of a vertebrate host [55]. The incubation period of WNV infection in human is 2-14 
days and infections in immunocompetent humans are either asymptomatic or self-limited febrile 
illness with general body weakness, muscle and joint pains, headache, gastrointestinal complaints, 
skin rash and lymphadenopathy. However in immunocompromised individuals, infants, elderly and 
rare situations, a small proportion of WNV cases develop neurological infections characterised by 
flaccid paralysis, meningitis and encephalitis, which can often lead to death [56]. Following WNV 
neuroinvasive infection, 10% of infected individuals die while greater than 50% of patients are left 
with long-term neurological sequelae [57, 58]. Most of the neural damage is seen in the brain stem 
and anterior horn of the spinal cord while in immunocompromised individuals the damage could 
spread to entire CNS [59]. Although viraemia seen in various mouse model organs is not 
comparable with that observed in humans and horses, mouse models are used to hypothesise how 
WNV infection occurs in vivo. As a result, viral and host genetic factors that influence WNV 
replication and pathogenesis have been identified and mechanisms of action of elucidated [54, 59-
62].  
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Following several WNV epidemics globally, several research studies have attempted to explain how 
both innate and adaptive immune systems protect hosts against WNV infection. Consequently 
pathogenesis of WNV has been described in three phases, namely: early, peripheral virus 
amplification and neuroinvasion phases [63, 64].  In the initial phase after subcutaneous infection of 
mice, WNV is infects and spreads to dermal dendritic cells and Langerhans cells to cause increased 
viraemia and stimulation of innate cytokines responses controlled by toll like receptor 7 [65-67]. 
Increased viraemia the represents amplification phase in which WNV spreads to organs, primarily 
the spleen and kidney [68]. Although specific viral target cells in the spleen are poorly understood, 
dendritic cells, macrophages and neutrophils are believed to be WNV targets [69-71]. By seven 
days post-infection viraemia is cleared and WNV is undetectable in sera but can be detected in 
spinal cords and brains of infected mice, thus marking the last phase of neuroinvasion. Increased 
viraemia enables WNV to enter, infect and spread within central nervous system (CNS) cells by 
breaking the integrity of blood brain barriers (BBB) to cause encephalitis.  
1.6 Neuroinvasiveness and Neuropathogenesis 
WNV enters the CNS and proficiently proliferates within neurons and myeloid cells [60]. WNV 
neuroinvasiveness is attributed to the glycosylation motif on envelope (E) protein although the 
precise mechanism of how WNV invades CNS is not fully understood [72]. The N-linked glycan 
domain of WNV-E protein is thought to increase virus attachment, entry into endothelial cells and 
eventual CNS invasion [73, 74]. Furthermore, changes in endothelial monolayer permeability are 
believed to trigger breakdown of blood brain barrier (BBB) thereby permitting WNV to invade the 
CNS [75]. In addition, activation of matrix metalloproteinase and release of tumor necrosis factor-α 
(TNF-α) impairs BBB tight junctions allowing WNV to penetrate and infect the nervous system 
[76, 77]. Dissemination of WNV in the mouse CNS causes into extensive neural damage, high 
WNV titres and increased leukocyte levels in the brain [78, 79]. Neuronal damage is attributed to 
increased apoptotic response following virus infection, release of toxic cytokines by dying neuronal 
cells, reduction of cytotoxic T lymphocytes and accumulation of ubiquitinated proteins in neuronal 
cells [80, 81]. 
1.7 Replication cycle of West Nile Virus  
WNV replication cycle is complex and involves well-coordinated steps (Figure 1.2). The cycle is 
initiated when the WNV virion binds to unknown cell surface receptor via its Envelope (E) protein, 
and enters the cell through clathrin-mediated endocytosis [82]. Subsequently WNV resides in an 
early endosome before maturation, causing a drop in endosomal pH. The drop in pH initiates virion-
endosomal membrane fusion, subsequent un-coating and release of the positive single-stranded 
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RNA (+ssRNA) genome into the cytoplasm [64, 83]. Consequently, +ssRNA migrates to the 
cytosolic face of the endoplasmic reticulum (ER) where the genome is translated into a single 
highly membrane-associated polyprotein polyprotein [84]. The single polyprotein is processed into 
mature proteins by cellular proteases and viral serine protease non-structural proteins (NS2B–NS3) 
[85]. Increase in non-structural proteins in the cytoplasm causes morphological changes that result 
in formation of vesicle pockets in the ER and viral +ssRNA is translocated into vesicle pockets with 
the ER membrane to form the viral envelope membrane [86, 87]. Non-structural proteins combine 
to form a replication complex that is utilised in forming complete negative-sense ssRNA (-ssRNA) 
intermediates [88]. The -ssRNA is used as template to synthesize positive single stranded RNA. 
Structural proteins capsid, envelope and pre-membrane are utilised in early stages of WNV 
replication. Pre-membrane protein (prM) ensures proper folding of the envelope (E) protein and 
inhibits early fusion during virus release [89]. The capsid protein then encapsidates the viral 
genome RNA at the ER, and the vesicle pocket buds as a virion into the ER. Immature virus 
particles are transported through secretory pathway and processed to form mature virions. Mature 
virions are released by exocytosis and the process is repeated [89, 90]. 
 
Figure 1.2 Diagram of WNV replication cycle.  1. WNV infects a wide range of target cells and 
attaches to host cells through unknown receptors. 2. WNV-E protein facilitates virion entry into 
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target cells via receptor-mediated endocytosis. 3. A drop in pH within the endosomal vesicles 
allows virion-membrane fusion. 4. This leads to un-coating and release of viral genome into the 
cytosol where +ssRNA genome is translated and processed into a single poly protein at the 
endoplasmic reticulum (5 and 6). The polyprotein is cleaved into mature proteins by NS2B-NS3 
serine protease and cellular proteases. The non-structural proteins form the replication complex 
utilised in formation of −ssRNA intermediates and synthesis of full-length +ssRNA (7). The capsid 
protein encapsulates viral genome (8) at the ER membrane and virus buds into the ER. RNA 
replication stages (5, 6, 7 and 8) occur in the vesicle packets formed in the endoplasmic reticulum 
membrane. Immature virions are shuttled through host secretory pathway causing WNV-E 
glycosylation and cleavage of prM into mature M by furin (9). Consequently, mature virions are 
shuttled and released from the plasma membrane by exocytosis (10).  (Adapted from Suthar et al., 
2013 ^ [64]). 
  
 
1.8 West Nile Virus genome 
West Nile virion is an icosahedral-enveloped virus about 40-60nm in diameter with a single 
stranded positive sense RNA genome. It is translated into a polyprotein that is cleaved co- and post-
translationally into three structural, and seven non-structural proteins [69, 84, 91].  
 
Figure 1.3 Diagram showing WNV genome organisation. WNV encodes a single open reading 
frame of about 11,000 nucleotides that is flanked with two non-coding regions, 5' UTR and 3' UTR. 
It encodes three structural proteins (C, PrM and E, brown colour) and 7 non-structural proteins 
(NS1-NS5, blue colour). 
 
1.8.1 Structural proteins  
Structural proteins capsid (C), pre-membrane (PrM) and envelope (E) are vital in viral attachment, 
entry, encapsidation and formation of virions. Specifically E protein facilitates viral entry and 
assembly and is the most immunogenic virus protein [92]. Envelope protein is often glycosylated at 
position 154 to facilitate infection in different hosts. Furthermore, E glycosylation has been linked 
to increased virulence and dissemination of WNV into brains [72]. Capsid binds viral RNA to form 
the nucleocapsid and contains α helices, believed to aid in viral RNA binding [93-95]. Structural 
analysis of capsid N- and C-terminal suggests that both termini could aid RNA folding and control 
the role of capsid during viral replication [96]. PrM inhibits premature fusion and has been linked to 
virulence [89].  
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1.8.2 Non-structural proteins 
Non-structural proteins (NS1 to NS5) facilitate viral RNA synthesis, WNV transcription, 
replication, maturation and immune evasion [97]. NS1 is a glycoprotein with three highly conserved 
N-linked glycosylation sites and several cysteines, which form disulphide bonds. The disulphide 
bonds are potentially involved in dimerisation and influence hydrophobic nature of NS1 [98]. 
Members of the JEV sero-comp lex including WNV can encode both NS1 and an alternative form 
of NS1 with a 52 amino acid N-terminal or C-terminal extension termed NS1′.  Removal of NS1′ 
reduces the neurovirulence of both WNV and JEV [99]. Although the actual function of NS1′ is 
unknown, NS1′ can function as NS1 during virus replication [100]. Intracellular and secreted NS1 
forms serve as co-factor for viral replication and control complement activation as well as Toll-like 
receptor signalling respectively [101]. NS2A protein is a 25 kDa hydrophobic trans-membrane 
protein utilised during viral RNA replication, virion assembly, control of host immune responses 
and virus dissemination [102-104]. NS2B is a small hydrophobic protein that serves as a co-factor 
for NS3 protease that cuts the viral protein into structural and non-structural viral proteins [105, 
106].  NS3 is both a helicase and a viral serine protease in the C and N-termini respectively and 
NS3 is only active when coupled with its co-factor NS2B [107, 108]. In addition, the helicase 
domain of NS3 hinders type I interferon (IFN-I) signalling by blocking Signal transducer and 
activator of transcription 1 (STAT1) phosphorylation [109]. NS4A and NS4B are hydrophobic 
proteins that possess several trans-membrane domains and are bound to the viral replication 
complex in virus-induced ER membrane compartments. NS4A acts as co-factor that controls 
ATPase activity of NS3 helicase while NS4B inhibits interferon signalling [110, 111]. Flavivirus 
NS5 constitutes the largest WNV protein that co-localises with genomic RNA at viral replication 
complex sites [112]. NS5 encodes N-terminal methyltransferase (MTase) and C-terminal RNA-
dependent RNA polymerase (RdRp) domains, which facilitate flavivirus replication [113, 114]. The 
RdRp is utilised during viral genome replication to synthesise negative and positive RNA strands 
[115, 116]. The MTase has guanylyltransferase and methyltransferase enzymatic actions and 
facilitates 5'-RNA capping and methylation of the viral genome [117, 118].  In addition, studies 
have shown that NS5 protein antagonises interferon production by blocking alpha/beta interferon–
mediated JAK-STAT signalling pathway as discussed in detail in section 1.10.4. Particularly, NS5 
protein impedes interferon-dependent STAT1 phosphorylation by reducing accumulation of 
phosphorylated STAT1 and subsequent IFN-dependent gene expression [119, 120]. 
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1.8.3 The 5′ UTR  
The WNV RNA genome is devoid of a polyadenylate (poly-A) tail and is monocistronic in that 
there is a single translation start for the polyprotein [14, 121, 122]. The Open reading frame (ORF) 
is flanked by highly conserved 5′ UTR and 3′ UTR involved in initiation of RNA replication, 
translation and immunomodulation and likely determines genome packaging [123-126].  
1.8.4 The 3′ UTR 
The 3′ UTR of WNV is about 380–600 nucleotides long with highly structured RNA including 4 
stem-loop (SL) structures and two dumbbell (DB) structures [14]. In between these structures are 
spacer sequences with unrevealed functions although evidence suggests that these sequences may 
induce correct folding of viral protein and protect neighbouring structural domains from 
interference [127].  
 
Figure 1.4 Structural components within the 3'UTR of WNV:  Diagram showing the parts of the 
3' UTR of WNV. The 3' UTR of WNV encodes stem-loops (SL), Dumb bell structures (DB) and 
pseudo knots (PK).  SL-II and SL-1V constitute two pseudo knots that provide steric hindrance to 
5'-3' exoribonuclease enzyme and block complete degradation of WNV genome resulting in sfRNA 
accumulation.  Adopted from Pijlman et al., 2008 ^ [122] and  Roby et al., 2014^  [14]. 
 
The 3' UTR of WNV is not only vital in viral RNA replication, translation, genome packing but 
also generates a sub-genomic flavivirus RNA (sfRNA) fragment. The WNV sfRNA is about 525-nt 
long noncoding RNA structure produced due to stalling of cellular 5'-3'  exoribonuclease XRN-1 on 
a rigid RNA structure about 100 nucleotides from the start of the 3' UTR [122, 128, 129]. 
Crystallographic study of sfRNA structures has shown intertwined pseudoknots that directly 
interact with XRN-1 enzyme [130]. Consequently, SfRNA controls numerous functions in virus-
host interactions and pathogenesis. Specifically, sfRNA production subverts the interferon response 
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by inactivating cellular RNA sensors such as Toll-like receptor 3, RIG-I, and MDA5 (discussed in 
details in section 1.10), regulates host mRNA decay and RNAi pathways [14, 131-133]. 
Furthermore, previous studies have shown that mutations leading to loss of normal sfRNA structure 
attenuate flaviviruses, reducing cytopathic effect and virulence in both in vitro and in vivo studies 
[131, 132].  
1.9 RNA interference 
RNA interference (RNAi) is a post-transcriptional response, which controls sequence-specific 
degradation or down-regulation of the target messenger RNA [134]. RNAi is a concise nucleic acid-
based gene silencing strategy in which small noncoding RNAs are used to control gene expression. 
During flavivirus replication in vectors such as mosquitoes and ticks, flaviviruses are subjected to 
the vectors’ innate immune response known as antiviral RNAi to produce small interfering (siRNA) 
that degrade viral RNA and ultimately inhibit flavivirus replication (reviewed in [135]), In 
mosquito cells, micro RNA (miRNA)-mediated response to WNV Aae-miR-2940-5p, which is a 
mosquito microRNA is down-regulated during WNV infection to inhibit WNV replication. This is 
achieved by blocking metalloprotease m41 FtsH gene expression that is vital for WNV replication 
[136]. In addition, WNV has been shown to encode microRNA-like small RNA known as KUN-
miR-1 with in its 3' UTR, which facilitates WNV replication in mosquito cells by up regulating 
GATA4 mRNA expression [137]. A number of studies have utilized RNAi to directly inhibit virus 
replication in cells and organisms such as siRNAs targeting WNV Capsid and NS5 genes resulted 
into close to 80% inhibition of WNV replication [138]. Furthermore, in another study RNAi was 
used to inhibit NS5 expression and subsequent viral replication in vitro [139]. Since its discovery, 
the RNAi concept has been used as valuable research tool in generation of therapeutics, study of 
virus-host interactions among others. 
 
1.9.1 Canonical Biogenesis of miRNA 
Micro RNAs (miRNAs) are small noncoding RNAs expressed by all eukaryotic multicellular 
organisms. They regulate cellular processes and are promising therapeutic targets and disease 
biomarkers [140]. MiRNAs are about 22 nucleotides single stranded genome-encoded noncoding 
RNA molecules produced from precursor miRNA (pre-miRNA) hairpins [141, 142]. Genes 
encoding miRNAs are transcribed by RNA polymerase II into long primary transcripts (pri-
miRNAs). RNase III enzyme, Drosha coupled with Di-George critical Region factor (Drosha-
DGCR8) cleaves the pri-miRNA transcript to produce a pre-miRNA [143]. Exportin 5 transports 
the pre-miRNA from the nucleus into the cytoplasm [144, 145]. In the cytoplasm pre-miRNA 
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undergoes further processing by dicer-TAR binding Protein complex (dicer-TRBP), eliminating the 
loop sequence on the hairpin to form a double stranded RNA (dsRNA) [146]. This RNA duplex is 
passed onto an argonaute (AGo2) protein in the RNA-induced silencing complex (RISC) for further 
processing [147]. Consequently, a 22-nucleotide long strand is retained in the argonaute complex as 
the guide strand while the other, passenger strand, is discarded [141, 142]. Nucleotide 2-7 of the 
miRNA referred to as the seed region, is presented to target mRNA and when complementary, post-
transcriptional repression and subsequent mRNA degradation occurs [148]. MicroRNA bind the 
target mRNA forming an imperfect duplex. While mismatches are tolerated in the duplex, the seed 
region of the miRNA should be perfectly complementary to target mRNA if target recognition is to 
occur [149]. 
 
Figure 1.5 Canonical Micro RNA biogenesis  Genes encoding miRNAs are transcribed by RNA 
polymerase II into long primary transcripts (pri-miRNAs). RNase III enzyme, Drosha coupled with 
Di-George critical region factor (Drosha-DGCR8) cleaves the Pri-microRNA transcript to produce 
a precursor microRNA. Exportin 5 transports the pre-miRNA from the nucleus into the cytoplasm 
in a GTP dependent manner. In the cytoplasm pre-microRNA undergoes further processing by 
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Dicer-TAR binding Protein complex (Dicer-TRBP) to eliminate the loop sequence on the hairpin 
and a double stranded RNA micro RNA duplex is formed that is loaded onto Argonaute 2 (AGo2) 
to form the RNA-induced silencing complex (RISC). The leading strand (red) is retained while the 
passenger strand (black) is degraded. The leading strand constitutes the mature miRNA that binds 
the 3′ UTR of mRNA to cleave, repress translation or deadenylate mRNA and subsequent 
regulation of gene expression. 
 
1.9.2 The use of artificial miRNA  
Artificial microRNAs (amiRs) are chemically synthesised small RNAs in which the miRNA guide 
strand and corresponding passenger strand are modified to silence a target gene. AmiRs can encode 
sequences in the stem region, which when processed by host cell microprocessor produce siRNAs 
that precisely target mRNA transcripts with 100% complementarity. Introducing artificial miRNA 
(amiRs) into human cells could be used to induce degradation of homologous mRNA molecules. 
Although canonical miRNA biogenesis starts from the nucleus, previous studies have that shown 
cytoplasmic RNA viruses can be modified to produce functional amiRs. Regardless of the site of 
replication and genomic structure, a virus can encode miRNA, which restrict specific host gene 
activity [150-154]. Since miRNAs are cell/species-specific in nature, viruses can be modified to 
efficiently control viral tropism [154, 155]. AmiRs can be designed to maintain the general 
structure and loop sequence of precursors of amiR (pre-amiR) hairpin but with various specific 
miRNA sequences inserted in the stem. The pre-amiRs are processed and loaded into the RISC 
similarly to native host pre-miRNAs. Artificial microRNAs (amiRNA) are essentially a hybrid of 
the two miRNA and siRNAs. They encode vital structures recognised and processed by the host’s 
cellular miRNA bioprocessor i.e., Drosha and Dicer to produce pre-amiRs. The amiRs also encode 
artificially engineered sequence within the stem region which when processed, produce siRNA that 
specifically targets a single mRNA transcript with 100% complementarity (Figure 1.6). Different 
pre-amiR encoding viruses can be generated with each virus targeting different host genes, to study 
virus-host interactions. This approach has been used to analyse effect of knocking down various 
interferon stimulated genes (ISGs) on WNV virulence [154].  Insertions such as hairpin precursors 
of amiR (pre-amiR) targeting specific host genes are easily tolerated in particular sites of flavivirus 
genome [153, 156]. When multiple brain-specific miRNAs were inserted in the 3' UTR of a 
flavivirus genome, there was increased viral suppression in the CNS of mice versus when a single 
brain-specific miRNA was used [157, 158]. Conversely, studies have shown that insertion of 
miRNA target sequences at two distant positions of the 3' UTR could result in effective viral 
repression in cell cultures [159]. With advancement in technology and rising need for safe flavivirus 
vaccines and therapeutics, microRNA-based approaches are being employed to study virus-host 
interactions [153, 160]. This is proven an efficient method capable of inhibiting replication and 
pathogenesis of DNA and RNA viruses in a cell, tissue or species-specific manner [154, 155, 161]. 
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1.9.3 Small interfering RNAs compared to microRNAs   
Small interfering RNAs (siRNAs) and microRNAs (miRNAs) affect gene regulation and have been 
utilised in drug discovery and development against various cancers [162-164] and viral infections 
[165-167]. Small interfering RNAs are chemically synthesised dsRNA molecules processed in the 
cytoplasm by Dicer into a smaller dsRNA molecule of approximately 20-23 nucleotides long. This 
dsRNA is then loaded into RISC, where AGo2 cleaves the passenger strand of the siRNA, leaving 
the guide strand associated with RISC. The guide strands are designed with 100% complementarity 
to mRNA. Consequently, RISC binds to mRNA with full complementarity causing specific mRNA 
target cleavage [168] (Figure 1.6). The unique feature for siRNA is that 100% complementarity is 
prerequisite to induce mRNA target cleavage and subsequent gene silencing. In contrast, miRNAs 
do not generally have 100% complementarity to targets, and they tend to block translation rather 
than mRNA cleavage. Artificial microRNAs (amiRs) are able to serve as siRNAs or miRNA 
depending on the degree of complementarity to targets with a common outcome of target cleavage. 
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Figure 1.6 Processing of amiR and siRNA in cells compared to miRNA processing.  The 
processing of amiR and siRNA is essentially similar. However, when amiR has 100% 
complementarity to the corresponding mRNA, it can act as siRNA to cause mRNA target cleavage. 
Both siRNA and amiR processing require host cell machinery to control gene expression. 
 
1.10 Host anti-viral response against RNA viruses 
Following several years of research in how the host immune system fights WNV infection, the 
antiviral response has been described in three steps namely: (i) detection of invading viruses, (ii) 
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induction of interferon (IFN) response and (iii) expression of interferon stimulated genes. The early 
detection of invading viruses is very crucial in controlling virus infections and host cells are adept 
at detecting virus invasion to establish antiviral responses. Pattern recognition receptors detect 
unique features on invading pathogens known as pathogen associated molecular patterns (PAMPs), 
and distinguish between self and non-self. There are at least three classes of pattern recognition 
receptors relevant to WNV responses, namely retinoic acid-inducible gene I protein (RIG-I)-like 
receptors (RLRs), toll-like receptors (TLRs), and nucleotide-binding oligomerisation domain 
(NOD)-like receptors (NLRs). The detection of viral double-stranded RNA (dsRNA), and single-
stranded RNA is of particular importance during antiviral signalling against WNV infection [169, 
170].  
1.10.1 Toll-like Receptors  
Toll-like Receptors (TLRs) are type 1 trans-membrane proteins, which possess leucine-rich repeat 
(LRR) ligand-binding domains and conserved Toll/IL-1 receptor (TIR) signalling domains in the 
cytoplasmic tail [171, 172]. The TLR family contains ten members named TLR1 to TLR10 in 
humans and twelve TLR1 to TLR9, TLR11 to TLR13, in mice, shown facilitate innate immune 
response to viral infections [169, 173]. TLRs are found on cell surfaces, intracellular compartments 
such as ER, endosomes and lysosomes [174]. TLRs are generally categorized into cell surface 
TLRs and intracellular TLRs. Cell surface TLRs include TLR1, TLR2, TLR4, TLR5, TLR6, and 
TLR10 while intracellular TLRs are found in endosomes include TLR3, TLR7, TLR8, TLR9, 
TLR11 and TLR12 [175, 176]. TLRs identify PAMPs, structures or molecules from damaged cells 
that are termed as danger associated molecular patterns (DAMPs) to initiate immune responses 
[177, 178]. TLRs sense various PAMPs such as bacterial lipopolysaccharides, bacterial proteins and 
viral nucleic acids, bacterial lipoproteins, and flagella among others [179].  
	
Activation of TLRs initiates a cascade of events that lead to activation of transcription factors 
mainly activator protein 1 (AP-1), interferon regulatory factor (IRF) and Nuclear factor kappa B 
(NF-κB) [180]. NF-κB drives the expression of many pro-inflammatory cytokines including TNF-α, 
pro-interleukin-18  (pro-IL-18) and pro-interleukin-1b (pro-IL-1b). Pro-IL-18 and pro-IL-1b are 
inactive forms that are activated by cytoplasmic caspase-1 protease. Caspase-1 activation is the 
outcome of activation of the inflammasomes, which can be initiated by a number of NLR proteins. 
The release of IL-1b and IL-18 enhances the immune response by activating lymphocytes. TNF-α 
enhances immune response and induces apoptosis by binding onto receptors of infected cells 
causing cell death [181]. 
TLR3 found in endosomes is important in activating host immune responses to viral infections. 
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TLR3 senses viral double-stranded RNA (dsRNA), siRNAs, and self RNAs derived from damaged 
cells [174]. During WNV infections in a mammalian cell, TLR3 recognizes dsRNAs produced as 
RNA replication intermediates [182]. Consequently TLR3 TIR domains dimerise and bind to 
Toll/IL-1R domain-containing adaptor-inducing IFN-β  (TRIF) to stimulate IRF-3, NF-κB and IFN-
I production [178, 183]. TLR3-deficient (Tlr3-/-) mice showed susceptibility to lethal WNV as 
compared to wild type. Additionally, infected mice showed increased viraemia in the periphery and 
less viraemia and neuropathology in the brain as compared to wild-type mice [184]. Consequently 
WNV infection in the periphery was thought to damage the blood-brain barrier and facilitate CNS 
infection in wild-type mice but not in Tlr3-/- mice [185].  
 TLR7 and TLR8 located in endosome recognise ssRNAs to activate IRF-7 and NF-κB and initiate 
IFN-I response through myeloid differentiation factor 88 (MyD88) signalling [186]. TLR7 is 
expressed in plasmacytoid dendritic cells (pDCs), and senses viral single stranded ssRNA [174]. 
TLR7 is shown to foster movement of Langerhans cells from the skin when WNV is inoculated into 
mice through the skin, leading to WNV clearance in mice [187]. MyD88 is a signalling protein 
utilised by most of the toll-like receptors except TLR3 to stimulate NF-κB activity. MyD88 is an 
innate immune adaptor molecule shown to control WNV dissemination and replication in the CNS. 
WNV Infection of MyD88-deficient (MyD88-/-) micewith WNV increased neurological burden 
compared to WNV infection in wild type mice [188]. Furthermore TRIF and MyD88 double-
deficient (MyD88/Trif-/-) mice showed severe WNV infection characterized by increased 
encephalitis signs and mortality compared to the same infection in wild type mice. Therefore these 
studies highlighted the role of TLR signalling during early WNV infection [189].  
1.10.2 RIG-like receptors  
RIG-I-like receptors (RLR) comprise a cytosolic PRR protein family that sense intracellular viral 
RNA produced by actively replicating viruses [190]. The family consists of retinoic acid-inducible 
gene I protein, (RIG-I), melanoma differentiation antigen 5 (MDA5) and LGP2 [64, 191].  RLRs 
contain a DExD/H helicase domain and signal via two caspase activation and recruitment domains 
(CARDs) at their N termini, leading to subsequent type I interferon (IFN-I) gene expression [192, 
193]. Studies have shown that RIG-I signalling occurs is during early stages of WNV infections 
while MDA5 signalling occurs at later stages of infection [191, 194]. RLRs are ubiquitous in almost 
all cell types. Following virus infection and stimulation by interferon, levels of RIG-like receptors 
increase [195].  
Cytosolic RIG-I senses short dsRNA sequences, short dsRNAs and adenosine/uridine rich RNAs 
PAMPs through its repressor domain as non-self (reviewed in [196, 197]). RIG-I binds to RNA 
structures in a ubiquitination ligase Tripartite motif 25 (TRIM-25) dependent manner to activate 
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RIG-I signalling [198]. TRIM25 activates RIG-I by adding ubiquitin, stimulating RIG-I signalling 
pathway in a process controlled by Caspase-12 and 14-3-3-ε proteins [198-201]. Furthermore one 
study showed that caspase-12 deficient mice exhibited increased WNV disease depicted by CNS 
dissemination and death, and impaired interferon β (IFN- β) production as compared wild-type mice 
[199]. Protein 14-3-3-ε stabilizes RIG-I and TRIM25 interaction enabling RIG-I activation [200]. 
Consequently active RIG-I binds mitochondrial antiviral signalling (MAVS) protein through CARD 
interactions to form MAVS signalosome, which initiates IRF-3 and NF-κB activation and later IFN-
β production [200, 202].  
MDA5 is activated by long double-stranded RNA (dsRNA) during virus acute infection and 
through CARD interactions initiates downstream signalling to induce IFN-I [193]. In vitro studies 
have shown that during acute WNV infection RIG-I and MDA5 sense unique viral RNA features 
normally absent in mature host RNA species [192, 203]. MDA5 enhances CD8 T cell activation and 
clears WNV from CNS. When MDA5-deficient (Mda5-/-) mice were infected with WNV, mice 
showed increased encephalitis and higher virus burden in CNS than wild type mice [204, 205]. The 
absence or RIG-I or MDA5 alone reduced innate immune signalling in cells and increased mortality 
in mice. Furthermore, knock-down of both RLRs caused severe CNS dissemination of WNV and 
absolute inactivation of innate immune signalling in mice and mammalian cells respectively [191]. 
Therefore RLR signalling is crucial in initiating IFN-I signalling, innate antiviral responses and 
control of dissemination of WNV to the CNS [191].  Current research has focused on understanding 
host PRRs and mechanisms by which these receptors activate antiviral immunity. 
1.10.3 Interferon system 
Interferons (IFNs) are secreted cytokines that control host processes and possess antiviral and anti-
proliferative properties. Interferons directly or indirectly control host immune system by inducing 
expression of interferon-stimulated genes or inducing major histocompatibility complex expression 
to subsequently activate immune cells respectively [206]. They are categorised into three classes 
based on amino acid sequence and recognition by specific receptors, including IFN-I, Type II 
interferon and Type III interferon [207, 208].  Although IFN-I include Interferon - alpha (α), -beta 
(β), omega (ω), -epsilon (ε), -kappa (κ), - delta (Δ), -tau (τ) and – zeta (ζ), IFN-α and IFN-β are the 
most studied members of IFN-I.  In addition, numerous cells such as macrophages, lymphocytes, 
fibroblasts, endothelial cells, osteoblasts and plasmacytoid dendritic cells secrete IFN-α and IFN-β 
in large quantities during infection. Type I interferons mediate host innate antiviral immune 
responses by inducing transcription of ISGs, which ultimately control virus replication [209]. When 
mice deficient in interferon-alpha/beta receptor (Ifnar1-/-) were infected with sub-lethal WNV, they 
presented with severe WNV infection as depicted by rapid progression of clinical signs, weight 
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loss, encephalitis and death compared to wild type mice [210, 211]. These studies highlighted the 
role of IFN-I in controlling WNV infection. This review will exclusively focus on IFN-α and IFN-β 
as numerous research studies have shown that IFN-α and IFN-β influence secretion and 
transcription of ISGs that were studied in the subsequent chapters of this thesis (reviewed in [212]) . 
In addition, IFN-α and IFN-β are shown to regulate innate immune response to flaviviruses 
particularly WNV infection [211, 213].  
The type II IFN class has only one member, IFN-γ that has been shown to play a critical antiviral 
role by limiting WNV spread to the CNS. The IFN-γ deficient (Ifn-γ-/-) mice infected with WNV 
showed increased viraemia and elevated virus replication in lymphoid tissues [214]. IFN-γ can be 
secreted by macrophages, natural killer cells (NK), CD4 T helper cells and CD8 cytotoxic T cells. 
Lastly Type III IFNs includes IFN-lambda λ members such as IFN- λ1, IFN- λ2 and IFN- λ3, which 
are closely related to type I IFNs and have been shown to restrict WNV infection by maintaining 
integrity of blood brain barriers [215].  
1.10.4 Type I Interferon signalling pathway 
Following entry into a host cell, WNV replicates and accumulates dsRNA and ssRNA intermediates 
that can be recognised via RIG-I, MDA5 in the cytosol and cytosolic DNA sensor known as cyclic 
GMP-AMP synthase (cGAS), or otherwise by TLR3 and TLR7 in the endosome. Interferons are 
produced after sensing PAMPs, secreted IFN-α and IFN-β bind to interferon-α/β receptor 1/2 
(IFNAR1/2) heterodimer (Figure 1.6) to activate tyrosine kinases of the Janus kinase (JAK) family 
of proteins. Subsequently the activated JAK proteins phosphorylate STAT proteins to form a 
complex with IRF9 known as interferon stimulated gene factor 3 (ISGF3) complex. The 
phosphorylated ISGF3 complex that consists activated forms of STAT1 and STAT2 and IRF9 then 
translocates to the nucleus where it preferentially binds to interferon stimulated response element 
(ISRE) to initiate transcription of ISGs (reviewed in [208, 212, 216, 217]. The role of ISGs in virus 
replication is well studied in mice and humans [218]. Infection of Ifnar1-/- and Stat-/- mice with sub-
lethal WNV strains showed high susceptibility to WNV compared to wild type mice. Host genes 
such as RigI, Mda5, cGas, tlr3, Mavs, Irf1, Irf3 and Irf7 have been shown to possess antiviral 
effects during WNV infection as further discussed in section 1.12. In addition, knockout of RigI, 
Mda5, cGas, tlr3, Mavs, Irf1, Irf3 and Irf7 mice showed increased viral burden, dissemination of 
virus to mouse brains, increased weight loss and elevated progression of clinical symptoms on 
infection with sub-lethal WNV strains (reviewed in [216]). 
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Figure 1.7 Induction of type I interferon signaling during WNV infection:  During WNV 
infection, endosomal RNA sensors TLR3 and TLR7, together with cytoplasmic RNA helicases 
RIG-I and MDA5 detect viral dsRNA and ssRNA. As a result, these PRR are activated and 
subsequent adaptor molecules recruited. In case of TLRs, TRIF and MyD88 interact with TLR3 and 
TLR7 respectively. Consequently, two kinase complexes TAK1 (transforming growth factor-β-
activated kinase 1), TBK1 (TANK-binding kinase 1) and IKKε (inhibitor of κB kinase epsilon) are 
activated together with IKKα and IKKβ. On the other hand, RIG-I and MDA5 interact with the 
adaptor molecule mitochondrial anti-viral signaling (MAVS), which is localized to mitochondria to 
activate TBK1 and IKKβ and eventual activation of IRF3, IRF7 and nuclear factor-κB (NF-κB) 
respectively. The activated transcriptional factors translocate into the nucleus and induce the 
expression of IFNs as well as pro-inflammatory cytokines. Secreted IFN-α and IFN-β bind to 
IFNAR1/2 receptor complex. This in turn leads to activation of tyrosine and Janus kinases (TYK2 
and JAK1) that recruit and activate STAT1 and STAT2 by phosphorylation. Phosphorylated 
STAT1 and STAT2 then form a trimeric complex with IRF9 known as ISGF-3 that is translocated 
to the nucleus. In the nucleus ISGF-3 binds to ISRE promoter element to initiate expression of more 
than 300 interferon-stimulated genes, which possess antiviral activities. (Adapted and modified 
from Ivashkiv et al., 2014 [212]) 
 
1.11 West Nile virus evasion of the host immune response 
West Nile virus is an obligate intracellular parasite that requires access to host cellular 
compartments and as such this requires evasion, inhibition and subversion of host innate immune 
response to permit productive infection. WNV NS4B inhibits the IFN-I signalling by blocking 
phosphorylation of JAK and STAT transcription factors to inhibit expression of interferon 
stimulated genes [219]. Furthermore, WNV overcomes IFN signalling by reducing IFNAR1 
production and blocking IFN-β transcription [220, 221]. WNV-E protein has been shown to block 
RIG-1 and TLR3 signalling through receptor-interacting protein 1to inhibit prompt production of 
antiviral cytokines and activation of immune cells against WNV infection [222]. In addition, WNV 
NS1 protein antagonises the TLR3 pathway by inhibiting IRF3 and NF-κB translocation to the 
nucleus [223]. Furthermore, WNV NS5 inhibits IFN-I signalling by blocking STAT1 and STAT2 
phosphorylation [102, 119]. WNV also limits the effects of the expressed ISGs such as OAS1b, 
IFIT, MxA proteins [224-227]. Just as WNV is equipped to evade the host immune response, the 
host immune system has a well-established defence mechanisms that recognise WNV evasion and 
eventually limit its spread and CNS dissemination, such as use of PAMPS, induction of interferon 
response and activation of ISGs (reviewed in [228]). 
1.12 Host determinants controlling WNV infection 
In the past twelve years an immense amount of work has been done to understand host factors that 
influence WNV infection through in vitro and small interfering RNA (siRNA) screens. As a result, 
the role of various host factors that influence viral infection in mice, and human cells has been 
highlighted. Host factors such as known PRRs (RIG-I, MDA5, cGAS), TLRs (TLR3 and TLR7), 
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NLRs (NLRP3, ASC, AIM2), transcription factors (IRF 1, 3, 5 and 7 and ATF3), and ISGs (Mavs, 
Stat2, IFITM2, IFITM3, IFIT2, IFIT3, PKR, Viperin, ASCC3) have been identified [15, 218]. 
Although the precise mechanisms of action of the identified novel host genes against WNV are still 
undefined, novel anti-viral proteins such as HPSE, NAMPT, PBEF1, SAAI, PHF15, DDX24, 
IFI44L, IFI6, TRIM21, TRIM6 among others have been identified [209, 229-231]. The use of Rig-I-
/-, Mda5-/-, Mavs-/-, Irf3-/-, Irf5-/-, Irf7-/-, Viperin-/- and Pkr-/- mice has revealed their antiviral 
mechanisms [191, 232, 233]. Furthermore, novel host antiviral factors that influence WNV 
infections have been identified [234, 235]. However more extensive research is still required to 
understand how these host factors suppress WNV infection, and use of WNVNSW2011 provides a 
convenient tool to allow studies under PC2 containment conditions. 
1.13 Overall aim of the project 
The overall aim of this thesis was to provide a better understanding of WNV-host interactions in 
context of natural disease and identify host genes that control West Nile Virus infection in vitro and 
in vivo. In order to achieve this, WNVNSW2011 was modified to encode artificial micro RNA (refered 
to as amiR) in the 3' UTR. Each inserted precursor of amiR hairpin (pre-amiR) encodes a unique 
amiR sequence that targets a specific region of cognate mouse gene. Consequently amiR-encoding 
WNVNSW2011 virus libraries were generated and used as a tool to study WNV-host interactions.  
1.14 Hypothesis  
In vivo and in vitro RNAi screening with libraries of WNV producing siRNAs that target specific 
mouse interferon stimulated genes will allow identification of host genes that influence west Nile 
virus replication.   
1.15 Specific aims to test the hypotheses 
To identify host factors controlling WNV infection under in vitro and in vivo conditions by RNAi 
screening with WNV libraries three aims were stipulated.  
• Firstly, an amiR-encoding plasmid library was to be generated as a tool for generating 
subsequent amiR encoding virus libraries.  
• Next we aimed at performing in vitro and in vivo RNAi screening to identify host factors that 
control virus replication both in vitro and in vivo using the generated virus libraries.  
• The last aim of this thesis was to characterise the identified host factors to determine how 
these host factors influence West Nile virus replication 
  
 23 
Chapter 2:  General Materials and methods 
This chapter describes the general materials and methods used across all the three results chapters. 
Specific materials and methods are included in each respective chapter. 
2.1 Materials and Reagents 
Table 2.1: Table showing list of reagents and materials used to perform the different 
experiments performed to test hypothesis and achieve set project aims. 
Reagents Manufacturer 
Amicon Ultra-15 centrifugal filter units 
(100K) Merck (USA) 
RNA Nucleospin Extraction kit Machery-Nagel ( GmbH & Co. KG, Germany) 
TRI LS Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
TRI  reagent Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
DNA gel extraction Kit New England BioLabs ( Ipswich, MA USA) 
10 × Blocking Buffer Thermo Scientific (Waltham MA, USA) 
Lipofectamine LTX Thermo Scientific (Waltham MA, USA) 
Optimem  Thermo Scientific (Waltham MA, USA) 
GXL polymerase Kit Taraka Bio (USA, Mountain view, California) 
One Step RT-PCR Thermo  Scientific (Waltham MA, USA) 
Agarose Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
RedSafe Montreal Biotech Inc (Canada) 
Protein Ladder Kaleidoscope BioRad (California, USA) 
IFITM3 Polyclonal Rabbit IgG ProteinTech, Rosemont, Illinois, USA 
CLEC4E Monoclonal mouse Abcam, Cambridge, UK 
PARP11 Rabbit Polyclonal Proteintech, Rosemont, Illinois, USA 
ATF3 (D2Y5W) Rabbit monoclonal Ab Cell signalling Technology, (Massachusetts, USA) 
IRF7 (H-246) Rabbit Polyclonal IgG Santa Cruz Biotechnology, Inc (Dallas, U.S.A) 
Mouse WNV-E 4G2 In house  
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Human WNV-E E-16 In house 
Dulbecco's Modified Eagle Media Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
Phosphate Buffered Saline ChemStore, Australia 
Tween 20 Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
NuPage 4-12 bis-tris 15 well Protein gels Thermo Scientific (Waltham MA, USA) 
NuPage 4-12 bis-tris 10 well Protein gels Thermo Scientific (Waltham MA, USA) 
RPMI  Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
Glutamax Thermo Scientific (Waltham MA, USA) 
Penicillin-Streptomycin Thermo Scientific (Waltham MA, USA) 
Carboxymethyl cellulose Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
M199 Media Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
Q5 high-fidelity DNA Polymerase New England BioLabs, ( Ipswich, MA USA) 
Wizard Plus SV miniPreps DNA 
purification system  Promega (Madison, Wisconsin, USA) 
Fetal Bovine Serum Sigma Aldrich Pty Ltd (St Louis Missouri, USA) 
1× PBS-T  In house 
1X PBS In house 
 
2.2 DNA manipulations 
The exact primer sets, DNA and RNA templates as well as plasmids used to perform experiments 
included in this table below  
Table 2.2: List of primers, PCR templates sequences and corresponding PCR amplicon 
generated 
Primer Name Amplicon Name  Sequence 5 ′- 3 ′ 
Amplicon_adaptor_F  Δ15-89 cDNA TCGTCGGCAGCGTCAGATGTGTATAAGAGACA
GGAAGACACGACATTTGTTGAGGATACAGTAT
TGTAAATAGTTTG 
Amplicon_adaptor_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGAC
AG CAT TCA AGT GCA GCC GTA GGC TCC GC 
Flavi UTRlinker_F  UTR-linker  GTGGTGCGAGAACACAGGA  
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Flavi UTRlinker_r CAGCTCACACAGGCGAACTACT  
5′ UTR_F 5′ UTR+ 
C-prM-E 
AGTAGTTCGCCTGTGTGAGCTG  
C-prM-E_R GGAAAGAAAGAGCAGAACTCCTCCAAC  
NS1_F  NS1-2A-2B GTTGGAGGAGTTCTGCTCTTTCTTTCC  
NS2B_R  CTCCTCTCTTTGTGTATTGGAGAGTTATC  
NS3_F  NS3 GATAACTCTCCAATACACAAAGAGAGGAG  
NS3_R CCTGAGGCGAAGTCTTTGAA  
NS4_F NS4A-4B TTCAAAGACTTCGCCTCAGG 
NS4B-R CGTCCTTTTGCCCCACCTC  
NS5_F NS5 GAGGTGGGGCAAAAGGACG 
NS5_R GTGTATCCTCAACAAATGTCGTGTCTTC 
3’UTR_F 3’UTR GAAGACACGACATTTGTTGAGGATACAG 
3’UTR_R TCCTGTGTTCTCGCACCAC  
Bef AmiR_R NS5-Before 
AmiR 
AGAGCAGAGTCTCTGATCTTGAT 
AmiR_F AmiR ATCAAGATCAGAGACTCTGCT 
AmiR_R TTCAAGTGCAGCCGTAGGCTCCGCTCT 
 
2.2.1 Polymerase chain Reaction (PCR) 
Before performing any PCR, laboratory bench tops were thoroughly cleaned and disinfected using 
70% ethanol. PCR mixes were prepared as per manufacturer’s instructions using nuclease free 
water. The Q5 high fidelity DNA polymerase (New England Biolabs, USA) or PrimeSTAR GXL 
DNA Polymerase (Clontech, USA) PCRs were performed to generate high fidelity amplifications. 
Taq Polymerase kit (Thermo Scientific, USA) for PCR was used to generate low fidelity reactions 
such as DNA contamination tests. Primers used for PCR reactions were designed according to 
Integrated DNA Technologies (IDT, USA) primer design instructions and PCR thermal cycles were 
performed using SimpliAmp™ Thermal Cycler (Thermo Scientific USA). 
2.2.2 Agarose gel Electrophoresis 
Depending on the expected DNA bands size, agarose gels were cast by disolving 1% or 2% (w/v) 
agarose in 1 × TAE buffer containing 0.2 µg/mL RedSafe and left to set. A mixture of 1× loading 
dye and DNA samples were loaded into gel along with an appropriate DNA Ladder loaded and 
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electrophoresis performed in 1 × TAE buffer at 110V for 40 minutes. The gel was visualized under 
Gel Logic 212 PRO UV/white light trans-illuminator (Carestream, USA) and gel image captured 
using a camera for documentation. DNA band sizes were compared to appropriate DNA Ladder in 
order to determine their sizes. The UV trans-illuminator was only used to determine the band sizes 
and capture the gel picture since UV distorts DNA. In cases where the DNA bands were required 
for subsequent experiments, Safe Imager Blue light trans-illuminator (Invitrogen, USA) was used to 
view gel images. Thereafter, bands were excised, purified and quantified as described below. 
2.2.3 DNA extraction from gels and quantification  
Basing on the DNA ladder, the correct DNA fragments were excised from the agarose gel using a 
sterile scalpel blade and placed in a DNase free-labelled microfuge tube. The DNA fragments were 
purified using Monarch DNA Gel Extraction Kit (New England BioLabs, USA) according to 
manufacturer’s instructions. DNA concentrations were determined by either using Nanodrop 1000 
spectrophotometry (Thermo Scientific, USA) or Qubit fluorometer and Qubit dsDNA BR Assay Kit 
(Thermo Scientific, USA) following manufacturers’ instructions. 
2.2.4 DNA Sequencing 
Purified plasmid DNA was prepared for sequencing following Australian Genome Research 
Facility’s (AGRF) recommendations. 0.2-1µg of DNA was prepared into 12 µL reaction by adding 
1uL of 10µM sequencing primer and topping up with ultra pure nuclease free water. The resultant 
DNA mix was sent to AGRF for Sanger DNA sequencing. For Deep sequencing the correct DNA 
purified amplicon PCR fragment was diluted to at least 20 ng/ µL and sent Australian Centre of 
Ecogenomics (ACE) for amplicon deep sequencing. 
2.3 RNA manipulations 
2.3.1 Viral RNA isolation from culture fluid 
Viral RNA was isolated from virus culture fluid using Nucleospin RNA virus kit and protocol 
(Macherey-Nagel, Germany). Extracted purified RNA was treated with RQ1 RNase-Free DNase I 
kit (Promega USA) according to manufacturer’s protocol to remove of any DNA contamination 
from transfection. 
2.3.2 Viral RNA isolation from cells 
Total RNA was extracted from Vero cells at 3 days post infection (dpi) using TRI Reagent (Sigma-
Aldrich, USA), according to manufacturer’s instructions. Extracted RNA was re-suspended into 50 
µL of ultra pure nuclease free water and RNA concentration determined by using Nanodrop 
spectrophotometry (Thermo Scientific, USA). 
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2.3.3 Generation of WNVNSW2011 cDNA fragments 
RNA was extracted from wild-type WNVNSW2011 (WT-WNV) stocks previously generated by 
infecting Vero cells using TRI Reagent Sigma-Aldrich (St Louis Missouri, USA) according to 
manufacturer’s instructions. Complementary DNA (cDNA) was synthesised from purified RNA 
using Superscript IV reverse transcriptase (Thermo Scientific, USA) kit and protocol. Subsequently 
generated cDNA was used as DNA template for, Q5 high-fidelity DNA polymerase PCR (New 
England Biolabs, USA) PCR along with precise sets of oligonucleotide primers (Table 2.1). As 
aresult , overlapping cDNA fragments of  WNVNSW2011 genome were generated. Thereafter, 1% 
(w/v) agarose TAE gel electrophoresis was performed and generated WNVNSW2011 cDNA fragments 
were excised from gel and later purified using Monarch DNA Gel Extraction Kit (New England 
BioLabs, USA) as per manufacturer’s instruction. Purified fragments were eluted in ultra nuclease-
free water and DNA concentrations determined using Nanodrop spectrophotometry (Thermo 
Scientific, USA). The fragments were stored at −20°C until required for Circular polymerase 
Extension Reaction (CPER) reaction to make infectious WNVNSW2011 cDNA. 
2.4 Culturing of cells 
Mammalian cells such as green monkey kidney epithelial Vero cells, 293T human embryonic 
kidney (HEK), wild type (WT MEF) and IFNAR knock out mouse embryonic fibroblasts (Ifnar1-/-
MEF) were cultured in Dulbecco’s modified Eagle medium (DMEM) while A549 cells were 
cultured in F-12K media. Cells were supplemented with 10% foetal calf serum (FCS), 50 units/mL 
of penicillin and 50 µg/mL of streptomycin. Mammalian cells were cultured at 37°C in a 5% 
Carbon dioxide (CO2) humidified incubator. Aedes albopictus clone C6/36 mosquito cells were 
propagated in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% 
foetal bovine serum 50 units/mL of penicillin and 50 µg/mL of streptomycin and incubated at 28°C 
in a 5% CO2 humidified incubator. 
2.5 Circular Polymerase Extension Reaction 
Circular Polymerase extension Reaction (CPER) is an accurate rapid and cheap method used to 
generate infectious cDNA [236, 237]. It assembles multiple overlapping cDNA fragments along 
with UTR flavi-linker and a CMV promoter upstream of the WNV cDNA to produce full-length 
infectious WNVNSW2011 cDNA. The UTR linker consists of a CMV promoter for constitutive 
expression in mammalian cells while Hepatitis Delta Virus ribozyme (HDVr) region for cleavage of 
poly adenylation tail added to WNV genome during transfection. Lastly, the poly Adenylation 
signal (pA-signal) allows effective termination of WNV transcription by RNA polymerase II as a 
poly-A tail is added to WNV genome and cleaved to form an authentic 3' UTR [237]. To generate 
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individual viruses, a total of 0.5 ρmol concentration of each viral reverse transcriptase (RT) 
amplicon was assembled using Q5 high fidelity DNA polymerase (New England Biolabs, USA), 
Deoxynucleotides (dNTPs) and under low cycle PCR conditions to form infectious cDNA product. 
Reverse transcriptase amplicons were designed to have over-lapping ends and the last RT-PCR 
amplicon end overlapped with the UTR linker fragment for correct circularization of cDNA. During 
CPER, RT-amplicons are denatured and overlapping ends anneal to each other. Thereafter, Q5 
high-fidelity DNA polymerase then extends neighbouring fragment as a primer to form circular 
infectious cDNA product [237].  The generated CPER products were stored at −20°C until required 
for transfection into human embryonic kidney (HEK) 293 cells 
2.6 Transfection of HEK 293T cells to passage zero (p0) to recover virus stocks 
Human embryonic kidney fibroblast cells were seeded at 5×105 cells per well in a six well plate and 
incubated in a 5% CO2 humidified incubator at 37 °C for 12 hour until 95% confluent. The next 
day, HEK 293 cells were transfected with CPER products using Lipofectamine LTX following 
manufacturer’s protocol and plates returned to a 5% CO2 humidified incubator. At 5 hours post 
transfection, CPER-transfection mix was removed and replaced with DMEM supplemented with 
10% FCS, 50 units/mL of penicillin and 50 µg/mL of streptomycin. The plates were incubated at 
37°C in a 5% CO2 humidified incubator for 3 days or until cytopathic effect (CPE) was observed 
when cells were viewed under microscope. Thereafter, virus culture fluid was collected as p0-293T 
virus stock and virus stock titres determined by immunoplaque assay on Vero cells monolayer. 
2.7 Immuno-plaque assay 
Vero and C6/36 cells were seeded at 2×104 cells and 1×105 cells per well in 96-well plates 
respectively and incubated at 37 °C and 28°C for 12 hour in 5% CO2 incubator until 95% confluent 
respectively. The next day, virus samples were diluted in ten fold serial dilutions in DMEM 
supplemented with 50 units/mL of penicillin and 50 µg/mL of streptomycin and 5% FCS. 
Thereafter, 25 µL from each dilution was added to each well of cells and incubated at 37 °C for two 
hours. At two hours post-infection, 175 µL of overlay media, made by mixing ×2 M199 medium (2 
M199 medium supplemented with 5% FCS, 50 units/mL of penicillin and 50 µg/mL of 
streptomycin) with 2% carboxymethyl cellulose in a ratio of 1:1 was added to each well and plates 
incubated for 36 hours and 96 hours for Vero and C6/36 cells respectively. At 36 hpi and 96 hpi, the 
overlay was removed and 100 µL of ice-cold 80% acetone in phosphate buffered saline (PBS) was 
added and incubated at –20°C for 1 hour to fix the cells before completely air-drying the plates. To 
detect WNV-E protein, plates were first blocked by adding 50 µL of Pierce Clear Milk Blocking 
Buffer (Thermo Scientific, USA) to each well and incubating the plates at 37 °C for 1 hour.  
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Thereafter, 50 µL of mAb 4G2 (mouse anti-E) was added to each well and plates incubated at 37°C. 
Plates were then washed six times using 1× PBS containing 0.05% Tween 20 (PBS-T) to remove 
any traces of unbound primary antibody before adding 25 µl of IRDye 800 cw Goat anti-Mouse, 
(LI-COR, USA) as secondary antibody to each well. Plates were then incubated at 37 °C for 1 hour 
and thereafter washed six times, air-dried and then kept in the dark at room temperature until ready 
for imaging. Plates were scanned using the LI-COR Biosciences Odyssey Infrared Imaging System 
with the following specifications: channel =800, intensity = auto, focal length = 3 mm, resolution = 
42 µm. Viral titres from iPA are expressed as pfu/mL  
2.8 Generation of passage one (p1) of virus on Vero cells  
To generate p1-vero virus stocks, Vero cells were seeded at 2×106 cells in a T175 flask and flask 
incubated at 37 °C for 12 hour until 95% confluent. The next day, cells were infected with p0-293T 
virus stock at MOI =1 in 3 mL of DMEM media supplemented with 50 units/mL of penicillin and 
50 µg/mL of streptomycin and flasks incubated at 37 °C for 2 hours, with rocking the flask every 15 
minutes. At 2 hours post infection, virus-DMEM mix was removed and replaced with fresh DMEM 
supplemented with 5% FCS, 50 units/mL of penicillin and 50 µg/mL of streptomycin. The flasks 
were incubated at 37°C in a 5% CO2 humidified incubator for 3 days or until cytopathic effect 
(CPE) was evident. Thereafter, virus culture fluid was harvested as p1-Vero virus stock and virus 
titres determined by immunoplaque assay on Vero cells monolayer. Each generated virus stock was 
Sanger sequenced to confirm that the correct intended virus was generated as described above. 
2.9 Deep sequencing and analysis of deep sequence  
On generation of amplicons for deep sequencing, DNA gel extraction was performed; samples 
eluted in nuclease free water and submitted to Australian Centre for Ecogenetics (ACE) for deep 
sequencing. On deep sequencing, data were downloaded from ACE website and analysed using a 
Salmon transcription tool and protocol as described in appendix 2. Deep sequence reads produced 
pre-miRNA encoding the following sequence, ATCAAGATCAGAGACTCTGCTCT-
XXXXXXXXXXXXXXXXXXXXX-ATTTAATGTCATACAAT-
XXXXXXXXXXXXXXXXXXXXX-AGAGCGGAGCCTACGGCTGCACTTGAA. All reads 
possessed the known sequence shown and Xs (two stretches of 21 nucleotides on either side) were 
the region of interest containing unique corresponding siRNA sequences. 
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Chapter 3: Generation of amiR-encoding libraries  
3.1 Introduction 
This chapter describes how amiR-encoding plasmid library was generated as a tool for generation 
of subsequent p0-293T and p1-Vero amiR-encoding virus libraries. It highlights the advantages of 
using CPER to generate virus libraries and some of the bottlenecks encountered during generation 
of libraries. 
3.1.1 Use of Artificial micro RNA to study flavivirus-host interactions  
Conventional approaches have facilitated study of host responses to flavivirus infections and 
subsequently enabled identification of host genes that influence flavivirus infection. Some well-
studied approaches include use of knockout mouse models and reverse genetics using both cell 
culture infections and ex-vivo analysis (reviewed in [63]). Knockout mice with defects in type I IFN 
production or sensing pathways, such as Rig-I-/-, Ifih1-/-, Mavs-/- and Ifnar1-/- infected with sub-
lethal WNV strains showed significant increase in mortality and morbidity compared to wild type 
controls [191, 202, 211]. Further mechanistic studies corroborated the role of these genes in 
controlling WNV [223, 238-240]. Therefore, knockout mice studies have been used to elucidate 
role of RLR signaling pathways in controlling WNV infection in vivo. 
Numerous known and novel ISGs have been confirmed to hinder flavivirus infection, by in vitro 
ISG over-expression and RNAi screens [150, 229, 230, 235, 241-249]. The gain-of-function 
approach involves over-expression of specific host gene and studying the effects on virus infection. 
A decline in virus replication following ISG over-expression indicates that the over-expressed gene 
inhibits virus replication and vice versa. In vitro over-expression of 36 ISGs in HEK 293 cells 
revealed viperin and ISG-20 as novel antiviral host genes against West Nile and dengue viruses and 
confirmed the role of IFITM2 and IFITM3 in antagonising the initial steps of WNV and dengue 
virus lifecycle [209]. Mechanistic studies revealed that both viperin and ISG-20 genes hindered 
RNA virus replication. This study not only identified novel ISGs that antagonise WNV infection 
but also revealed that the flavivirus antiviral system is mediated by numerous ISGs that work 
together to hinder different stages of flavivirus life cycle. Additionally, a Lentivirus-based 
screening approach with 380 human ISGs identified MDA5, cGAS, IRF1, ATF3, IRF7 as well as 
NAMPT, PBEFI, SAAI and PHFIS to restrict West Nile virus infection [218, 245].  
Conversely, use of loss-of-function approach can utilise RNAi to understand host-virus interactions. 
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RNAi studies predominantly use an artificial microRNA (amiR) platform such as siRNA or small 
hairpin RNA (shRNA) to knockdown gene expression and evaluate the impact of gene knockdown 
on virus replication. These act similarly to microRNAs (miRNAs), that are genome-encoded small 
non-coding RNAs usually 21-23 nucleotides long that regulate post-transcriptional gene expression 
in eukaryotic organisms [250]. RNA interference screening methods involve introduction of amiRs 
particularly siRNA into cells to induce degradation of homologous mRNA molecules. Artificial 
miRNAs can be designed to maintain the general structure of pre-amiR hairpin with specific miR 
sequence in the stem that targets a cognate mRNA sequence to inhibit gene expression. Most RNAi 
screening methods result into sequence-specific cleavage, suppression of translation and de-
adenylation of cognate mRNA targets causing post-transcriptional gene silencing (reviewed in [251, 
252]). Following gene knockdown, an increase in virus replication implies that the gene that is 
knocked down inhibits virus replication and is an antiviral gene. Consequently loss-of-function 
studies are used to identify and define the roles of novel or known virus-host factors that influence 
virus replication.  
Numerous RNAi screening approaches have been employed to study virus-host interactions. For 
instance, a genome-wide RNAi screen containing 21,000 human genes identified host genes 
associated with virus infection in cells. Consequently 305 human host genes that affected West Nile 
virus infection were identified. Of these, 283 genes were host susceptibility factors required for 
optimal virus infection, and 22 were host factors restricting viral output [229]. Furthermore, another 
RNAi screen used an shRNA flow cytometry approach to screen for host genes that influence West 
Nile virus infection in human cells. Subsequently, 46 antiviral genes including MAVS, STAT2, 
IRF1, IFITM2, PKR, known ISGs DDX24, IFI44L, IFI6, TRIM2, TRIM6 and novel genes such as 
activating signal co-integrator complex 3 (ASCC3) were identified as antiviral genes against West 
Nile virus infection. Mechanistic studies and RNA sequencing revealed that ASCC3 utilises IRF-3 
and IRF-7 transcription factors to regulate ISG activity [230]. Furthermore, Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) based study with library containing 77,406 single 
genome RNAs targeting 20,121 genes identified seven genes such as EMC2, EMC3, SEL1L, 
DERL2, UBE2G2, UBE2J1, and HRD1. Further mechanistic knockout studies showed that the 
identified genes were linked to WNV-induced cell death [253]. 
 
Collectively large-scale over-expression and RNAi screens have facilitated understanding of host-
virus interactions in vitro [209, 218, 229, 230]. Both approaches have not only identified previously 
known ISGs and uncovered novel ISGs that control West Nile virus infection but revealed novel 
cellular pathways and possible drug targets for development of antivirals (Reviewed in [232, 254]). 
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Although conventional methods have greatly facilitated the understanding of West Nile virus 
immunobiology, these strategies have several drawbacks. Conventional approaches exclusively rely 
on studying a single immune component or pre-selected collections of knockdown gene targets. 
However, virus infections induce an arsenal of antiviral host pathways that work in concert to limit 
severity of infection. Therefore, conventional approaches often portray a non-comprehensive 
representation of host response to virus infection (reviewed in [63, 242, 249]). Eliminating one 
antiviral gene could be counteracted by alternative antiviral pathway [209]. Individually over-
expressed ISGs often do not interact with other regulatory ISGs present during antiviral response 
and virus infection. Furthermore most previous screens have been performed in cell lines such as 
HeLa and Huh-7 cell lines, that could portray different antiviral effects than the host cells normally 
infected in an in vivo infection model. Lastly, all genome-wide studies are limited to in vitro 
experiments due to it being unfeasible to study large panels of knockout mice.  
Recently, a novel in vivo RNA interference screening method that allows direct measure of virus 
infection and study of host-virus interactions in a biological setting was developed [151]. This 
RNAi screening approach bypassed some of these hurdles as it allowed identification of host genes 
closely linked with virus pathogenesis. In order to identify novel host genes controlling Sindbis 
virus replication, this RNA virus was designed to encode unique amiRs that target specific host 
genes. Under normal infection, Sindbis amiR-encoding virus libraries were subjected to selective 
pressure to identify host factors that control virus replication in vitro and in vivo. Consequently 
known ISGs and two new mouse host genes related to transcription; zinc finger protein x (Zfx) and 
MAX gene-associated protein (Mga), restricted Sindbis virus replication in vitro and in mice 
respectively. Notably, further conventional siRNA-depletion studies in cells followed by RNA-seq 
analysis showed that loss of Zfx and Mga resulted in an intense re-modeling of the cellular 
transcriptome and an extensive loss of activation of many anti-viral genes, implicating the broader 
role of Zfx and Mga in induction of antiviral responses [255, 256]. Thus this in vivo RNAi screening 
approach represented a unique strategy for studying virus-host interactions in the context of viral 
infection as it relied on the power of virus competition and selection. Based on this approach, we 
aimed to identify novel host genes that influence West Nile virus replication both in vitro and in 
vivo by utilising ISG-targeting amiR-encoding West Nile virus libraries.  
3.1.2 Prior optimisation of pre-amiR hairpin insertion site in 3′ UTR of WNVNSW2011 
In order to generate virus libraries that encode ISG-targeting pre-amiR hairpins, it was first 
necessary to find a suitable site in the WNV genome for insertion of the pre-amiR sequence, that 
would minimally disrupt viral replication. Furthermore the chosen site would have to stably retain 
the inserted pre-miRNA hairpin and also allow proper processing of pre-miRNA into a functional 
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amiR. A prior preliminary study (Setoh et al., unpublished data) screened different sites in 3′ UTR 
of WNVNSW2011 to identify an optimal site for insertion of a hairpin encoding artificial microRNA 
targeting GFP (GFP amiR). 
A 109-nucleotide pre-miR-124 hairpin in which miR-124 3p sequence was replaced with an siRNA 
targeting the coding region of green fluorescent protein (GFP) was designed (Figure 3.1 A) (Setoh 
et al., unpublished). To enable efficient processing of GFP-siRNA by host miRNA-processing 
machinery, the sequence complementary to GFP-siRNA (5p region) was also modified to maintain 
the pre-miR-124 RNA structure (Figure 3.1 A) [151].  
Four sites within domain I of  WNVNSW2011 3′ UTR, which contains SL-I to CS3, were selected for 
insertion because this region contains the least conserved sequences in flaviviruses (Figure 3.1 B) 
[14, 257]. Mutants 44 (top of SL-I loop), 177 (between RCS3 and SL-III), 214 (top of SL-III loop) 
and 331 (after CS3) consisted of GFP pre-amiR inserted at respective nucleotide positions in the 3′ 
UTR. The ∆15-89 and ∆187-244 mutants had the native SL-I and SL-III structures deleted and 
replaced with GFP pre-amiRs respectively (Figure 3.1 B). The CPER approach, as described in 
methods [109, 237, 258], was then used to recover all 6 viruses (44, 177, 214, 313, ∆15-89 and 
∆187-244). Further in vitro and in vivo characterisation of mutant viruses revealed that both ∆15-89 
and 44 mutants stably retained GFP pre-amiR insertion. However, the ∆15-89 mutant displayed the 
least attenuation in mice compared to WT-WNV (Setoh et al., unpublished). Therefore ∆15-89 
insertion site was chosen for this project.  
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Figure 3.1 Generation of recombinant WNVNSW2011 expressing GFP amiR.  A) Sequence of 
miR-124-based GFP pre-amiR hairpin and processed mature GFP amiR. B) Diagram representation 
of sites in WNVNSW2011 3′ UTR where the GFP pre-amiR was inserted. The ∆15-89 and ∆187-244 
mutants have the specified nucleotides deleted and GFP pre-amiR inserted in place of deleted 
nucleotides at positions 15 nt and 187 nt respectively. The 44, 177, 214 and 331 mutants have the 
GFP pre-amiR inserted at the indicated nucleotide positions (Setoh et al., unpublished). 
 
3.1.3 Aims 
The aim of this chapter was to prepare a library of viruses containing amiRs targetting ISGs. A total 
of 204 ISG targeting pre-amiR hairpins were cloned into ∆15-89 site of WNV 3′ UTR to generate 
an amiR-encoding plasmid library. With the generated plasmid library, two virus libraries, named 
p0-293T and subsequently p1-Vero were generated as tools for in vitro and in vivo RNAi screening 
to study West Nile virus-host interaction. Using the same approach, a miR-124 scrambled 
sequences virus library was generated as an internal control for in vitro and in vivo RNAi screening 
studies. 
3.2 Materials and methods 
For ease of reading, materials and methods specific to this chapter are included below. 
3.2.1 Preparation of chemical competent cells 
To perform bacterial transformation, chemically competent DH5α E.coli cells were first prepared 
using the Inoue method for preparation of ultra competent E. coli cells and tested for transformation 
efficiency prior to transformation. The generated DH5α E.coli stocks were stored at −80°C until 
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required for transformation. 
3.2.2 Mutagenesis PCR 
Mutagenesis PCR was performed using GFP-amiR encoding plasmid as template, Q5 high-fidelity 
DNA polymerase kit (New England Biolabs, USA)  and specific mutagenesis forward and reverse 
set of primers. DpnI digestion was performed to eliminate  methylated DNA template. Thereafter,  
1% (w/v) TAE agarose gel electrophoresis was performed on DpnI digested product. DNA bands 
were excised from gels, purified using Monarch DNA Gel Extraction Kit, (New England Biolabs, 
USA) and DNA concentration determined by Nanodrop spectrophotometry. 
3.2.3 Chemical transformation   
 A total of 1.5 µL of DpnI digested gel purified DNA was mixed with 50µL of chemically 
competent DH5α E. coli cells and incubated on ice for 30 minutes. The tube containing the mixture 
was heat shocked at 42°C for 45 seconds before returning it on ice for 2 minutes. Pre-warmed 
additive free Luria-Bertani (LB) broth (1% tryptone, 0.5% yeast extract, 1% NaCl) was added to 
transformed cells and incubated in at 37°C at maximum speed in a heat block for one hour to revive 
the cells. Thereafter 100 µL of revived cells were inoculated onto on LB agar plates containing 100 
µg/mL of ampicillin (AMP) by surface spreading. The plates were then incubated overnight at 37°C 
in an incubator to allow formation of ampicillin resistant colonies.  The following day, formed 
single colonies were randomly picked and each colony grown overnight in 5 mL of LB broth 
containing with 100 µL/L of ampicillin at 37°C in an aerobic shaker.  
3.2.4 Purification and plasmid Sequencing 
A total 2 mL of overnight bacteria culture broth was purified to obtain plasmid DNA using the 
Wizard Plus SV Plasmid Miniprep System (Promega, USA) kit and protocol. Purified plasmid 
DNA was quantified using Nanodrop spectrophotometry (Thermo Scientific, USA). Each plasmid 
was later Sanger sequenced to confirm that it contained a correct amiR sequence. 
 
3.3 Results 
3.3.1 Generation of an amiR-encoding plasmid library 
In this study an in vitro and in vivo RNA interference (RNAi) screening technique was employed 
with the aim of identifying antiviral host genes that could potentially affect West Nile virus 
replication. In order to do that, a library of recombinant WNV, each virus capable of producing a 
unique artificial microRNA (amiR) hairpin that silences a corresponding host gene was generated. 
To generate subsequent amiR-encoding virus libraries, an amiR-encoding plasmid library was first 
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constructed. A total of 204 amiR sequences targeting 102 ISGs obtained from Professor Benjamin 
tenOever of Icahn School of Medicine at Mount Sinai, USA. The library was selected based on the 
Influenza A virus screen performed by our collaborator Professor Benjamin tenOever [151]. Several 
of these ISGs previously shown to limit West Nile virus infection in conventional RNAi screens 
were included in plasmid library [151]. To increase possibility of gene knockdown, two pre-amiR 
hairpins were utilised with each targeting a unique site on the same host gene open reading frame 
(Table 3.1).  
Table 3.1 List of murine ISGs and corresponding siRNA sequences and Gene IDs that were 
included in the plasmid library.  
Clone # Gene Name Gene ID siRNA (3p region) 
1 
Adar 56417 
TTTCTGAGAGTCACACTCCTG 
2 TCTTGTAGGGTGAACACCGTG 
3 
Atf2 11909 
AAAGACACTTTGTAGCTGGTG 
4 TGACACTGTCATTACGTGCTG 
5 
Atf3 11910 
TTGAGTGGGATTAAACACTGA 
6 TCAAGGTAGACACTTCTGCCT 
7 
B2m 12010 
TTGGATTTCAATGTGAGGCGG 
8 TTATTGCTCAGCTATCTAGGA 
9 
Birc6 12211 
TAACAGTCTTTCTAACTGCGG 
10 TCTATGATGACACTGCACCGG 
11 
Brd4 57261 
TAATCTTATAGTAATCAGGGA 
12 TTAAGCTATAGCTCGCTGGGA 
13 
Cdkl4 381113 
TATAGCTTTCTTAAACATCTT 
14 TTTAGAACACTTCTGCTTCTA 
15 Clec4d 17474 TACATCTGTCTTATTCTGGTA 
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16 TTAACAGTGGTCTATGACCCA 
17 
Clec4e 56619 
AATAATTTCACTTTGAACCTA 
18 TTTGTTAGAGAATTGATCTGT 
19 
Cmpk2 22169 
TACAATAACAGGAAAGTTGGT 
20 AACTAGGTCAAGTACTGCCCG 
21 
Cpeb3 208922 
TATAACATTAAGAACTTGGGG 
22 TCCATCTGCATCTTGTCGGGG 
23 
Cxcl10 15945 
ATAGCTTACAGTACAGAGCTA 
24 TTGATGACACAAGTTCTTCCA 
25 
Cytip 227929 
TTGTCTTCCATCGTGAGCTGG 
26 TCCACAGTAACAACCTTCCTT 
27 
Daxx 13163 
TTAATGTACACATAGATCTTA 
28 TACAATGATGCTGTCATCGGT 
29 
Ddx58 230073 
TTAGTGTCTCGGATCTGTCTG 
30 TAGCTGTCAACTATAGTCTTT 
31 
Ddx60 234311 
TAAGCTGGAGTAGTCAGCCTT 
32 TAATGAAATGTCGTATCGGGA 
33 
Dhx9 13211 
TTGTACTTCTTGTTCTTCCTT 
34 TCACACATGAATTTCTGTCTG 
35 
Dtx3l 209200 
TACTCTATGAACTCTAGTCTA 
36 TAAACAACTAATGTATTGCTA 
37 
Eif2ak2 19106 
TTTGAGGACTTCTCTAACCTG 
38 TTGTACTTCGTGCTCCGCCTT 
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39 
Fa2h 338521 
TTGAATACTCTCTTGTGAGTG 
40 TAGTACAGCTGGTATCTGGGG 
41 
Fbxo39 628100 
TTATTGTTGAACTCGAACGTT 
42 TTGTTCTCGCTCAAGGTCTCG 
43 
Gbp2 14469 
TTGTAGATGAAGGTGCTGCTG 
44 TGTTTCAACAACATCTGCCTT 
45 
Gbp3 55932 
TTGGTTTGTATCTTTAACCTT 
46 TTTATCTGTAGTGTACAACTG 
47 
Gbp6 100702 
TTTCTGTCTTAGTAGCTCCTG 
48 TTCTGTGACATAGTGCAGCTG 
49 
Gcc 14917 
TTAAAGAACAGAATTAACCAA 
50 TATACTTGTCCTTCAGCTCTG 
51 
Gvin 74558 
TTCTCTTCTAGGTTTGATCTG 
52 TTAATTACATCACTGAAGCGG 
53 
Ifi35 70110 
TTAGAAACTACAAACTTGGGC 
54 TATACAGAGAAATCTAGTCTC 
55 
Ifi44 99899 
TATTGATCCAACACAGTTCTA 
56 TAATATAGCACTCTAAAGGGA 
57 
Ifih1 71586 
TTATACATCATCTTCTCTCGG 
58 TAAGATTTGACAACTTCTGGA 
59 
Ifit1 15957 
TATATTAACGTCACAGAGGTG 
60 TTCTCCTAAATCCTGAAGCTT 
61 Ifit3 15959 TTCTGCATGAACTCCATCGTT 
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62 TTGTCTCACCTTGTCAACGTA 
63 
Ifitm3 66141 
TTGATTCTTTCGTAGTTTGGG 
64 TAAATGAGTGTTACACCTGCG 
65 
Ifna1 15962 
TTCTCTCTCAGGTACACAGTG 
66 TTTGATGTGAAGATGTTCAGG 
67 
Ifna4 15967 
TTGTGGGTCTTGTAGATGCTG 
68 TTATCCACCTTCTCCAAGGGG 
69 
Ifnb1 15977 
TACAACAATAGTCTCATTCCA 
70 TTCCTGAAGATCTCTGCTCGG 
71 
Ikbka 12675 
TAACACTCTCTCAACAGTGTT 
72 TTTGTGACATCTTCTTCCCTG 
73 
Ikbkb 16150 
TATACTATGGAAATACACCTT 
74 TTGGACTAGCTGAAGTTCCTG 
75 
Ikbke 56489 
TAGATGACTGAAATTTACCTT 
76 TAGACAGAAACAAACTTCTCA 
77 
Il15 16168 
TATCTTACATCTATCCAGTTG 
78 TATCCATACAACTTTATTCCA 
79 
Il6 16193 
TAGAGTTTCTGTATCTCTCTG 
80 TACATTCCAAGAAACCATCTG 
81 
Irf1 16362 
TTATTGATCCAGATCAGCCCT 
82 TTGTCTCCTAGTACAGAGCCA 
83 
Irf2 16363 
TTTCTTTATGCTTCTGTCCTT 
84 TACAACTATGATGTTCACCGT 
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85 
Irf3 54131 
TAGTTCTGAGACTCGCAGCCA 
86 TTGTTCCTCAGCTAGCAGCTG 
87 
Irf5 27056 
TAGAACAGCTGGAAGTCACGG 
88 TTGAAGATGGTGTTGTCCCCA 
89 
Irf7 54123 
TTCCTCGTAAACACGGTCTTG 
90 TCTTCGTAGAGACTGTTGGTG 
91 
Irf9 16391 
TATGTAAGTATACTGTAGCTG 
92 TAAGTTTCAATTCTCCTCCGG 
93 
Irgm 15944 
TATGTAAGTACACTGTAGCTG 
94 TTCTCTTAAAGCTCTTTCGGT 
95 
Lgals3bp 19039 
TTGTCCTTGAAGAGGAAGCTG 
96 TTAACCAAGCGCATGTCTCCA 
97 
Lgals8 56048 
TTTGCTTTGATAGTGCTTGTT 
98 TTCCATACTCTGTAAATCCGA 
99 
Lrp4 228357 
TTTCAGAGCATCTTCCTCCTG 
100 TTGTTGATTAGCACTTTGCGA 
101 
Ly6e 17069 
TTAGACATCCTTGTCAGTGTG 
102 TAACATAGCGAGACCGTCTTA 
103 
Map3K8 26410 
TTAAACTTACACTAGAGTCGA 
104 TTGACTAGTCACATTGGACTA 
105 
Map4k2 293694 
TTAACAATTCTCACACAGCGT 
106 TTTGGTGTCAGGAATCTTGGT 
107 Mapk8 26419 TTCTTGATTGCAACATTTCTT 
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108 TTGTTGTCACGTTTGCTTCTG 
109 
Mbnl1 56758 
TTAGTACCAACCTCTCACGTG 
110 TCTTCTAAACTAAAGCAGCCT 
111 
Mitd1 69028 
ATCACTGTGACAACTCCTGGG 
112 AACTTCTGTAACTGTCTCGTG 
113 
Mlkl 74568 
TATTCCAACACTTTCGGCCTG 
114 TTGAACTGGATCTCTCTGCTT 
115 
Mov10 17454 
TAGATGTGGAGTTCATAGCTT 
116 TCGTGGTTGTAAATCGTCCGC 
117 
Myd88 17874 
TTTGTTTGTGGGACACTGCTT 
118 TAAGCCGATAGTCTGTCTGTT 
119 
Nfkbia 18035 
TAAATATACATCTTAGAAGTA 
120 TTGTACAAATATACAAGTCCA 
121 
Nmi 64685 
TAGAACTGAACTCTACCTCGA 
122 TTATTTATGTGCATTATGCGG 
123 
Oas1a 246730 
TAAGTCTGGAGCTTCCTGGGT 
124 TTTGACATCAGCACCAAAGGT 
125 
Oas2 246728 
TTCTCTGTTAGGTTTGAGGTT 
126 TATAATGTCAACAGCTTCCTT 
127 
Oasl1 231655 
TCTTCTTTCCACTCTCTGGTT 
128 TTGTCTCTCACATACTGCTGG 
129 
Oasl2 23962 
TTGAAAGTGAAACTGCAGGGA 
130 TATTTCATTCTTAATCACGCA 
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131 
p50 (RelB) 19698 
AATCTCTGAGAATCTGTCCTG 
132 TTTCGCTTCTTGTCCACACCG 
133 
p65 (RelA) 19697 
TTGAAGGTCTCATAGGTCCTT 
134 TTGTTGGTCTGGATTCGCTGG 
135 
Parp14 
547253 TTGTTTCACAGCATCTTCTTT 
136 547253 TTGTTGATCAAGTTCTTTGGG  
137 
Parp11 101187 
TTGAATGTTGGTATCCGGCTG 
138 TAACGGTGCGAAATCGAGCGG 
139 
Parp12 243771 
TTGGAAGCTACAACTCTTCCG 
140 TTGTGATCAGTCTTCAAGTTG 
141 
Parp9 80285 
TAGCTGACTCTCATTGCTCTT 
142 TTGTCTTGGAAATAAAGCCGG 
143 
Plec 18810 
TACAGGTCACTGATGTGCCTC 
144 TAGCTTGCTCACAATGCGCTG 
145 
Ppm1k 243382 
TAAACTAGACTGACTTCTCTG 
146 TAGAGCAATAATAGTATTCCG 
147 
Ppp3cb 19056 
TTCTTCAGAACATCAACCCTG 
148 TTAAATCTATCTAATCTCCTA 
149 
Rnasel 24014 
TAATCTTGGTCCATCTGACTT 
150 TTTCTGTTCGTTCTCTCCGTC 
151 
Rsad 237926 
TTAACCTGCTCATCGAAGCTG 
152 TATTCTAATAACAACAGTCCG 
153 Rtp4 67775 TTCTTGAAATGTCTGCTCCCA 
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154 TTTATTTAATCAACATAGCTT 
155 
Samd9l 209086 
TTGGTGGTCTTAACCAGTCTG 
156 TTCTCTGGAATCTTGATTGTG 
157 
Sfxn2 94279 
TTGTTCACAAACTACAGACTG 
158 TAGAACTGGAGCATGAAGCCC 
159 
Sh3bgrl 56726 
TATACACGGATCACCATCCTG 
160 TAACATATGAACATAACCTGT 
161 
Stat1 20846 
TTTACTGTCCAGCTCCTTCTG 
162 TTTAAAGTCATATTCATCTTG 
163 
Stat2 20847 
TTCTGGTCTTCAATCCAGGTA 
164 TTCTGCAACATCTCCCACTGC 
165 
Stat3 20848 
TTAAGTTTCTGAACAGCTCCA 
166 TTGAAATCAAAGTCGTCCTGG 
167 
Tap1 21354 
TTTAGAGGAAGAAGAAACCGA 
168 TTCTCCATGAATCTCATTCTC 
169 
Tapbp 21356 
TAGCTTTGGGTCAAGATCTGG 
170 ATAGTGAACTCCATGCTGCTT 
171 
Tbk1 56480 
TCTCATTTGAACATCCACTGG 
172 TTGATTTGAGGAAACAATCTT 
173 
Ticam1 106759 
TTGAGCTGGTAGATCTCCCGG 
174 TTGATATCTGAACTGCACCGA 
175 
Tlr3 142980 
TTAGATAAGAGGAACACCCTT 
176 TAAAGTCGAACTTAATCTCTT 
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177 
Tlr7 51284 
TTTACTTTAACTTCACAAGGT 
178 TAGAGTGGTTCTATAGATGGA 
179 
Tlr9 81897 
TATAGCTCAAGTTCAGCTCCT 
180 TTAGCATCTAGAACCAGGATG 
181 
Tmem140 68487 
TATCTTCTGCTGTTGCAGGGA 
182 TTCTAGTTTGACACTTTGCCA 
183 
Tor3a 30935 
TACGTGTCCACATACTTGGGG 
184 TAAGCCTGTCAAGTTGTTGGA 
185 
Trex1 22040 
TATGTGAGTCTGTCGGTGCTT 
186 TAGGTTGGTTGTTCCAGTGGT 
187 
Trim21 20821 
TAGAGGGTGATATCTGCCGTG 
188 TTAGTTATGTGCTCCCAGCTT 
189 
Trim25 217069 
TTTAACTTGCGCAAGGAGCTG 
190 TTCATTTCCATATACTCCTGT 
191 
Wwoxv 80707 
ATCTCTAAAGAATTGCTTGTG 
192 TATCAGGTTATTCTAAGGTTG 
193 
Zc3hav1 78781 
TTAGTGAACTTCATCTCTCCA 
194 TATTCGTCTGAATCATCCCTT 
195 
Zfp182 319535 
TTGTTTATCTTGATGTTGCCT 
196 TTGTCTACCATAGTATTTCCA 
197 
Isg15 100038882 
TGCTTGATCACTGTGCACTGG 
198 TTAAGCGTGTCTACAGTCTGC 
199 Ifi27 52668 TTGAGCTGATAGAAGTGTCAT 
 45 
200 TTGATGTGGAGAGTCCAAGGA 
201 
Usp18 24110 
TATTTCAGACTGTTCCTTGGT 
202 ATGTTCATCATGAACACTTGA 
203 
Parp10 671535 
TTAAGGACTTTGTAGAGCAGG 
204 TTGGAGACTCACTGTCTCCTC 
205 EGFP 
 
TGAACTTCAGGGTCAGCTTGC 
206 MiR-24 
 
TAAGGCACGCGGTGAATGCCA 
 
A pIDTSmart (AmpR) plasmid vector was designed to encode the last 32 nucleotides of WNV 
NS5, the first 14 nucleotides of  3′ UTR, a 109 nucleotide GFP pre-amiR hairpin at Δ15-89 position 
at the start of WNVNSW2011 3′ UTR and 44 nucelotides of the 3′ UTR from 90th nucelotide (Setoh et 
al., unpublished) (Figure 3.2). Based on the pre-miR-124 hairpin structure, miR-124 sequence was 
replaced with a GFP siRNA sequence that targets GFP coding region, shown in Figure 3.1 A. The 
GFP pre-amiR hairpin encodes: 5′ arm, 5p, loop, 3p and 3′ arm sequences. For proper miRNA 
processing by the host cell, the 3p (GFP siRNA) sequence is partially complementary with 5p and 
includes non-complementary residues and maintains bulges to mimic the original pre-miR-124 
structure (Figure 3.1). The loop comprises non-hybridising miR-124 sequences vital for proper 
processing of the GFP pre-amiR [259]  
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Figure 3.2 Diagram of pIDTSMART-d15GFP plasmid vector.  A 109-nucleotide miR-124 
based GFP pre-amiR hairpin was inserted at Δ15-89 nucleotide position at the start of the 
WNVNSW2011 3′ UTR (3′ UTR sequences highlighted blue box). The last 32 nucleotides at the end of 
WNVNSW2011 NS5 are also included in the construct (highlighted light green box). The GFP pre-
amiR hairpin includes 5p and 3p stem regions, which are partially complementary, and 5′ arm 
3′ arm and loop sequences, which are miR-124 sequence and d15 stands for (Δ15-89). Adaptor 
sequence primers (amplicon adaptor_F and amplicon adaptor_R with flanking illumina sequences 
bind to either ends of 3′ UTR are used for generating illumina deep sequence amplicons.  
 
The pIDTSMART-d15GFP plasmid was mutagenised into 204 different plasmid clones with each 
plasmid encoding a unique pre-amiR hairpin (Table 3.1). For instance, to generate Adar clone #2 
amiR-encoding plasmid, PCR was performed using pIDTSMART-d15GFP as DNA template, a Q5 
high fidelity DNA polymerase (New England Biolabs, USA)  kit and Adar clone #2 forward and 
pIDT-SMART-d15-GFP
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reverse mutagenesis primers as shown in Figure 3.3 ( all mutagenesis primer sequences are listed in 
Appendix 1). As a result, the 3p sequence i.e., Adar clone #2 siRNA and corresponding 5p 
sequence were introduced in the stem whilst retaining pre-amiR hairpin structure. Thereafter, DpnI 
digestion was performed to eliminate methylated pIDTSMASRT-d1515GFP DNA template since 
DpnI restriction enzyme recognises methylated sequences that will not be present in the amplified 
product. 
Following DpnI digestion, pIDTSMART-d15-Adar clone #2 plasmid DNA was purified by DNA 
gel extraction to completely remove DpnI reagents and cleaved template DNA as well as maximise 
the chances of obtaining the new mutagenised plasmid. Thereafter, products were transformed into 
chemically-competent DH5α E.coli to allow re-circularisation of  pIDTSMASRT-d15-Adar plasmid 
by homologous recombination (Figure 3.3). The resultant plasmid sequence was Sanger sequenced 
to confirm that the correct pre-amiR hairpin was introduced. Therefore, to generate a complete 
amiR-encoding plasmid library, these steps were repeated until 204 amiR-encoding plasmids were 
successfully cloned and confirmed by Sanger sequencing (Figure 3.4).  
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Figure 3.3: The strategy for mutagenesis to introduce 204 different siRNA-encoding 
sequences into the stem region of miR-124 in the pIDTSMART-d15.  Mut-Forward and Mut-
Reverse (green) maintained the miR-124 3' and 5' arms, respectively, and the loop region. Mut-
Forward mutagenesis region encodes Adar clone #2 siRNA sequence that replaces GFP-siRNA (3p) 
during mutagenesis PCR. Mut-R mutagenesis region encodes a unique sequence partially 
complementary to Adar clone #2 siRNA that replaces the GFP miRNA 5p sequence. The 5p and 3p 
sequences are partially complementary with bulges to mimic miR-124 structure for proper 
processing by the host cell microRNA processor. Mutagenised plasmids were DpnI digested to 
remove methylated parental plasmid DNA by slicing it into small pieces, gel  purified  and  
transformed into DH5α E.coli to recover the Adar clone #2 plasmid. This strategy was used to 
generate a complete set of 204 amiR-encoding plasmids  (Appendix 1).   
Mutagenesis region Mutagenesis region
DpnI enzyme digestion to remove
pIDT-SMART-d15-GFP template plasmid
DNA purification by gel extraction
Transformation into DH5α
Q5 polymerase PCR
Mut - Forward
Mut - Reverse
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Figure 3.4 Flowchart showing logical steps taken to generate the Adar clone #2 amiR 
encoding plasmid.  These steps were repeated until a plasmid library containing 204 ISG amiR-
encoding plasmids was generated. 
 
3.3.2 Characterisation of amiR encoding plasmid library by deep sequencing 
Each plasmid concentration was determined by Qubit fluorometer using Qubit dsDNA BR Assay 
kit and protocol (Thermo Scientific, USA). A total of 204 individual amiR-encoding plasmids were 
combined in equimolar amounts (100 ng of each plasmid) to generate a complete ISG-targeting 
amiR-encoding plasmid library. Thereafter 10-cycle PCR was performed using Q5 high-fidelity 
DNA Polymerase PCR kit (New England Biolabs, USA), plasmid library as DNA template and  
amplicon_adaptor_F and amplicon_adaptor_R set of  primers to generate a single amiR-encoding 
plasmid library amplicon for Illumina deep sequencing (Figure 3.5). Deep sequence reads produced 
pre-miRNA encoding the following sequence: ATCAAGATCAGAGACTCTGCTCT-
XXXXXXXXXXXXXXXXXXXXX-ATTTAATGTCATACAAT-
XXXXXXXXXXXXXXXXXXXXX-AGAGCGGAGCCTACGGCTGCACTTGAA. All reads 
possessed the known sequence shown and Xs (two stretches of 21 nt on either side) were the region 
of interest containing unique corresponding siRNA sequences.  
Deep sequencing data were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using Salmon transcript quantification data script tool to ascertain number of each amiR-
encoding transcript variant in the plasmid library. Library diversity was determined by quantifying 
the proportion of each amiR-encoding transcript variant in relation to the total number of amiR-
Adar Clone #2  amiR Plasmid 
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Pick 4  colonies, Generate Glycerol 
 stocks
Amplify 1 Stock in LB-AMP Broth
Purify plasmid
Correct Sequence Wrong Sequence
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encoding transcript variants within the library. The mean frequency of reads for individual amiRs  
will be 1/204 (0.49%) of the total reads. Results showed that 196/204 of the amiR-encoding 
plasmids were (0.1%  ≤ x  ≤1%) whereas 8/204 and 4/204 of the amiR-encoding plasmids were 
over-represented (x >1%) and under-represented (x<0.05%) respectively, where x is the percentage 
number of reads for each amiR encoding plasmid. (Figure 3.5)  Clones Atf3 #2 (1.96%), Atf2 #2 
(1.19%), Cmpk2 #1 (1.54%), II5 #2 (1.25%), p50-(Rel B) (0.95%), Stat3 #2 (0.99%), Stat1 #2 
(1.142%) and Sh3bgrl #1(1.22%) amiR-encoding plasmids were over-represented as highlighted on 
Figure 3.5 . Clones Adar #1, Gbp6 #1, Irf7 #1 and Gfp amiR-encoding plasmids were not detected 
in the plasmid library. 
The majority of amiR-encoding plasmids clustered close to the mean (Figure 3.5), but it is notable 
that there was a distinct drop in frequencies of reads from plasmids #140 and above. This could be 
because the equimolar mixing of all plasmids was done on  three different days; that is, each day 70 
plasmids were mixed, and the drop from #140 suggests a systematic pipetting error, perhaps due to 
poor pipette calibration. In addition, descriptive statistical analysis of plasmid library revealed that  
mean, median as well as standard deviation of the mean (SEM) were 0.49%, 0.47% and 0.24% 
respectively. The closeness of the mean to median implied that amiR-encoding plasmids in the 
plasmid library were not greatly skewed.  
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Figure 3.5: Generation of an amiR-encoding plasmid library.  Results from deep sequencing 
confirmed a largely uniform distribution of amiR-encoding plasmids within the plasmid library as 
shown by percentage number of reads per amiR-encoding plasmid within the plasmid library. 
Highlighted clones represent clones with percentage reads ≥ 1% or < 0.05% of the entire library. 
The dotted line depicts the mean frequency of reads for each plasmid, i.e., 100%/204=~0.49%.  
 
3.3.3 Generation of amiR-encoding virus library 
Having constructed an amiR-encoding plasmid library, the next step was to generate an amiR-
encoding virus library. To facilitate this, WNVNSW2011 CPER fragments (fragments 1 to 5) were 
amplified from WNVNSW2011 cDNA using specific primers (see chapter two, Table 2.2) that 
generate amplicons with overlapping regions for CPER assembly (Figure 3.6 B)  [237].  To 
generate the 3' UTR containing the amiR library, the 3' UTR was divided into two CPER fragments, 
fragment 6 (containing the amiR library) and fragment 7 (remainder of 3' UTR). The library 
fragment was generated by a 15-cycle PCR using Q5 high-fidelity DNA Polymerase PCR kit (New 
England Biolabs, USA), amiR-encoding plasmid library as DNA template and 3' UTR_Forward and 
amiR_Reverse set of primers. The 3' UTR _Forward binds to flanking NS5 sequences and the start 
of 3' UTR  while the amiR_Reverse primer that binds to end of the amiR hairpin (Figure 3.6A). The 
after amiR fragment was generated from d15GFP-amiR WNV cDNA using after amiR_Forward 
and 3' UTR _Reverse set of primers that bind to the end of amiR hairpin and the end of 3' UTR 
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respectively (Figure 3.6A). A UTR-linker that encodes first 22 and last 22 nucleotides of the 5' 
UTR and 3' UTR of flaviviruses was used as fragment 8. The UTR-linker was amplified from a 
previously constructed pUC19-flavi-UTR-linker plasmid, using UTR_Forward and UTR_Reverse 
primers [237]. The UTR linker encodes a CMV promoter, hepatitis delta virus ribozyme and a 
polyadenylation signal for effective expression in mammalian cells, authentic formation of 3' UTR 
and efficient termination of transcription by RNA polymerase II respectively [237].  
Thereafter, using 0.45 pmol of each fragment, equivalent to 2.7 X 1011 DNA copies of generated 
amiR library fragment, RT-PCR-amplified fragments encompassing the rest of the WNVNSW2011 
genome, and CMV UTR-linker, were assembled by CPER. In this procedure denaturation and 
annealing of all CPER fragments followed by polymerase-mediated fragment extension generates a 
complete circular infectious cDNA product for transfection into HEK 293 cells [109, 237, 258] 
(Figure 3.6B) 
 
Figure 3.6: Generation of p0-293T amiR encoding virus library.  A) Diagram showing the 3' 
UTR of WNVNSW2011 and primer binding sites of respective primers used to generate the 3' UTR 
fragments. The 3' UTR was divided into two fragments, the amiR library fragment and after amiR 
fragment. To generate library fragment the plasmid library was used as PCR template with 3' 
UTR_Forward and AmiR_Reverse set of primers. To generate the after amiR fragment, the 
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A 
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d15GFP-amiR WNV cDNA was used as PCR template along with the after amiR_Forward and 3' 
UTR_Reverse set of primers. B) Diagram showing CPER strategy used to generate infectious 
amiR-encoding cDNA library. Fragments are generated in separate PCR amplifications, assembled 
by CPER through denaturation and annealing of overlapping sequences, followed by polymerase  
extension  of fragments. Fragment 6 represents the amiR library fragment containing 204 amiR-
encoding fragments generated by low-cycle PCR and represents the first fragment of the 3' UTR 
while fragment 7 represents the rest of the 3' UTR of WNVNSW2011 (after amiR fragment). 
Fragments 1-5 were amplified from WNVNSW2011 cDNA and the UTR-linker was amplified from a 
previously constructed pUC19-flavi-UTR-linker plasmid. 
 
The resultant CPER product was transfected into HEK 293 cells to recover amiR-encoding virus 
library (we named it passage zero; p0-293T). At three days post transfection, 2 mL of p0-293T 
virus culture supernatant was collected as p0-293T virus stock, immunoplaque assay on Vero cell 
was performed and virus titre determined as 2.8 x 106 pfu/mL (Figure 3.7 A).  
Using Nucleospin RNA kit and protocol (Macherey Nagel, Germany), viral RNA was purified from 
virus culture supernatant. To generate p0-293T virus library amplicon for deep sequencing, RT-
PCR was performed using superscript III one-step RT-PCR system with platinum Taq high fidelity 
DNA polymerase kit (Thermo Scientific, USA), purified RNA and Amplicon_adaptor_F and 
Amplicon_adaptor_R set of  primers (Figure 3.7 B).  
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Figure 3.7 Generation of p0-293T amiR-encoding virus library.  CPER product was transfected 
in HEK 293 cells, 3 days post transfection (dpt) virus culture supernatant was harvested. A) Virus 
titre was determined on Vero cells by immunoplaque assay. B) Viral RNA was purified from 
culture supernatant and treated with DNAse I enzyme to remove traces of CPER DNA products. 
Using purified RNA, RT-PCR was performed and an amplicon for deep sequencing generated. A 
no RT control PCR was added to determine the purity of purified RNA. A 100bp DNA ladder was 
loaded in to Left lane as a marker. Expected DNA band size of 215 bp was obtained, purified by 
DNA gel extraction and deep sequenced. 
 
Deep sequencing data were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using Salmon transcript quantification data script tool to determine percentage number of 
each amiR-encoding virus variant in p0-293T amiR-encoding virus library (Appendix 2). Analysis 
of p0-293T deep sequence data revealed  that  most of the amiR-encoding viruses clustered between 
0.2  and 0.8% representation (Figure 3.8). Descriptive statistical analysis of p0-293T deep 
sequencing results showed that a median frequency and  standard deviation of the mean of amiR 
encoding viruses in the virus library as 0.39% and 0.39% respectivlely, indicating increased spread 
of frequencies compared to the data from obtained from amiR encodong plasmid library (Figure 
3.8) and (Figure 3.5).  
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Figure 3.8 The distribution of amiR-encoding West Nile viruses in p0-293T virus library.  
Deep sequencing of p0-293T virus library depicted by a scatter plot showing the percentage reads 
for each amiR-encoding virus within the entire virus library. Highlighted clones present clones with 
percentage reads ≥ 1%. The dotted line depicts the mean frequency of reads for each plasmid, i.e. 
100%/204 = ~0.49%.  
 
To generate p1-Vero virus stocks for subsequent experiments, p0-293T amiR-encoding virus library 
was passaged on Vero cells. Vero cells were infected with p0-293T amiR-encoding virus library 
stock at multiplicity of infection (MOI) =1. At 3 days post infection (dpi) culture supernatant was 
harvested as p1-Vero virus stock. Virus stock titre was determined by immunoplaque assay on Vero 
cells (Figure 3.9 A) as previously described [260]. Titration of p1-Vero virus library showed a titre 
of 4.27 X 107 pfu/mL. Next, viral RNA was purified from harvested culture supernatant using 
Nucleospin RNA kit and protocol (Macherey Nagel, Germany). Purified RNA was eluted in 30 µL 
of nuclease free water and treated with RQ1 RNase-free DNase enzyme (Promega, USA) to remove 
any traces of DNA. To generate p1-Vero virus library amplicon for deep sequencing, RT-PCR was 
performed using superscript III one-step RT-PCR system with platinum Taq high fidelity DNA 
polymerase kit (Thermo Scientific, USA), RNA and amplicon_adaptor_F and amplicon_adaptor_R 
set of  primers (Figure 3.9 B).  
1 51 10
1
15
1
20
1
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Number of AmiR encoding viruses in the library
Pe
rc
en
ta
ge
 o
f r
ea
ds
 c
or
re
sp
on
di
ng
 to
 e
ac
h 
cl
on
e
p0-293T virus libraray
Atf3 #2
Brd4 #1
Gbp2 #2
Ifi35 #2
Irf7 #2
Mlkl #2
Nmi #2
Stat1#2
Ifi27 #2
Ifi27 #1
Rtp4 #2 Tlr3	#2
Daxx #1
 56 
  
The resultant RT-PCR amplicon was deep sequenced (Figure 3.9 B). Statistical analysis of p1-Vero 
deep sequencing results revealed that percentage mean, median and standard deviation from the 
mean of amiR-encoding virus variants as 0.49%, 0.32% and 0.56% respectively. Ninety six percent 
of  the amiR-encoding virus variants clustered between 0.05% and 1% representation in the library. 
This range of 0.05 to 1% was chosen because the expected mean of the library would be 0.49% 
(100/204) if equally distributed (Figure 3.10). 
 
Figure 3.9 Generation of p1-Vero amiR-encoding virus library.  A) Virus titre was determined 
on Vero cells by immunoplaque assay. B) Viral RNA was purified from culture supernatant, DNase 
treated and RT-PCR performed to generate amplicon for deep sequencing. A no RT PCR was 
performed using RNA as template for Taq DNA polymerase PCR as a control to determine the 
purity of purified RNA. A 100bp DNA ladder was loaded in to the left lane as a marker. Expected 
DNA band size of 215 bp was obtained, purified by DNA gel extraction and deep sequenced. 
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Figure 3.10 Deep sequencing of p1-Vero amiR-encoding virus library.  A) A scatter plot 
showing percentage number of each amiR-encoding virus in the entire p1-Vero amiR-encoding 
virus library Highlighted variants represent viruses with percentage reads ≥ 1.3%. Dotted line 
depicts expected percentage for an even distribution of plasmids within the plasmid library i.e., 
(100% /204 = ~0.49 %).  
 
3.3.4 Evaluation of generated plasmid and virus libraries  
 Scatter plots were generated based on percentage reads of each amiR-encoding plasmid or virus in 
the plasmid or virus libraries respectively. The  expected mean percentage representation of each 
amiR-encoding plasmid or virus in respective library was determined as 1/204 × 100 = ~0.49%. 
Descriptive statistical analysis of the three amiR-encoding libraries revealed an increasing lowering 
of the percentage median in comparison to the constant mean of 0.49%. The median reduced from 
0.474%, to 0.39% and 0.32% for plasmid library, p0-293T and p1-Vero amiR encoding libraries 
respectively. This highlighted the increased skewing of the libraries at each stage of generation 
(plasmid library to p0-293T and p1-Vero library). Furthermore, the correspondingly increasing 
standard deviation of each amiR-encoding library at each the stage in library generation highlighted 
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an increased variance in each subsequently generated library. The standard deviation for the 
plasmid library was 0.24%, but increased to 0.39% for p0-293T and 0.56% for p1-Vero libraries 
(Figure 3.11 A).  A total of four amiRs that were not represented in plasmid amiR encoding library 
was maintained through p0-293T and p1-Vero amiR-encoding virus libraries. Despite the 
increasing variance and skewing as the virus library was amplified, a stacked bar plot for each 
amiR-encoding library emphasised that the libraries still encoded mixed poputions of either plasmid 
or viruses (Figure 3.11 B).   
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Figure 3.11 Distribution of amiR-encoding variants within the respective libraries. A) 
Scatterplot showing distribution of amiR-encoding variants within the respective libraries. The 
mean percentage representation was determined as 100/204 ~0.49%, shown by the dotted line. The 
median value for each library is indicated by a black horizontal line. B) Stacked interpolated bar 
plot showing distribution of amiR-encoding variants within the respective libraries. Each colour 
represents a single amiR whose relative proportion corresponds to its composition in the respective 
library.  
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3.3.5 Generation of scrambled amiR virus library as a control library 
In order to ensure that selection is not occurring stochastically during in vitro and in vivo RNAi 
screening, a scrambled-amiR virus library was generated as control for studies performed in the 
subsequent chapters. A scrambled-amiR plasmid library was provided by Professor Benjamin 
tenOever of Icahn School of Medicine at Mount Sinai, USA. This scrambled-amiR plasmid library 
is essentially a scrambled version of miR-124 pre-amiR in which miR-124 3p region 
(TAAGGCACGCGGTGAATGCCA) is scrambled at specific locations as indicated by an “N” 
(TAANNNNCGTNGTTNNTGCCA) to render it non-functional or unable to any target host. This 
scrambled library would have a theoretical maximum of 47 (i.e. 16,384) variants, but it was not 
essential for us to recover the entire library. The scrambled amiR library was inserted into the Δ15-
89 nucleotide position in the 3' UTR of WNVNSW2011 to generate full length WNV scrambled-amiR 
virus library by  CPER, similar to the targetted library already prepared. To do this, CPER fragment 
5 that encompasses NS5 and part of the 3′ UTR (before Δ15-89 amiR insertion site) was generated 
from d15GFP-amiR WNV cDNA, NS5_Forward and Before amiR_Reverse set of primers by PCR 
(Figure 3.6 A). Fragment 6, scrambled amiR library fragment, was generated by performing a 15-
cycle PCR using scrambled-amiR plasmid library as template, Q5 high-fidelity DNA Polymerase 
PCR kit (New England Biolabs, USA), amiR_Forward and amiR_Reverse primers (Figure 3.6 A). 
Thereafter 0.45pmol of each fragment equivalent to 2.709 X 1011 DNA copies of the generated 
scrambled amiR library fragment, RT-PCR-amplified fragments encompassing the rest of the 
WNVNSW2011 genome and CMV UTR-linker were assembled by CPER to generate infectious cDNA 
for transfection.  
 The resultant CPER product was transfected into HEK 293 cells to recover p0-293T scrambled 
amiR virus library. At three days post transfection, 2 mL of p0-293T virus culture supernatant was 
collected as p0-293T virus stock. Immunoplaque assay on Vero cell was performed on p0-293T 
stock and virus titre determined as 4 × 106 pfu/mL. To generate p1-Vero virus stock for subsequent 
experiments, Vero cells were infected at MOI =1 with p0-293T virus stock. At 3 days post 
infection, virus culture supernatant was harvested as p1-Vero virus stock and virus titre determined 
by immunoplaque assay on Vero as 4.66 × 106 pfu/mL (Figure 3.12 A). Viral RNA was purified 
from virus culture supernatant using Nucleospin RNA kit and protocol (Macherey Nagel, 
Germany). Viral cDNA was made using superscript IV reverse transcriptase kit and protocol 
(Thermo Scientific, USA). To generate p1-Vero virus library amplicon for deep sequencing, PCR 
was performed using Q5 high-fidelity DNA Polymerase PCR kit (New England Biolabs, USA), 
scrambled amiR library cDNA and amplicon_adaptor_F and amplicon_adaptor_R primers (Figure 
3.12 B). Different amounts of cDNA for each PCR were used to obtain the best amplicon for deep 
sequencing. Therefore, the 10µL cDNA band, which was brightest of the three bands was chosen, 
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purified by DNA gel extraction and deep sequenced (Figure 3.12 B).   
 
Figure 3.12 Generation of p1-Vero scrambled amiR encoding virus library.  A) Virus titre was 
determined on Vero cells by immunoplaque assay. B) Viral RNA was purified from culture 
supernatant and treated with DNase I enzyme. Products of a 15-cycle PCR using cDNA generated 
using 1µL, 5µL, 10µL of cDNA was loaded in Lanes 1, 2 and 3 while 0.562µL of RNA was loaded 
in Lane 4 as no RT control. A 100bp DNA ladder was loaded in to Lane 5 as a marker.  Expected 
DNA band size is 215bp. 
 
Deep sequence results were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using Salmon transcript quantification tool to ascertain enrichment of p1-Vero scrambled 
amiR-encoding virus library (Appendix 2). Deep sequencing revealed that the scrambled library 
contained 6719 scrambled amiR sequences. Fequency percentage distribution of reads 
corresponding to percentage enrichment of scrambled amiR-encoding viruses with in the library 
was determined (Figure 3.13). Analysis of deep sequence results revealed that 84.58% (5683 / 
6719), 8.28% (556 / 6719), 2.13% (143 / 671) and 1.1% (143 / 6719) scrambled amiR viruses were 
enriched to 0.01%, 0.02%, 0.03% and 0.04% of the total scrambled amiR-encoding viruses with in 
the p1-Vero library respectively.  
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Figure 3.13 Deep sequence of p1-vero scrambled amiR virus library.  A frequency distribution 
plot showing the percentage number of scrambled amiR-encoding virus in the entire p1-Vero 
scrambled amiR-encoding virus library. 
 
3.4 Discussion 
3.4.1 Generation of the amiR-encoding plasmid library 
The 3' UTRs of flaviviruses have been previously shown to allow insertion of heterologous 
sequences [261]. Bearing this in mind the 3' UTR of WNVNSW2011 was modified to encode a unique 
pre-amiR hairpin at nucleotide position Δ15-89 from the start of the 3' UTR. The pre-amiR hairpin 
inserted was based on miR-124, predominantly expressed in mice brains.  Previous work performed 
using Kunjin virus replicon showed that deletion of nucleotides 29 to 102 of 3' UTR, a region, 
which encompasses nucleotide positions ∆15-89 does not alter replication of resultant virus [262]. 
When 76 nucleotides starting form nucleotide 29 in the 3' UTR of Kunjin were deleted replicon, the 
resultant replicon replicated efficiently. In contrast, deletion from nt 29 to 382 of 3' UTR resulted in 
significantly reduced replication rates [262].   
Analysis of deep sequencing results of amiR-encoding plasmid library revealed that 96% (196/204) 
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amiR-encoding plasmids were represented at least once in the library while 3.92% (8/204) and 
1.96% (4/204) plasmids were over and under represented respectively (Figure 3.11). Over-
representation and under-representation could have potentially resulted from pipette mixing errors 
during manual combining of plasmids to generate amiR-encoding plasmid library. Some of the bias 
in this plasmid library was carried over to generation of virus library by CPER. To eliminate this 
hurdle, individual viruses would be generated by CPER, virus titre determined and individual 
viruses pooled together in equal amounts. However, this approach is not feasible especially when 
generating large-scale virus libraries, due to the intense labour involved in generating a single virus 
let alone generating an entire virus library individually. Nevertheless, the representation of each 
amiR-encoding plasmid with in plasmid library was considered adequate for subsequent generation 
of virus libraries. Therefore CPER approach was utilised to generate p0-293T virus library. 
3.4.2 CPER approach for construction of amiR-encoding virus libraries 
Traditional cloning approaches previously used for generation of large virus libraries involve 
extensive cloning and purification of large bacterial stocks of infectious plasmid clones before 
transfection or RNA electroporation in cells [263]. However cloning of full-length cDNA sequences 
during plasmid DNA propagation in bacteria often results in toxicity due to cryptic promoter 
sequences, and subsequent unsuccessful recovery of plasmid clones, or unwanted deletions and 
mutations (reviewed in [264]). Although this bottleneck could be countered by inserting introns into 
difficult regions of viral cDNA, traditional approaches would still necessitate propagation of full-
length cDNA plasmid in bacteria [265]. Introns break up cryptic sequences, which are spliced when 
processed in vertebrate cells. 
The innovation of CPER completely abolished the need for plasmid DNA propagation in bacteria 
and subsequent RNA transcription, reducing possible introduction of mutations from error-prone 
cloning and bacterial propagation steps. CPER is a next-generation reverse genetics approach 
streamlined to rapidly generate authentic viruses from sequence data [109, 237, 258, 260, 266, 267]. 
Therefore the use of CPER approach to construct ISG-targeting amiR virus libraries described in 
this chapter further validates the robustness and effectiveness of the CPER methodology. 
3.4.3 Clone representation in virus libraries 
Although both p0-293T and p1-Vero amiR-encoding virus libraries generated encoded mixed virus 
populations,  it was noted that varaince and skewness increased down stream generation of p1-Vero 
virus library form p0-293T virus library. Transfection of virus library into a human cell line (HEK 
293) and then infection of a monkey cell line (Vero) was expected to allow generation of an 
unbiased virus library as each pre-amiR sequence solely targeted mouse genes. Significant off-target 
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each amiR-encoding siRNA sequence included in the library. However, prediction of target sequences 
of siRNAs is often imperfect, as a number of mismatches can be tolerated [268, 269]. A total of  16/204 
(7.84 %) and 21/204 (10.29%) of amiR-encoding viruses were over represented with x ≥ 1% reads after 
passage in  HEK and Vero cells respectively. In addition comparison between plasmid and p0-293T 
amiR encoding libraries showed 12/ 204 (5.88%) amiR encoding clones that were not over-represented  
(x ≥ 1%  reads) in the plasmid library were over represented after transfection in HEK 293 cells. In 
addition at p1-vero generation, amiR-encoding viruses with higher percentage reads were further 
amplified to greater enrichement suggesting that the input amount of each amiR-encoding virus was 
systematically amplified to higher levels (Figure 3.11). For instance, Nmi clone #2 amiR-encoding virus  
(NMI-amiR WNV) at p0-293T had a percentage number of 2.74% and on passage in Vero cells the 
percentage  number of reads increased to 4.58%. The trend observed when p0-293T virus stock was 
amplified by passaging in Vero cells, showed that over-expressed amiR-encoding viruses at p0-293T 
were further amplified higher levels in p1-Vero virus stock. In addition, at least one amiR-encoding 
virus was represented in either p0-293T or p1-Vero thus suggesting that all intended mouse genes were 
targeted by at least one amiR-encoding virus.  
Although there was small degree of bias in the generated amiR-encoding virus library, the library 
still maintained a good representation amiR population, with at least one amiR-encoding virus 
targeting a single host gene. Therefore given that the proportion of different amiR encoding viruses 
in the input  virus library used for subsequent experiments was known, changes in virus populations 
could be easily assessed. 
3.4.4 Use of Drosha-/- 293T cells to improve amplification of virus libraries 
A potential way to further reduce bias in the virus library during mammalian cell amplification 
would be to use Drosha-/- HEK 293 cells. Drosha is an RNase III enzyme that initiates microRNA 
processing. Drosha cleaves primary miRNA (pri-miRNA) transcript in the nucleus to release 
precursor micro RNA (pre-miR), which is transported by exportin to the cytoplasm and further 
cleaved by Dicer to generate a 21-22 nt long mature miRNA for gene regulation [143, 270]. 
Therefore transfection of Drosha-/- HEK 293 cells would prevent the cleavage of pri-miRNA from 
the viral RNA genome since the pri-miRNA hairpin inserted in the 3' UTR would not be recognised 
in absence of Drosha. Therefore the amiR-encoding virus genome would not be cleaved to release 
the pre-miR haipin, no viral RNA would be destroyed and therefore no selection of amiR sequences 
would occur. 
In summary, despite over- and under-represention of a small proportion amiRs in the library, an 
amiR-encoding plasmid DNA library was successfully generated, and a diverse virus library was 
recovered in p0 and propagated in p1, and represents an important tool for the study of host genes 
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important for control of WNV replication by in vivo screening.  
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Chapter 4: In vitro RNA interference screening identifies IFITM3 as a crucial 
antiviral gene against West Nile virus infection. 
4.1 Introduction 
Having generated a mouse ISG-targeting amiR-encoding virus library including a scrambled 
sequence amiR virus library as control, the next step was to perform RNAi screening, initially in 
vitro. Our hypothesis was that screening in wild type mouse embryonic fibroblasts (WT MEF) vs. 
interferon-alpha/beta receptor deficient (Ifnar1-/-) MEF cells will allow us to identify new host 
determinants and their relative importance in controlling replication of WNV.  Both mouse-derived 
cell lines were used because the amiR-encoding virus library targeted mouse specific ISGs. In 
addition, WT MEF and Ifnar1-/- MEF cells were used to assess and compare the effect of in vitro 
RNAi between an immune competent and immune compromised host respectively. To perform in 
vitro RNAi screening, three passages in WT MEFs and Ifnar1-/- MEF were performed at a low MOI 
of 0.1 to subject virus libraries to selective pressure and allow for natural selection to occur. West 
Nile virus variants that are enriched would therefore encode amiRs that down-regulate expression 
of antiviral host gene(s) important for restricting West Nile virus replication.  
4.2 Methods and Materials  
For ease of reading, I have included materials and methods specific to this chapter. 
4.2.1 Generating amiR amplicons by PCR for deep sequencing 
To generate amplicons for deep sequencing by PCR, virus culture fluid was first clarified to remove 
any cell debris by centrifugation at 1000 g for 5 minutes, and thereafter 5 mL of virus culture fluid 
was concentrated to 250 µL using Amicon ultra-15 mL 100 kDa centrifugal filter units, (Merck 
Millipore, USA) before RNA extraction. To purify viral RNA, Nucleospin RNA kit (Macherey 
Nagel, Germany) was used following manufacturer’s instruction. Purified RNA was eluted in 30 µL 
of nuclease free water and treated with RQ1 RNase-free DNase enzyme (Promega, USA) to remove 
any traces of DNA. Thereafter a 15-cycle one-step RT-PCR was performed using purified DNase-
treated RNA as template, Adaptor amplicon_Forward and Adaptor amplicon_Reverse primers 
(Table 4.1) and superscript III one-step RT-PCR system with platinum Taq high fidelity DNA 
polymerase kit (Thermo Scientific, USA). To obtain amplicons for deep sequencing, 2% (w/v) TAE 
agarose gel electrophoresis was performed; bands were excised from gels, purified using Monarch 
DNA Gel Extraction Kit, (New England Biolabs, USA). Thereafter DNA fragments concentration 
was determined by Nanodrop spectrophotometry before Illumina sequencing. The Expected DNA 
band size was 215 bp. 
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Table 4.1 Primers and primer sequences used to generate PCR amplicons  
Primer Name PCR Amplicon Sequence 5 ′- 3 ′ 
Adaptor_amplicon
_ Forward 
 
AmiR Adaptor 
amplicon for 
deep sequencing 
TCGTCGGCAGCGTCAGATGTGTATAAGAGA
CAGGAAGACACGACATTTGTTGAGGATACA
GTATTGTAAATAGTTTG 
Adaptor_amplicon
_ Reverse 
GTCTCGTGGGCTCGGAGATGTGTATAAGAG
ACAG CAT TCA AGT GCA GCC GTA GGC 
TCC GC 
3′ UTR_ Forward IFITM3-amiR 
or GFP-amiR 
WNV RNA 
GAAGACACGACATTTGTTGAGGATACA 
3′ UTR_Reverse TCCTGTGTTCTCGCACCAC 
NS3_Forward  
NS3NS4B 
GATAACTCTCCAATACACAAAGAGAGGAG 
NS4_Reverse CGTCCTTTTGCCCCACCTC 
NS4A_Forward  
NS4A 
TTGAGTGTGATGACCATGGGAG 
NS4A_Reverse TAGCTGGTTGTCTGTCTGCG 
 
4.2.2 Western blot analysis 
Western blot analysis was performed to determine expression of proteins in cells infected with 
respective viruses as described in the result section. To perform western blot analysis, WT MEF and 
Ifnar1-/- MEF were seeded at 5 ×105 cells per well in 6-well plate and incubated at 37°C in 5% CO2 
humidified incubator for 12 hours until 90% confluent. The following day, MOI was determined as 
indicated in the figure legends and cells were infected with IFITM3-amiR WNV, GFP-amiR WNV, 
WT-WNVNSW2011 or mock infected. At 48 hours post infection, infected cells were lysed in NP-40 
lysis buffer, sonicated and 75 µL of each sample heated with 25 µL of 4 × NuPAGE protein loading 
dye at 95°C for 5 minutes. Thereafter, pre-cast NuPAGE 4-12% Bis-Tris protein gels, (Invitrogen, 
USA) were loaded with 25 µL of each sample per lane along with precision plus protein 
kaleidoscope ladder (BioRad, USA) and 1 × NuPAGE running buffer added before electrophoresis. 
Electrophoresis was performed at 165 V for 45 minutes. Thereafter proteins were transferred onto 
nitrocellulose membrane using iBlot2 dry blotting system, (Thermo Scientific, USA) following 
manufacturer’s instruction. On completion of transfer, membranes were blocked in 1 × Pierce 
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blocking buffer (Thermo Scientific, USA) for 1 hour at 37°C before probing with intended primary 
antibody for 1 hour at 37°C. Blots were then washed five times using 1× PBS containing 0.05% 
Tween 20 (PBS-T) to remove unbound primary antibody, with each wash lasting for five minutes 
before probing with respective secondary antibody for 1 hour at 37°C in the dark. Membranes were 
washed five times using 1× PBS containing 0.05% Tween 20 (PBS-T) to remove unbound 
secondary antibody. To scan membranes LI-COR Biosciences Odyssey Infrared Imaging System 
with the following specifications: channel = 680/800, intensity = auto, focal length = 3 mm, 
resolution = 169 µM was used to visualise protein bands.  
4.2.3 Northern blot analysis 
To perform northern blot analysis, Vero cells were seeded at 5 × 105 cells per well in a 6-well plate 
and incubated at 37°C in a 5% CO2 incubator for 12 hours until 90% confluent. The following day, 
cells were infected with MOI =1 with p1-Vero virus stock reconstituted in 1 mL for 1 hour, rocking 
every 15 minutes to prevent cells from drying. Thereafter, virus inoculum was removed and 
replaced with DMEM supplemented with 5% FCS, 50 units/mL of penicillin and 50 µg/mL of 
streptomycin and plates incubated at 37°C in a 5% CO2 incubator for 48 hours. At 48 hpi, cells 
were harvested and total RNA purified using TRI Reagent kit (Sigma-Aldrich, USA) following 
manufacturer’s instructions. RNA concentration was determined by Nanodrop spectrophotometry 
and 5 µg was subjected to electrophoresis in 15% TBE-urea polyacrylamide gel (Invitrogen, USA) 
to denature and separate RNA molecules. The gel was then stained with ethidium bromide for 1 
hour at room temperature with constant rocking. Thereafter, RNA was electro-transferred to an 
Amersham Hybond-N+ membrane (GE Health Care Life sciences, USA) at constant 35 Voltage for 
90 minutes in 0.5× tris-borate-EDTA (TBE) buffer. Transferred RNA was cross-linked to the 
membrane by UV cross-linking at 1,200 kDj/cm2. The resultant was hybridised overnight with γ-P32-
labeled DNA oligonucleotide probe complementary to mature IFITM3-amiR sequence at 37°C in 
ExpressHyb hybridization solution (Clontech, USA). The following day membranes were washed four 
times in NorthernMax high stringency wash buffer (Thermo Scientific, USA) at 37°C and exposed 
overnight to phosphor imager screen (GE Healthcare). Thereafter, the nylon membrane was scanned 
using Typhoon 9400 variable mode imager (Amersham Pharmacia Biotech, USA). 
4.2.4 Immunoprecipitation of WNV–E protein  
To immunoprecipitate WNV-E protein from virus culture fluid, Ifnar1-/- MEFs were infected at 
MOI =1 with IFITM3-amiR WNV, GFP-amiR WNV and WT-WNVNSW2011 viruses. At 48 hpi, 
virus culture fluid was harvested for each respective virus; cells washed three times with PBS and 
then replaced with 20mL of DMEM supplemented with 5% FCS, 50 units/mL of penicillin and 50 
µg/mL of streptomycin. The cells were incubated for a further 24 hours, and then virus culture fluid 
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harvested as 72 hpi sample. The samples harvested at 48 hpi and 72 hpi time point samples were 
clarified, and concentrated using Amicon ultra- 15 mL 100 kDa centrifugal filter units, (Merck 
Millipore, USA). An equal amount (250 µL) of virus particles were immunoprecipitated from each 
sample by binding a fixed amount (5 µg) of purified anti-E monoclonal antibody (6B6C-1) as the 
capture antibody on Dynabead protein G (Invitrogen, USA). Immunoprecipitated WNV-E protein 
was then subjected to western blot analysis as described above. Membranes were transferred onto a 
nitrocellulose membrane using iBlot 2 dry blotting system, (Thermo Scientific, USA) following 
manufacturer’s instruction. Thereafter, blots were blocked for 1 hour using 50 µL of 1 × Pierce 
Clear Milk Blocking Buffer (Thermo Scientific, USA). To determine amount of IFITM3 protein 
incorporated into membranes of secreted WNV virions, nitrocellulose membranes were probed with 
rabbit polyclonal IFITM3 antibody (ProteinTech, USA) for 1 hour at 37°C with constant rocking. 
Thereafter, blots were washed five times using 1× PBS containing 0.05% Tween 20 (PBS-T) to 
remove traces of unbound primary antibody and probed with IRDye 800 cw anti-rabbit secondary 
antibody (LI-COR Biosciences, USA) with constant rocking for 1 hour at 37°C in the dark. 
Nitrocellulose membranes were then washed five times using 1× PBS containing 0.05% Tween 20 
(PBS-T) to remove any traces of unbound secondary antibody before scanning. To scan, LI-COR 
Biosciences Odyssey Infrared Imaging System with following specifications: channel =680/800, 
intensity = auto, focal length = 3 mm, resolution = 169 µM was used to visualise protein bands.  
4.2.5 Determining RNA copy numbers of Ifnar1-/- MEF generated virus stocks 
To ascertain RNA copy numbers of Ifnar1-/- MEF generated virus stocks, a standard curve was first 
generated. A CPER fragment spanning WNVNSW2011 NS3-NS4A and NS4B regions (termed here 
NS3NS4B) was generated from WNVNSW2011 cDNA using NS3_Forward and NS4_Reverse sets of 
primers (Table 4.1), PrimeSTAR GXL DNA Polymerase (Clontech, USA) kit and protocol. To 
obtain NS3NS4B CPER fragment, 1% (w/v) TAE agarose gel electrophoresis was performed; band 
was excised from gel and purified using Monarch DNA Gel Extraction Kit, (New England Biolabs, 
USA). Thereafter, DNA fragment concentration was determined by Qubit fluorometer using Qubit 
dsDNA BR Assay kit and protocol (Thermo Scientific, USA). RNA copy numbers were calculated 
basing on the concentration obtained and 10-fold serial dilutions from 1011 to 107 RNA copies made 
to generate quantitative reverse transcriptase PCR (qRT-PCR) standards. Using Ifnar1-/- MEF 
generated virus stocks, viral RNA was extracted from 150 µL of IFITM3-amiR WNV, GFP-amiR 
WNV and WT-WNV using NucleoSpin RNA, (Macherey-Nagel, Germany) isolation kit and 
protocol. Subsequently qRT-PCR was performed using extracted RNA, serial diluted standards, 
NS4A_Forward and NS4A_Reverse primers upstream NS4A region of WNV (Table 4.1) and 
superscript III platinum SYBR Green one-step qRT-PCR (Thermo Scientific, USA) kit and 
protocol. A standard curve was obtained and RNA copy numbers of IFITM3-amiR WNV, GFP-
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amiR WNV and WT-WNV determined. 
4.2.6 Infection of mice  
For every animal experiment included in this chapter, 4-week old CD-1 mice were infected via the 
intraperitoneal route with respective viruses as stated in the figure legends. Mice were monitored 
for clinical signs and each day a clinical score was recorded for a period of 21 days. To determine 
viraemia, mice were tail-bled from one day to seven days post infection, collected blood allowed to 
clot for 30 on ice and centrifuged at 500 g to obtain sera for immunoplaque assay on C6/36 cells as 
described below. To determine virus burden in the brains, mice that presented with encephalitic 
signs were culled and brains harvested for subsequent experiments such as confirming virus identity 
and viral load in the brain. 
4.2.7 RNA extraction and generation of amplicons for Sanger sequencing from mouse brains 
Harvested mouse brains were suspended in 1 mL of PBS and homogenised with 3 mm stainless 
steel beads at 30/second frequency for 3 minutes using TissueLyser II, (Qiagen, USA). Total RNA 
was extracted from 150 µL of brain homogenates using TRI Reagent LS (Sigma, USA) according 
to following manufacturer’s instructions. Thereafter, RT-PCR was performed using total RNA as 
template, superscript III one-step RT-PCR system with platinum Taq high fidelity DNA polymerase 
kit (Thermo Scientific, USA) and WNVNSW2011 3′ UTR_Forward and 3′ UTR_Reverse primers 
(Table 4.1) as well as purified RNA as template. The generated 3′ UTR amplicons were visualised 
on 1.4%(w/v) TAE agarose gel electrophoresis, obtained bands were excised from gels and purified 
using Monarch DNA Gel Extraction Kit (New England, USA). Thereafter, DNA concentrations 
were determined by using Nanodrop spectrophotometry before Sanger sequencing.  
4.2.8 Virus titration of mouse-derived samples  
To determine virus titres an immunoplaque assay on C6/36 monolayer of cells was performed. 
C6/36 cells were seeded at 1 × 106 cells per well in a 96 well plate one day before. The next day, 
sera, brain or spleen homogenate samples were serially diluted with RPMI media to infect C6/36 
cells for 2 hours. At two hours post-infection, 175 µL of overlay medium was added to each well. 
The overlay medium was made by mixing ×2 M199 medium supplemented with 5% FCS, 50 
units/mL of penicillin and 50 µg/mL of streptomycin with 2% carboxymethyl cellulose in a ratio of 
1:1 and plates incubated for 96 hours for C6/36 cells. At 96 hpi, the overlay was removed and 100 
µL of ice-cold 80% acetone in PBS added and incubated at –20°C for 1 hour to fix the cells before 
completely air-drying the plates. To detect WNV-E protein, plates were first blocked by adding 50 
µL of Pierce clear milk blocking buffer (Thermo Scientific, USA) to each well and incubating the 
plates at 37 °C for 1 hour. Thereafter, 50 µL of mAb E-16 (human anti-E) was added to each well 
and plates incubated at 37°C. Plates were then washed six times using 1× PBS containing 0.05% 
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tween 20 (PBS-T) to remove any traces of unbound primary antibody before adding 50 µL of 
IRDye 800 cw goat anti-human secondary antibody (LI-COR Biosciences, USA) to each well. 
Plates were then incubated at 37°C for 1 hour and thereafter washed six times, air-dried and then 
kept in the dark at room temperature until ready for imaging. Plates were scanned using the LI-COR 
Biosciences Odyssey Infrared Imaging System using following specifications: channel = 800, 
intensity = auto, focal length = 3 mm, resolution = 42 µm. Viral titres from iPA are expressed as 
pfu/mL. Obtained titres were log-transformed and plotted using GraphPad Prism version 8. 
4.3 Results 
4.3.1 In vitro RNAi screening with a library of West Nile viruses encoding artificial miRNAs 
targeting host antiviral genes identified IFITM3 as a major antiviral factor against 
West Nile virus. 
To determine the selection and enrichment of particular ISG-targeting amiR-encoding WNV during 
in vitro culture, three independent experiments were performed in WT MEF and Ifnar1-/- MEF 
cells, each with three serial passages of virus stocks (Figure 4.1). Both WT MEFs and Ifnar1-/- 
MEFs were infected at low MOI =0.1 (105 pfu) with p1-Vero mouse ISG-targeting amiR-encoding 
virus mixed with 200 pfu of scrambled amiR virus library. At 3 days post infection, culture fluid 
was collected from WT MEF and Ifnar1-/- MEF as p2-WT MEF and p2- Ifnar1-/- MEF virus stocks 
respectively. Passage two (p2) virus titres were determined by immunoplaque assay on Vero cells, 
and WT MEF and Ifnar1-/- MEF infected at MOI = 0.1 to generate p3-WT MEFs and p3- Ifnar1-/ -
MEF virus stocks. Thereafter process was repeated to generate p4 virus stocks. These series of 
experiments generated three passages in WT MEF and three passages in Ifnar1-/- MEF as shown in 
Figure 4.1. 
 
Figure 4.1 Diagram representation of experimental plan used to perform in vitro screening 
RNAi in WT MEF and Ifnar1-/- MEF cell lines.  P1-Vero generated virus library (MOI = 0.1, 105 
pfu) was mixed with 200 pfu of scrambled amiR WNV library for infection of WT MEF and Ifnar1-
/- MEF. Three independent passages were performed, each time infecting at MOI =0.1. 
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Deep sequencing data were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using Salmon transcript quantification data script tool to determine the population of virus 
variants in each passage and experiment following Salmon transcript’s workflow (Appendix 2).   
Results showed that IFITM3 clone #2 amiR WNV (herein referred to as IFITM3 amiR-WNV) was 
selected and enriched across three independent passages in WT MEF (Figure 4.2 A) and Ifnar1-/- 
MEF (Figure 4.2 B). By passage four (p4) in WT MEFs, 90.2%, 99.3% and 99.5% of the viruses in 
each independent WT MEF library preparation were IFITM-amiR-encoding viruses, whereas in Ifnar1-/- 
MEFs by p4, 96.5%, 89.5% and 85% of the viruses in each independent Ifnar1-/- MEF virus library 
consisted of IFITM3-amiR encoding virus (Appendix 3). In addition, it is noted that none of the control 
viruses, either scrambled amiR-encoding viruses, GFP-amiR or miR-124-amiR West Nile viruses were 
selected or enriched in WT MEF and Ifnar1-/- MEF cells in all three passages and independent 
experiments. This showed that amiRs targeting irrelevant genes are not enriched or selected across 
passages. However, as noted earlier, the GFP-amiR virus was absent in sequencing of the plasmid, P0, 
P1 libraries, suggesting that it might have been lost from the population. Furthermore, the scrambled 
amiR library, intended as a control, were only 200 pfu, probably representing one copy of 200 different 
amiR sequences. Consequently, it is not surprising that they were not selected. However, the selection 
and enrichment of IFITM3-amiR WNV across three independent passages in WT MEFs and Ifnar1-/- 
MEF highlights IFITM3's role in restricting West Nile virus replication in cells.  
 
Figure 4.2 Passaging of ISG-amiR encoding West Nile virus library in WT MEF and Ifnar1-/- 
MEF cells selected for IFITM3-amiR encoding WNV.  (A) Three passages of virus library in 
WT MEF and Ifnar1-/- MEF cells were performed at MOI 0.1. Deep sequencing of pre-amiR-
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encoding region showed that by passage 3 (p3), more than 96% of virus library in WT-MEF 
consisted of IFITM3-amiR-encoding WNV. B) Deep sequencing of pre-amiR-encoding region 
showed that by p4, 96.5%, 89.5% and 85% of the Ifnar1-/- MEF virus library consisted of IFITM3-
amiR encoding virus. IFITM3-amiR (%) denotes percentage enrichment of IFITM3-amiR WNV in 
corresponding library.  
 
4.3.2 Characterisation of the role of IFITM3 in West Nile virus infection 
4.3.3 Generation of IFITM3-amiR West Nile virus 
Since IFITM3 amiR-encoding West Nile virus was selected and enriched during in vitro screening 
in WT MEF and Ifnar1-/- MEF, this suggested that IFITM3 plays an important role in restricting 
WNV replication. To investigate this, IFITM3-amiR WNV and GFP-amiR WNV (as a control 
virus) were generated using the CPER technique (Figure 4.3 A). To generate each individual virus, 
IFITM3-amiR and GFP-amiR CPER fragments were generated by PCR from respective amiR-
encoding plasmids using Q5 high-fidelity DNA Polymerase PCR kit (New England Biolabs, USA) 
and WNVNSW2011 3′ UTR_Forward and amiR_Reverse set of primers (Table 4.1) and (see Chapter 
3, Figure 3.6 A). Generated amiR fragments were purified by gel extraction and CPER performed 
(Figure 4.3 A). CPER products were transfected into HEK 293 cells to recover p0 virus stocks. At 3 
days post transfection virus culture fluids were collected as p0-293T virus stocks and virus titre 
determined by immunoplaque assay on Vero cell monolayer (Figure 4.3 B). 
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Figure 4.3 Generation of IFITM3-amiR and GFP-amiR West Nile viruses.  A): Diagram 
representation of CPER strategy used to generate infectious IFITM3-amiR encoding cDNA and 
GFP-amiR encoding cDNA transfected into HEK293 cells to generate p0-293T virus library. B) 
Recovered p0-293T virus stocks were titred on a Vero cell monolayer by immunoplaque assay. The 
virus titer for p0-293T IFITM3-amiR WNV stock was 6×105 pfu/mL while that of GFP-amiR 
WNV stock was 1.72 ×105 pfu/mL.  
 
Vero cells were then infected with p0-293T virus stocks at MOI =1 to generate larger volumes of 
virus stocks (named p1-Vero) for subsequent experiments. Virus titres for IFITM3-amiR and GFP-
amiR encoding p1-Vero virus stocks titres were determined by immunoplaque assay on Vero cells 
and plaque morphology recorded (Figure 4.4 A). To confirm that the generated virus stocks 
contained the correct amiR hairpins, the 3′ UTRs of IFITM3-amiR WNV and GFP-amiR WNV 
were generated and subjected to Sanger sequencing (Figure 4.4 B). This confirmed that IFITM3-
amiR and GFP-amiR encoding WNV viruses retained inserted pre-amiR hairpins. Predicted pre-
amiR structures were determined by mFold and conformed to the expected structures of IFITM3 
pre-amiR and GFP pre-amiR hairpin structures (Figure 4.4 C) and (Figure 4.4 D) respectively.  
A 
B 
IFITM3-amiR WNV GFP-amiR WNV 
p0-293T 
 75 
 
Figure 4.4 Generation of p1-Vero IFITM3-amiR and GFP-amiR West Nile virus stocks.  A) 
Vero cells were infected with p0-293T virus stocks to generate larger volumes of p1-Vero 
respective virus stocks. At 72hpi, virus culture fluids were harvested, clarified by centrifugation and 
stored for future experiments. Generated virus stocks were titrated on Vero cells by immunoplaque 
assay. B) Viral RNA was extracted from culture fluid and subjected to RT-PCR using 3′ UTR_ 
Forward and 3′ UTR_Reverse primers. Expected DNA band size is 720bp. C) and D) predicted 
structures of pre-amiR hairpin in IFITM3 -amiR WNV and GFP-amiR WNV p1-Vero virus stocks 
respectively. 
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4.3.4 The IFITM3 amiR hairpin is processed by cellular machinery into functional miRNA 
that target specific host genes. 
To determine whether inserted IFITM3 pre-amiR hairpin is processed into functional IFITM3- 
amiR by the host machinery, Vero cells were infected with IFITM3-amiR-encoding virus or mock 
infected. At 48 hpi, cellular RNA was isolated and northern blot [136] was performed to determine 
the expression of IFITM3 amiR. The IFITM3-amiR band (21 nt) was detected in cells infected with 
IFITM3-amiR encoding virus while the mock control did not produce any band as expected (Figure 
4.5). 
 
Figure 4.5 Detection of mature GFP amiR in infected Vero cells by northern blot analysis.   
Cells were infected with IFITM3 pre-amiR encoding WNV or mock infected. Enriched small RNA 
fractions were extracted at 48 hpi and 5µg of RNA was subjected to electrophoresis in 15% TBE-
urea polyacrylamide gel followed by northern blot analysis with γ-32P-labeled DNA probe 
complementary to IFITM3-amiR. The IFITM3-amiR band (21 nts) was detected in RNA samples 
from cells infected with IFITM3-amiR WNV. The nt denotes nucleotides. 
 
4.3.5 The IFITM3-amiR WNV controls expression of IFITM3 expression in WT MEF cells 
To ascertain whether knock down of IFITM3 in cells infected with IFITM3-amiR WNV, WT MEF 
were infected with IFITM3-amiR WNV, GFP-amiR WNV and WT-WNV at MOI =15 and 20 or 
mock infected. At 48 hpi, cell lysates were prepared and subjected to western blot analysis. Blots 
were probed with polyclonal rabbit anti-IFITM3, mouse anti-GAPDH and 4G2 antibody against 
WNV-E. Both MOI =15 and 20 produced productive virus infection of WT MEFs (positive for 
WNV Envelope protein) unlike lower MOI =10 (Appendix 4). IFITM3 expression was analysed 
using ImageJ analysis to quantify relative density of IFITM3 expression in infected cells relative to 
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mock-uninfected WT MEF cells (Figure 4.6 A and B). 
  
Figure 4.6 Expression of IFITM3 in WT MEF infected with respective viruses WT MEF were 
infected with IFITM3-amiR WNV, GFP-amiR WNV, WT-WNV at MOI =15 and MO1=20 or 
mock infected. At 48hpi, cell lysates were harvested in NP-40 lysis buffer and subjected to western 
blot analysis. Results of three independent experiments are shown. Blots were probed with rabbit 
polyclonal anti-IFITM3, anti-WNV-E and mouse anti-GAPDH antibodies. Expected band sizes 
were 14 kDa (IFITM3), 42 kDa (WNV-E) and 37 kDa (GAPDH). B) IFITM3 protein is induced by 
infection in WT MEF, but no decrease in protein was detected with IFITM3-amiR-WNV relative to 
WT-WNV. WT MEF were infected with IFITM3-amiR WNV, GFP-amiR WNV, WT-WNV or 
mock at MOI =15 and MO1=20. IFITM3 band integrated density ± SEM analysed by ImageJ 
densitometry.  
 
 
A 
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4.3.6 The IFITM3-amiR WNV down-regulates expression of IFITM3 expression in Ifnar1-/- 
MEF cells 
Similarly, Ifnar1-/- MEF cells were infected with IFITM3-amiR WNV, GFP-amiR WNV and WT-
WNV at MOI =1, and at 48 hpi, cell lysates were prepared and subjected to western blot analysis. 
Probing for IFITM3 expression indicated knockdown of IFITM3 expression in cells infected with 
IFITM3-amiR WNV when compared to cells infected with GFP-amiR WNV and WT-WNV 
(Figure 4.7 A). Analysis of IFITM3 integrated density substantiated this observation, as knockdown 
of IFITM3 was significant in Ifnar1-/- MEF cells infected with IFITM3-amiR WNV compared to 
cells infected GFP-amiR WNV, WT-WNV and or mock uninfected  (Figure 4.7 B).  In contrast to 
WT cells (Figure 4.6), IFITM3 was not induced in the Ifnar1-/- MEF by WT-WNV infection, 
consistent with induction of IFITM3 by autocrine type I IFN production. 
 
Figure 4.7 Knockdown of IFITM3 expression in Ifnar1-/- MEF infected with IFITM3-amiR 
WNV. A) Ifnar1-/- MEF cells were infected with IFITM3-amiR, GFP-amiR, and WTNSW2011 viruses 
at MOI = 0.1, and mock uninfected. At 48 hpi cells were lysed in NP40-containing lysis buffer and 
subjected to western blot. Blots were probed with rabbit polyclonal anti-IFITM3, anti- WNV-E 4G2 
and mouse anti-GAPDH antibodies. Predicted sizes are 14 kDa, 37 kDa and 42 kDa for IFITM3, 
GAPDH and E-protein respectively. B) IFITM3 integrated density ± SEM analysed by ImageJ 
densitometry. Results indicate that IFITM3 expression is reduced in Ifnar1-/- MEF when cells are 
infected with IFITM3-amiR WNV.  The * denotes p < 0.05. 
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4.3.7 IFITM3-amiR WNV replicates better than GFP-amiR WNV 
A growth kinetics experiment was performed on WT MEFs and Ifnar1-/- MEF cells to determine 
replication efficiency of IFITM3-amiR WNV compared to GFP-amiR WNV control virus. Both 
WT MEF and I Ifnar1-/- MEF cells were infected with IFITM3-amiR WNV and GFP-amiR WNV at 
MOI =1, culture medium was harvested at 0, 24, 48 and 72 hpi and virus titre determined by 
immunoplaque assay on Vero cell monolayer. Three independent experiments were performed. 
Results showed that IFITM3-amiR WNV replicated significantly better than GFP-amiR in both WT 
MEFs and Ifnar1-/- MEF cell lines (Figure 4.8 A and B), although in Ifnar1-/- MEF titres were only 
marginally higher, at 48 and 72 hours. 
 
Figure 4.8 Comparison of growth kinetics between IFITM3-amiR WNV and GFP-amiR WNV 
on different cell lines.  Cells were infected at MOI =1 for up to 72 hours using virus stocks 
prepared in Vero cells. Virus titres shown are log10 transformed mean values and represented as 
pfu/mL ± SEM, as determined by immunoplaque assay on Vero cells. Three independent 
experiments were performed for each cell line. Significant differences between the means are 
differentiated using two-way ANOVA with Sidak’s multiple comparison tests where *p < 0.05, **p 
<0.005, ***p < 0.001, ****p < 0.0001.  
 
4.3.8   Immunoprecipitation of West Nile virus particles using Flavivirus anti-E antibody 
shows that infection with WNV encoding IFITM3 pre-amiR reduces incorporation of 
IFITM3 into secreted virus particles  
From the initial discovery of IFITM3 as an interferon-inducible transmembrane protein that inhibits 
replication of numerous unrelated viruses, various research studies have elucidated how IFITM3 
antagonises virus infections. Research has shown that IFITM3 is a type II transmembrane protein 
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that is translocated to the plasma membrane, endocytosed and incorporated into secreted virions 
during biogenesis to reduce infectivity of secreted virions [271-274]. Furthermore, West Nile virus 
N-linked glycosylation of envelope protein controls virion assembly and infectivity [74, 275]. 
Based on this knowledge and observation that infection of Ifnar1-/- MEF cells with IFITM3 amiR-
encoding WNV knocks down expression of IFITM3 in cells (Figure 4.7), we hypothesised that 
knockdown of IFITM3 in cells reduces incorporation of IFITM3 into membranes of the secreted 
virions. Therefore, West Nile virus particles were immunoprecipitated using anti-E monoclonal 
antibody (6B6C-1) and incorporation of IFITM3 in virus particles were determined by probing for 
IFITM3 on Western blot.   
Since knockdown of IFITM3 in Ifnar1-/- MEFs infected with IFITM3-amiR encoding virus occurred 
as early as 48hpi in cells (Figure 4.7 A), it was assumed that newly secreted virions from this point 
forth would contain less IFITM3. Therefore Ifnar1-/- MEF were infected with IFITM3-amiR-
encoding WNV, GFP-amiR WNV encoding and WT-WNV at MOI = 1. At 48 hpi, culture medium 
was removed, cells washed and new medium added to generate 72 hpi samples as described in 
methods. Thereafter, harvested virus samples were clarified by centrifugation, concentrated before 
immunoprecipitation of WNV-E performed and subsequent probing for IFITM3 expression to 
determine incorporation of IFITM3 into membranes of secreted virions. Results showed that less 
IFITM3 was incorporated into virions at 72 hpi compared to 48 hpi (Appendix 5). Therefore the 72 
hpi was chosen as an optimal time point for immunoprecipitation and experiment was repeated as 
described in methods section. Results showed that less IFITM3 was incorporated in IFITM3-amiR 
WNV while amount of IFITM3 incorporated into GFP amiR-encoding WNV and WT-NSW2011 WNV 
remained unchanged (Figure 4.9). Probing for WNV-E protein in culture medium showed that 
regardless of less incorporation of IFITM3 in secreted virions, the level of WNV-E remained 
unchanged. Therefore the obtained data confirmed that knockdown of IFITM3 expression in cells 
subsequently reduces the amount of IFITM3 incorporated into secreted virions (Figure 4.9 A, B) 
despite similar levels of WNV-E protein in the virus culture fluid (Figure 4.9 A, C).  
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Figure 4.9 Infection with IFITM3 pre-amiR encoding WNV reduces incorporation of IFITM3 
into secreted virus particles. A) Ifnar1-/- MEFs were infected at MOI =1, 48 hpi, virus culture 
fluid was removed, cells washed with PBS and new DMEM to generate 72 hpi sample. At 72 hpi, 
virions secreted into culture medium contained less IFITM3 on immunoprecipitation of WNV-E 
protein. The same volume of virus culture fluid was subjected to western blot analysis to determine 
amount WNV-E protein in secreted virions. B) Analysis of IFITM3 expression in secreted virions 
using ImageJ densitometry. IFITM3 Integrated density in virus culture fluid of IFITM3-amiR 
WNV, GFP-amiR WNV and WT-WNV Ifnar1-/- MEF stocks was determined. C) Analysis of 
WNV-E expression in virus culture fluid was determined by WNV-E protein western blot analysis. 
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4.3.9 Less incorporation of IFITM3 in virions increases infectivity of secreted virions 
Given that IFITM3 is incorporated in membranes of secreted virions and negatively represses 
infectivity [273, 276], we sought to determine whether less incorporation of IFITM3 in secreted 
virions affected WNV infectivity in different cell lines. The Ifnar1-/- MEF cells were infected with 
p1-Vero generated IFITM3-amiR WNV, GFP-amiR WNV and WT-WNV virus stocks at MOI =1 
and virus stocks harvested at 48 hpi. Thereafter, Ifnar1-/- MEF generated virus stocks were 
normalised by RNA copy number (Figure 4.10 A) and western performed on normalised virus 
stocks to determine whether similar levels of WNV-E protein were expressed in the virus stocks. 
Results revealed that similar number of virions in the normalised virus stocks, further validating the 
equivalent numbers of virions in the viral preparations (Figure 4.10 B). Using normalised virus 
stocks, viral infectious titres were determined by immunoplaque assay on Vero, WT MEF, Ifnar1-/- 
MEF, C6/36 and A549 cell monolayers. Results revealed that IFITM3-amiR WNV was more 
infectious than virions containing a normal level of IFITM3 on WT MEF and Ifnar1-/- MEF. This 
implied that knockdown of IFITM3 in murine derived cell lines, resulted into less incorporation of 
IFITM3 in secreted virions and subsequently improved infectivity of IFITM3-amiR WNV (Figure 
4.10 C). In addition, mosquito (C6/36) and human (A549) cell lines showed a trend towards 
improved infectivity although there was no statistically significant difference in replication on Vero, 
C6/36 and A549 cells.  
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Figure 4.10 Increased infectivity of IFITM3-amiR virions prepared in Ifnar1-/- MEF.  A) RNA 
copy numbers of Ifnar1-/- MEF-grown virus stocks were determined and found to be similar. Error 
bars could not be seen, because they were very short. B): Detection of WNV- E protein in 
normalised virus culture fluid revealed similar WNV-E expression in virus culture fluid in the three 
viral stocks used for infectivity assay. Two independent experiments were performed. C) A uniform 
volume of Ifnar1-/- MEF-grown virus stocks were used for immunoplaque assay to determine 
infectivity on different cell lines. For Vero, WT MEF, A549 and Ifnar1-/- MEF cells, immunoplaque 
assay plates were fixed 30 hpi with ice cold 80% Acetone in PBS while C6/36 were fixed at 72 hpi. 
Plates were probed with anti-WNV-E 4G2 to determine virus titres. Four independent experiments 
were performed for each of the cell line and virus. Error bars represent standard error of the mean. 
** P< 0.005 and *** P<0.0005 as analysed by two-way ANOVA with Tukey’s multiple 
comparisons test.  
 
4.3.10 Increased mortality in mice infected with IFITM3-amiR WNV  
IFITM3 knockdown in cells resulted in less incorporation of IFITM3 in membranes of secreted 
virions, and subsequent increased infectivity of IFITM3-amiR WNV in vitro. Next we determined 
whether virions containing less IFITM3 showed enhanced virulence in vivo.  To determine this, 40 
four-week-old CD-1 mixed sex mice were infected with IFITM3-amiR or GFP-amiR WNV 
generated from Ifnar1-/- MEF cells via intraperitoneal route and monitored for 21 days. Two doses 
were used (105 pfu and 106 pfu) to determine the optimal infection dose for subsequent animal 
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experiments. The 105 pfu cohort (Figure 4.11 A) presented with 100% (10/10) and 60% (6/10) 
mortality in IFITM3-amiR and GFP-amiR WNV control groups respectively; while the 106 pfu 
cohort (Figure 4.11 B) caused 100% (10/10) and 40% (4/10) mortality in IFITM3-amiR WNV and 
GFP-amiR WNV respectively. Therefore 106 pfu infection dose was chosen as the optimal dosage 
for viraemia, clinical score and virus burden in the brain as discussed below. 
 
Figure 4.11 In vivo characterisation of IFITM3-amiR encoding WNVNSW2011 viruses.  A) 4 
week old CD1 mice were challenged via the intraperitoneal route with either 105 pfu (A) or 106 pfu 
(B) of the IFITM3-amiR WNV or GFP-amiR WNV generated in Ifnar1-/- MEF. Each group 
contained 10 mice, which were monitored for 21 days and at the survival curve generated.  
 
4.3.11 Viraemia 
To determine viraemia, mice were tail bled for the first seven days to obtain sera for immunoplaque 
assay on C6/36 mosquito cells. The C6/36 cell line is an Aedes albopictus mosquito-derived cell 
line that is Dicer-1 deficient and lacks a functional RNAi pathway commonly used in flavivirus 
research and can be used for miRNA studies. After 1-2 days, mice infected with IFITM3-amiR 
WNV presented with apparently increased viraemia compared to mice infected with the control 
virus, GFP-amiR WNV, although this did not reach statistical significance (Figure 4.12). 
Furthermore viraemia lasted until 4dpi and by 5dpi no virus was detected in the sera. 
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Figure 4.12 Increased early viraemia in mice infected IFTM3-amiR WNV.  To determine 
viraemia, mice were tail bled from 1dpi to 7dpi. Sera virus titres were determined by C6/36 
immunoplaque assay using WNV mAb E-16 (human anti-E). Obtained titres were log transformed 
and plotted using GraphPad prism version 8. Solid bars represent median of log transformed virus 
titre per group. L. O. D denotes Limit of Detection, which is 40 pfu/mL, equivalent to 1.602 log 10. 
 
4.3.12 Increased progression of clinical signs in mice infected with IFITM3-amiR WNV  
Mice infected with IFITM3-amiR WNV presented an increase in progression and severity of 
observed clinical signs, such as ruffled fur and/or general loss of condition, loss of weight, change 
in breathing, twitching, anti-social behaviour, severely hunched posture, paralysis among others 
(Figure 4.13 A, B). By 10 dpi all mice infected with IFITM3-amiR WNV had succumbed to 
encephalitis compared to mice infected with GFP-amiR WNV, which had 6/10 (60%) mice survive 
until 21dpi (Figure 4.11) 
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Figure 4.13 Increased progression of clinical signs in IFITM3-amiR WNV infected mice.  (A) 
IFITM3-amiR WNV and GFP-amiR WNV (B) mouse groups were infected with 106 pfu of 
respective viruses and each group monitored daily for signs of encephalitis. Clinical scores for each 
group were recorded each day for 21 days. For the clinical score 0 denoted Normal feeding and 
appearance. Clinical score 1: denoted slightly ruffled fur and/or general loss of condition 
respectively. Clinical score 2: denoted increase in general loss of behaviour, appearance, breathing 
changes, twitching and anti-social behaviour. Clinical score 3 denoted first signs of encephalitis 
such as severely hunched posture, partial paralysis and or full paralysis while clinical score 4 
denoted death.  
 
4.3.13 Increased viral burden in the brains of mice infected IFITM3-amiR WNV  
Mice infected with IFITM3-amiR WNV and GFP-amiR WNV that showed signs of encephalitis 
were culled and brains harvested to determine virus burden in the brain and whether mice retained 
IFITM3 pre-amiR and GFP pre-amiR insertions respectively. Total RNA was extracted and RT-
PCR performed using superscript III one-step RT-PCR system with platinum Taq high fidelity 
DNA polymerase kit (Thermo Scientific, USA), 3′ UTR-Forward and 3′ UTR-Reverse primers 
(Table 4.1). Results showed that both viruses stably retained the inserted pre-amiR hairpins through 
virus spread to the CNS as correct sized  amplicons were obtained. It should be noted that the three 
mouse brains from the IFITM3-amiR WNV group were harvested at 5dpi while one mouse brain 
for the GFP-amiR WNV group was harvested at 8dpi and the remaining two brains at 9 dpi. (Figure 
4.14 A) Sanger sequencing confirmed that inserted pre-amiR hairpins were retained through virus 
spread to the CNS. In addition, a second portion of the mouse brain homogenate was used to 
determine viral burden in the brain by immunoplaque assay on C6/36 cells. This revealed that 
despite using the same dose of virus (106 pfu) for both IFITM3-amiR WNV and GFP-amiR WNV 
to infect mice, brain virus titres in mice infected with IFITM3-amiR WNV were higher than in mice 
infected with GFP-amiR WNV (Figure 4.14 B). Mouse brains for the IFITM3-amiR WNV were 
harvested at 5dpi (5 brains), 7dpi (3 brains), 9 dpi (1 brain) and 10 dpi (1 brain), when signs of 
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encephalitis were apparent (Figure 4.11). For the GFP-amiR WNV group, mouse brains were 
harvested at 8dpi (1 brain), 9 dpi (2 brains) and 10 dpi (1 brain) when signs of encephalitis were 
apparent. In addition, regardless of the time of harvest, brains from IFITM3-amiR WNV infected 
mice had showed higher virus burden than brains of mice infected with GFP-amiR WNV. This is 
because even at 10 dpi, virus burden in the brain of IFITM3-amiR WNV infected mouse was higher 
than that of GFP-amiR WNV infected mouse brain. 
 
Figure 4.14 IFITM3 pre-amiR and GFP-pre-amiR inserted in 3′ UTR of WNVNSW2011 are 
stable throughout infection to CNS invasion. A) One step RT-PCR was performed using total 
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RNA and 3′ UTR_Forward and 3′ UTR_Reverse set of primers.  A 1 kB DNA Gene Ruler mark 
(Ladder) was loaded on the left side of the gel and the expected size of amplicons was 720 base 
pairs. Brains 1 to 3 denote brains from mice infected with IFITM3-amiR WNV while Brain 4 to 6 
are brains harvested from mice infected with GFP-amiR WNV. No RT-PCR was performed using 
brain homogenate derived RNA as template for Taq DNA polymerase PCR as control to determine 
the purity of purified RNA. B) Mouse brain homogenate titres were determined by immunoplaque 
assay on a C6/36 cell monolayer using WNV mAb E-16 (human anti-E). Obtained titres were log 
transformed and plotted using GraphPad prism version 8 software. Statistical test could not be 
performed since the brains were harvested on different days. Limit of Detection denotes 40 pfu/mL, 
equivalent to 1.602 log 10. 
 
4.4 Discussion 
4.4.1 IFITM3 restricts infection by several different viruses 
Obligate intracellular parasites such as viruses access, hijack and control host cellular compartments 
to survive and complete life cycles. Several pieces of evidence show that following endocytosis, a 
drop in pH induces the enveloped virus glycoproteins to undergo a conformational rearrangement. 
Consequently the enveloped virus glycoproteins fuse with host cellular receptors to dispense their 
viral genome into host cytosol, a process known as hemifusion (reviewed in [277, 278]). 
Consequently a series of events occur including recruitment of cellular antiviral factors and evasion 
of host restriction factors as viruses establish and complete their lifecycles [276, 279]. More 
evidence suggests structural modification in virus glycoproteins facilitate fusion of viral and 
cellular membranes [278, 280]. Therefore, fusion inhibitors and neutralising antibodies against viral 
envelope glycoproteins have developed to block entry of virus into cells.  
Recently a novel family of innate immune restriction factors, interferon inducible transmembrane 
proteins (IFITM) family was identified. The IFITM family of proteins hinders entry of numerous 
viruses into cells to block the first stages of virus life cycle such as hemifusion and pore formation 
to inhibit viruses from entering the cytoplasm [281]. The IFITM family consists of five genes in 
humans, IFITM1, IFITM2, IFITM3, IFITM5 and IFITM10 whereas murine family of IFITM 
consists of IFITM1, IFITM2, IFITM3 and four other IFITMs: 5, 6, 7 and 10, whose functions are 
currently undefined [282].  The IFITM family of proteins consists of structurally related proteins. 
IFITM1 contains a 13 amino acid (aa) extension at the C terminus while M2 and M3 have 20 and 
21 aa extensions at the N terminus and thus differ by only one aa [283, 284]. Although the name 
suggests that IFITMs are interferon inducible, only IFITM1, 2 and 3 are, and are detectable in 
moderate to high levels in several tissues even with absence of interferon [285, 286]. IFITM5 and 
IFITM10 have not been shown to have any immune-related functions but IFITM5 is predominantly 
expressed in osteoblasts and vital in bone formation whereas functions of IFITM10 are still 
unknown [232, 284]. 
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Interferon inducible IFITMs, IFITM1, IFITM2 and IFITM3, are crucial in virus-host interaction and 
viral pathogenesis. IFITMs prevent viral replication as well as effects of virus-associated disease 
such as cytopathic effects, cell death and inflammation. In vitro studies have shown that IFITM1, 
IFITM2 and IFITM3 incorporate into the membrane of various unrelated enveloped viruses to 
restrict virus infections of various families of viruses including cytomegalovirus (CMV), Ebola 
virus (EBOV), vesicular stomatitis virus (VSV), SARS coronavirus (SARS-CoV), human 
immunodeficiency virus (HIV), respiratory syncytial virus (RSV), hepatitis C virus (HCV), Dengue 
virus (DENV), Zika virus (ZIKV) and West Nile virus (WNV) [287-298]. However, infection by 
the non-enveloped virus reovirus is also restricted by IFITM3, with a suggested role in modifying 
proteolysis in endosomal compartment that is necessary for infection. Consequently, these proteins 
may have effects both within the host cell and as part of the virion. 
Cellular localisation of IFITMs is linked to the stage of virus life cycle that they antagonise [286, 
299]. Members of the IFITM family exist within cytoplasm, plasma membrane, nucleus and virus 
particle [232, 274, 285, 298]. For instance, in vitro studies have shown that IFITM1 is localised at 
the cell surface and early endosome to effectively restrict HIV-1 strains that utilise CCR5 co-factor 
to fuse envelope-cell membrane and enter into host cells [288, 300, 301]. IFITM2 and IFITM3 are 
localised at late endosome/ lysosome to restrict viruses that require conformation change in 
envelope glycoprotein prior to fusion [281, 302-305]. IFITM3 inhibits entry of virions into 
endosomal compartments and prevent viral infections before viruses can traverse the bilayer of 
target cells to access cytoplasm [282, 299].  
Using small interfering RNA screening studies, IFITMs were discovered as endogenous inhibitors 
of Influenza A virus (IAV), WNV, and DENV infections [281]. Evidence suggested that 
knockdown of IFITM1, 2 and 3 increased IAV, WNV and DENV infections in mammalian cell 
lines whereas overexpression of IFITM1, 2 and 3 inhibited infection. However, IAV was the most 
susceptible to IFITM3 [281]. Subsequent studies not only confirmed the role of IFITM3 in 
restricting IAV, WNV and DENV, but also defined the IFITM3’s role in restricting infection of 
other unrelated viruses (reviewed in [232, 286, 305]).  
To determine the role of IFITM3 in humans, many of the studies have mostly focused on influenza 
virus infection [306].  One study suggested that IFITM3 inhibits IAV infection by blocking pore 
formation during hemifusion in a pH-dependent manner [302, 307]. While several groups have 
disputed this mode of action, a recent study used live imaging to corroborate that IAV is trapped in 
endosomal compartments enriched in fluorescent IFITM3 which apparently inhibits fusion of IAV 
with cellular membranes [308]. Additionally IFITM3 binds to vesicle-associated membrane protein-
associated protein A (VAPA), a master regulator of endosome-ER lipid transport and alters 
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endosomal cholesterol levels to inhibit virus entry [300]. Further research has shown that 
cholesterol accumulates in the late endosome upon IFITM3 expression [274, 309]. 
While most of IFITM3 characterisation studies have been performed in vitro, IFITM3 has been 
shown to inhibit IAV in vivo. IFITM3 knockout (Ifitm3-/-) mice infected with a less pathogenic IAV 
succumbed to IAV and failed to clear virus infection when compared to WT mice infected with the 
same virus [286]. Moreover, in patients hospitalised with deadly and seasonal IAV a specific 
IFITM3 polymorphism was shown to enhance IAV infection [310].  
Lastly a recent in vitro study showed that IFITM3 is incorporated in HIV-1 glycoprotein (gp) 
particularly gp120, gp41 and gp160 to inhibit envelope processing and subsequently reducing 
infectivity of secreted virions [290]. Furthermore, evidence suggests that IFITM3 is incorporated 
into secreted virions thereby altering infectivity, impairing viral fusion and spread while another 
study showed that IFITM3 sequesters secreted virions in endosomal vesicles during virus assembly 
[273, 274, 276]. 
4.4.2 IFITM3 restricts West Nile virus infection  
Results presented here used a virus library containing 204 variants of WNV, with each virus 
encoding a unique pre-amiR hairpin in the 3′ UTR of its genome targeting specific mouse ISGs. 
Passaging of amiR-encoding virus library at low MOI of 0.1 subjected selective pressure to the 
virus library and allowed selection and enrichment of IFITM3-amiR WNV in WT MEF (Figure 4.2 
A) and Ifnar1-/- MEF (Figure 4.2 B). The IFITM3-amiR WNV came to completely dominate the 
pool of virus retrieved from culture from the second passage in the MEF cells (p3) onwards. This 
highlighted IFITM3 as a major antiviral host factor restricting WNV replication, consistent with the 
siRNA studies noted above, that showed increased WNV replication in vitro with Ifitm3 
knockdown [281]. Further assessment of the impact of incorporation of the IFITM3-amiR into 
WNV in vitro and in vivo required generation of individual IFITM3-amiR and GFP-amiR WNV 
using the CPER approach. Both viruses generated were viable and encoded the correct intended 
pre-amiR hairpins (Figure 4.4). Furthermore, when Vero cells were infected with IFITM3-amiR 
WNV and northern blot analysis performed, results showed that IFITM3-amiR was processed into 
functional mature artificial microRNA by the cellular machinery that targets specific IFITM3 
mRNA transcript to block translation (Figure 4.5).   
In addition, infection of Ifnar1-/- MEF cells with IFITM3-amiR WNV at MOI =0.1 down-regulated 
IFITM3 expression after 48 hours, as shown by western blot analysis (Figure 4.8). However, the 
same effect was not seen in WT MEF infected with either MOI =15 or 20. It is important to note 
that down-regulation of IFITM3 will only be seen in cells that are infected. Since the western blot 
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measures the levels of IFITM3 in the bulk population, the most likely reason for lack of apparent 
effect on IFITM3 expression in the WT MEF is that only a low proportion of cells were infected. 
This seems likely since infection at MOI =10 showed that WT MEF cells were not infected and 
thus at the doses presented of MOI =15 and 20, the percentage of cells infected may be minimal. 
This could be checked in future work by using more sensitive assay such as protein expression 
analysis using real time PCR. Thus, it was hypothesised that just like the Ifnar1-/- MEF, the actual 
infected WT MEF are likely to show IFITM3 knockdown. Consistent with this possibility infection 
of WT MEF at MOI =1 revealed that IFITM3-amiR WNV reached a higher titre than control virus, 
GFP-amiR WNV (Figure 4.9). It is possible that IFITM3 knockdown produced virions of increased 
infectivity limiting subsequent rounds of infection because all cells were already infected. However, 
IFITM3-amiR WNV had only a minor advantage in growth over the GFP-amiR WNV in Ifnar1-/- 
MEF when applied at MOI =1. This may be because the release of viral particles with reduced 
IFITM3 had minimal impact on later viral titre because at MOI =1 it was assumed that each cell 
was infected in the first round of infection. On balance, results in the WT MEF support the 
replicative advantage to the IFITM3-amiR WNV virus over GFP-amiR WNV. More convincing 
data in Ifnar1 -/- MEF may be obtained with a lower MOI for infection, allowing multiple rounds of 
infection. 
Lastly, the selection and enrichment of IFITM3 clone #2 amiR WNV in both WT MEF and Ifnar1-/- 
MEF highlighted the importance of IFITM3 in WNV replication. However only IFITM3-2-amiR 
WNV (IFITM3 #2) was generated and characterised. In future studies it would be wise to generate 
both IFITM3-1- amiR NWV and IFITM3-2- amiR WNV to check why IFITM3-1-amiR WNV was 
not selected. It is possible that IFITM3-1 amiR sequence was inefficient and unable to knock down 
IFITM3 expression as efficient as IFITM3-2 amiR. This could be confirmed by performing western 
blots to determine expression of IFITM3 in Ifnar1-/- MEF cells infected by both viruses. In addition, 
northern blot analysis would confirm whether IFITM3-1-amiR is processed inefficiently in cells. 
4.4.3 Less incorporation of IFITM3 in virions improves infectivity of secreted virus particles 
in vitro and in vivo 
Studies have revealed IFITM3 is incorporated into membranes of secreted virions to reduce their 
infectivity [273]. This implies that when IFITM3 expression is knocked down during infection, less 
IFITM3 is incorporated into secreted virions. Having shown that IFITM3 expression is knocked 
down as early as 48 hpi, meant that less IFITM3 in incorporated into virions from this point forth, 
and infectivity of IFITM3-amiR virus was expected to improve. Immunoprecipitation of virions 
from the medium of infected Ifnar1-/- MEF cells collected between 48 and 72 hpi showed that less 
IFITM3 was incorporated into secreted IFITM3-amiR virions than WT or GFP-amiR (Figure 4.10). 
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Based on this observation, we hypothesised that with less incorporation of IFITM3 in secreted 
virions, infectivity of the virus would improve. Using virus produced by Ifnar1-/- MEF between 48 
and 72 hpi, an infectivity assay showed that IFITM3-amiR WNV was more infectious on WT MEF 
and Ifnar1-/- MEF. Therefore IFITM3-amiR WNV Ifnar1-/- MEF culture supernatants contained less 
IFITM3 and were more infectious both in vitro and in vivo.  It was interesting that IFITM3-amiR 
virus was selected in vitro, given the lack of a cellular immune response; it can be assumed that the 
most critical factor for virus replication in a cell culture environment was to increase its infectivity. 
To further validate the role of IFITM3 in West Nile virus infection and conclusively demonstrate 
that IFITM3 is incorporated into virions to reduce infectivity, over expression studies using IFITM3 
human homologues would be performed. It is anticipated that overexpression of IFITM3 would 
negatively affect infectivity of the secreted virions. 
Published work has shown that mice lacking the Ifitm3 gene readily succumbed to WNV infection 
that was sub-lethal in WT mice, and showed increased progression of clinical signs [311]. 
Consistent with that, results here showed that IFITM3-amiR WNV was more virulent than GFP-
amiR WNV. IFITM3-amiR WNV infected mice showed higher and faster clinical score progression 
and by day 9, all mice had to be culled, whilst 60% of GFP-amiR WNV-infected mice survived. In 
addition, IFITM3-amiR infected mice depicted higher CNS virus infection than mice infected with 
GFP-amiR WNV despite similar infection doses (Figures 4.12 and 4.16 A). Thus, suggesting that 
IFITM3-amiR WNV was more virulent than GFP-amiR WNV.  It would be important to compare 
viral load in the brain through intracranial infection. Intracranial infection would bypass peripheral 
organs and allow a better assessment of effects of infection with IFITM3-amiR WNV on different 
parts of the brain compared to GFP-amiR WNV. 
Studies in this chapter used an in vitro RNAi screening technique and identified IFITM3 as a major 
antiviral factor during West Nile virus infection.  These studies identified a proposed mechanism of 
action by which IFITM3 inhibits West Nile virus infection, as IFITM3 in secreted virions reduced 
infectivity of viruses. Therefore, with knockdown of IFITM3 in Ifnar1-/- MEF cells, less IFITM3 
was incorporated into secreted virions and infectivity of IFITM3-amiR WNV in WT MEF, Ifnar1-/- 
MEF and in a West Nile virus mouse model improved.  
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Chapter 5: In vivo RNAi identifies ATF3 as an important antiviral factor in 
peripheral and CNS dissemination of West Nile virus infection  
5.1 Introduction 
Having identified IFITM3 as an important antiviral host gene against West Nile virus infection in 
vitro, the next step was to perform in vivo RNAi screening to determine which ISG-targeting amiR-
encoding viruses were enriched and selected in mice. We hypothesised that in vivo RNAi screening 
using the generated amiR-encoding West Nile virus libraries would allow identification of host 
determinants that influence WNV infection during peripheral and CNS invasion. Therefore, two 
experimental groups were planned, one to look at peripheral selection (spleen) and another to look 
at CNS invasion (brain).  
Previous work done by Varble et al., 2013 developed an in-vivo RNAi screening approach using 
Sindbis amiR-encoding virus library with each virus was capable of producing a functional amiR 
that targets a specific host gene. Infection of mice with amiR-encoding Sindbis virus libraries led to 
enrichment and selection of host factors that influence Sindbis virus replication. Consequently, two 
host factors involved in transcription, Zfx and Mga were identified as crucial to Sindbis virus. 
Furthermore knockdown of Mga and Zfx resulted in change of the host transcriptome and increased 
Sindbis virus replication [151]. This in vivo RNAi screening showed that it is possible to use this 
approach to identify host factors that influence WNV in vivo. Therefore, basing on this literature, 
we designed our experiment with the aim of identifying host genes that influence WNV infection in 
vivo. 
 
During WNV infection the spleen is the major site of virus replication before the virus can invade 
the CNS.  Following peripheral infection, WNV crosses the BBB to invade and disseminate in the 
CNS. Therefore, it was important to determine host factors that influence early stages of WNV 
infection in the peripheral organs and those that facilitate CNS invasion. Furthermore, the use of in 
vivo RNAi screening approach would allow selection and enrichment of amiR-encoding viruses that 
silence expression of specific host gene that restrict WNV infection.  
5.2 Methods and Materials  
5.2.1 Animal ethics approval for use of animals in experimentation 
Prior to performing animal experiments, animal ethical proposals and related statistical treatments 
were drafted and submitted to the University of Queensland’s Molecular Biosciences Animal Ethics 
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Committee for approval. All animal experiments were performed according to Australian code for 
the care and use of animals for scientific purposes, as defined by National Health and Medical 
Research Council of Australia.  
5.2.2 Infection of mice, blood and tissue sampling 
Four-week old CD-1 mice were infected via the intraperitoneal route with respective viruses as 
stated in the Figure legends. Mice were monitored for clinical signs and each day a clinical score 
was recorded for a period of 21 days. To determine viraemia, mice were tail bled every day until 
seven days post infection. The collected blood processed to obtain sera for immunoplaque assay on 
C6/36 cells. To determine virus burden in mouse brains, mice that presented with encephalitic signs 
were culled and brains harvested. To determine enrichment of viruses in the spleen, mice were 
culled at specified time points and spleens harvested for further experimentation. Harvested spleen 
or brain samples were weighed and homogenised in 1 mL of PBS (TissueLyser II, QIAGEN, USA). 
The generated brain or spleen homogenates were aliquoted into different micro tubes and used for 
RNA purification, passaging or immunoplaque assay on C6/36 cells as described below. 
5.2.3 Generation of amplicons by PCR for deep sequencing 
Total RNA was extracted from 250 µL of spleen or brain homogenate using TRI Reagent LS 
(Sigma Aldrich, USA). Purified RNA was recovered in 100 µL of nuclease-free water and treated 
with RQ1 RNase-free DNase enzyme (Promega, USA). Thereafter 15-cycle one-step RT-PCR was 
performed using 5 µL of purified DNase-treated RNA as template, superscript III one-step RT-PCR 
system with platinum Taq high fidelity DNA polymerase kit (Thermo Scientific, USA), adaptor 
amplion_Forward and adaptor amplicon_Reverse set of primers as shown in chapter four, Table 
4.1. This failed to provide RT-PCR product for spleen samples, and therefore 100 µL of spleen 
homogenate was used to infect C6/36 cells. Spleen homogenates from day 4 were used to infect 
C6/36 cells and at 3 dpi virus culture fluid was harvested. The 3 days time point was considered 
optimal to allow amplification of virus titres while minimising preferential selection of amiR-
encoding viruses during passaging. This is because adequate infection of C6/36 cells with WNV 
often last as long as 7 days post infection. Thereafter, viral RNA was extracted and 15-cycle one-
step RT-PCR performed as described in chapter four methods section.  To obtain amplicons for 
deep sequencing, 2% (w/v) TAE agarose gel electrophoresis was performed; bands were excised 
from gels, purified using Monarch DNA Gel Extraction Kit, (New England Biolabs, USA). 
Thereafter DNA fragments concentration was determined by Nanodrop spectrophotometry before 
Illumina sequencing. The Expected DNA band size was 215 bp 
5.2.4 RNA extraction and generation of amplicons for Sanger sequencing from mouse brains  
Harvested mouse brains were suspended in 1mL of PBS and homogenised with 3 mm stainless steel 
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beads at 30/second frequency for 3 minutes using TissueLyser II, (Qiagen, USA). Total RNA was 
extracted from 150 µL of brain homogenates using TRI Reagent LS (Sigma, USA) according to 
following manufacturer’s instructions. Thereafter, RT-PCR was performed using total RNA as 
template, superscript III one-step RT-PCR system with platinum Taq high fidelity DNA polymerase 
kit (Thermo Scientific, USA) and WNVNSW2011 3′ UTR_Forward and 3′ UTR_Reverse primers (as 
shown in chapter four, Table 4.1) as well as purified RNA as template. The generated 3′ UTR 
amplicons were visualised on 1.4% (w/v) TAE agarose gel electrophoresis, obtained bands were 
excised from gels and purified using Monarch DNA Gel Extraction Kit (New England, USA). 
Thereafter, DNA concentrations were determined by using Nanodrop spectrophotometry before 
Sanger sequencing.  
5.2.5 Growth Kinetics  
To perform in vitro growth kinetics WT MEFs and Ifnar1-/- MEF cells were seeded at 5×105 cells 
per well in six well plates and incubated at 37°C in a 5% CO2 incubator for 12 hours until 90% 
confluent. Thereafter cells were infected with respective viruses at specific MOI as indicated in the 
Figure legends. To perform the infection 200 µL of virus inoculum was diluted to the required 
MOI, added to each well in six well plates and incubated at 37 °C with 5% CO2 humidified 
incubator for 1 hour. For every 15 minutes plates were rocked to prevent the monolayer from drying 
up. Thereafter cell monolayers were washed three times with additive-free DMEM and 3 mL of 
DMEM supplemented with 5% FCS, 50 units/mL of penicillin and 50 µg/mL of streptomycin. At 
specified time point as indicated in Figure legends 150 µL of virus culture fluid was harvested and 
stored at –80°C. Thereafter sample titres were determined by immunoplaque assay on Vero cells as 
described in Chapter 2. The obtained virus titres were log transformed and analysed by GraphPad 
prism version 8.  
5.2.6 Northern blot analysis 
To perform northern blot analysis, Vero cells were seeded at 5×105 cells per well in a 6-well plate 
and incubated at 37°C in a 5% CO2 incubator for 12 hours until 90% confluent. The following day, 
cells were infected with MOI =1 with p1-Vero ATF3-amiR, IRF7-amiR, and PARP11-amiR West 
Nile viruses as previously described in chapter four. Total RNA concentration was determined by 
Nanodrop spectrophotometry and 5 µg of purified RNA was subjected to electrophoresis in 15% 
TBE-Urea polyacrylamide gel (Invitrogen, USA) to denature and separate RNA molecules. 
Thereafter, separated RNA was transferred, cross-linked onto a nylon membrane and hybridised 
with γ-P32-labeled DNA oligonucleotide probe complementary to respective amiRs. The membrane 
was exposed on a Storage Phosphor Screen (GE Healthcare Life Sciences) and imaged using the 
Typhoon FLA 7000 scanner (GE Healthcare Life Sciences). 
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5.2.7 Western blot analysis 
Ifnar1-/- MEF were seeded at 5×105 cells per well in 6-well plate and incubated at 37°C in 5% CO2 
humidified incubator for 12 hours until 90% confluent. The following day, cells were infected with 
ATF3-amiR, IRF7-amiR and PARP11-amiR West Nile viruses at MOI = 1, or mock infected as 
indicated. At 48 hours post infection, infected cells were lysed in NP-40 lysis buffer, sonicated and 
75 µL of each sample treated with 25 µL of 4 ×NuPAGE protein Loading dye at 95°C for 5 
minutes. Thereafter, pre-cast NuPAGE™ 4-12% Bis-Tris Protein Gels, Invitrogen, USA were 
loaded with 25 µL of each sample per lane along with precision Plus Protein  Kaleidoscope Ladder 
(BioRad, USA) and 1×NuPAGE running buffer added before electrophoresis. For electrophoresis, 
western blot power pack was set at 165 Volts for 45 minutes. Thereafter blots were transferred onto 
nitrocellulose membrane using iBlot 2 Dry Blotting System, (ThermoFisher, USA) following 
manufacturer’s instruction. On completion of transfer, membranes were blocked in 1× Pierce 
blocking buffer (ThermoFisher, USA) for 1 hour at 37°C before probing with respective primary 
antibody for 1 hour at 37°C. Subsequently, blots were washed five times using 1× PBS containing 
0.05% Tween 20 (PBS-T) to remove any traces of unbound primary antibody, with each wash 
lasting for five minutes before probing with respective secondary antibody as indicated in 
respective figure legends for 1 hour at 37°C in the dark. Membranes were then washed five times 
using 1× PBS containing 0.05% Tween 20 (PBS-T) to remove any traces of unbound secondary 
antibody. To scan membranes LI-COR Biosciences Odyssey Infrared Imaging System with the 
following specifications: channel =680/800, intensity = auto, focal length = 3 mm, resolution = 169 
µM was used to visualise protein bands.  
5.3 Results 
5.3.1 In vivo RNAi screening shows enrichment of ATF3 amiR-encoding West Nile virus in 
the spleen 
In order to identify host genes that influence WNV replication in peripheral organs, in vivo RNAi 
screening was performed. Four weeks old mice were infected via the intraperitoneal route with 106 
pfu of p1-Vero ISG-targeting amiR-encoding virus library mixed with 200 pfu of scrambled amiR-
encoding WNV virus library (Figure 5.1 A). For in vivo RNAi screening in the spleens, a higher 
infectious dose of 106 pfu was used to guarantee ample amplification of virus in peripheral since 
recovered virus titres for particularly WNVNSW2011 are often very low in spleens. In addition, 106 
pfu infection dosage was considered optimal basing on the initial weight of mice before infection. 
Ten mice were sacrificed at each time point (2, 3, and 4 dpi) and spleens harvested for further 
analysis. Splenic virus was detectable in 30-70% of mice at the various time points (Figure 5.1 B). 
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Several attempts to obtain an RT-PCR amplicon for deep sequencing from RNA purified from 
spleens failed. Hence, spleen homogenates were re-propagated on C6/36 cells, virus culture fluid 
harvested and RNA purified for RT-PCR. The latter method was successful with 6 out 7 spleens 
RT-PCR amplicons recovered at 4 dpi. This suggested that there were either inhibitory compounds 
in the spleen RNA that interfered with the RT-PCR, or the ratio of viral to cellular RNA was too 
small. 
 
Figure 5.1 In vivo screening RNAi screening in periphery.A): A representation of the 
experimental plan used to perform in vivo RNAi screening in spleen. A total of 106 pfu of p1-Vero 
ISG-targeting amiR-encoding virus library was mixed with 200 pfu of Scrambled amiR-encoding 
WNV virus library and used to infect CD-1 mice. At 2 dpi, 3 dpi and 4 dpi 10 mice for each time 
point were culled and spleens harvested. B) Spleens were homogenised in 1 mL PBS and virus 
titres were determined on C6/36 cells. Virus titres shown were log10 transformed mean values and 
represented as pfu/gram. 
 
Deep sequencing data were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using Salmon transcript quantification data script tool (Appendix 2) to determine 
enrichment of amiR-encoding virus variants in 4 dpi mouse spleens. Deep sequencing data revealed 
that ATF3-amiR WNV was enriched in 4 out of 6 spleens at percentages 18.31%, 76.86%, 46.85%, 
97.35% of the total amiR-encoding virus population while in the remaining two spleens ATF3-
amiR WNV was present at 0.22% and 0.13% (Table 5.1 and appendix 7). Thus, ATF3 is likely to 
be a critical antiviral factor controlling West Nile virus splenic infection. Therefore, a more in-
depth characterisation of ATF3-amiR WNV was warranted and experiments were designed to 
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further understand the role of ATF3 during peripheral WNV infection as discussed in subsequent 
sections of this thesis. Furthermore none of the scrambled amiR-encoding viurses or  GFP-amiR 
WNV and  MiR-124 amiR WNV added as internal controls were selected and enriched in the 
spleens. This showed that selection was not occuring at random. However to provide an adequate 
control for this experment p1-Vero ISG targeting amiR WNV library : p1-Vero scrambled amiR 
WNV library needed to be mixed in ratio of 1:1. This was not possible since the scrambled library 
contained more than 6000 individual amiR variants, as the control library was very large compared 
to the ISG- targeting virus library. Therefore it would be enlightening to repeat this experiment 
while using equal ratio of p1-Vero ISG targeting amiR WNV library : p1-Vero scrambled amiR 
WNV library. This would determine whether ATF3-amiR WNV is still selected and enriched in the 
spleens in presence of an equal amount of scrambled amiR-encoding viruses 
Table 5.1 The most enriched amiR-encoding West Nile viruses in the spleens 
Spleen 1 Spleen 2 Spleen 3 Spleen 4 Spleen 5 Spleen 6 
AmiR % AmiR % AmiR % AmiR % AmiR % AmiR % 
Parp10 34.45 Atf3 76.86 Atf3 46.85 Atf3 97.35 Fbxo39 80.29 Tlr3 32.77 
Atf3 18.31 Usp18 6.47 Mlkl 20.58 Fbxo39 1.15 Ly6e 12.88 Irf2 19.85 
Rtp4 15.77 Mapk8 5.05 Gbp2 14.64 Trex1 0.41 Adar 1.82 Mapk8 12.79 
Rtp4 14.75 Ikbkb 4.69 Brd4 9.53 Ifih1 0.21 Ifitm3 0.80 Mlkl 11.30 
Gbp6 6.12 Ifna1 1.38 Ddx58 4.10 Mlkl 0.07 Ifih1 0.49 Oas2 6.27 
Irf7 3.62 Cpeb3 1.16 Stat1 1.52 Oas1a 0.06 Ikbke 0.41 Ikbke 4.44 
Clec4d 2.03 Parp10 0.69 Wwoxv 0.87 Cytip 0.05 Mapk8 0.28 Ddx58 3.65 
Fbxo39 1.77 Irf5 0.51 Fa2h 0.55 Ddx58 0.05 Eif2ak2 0.22 Fbxo39 2.34 
Map4k2 1.12 Rtp4 0.37 Ifi27 0.18 Tlr9 0.04 Atf3 0.22 B2m 1.88 
Gbp2 0.68 Map4k2 0.31 Map3K8 0.13 Mapk8 0.04 Dhx9 0.16 Ifna4 1.84 
          
Mitd1 0.53 
          
Ifitm3 0.25 
          
Parp14 0.24 
          
Irgm 0.24 
          
Atf3 0.13 
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To further analyse deep sequence data obtained from peripheral RNAi screening, a comparison was 
made between enrichment of ATF3-amiR WNV in mouse spleens and the p1-Vero virus stock that 
was used to infect mice (Table 5.2). Percentage enrichment of ATF3-amiR WNV at p1-Vero and 
mouse spleens in the whole virus libraries were determined and recorded. It was noted that ATF3 
#2-amiR WNV was among the over represented amiR-encoding viruses in p1-Vero.  However, 
other overly represented amiR-encoding viruses such as NMI clone #2 amiR-encoding virus, IFI35 
clone #2-amiR WNV, which were enriched at 4.58% and 2.54% in p1-Vero respectively were not 
selected or enriched in any of the spleens. Furthermore, selection and enrichment of ATF3 clone #2 
amiR WNV in mouse spleens highlighted the importance of ATF3 during peripheral WNV 
replication. However only ATF3-amiR WNV (Clone 2) but not ATF3 #1-amiR WNV was selected 
and enriched in mouse spleens. It is possible that the ATF3-1 amiR sequence was not as effective as 
ATF3-2 amiR at knocking down expression of ATF3 in cells. Future experiments should aim at 
addressing this research question as to why ATF3 #1 was not enriched and selected in spleens. 
Table 5.2: Enrichment and selection of ATF3-amiR WNV in mouse spleen 
  Percentage enrichment 
AmiR p1-Vero Spleen 1 Spleen 2 Spleen 3 Spleen 4 Spleen 5 Spleen 6 
ATF3 #1 0.37 0 0 0 0 0 0.02 
ATF3 #2 3.41 18.31 76.86 46.85 97.35 0.22 0.13 
 
5.3.2 In vivo RNAi screening in the brain identifies ATF3, IRF7 and PARP11 as major 
antiviral factors that control West Nile virus infection 
A total of 10 mice were infected intraperitoneal route with 105 pfu of p1-Vero ISG-targeting amiR-
encoding WNV library mixed with 200 pfu of scrambled amiR-encoding WNV virus library. Mice 
were monitored for 21 days and clinical scores recorded each day (Figure 5.2). A relatively low 
infectious dose was used to allow virus competition, subsequent enrichment and selection of amiR-
encoding viruses that deplete host mRNAs whose products restrict virus replication. Mice were 
sacrificed when they presented with encephalitic signs, and brains harvested for further analysis. A 
survival curve showed that 50% of the mice succumbed to 105 pfu of amiR WNV library (Figure 
5.3A). 
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Figure 5.2 In vivo RNAi screening in the CNS. A) A representation of the experimental plan used 
to perform in vivo screening of RNAi in mouse brains. A total of 105 pfu of p1-Vero ISG-targeting 
amiR-encoding virus library was mixed with 200 pfu of scrambled amiR-encoding WNV virus 
library and used to infect ten 4-week old CD-1 mice, which were monitored for 21 days. Four 
mouse brains and one brain were harvested on signs of encephalitis at 8 and 10 dpi respectively. B) 
Clinical scores for each group were recorded each day for 21 days. For the clinical score 0 denoted 
Normal feeding and appearance. Clinical score 1: denoted slightly ruffled fur and/or general loss of 
condition respectively. Clinical score 2: denoted increase in general loss of behaviour, appearance, 
breathing changes, twitching and anti-social behaviour. Clinical score 3 denoted first signs of 
encephalitis such as severely hunched posture, partial paralysis and or full paralysis while clinical 
score 4 denoted death.  
 
 
Figure 5.3 Percentage survival and virus burden in mouse brains infected with p1-Vero ISG-
targeting amiR-encoding virus library.  A) Percentage survival of mice infected with 105 pfu of 
p1-Vero ISG-targeting amiR-encoding virus library mixed with 200 pfu of scrambled amiR-
encoding WNV virus library. Four mice and one mouse were culled on signs of encephalitis at 8 dpi 
and 10 dpi respectively and the remaining mice observed for signs of encephalitis until 21 dpi.  B) 
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Virus burden in mouse brains determined by immunoplaque assay on C6/36 cells and presented as 
three independent experiments per mouse brain. Virus titre was determined as pfu/gram of mouse 
brain. 
 
Brains of mice with encephalitic signs were homogenised in PBS and virus titre determined by 
immunoplaque assay (Figure 5.3B). Thereafter, using part of the brain homogenates (150 µL), total 
RNA was extracted and RT-PCR performed to generate an amplicon for deep sequencing. Results 
from RT-PCR showed that RNA extracted from three mouse brains (brains 2, 3, and 4) produced 
the correct sized RT-PCR amplicons, which were purified by DNA gel extraction. The two mouse 
brains that did not form RT-amplicons had low virus titres and it is possible that the ratio of virus 
RNA to cellular RNA in the brains could have been too small (Figure 5.3 B). Obtained RT-PCR 
amplicons were deep sequenced to determine enrichment of amiR-encoding viruses in mouse 
brains.  
Deep sequencing data were uploaded onto Galaxy Australia (UQ Research Computing Center) and 
analysed using the Salmon tool for transcript quantification (Appendix 2). The analysis revealed 
that each of the three mouse brains contained one predominantly enriched amiR-encoding virus. 
Mouse brains 2, 3 and 4 (Figure 5.3 B) contained PARP11-amiR WNV, ATF3-amiR WNV and 
IRF7-amiR WNV respectively (Table 5.2 and appendix 8).  Furthermore, each mouse had a single 
dominant virus with more than 97.9% representation. None of the control viruses, either scrambled 
amiR-encoding viruses, GFP-amiR or miR-124-amiR West Nile viruses were selected or enriched 
in mouse brains. 
Table 5.3  Enrichment and selection of ATF3, IRF7 and PARP11 amiR encoding in mouse 
brains 
Brain 2 Brain 3 Brain 4 
AmiR % AmiR % AmiR % 
Parp11 97.93 Atf3 99.44 Irf7 99.60 
Irf7 1.38 Parp11 0.25 Atf3 0.06 
Atf3 0.38 Irf7 0.06 Parp11 0.06 
 
As a summary, the log fold change of spleen and brain samples relative to the p1-Vero virus stock 
(input virus stock) was determined. To determine the log 10 fold change enrichment, percentage 
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enrichment of individual amiR-encoding encoding viruses at p1-vero was used as baseline for 
comparison between enrichment in mouse spleens and brains. A ratio depicting the enrichment was 
obtained and log transformed to obtain the log 10 fold change and plotted by using GraphPad prism 
version 8. Results revealed that ATF3-amiR WNV was the most enriched virus in mouse spleens 
and brains (Figure 5.4). 
 
Figure 5.4 Selection and enrichment of amiR-encoding viruses in mouse spleens and brains.  
Diagram showing log 10 fold change in number of reads between p1-Vero virus library deep 
sequencing and enrichment of amiR-encoding viruses in the brain or spleen of mice infected with 
amiR-encoding virus libraries.  
 
5.3.3 Generation of in vivo selected amiR-encoding West Nile viruses 
The selection and enrichment of a different amiR-encoding virus in each of the three mouse brains 
suggested that the selected amiRs-encoding WNV that target ATF3, IRF7 and PARP11 host genes 
could function in similar biological pathways. In order to further investigate the roles of the 
particular genes identified, individual ATF3-amiR, IRF7-amiR and PARP11-amiR WNV were 
generated. Briefly, plasmid DNA for ATF3-amiR, IRF7-amiR and PARP11-amiR were retrieved 
and amiR fragments generated for CPER as described in Chapter 4. Thereafter CPER was 
performed to generate infectious cDNA for ATF3-amiR, IRF-amiR and PARP11-amiR for 
transfection into HEK 293 (Figure 5.5 A). Virus culture fluid was harvested at 3 days post-
transfection and the p0-293T virus stocks titres determined by immunoplaque assay on Vero cells 
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(Figure 5.5 B).  
 
 
Figure 5.5 Generation of individual amiR-encoding viruses. A) Diagram representation of 
CPER strategy used to generate infectious ATF3-amiR, IRF7-amiR or PARP11-amiR encoding 
cDNA transfected into HEK293 cells to generate p0-293T virus library. B) Recovered p0-293T 
virus stocks were titred on a Vero cell monolayer by immunoplaque assay and plaque morphology 
recorded as similar between the different amiR-encoding viruses. 
 
Vero cells were infected with p0-293T virus stocks at MOI =1 to amplify the virus titres and 
generate large virus stocks for subsequent experiments. At 3 days post infection, virus culture 
supernatants were harvested as p1-Vero and virus stock titres determined by immunoplaque assay 
on Vero cells (Figure 5.6 A). Thereafter, RNA was extracted and one-step RT-PCR performed to 
generate 3′ UTR PCR amplicons as described in chapter four. Analysis of RT-PCR gel image 
revealed that the generated RT-amplicons produced correct sized bands. Therefore, the generated 
RT-amplicons were purified by DNA gel extraction and Sanger sequenced to further confirm 
whether they retained the inserted pre-amiR hairpins with no mutations. Sanger sequencing 
revealed that all three generated amiR-encoding virus stocks retained inserted pre-amiR hairpins. 
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Figure 5.6  Generation of p1-Vero virus stocks. Generation West Nile virus stocks. Vero cells 
were infected with p0-293T virus stocks of ATF3-amiR and IRF7- amiR and PARP11-amiR at 
MOI =1 to generate larger volumes of p1-Vero respective virus stocks. At 72 hpi, virus culture 
fluids were harvested, clarified by centrifugation and stored for future experiments. Generated virus 
stocks were titrated on Vero cells by immunoplaque assay. B) Viral RNA was extracted from 
culture fluid and subjected to RT-PCR using 3′ UTR_Forward and 3′ UTR_Reverse primers. 
Expected DNA band size (780bp).  
 
The obtained Sanger sequence results were validated by mfold to confirm the structure of pre-amiR 
hairpin. Results showed that all three amiR-encoding virus stocks conformed to pre-amiR hairpin 
structures (Figure 5.7).  
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Figure 5.7  Predicted pre-amiR hairpin structures of p1-Vero virus stocks.  A, B and C are 
predicted structures pre-amiR hairpin. All three p1-Vero virus stocks i.e., ATF3-amiR WNV, IRF7-
amiR WNV and PARP11-amiR WNV retained their respective pre-amiR hairpin structures. 
Highlighted sequences in red represent the mature amiR sequences when pre-amiR hairpins are 
processed into functional amiR.  
 
5.3.4 Generated ISG-amiR West Nile viruses produce mature amiR product in infected cells   
In order to determine whether the inserted pre-amiR hairpins were processed into functional mature 
micro RNAs by the host cellular machinery, expression of mature miRNAs in Vero cells infected 
with respective amiR-encoding viruses and uninfected Vero cells was established. To do this, Vero 
cells were infected with ATF3-amiR WNV, IRF7-amiR WNV, PARP11-amiR WNV at MOI =1 or 
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mock un infected. At 48 hpi, cells were lysed and RNA extracted for northern blot analysis. Results 
showed that all pre-amiR hairpins inserted in the 3′ UTR of WNVNSW2011 were processed by cellular 
machinery into miRNAs (Figure 5.8). 
 
Figure 5.8 Detection of mature amiRs in infected Vero cells by northern blot analysis.  Cells 
were infected with PARP11-amiR, IRF7-amiR and ATF3-amiR West Nile viruses or mock 
infected. Enriched small RNA fractions were extracted at 48 hpi using Tri reagent (Sigma Aldrich, 
USA) and 5 µg of RNA was subjected to electrophoresis in 15% TBE-Urea polyacrylamide gel 
followed by northern blot analysis with γ-P32-labeled DNA probes complementary to PARP11-
amiR, IRF7-amiR and ATF3-amiR respectively. The mature amiR band (21 nts) was detected in 
RNA samples from cells infected with respective amiR-encoding viruses. The nt denotes 
nucleotides. 
 
5.3.5 Mature amiR from ISG-amiR West Nile viruses effectively knock down expression of 
targeted ATF3 and IRF7 protein 
Ifnar1-/- MEF cells were infected with ATF3-amiR WNV, IRF7-amiR WNV, PARP11-amiR WNV 
at MOI =1. At 48 hpi, cells were lysed in NP-40 lysis buffer and western blot performed. Results 
showed that infection with ATF3-amiR, GFP-amiR and WT WNV generated equal amounts of 
WNV-E protein in infected cells. However ATF3 expression in ATF3-amiR infected cells was 
reduced compared to GFP-amiR and WT WNV infected Ifnar1-/- MEF cells (Figure 5.9).   
15 
20 
25 
30 
50 
75 
90 
100 
250 
nt 
amiR  
Pre-amiR 
 107 
 
Figure 5.9 Infection with ATF3-amiR WNV knocks down expression of ATF3 gene in Ifnar1-/- 
MEF.  Ifnar1-/- MEF cells were infected with ATF3-amiR, GFP amiR, and WT West Nile viruses 
at MOI =1 or mock uninfected. At 48 hpi, cells were lysed in NP40-containing lysis buffer and 
subjected to western blot electrophoresis. Blots were probed with anti-ATF3 mAb,, anti-WNV-E 
mAb (4G2) and anti-GAPDH mAbs. Predicted sizes are 24kDa, 37kDa and 42kDa for ATF3, 
GAPDH and E-protein respectively. 
 
Similarly, infection of Ifnar1-/- MEF with IRF7-amiR WNV resulted in the knock down of IRF7 in 
Ifnar1-/- MEF, with more evident knockdown in experiment 1 and less knockdown in experiment 2 
(Figure 5.10).   
 
Figure 5.10 Infection with IRF7-amiR WNV knocks down expression of IRF7 in Ifnar1-/- 
MEF.  The Ifnar1-/- MEF were infected with IRF7-amiR, GFP amiR, and WTNSW2011 West Nile 
viruses at MOI =1) and mock uninfected. At 48 hpi cells were lysed in NP40-containing lysis buffer 
and subjected to western blot electrophoresis. Blots were probed with anti-IRF7 mAb, 4G2 WNV-E 
and mouse IgG GAPDH antibodies recognising IRF7, WNV-E and GAPDH respectively. Predicted 
sizes are 44 kDa, 37 kDa and 42 kDa for IRF7, GAPDH and E-protein respectively. 
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Lastly, to determine whether PARP11-amiR WNV knocks down expression of PARP11 in Ifnar1-/- 
MEF cells, western blot was performed using obtained cell lysates at 48 hpi. The PARP11 antibody 
used was not effective at detecting PARP11 expression in Ifnar1-/- MEF cells although Ifnar1-/- 
MEF cells were greatly infected by WNV as shown by WNV envelope protein expression (Figure 
5.11). Furthermore, it is possible that PARP11-amiR did not successfully knockdown expression of 
PARP1l protein in cells. However, further work would have to be done to confirm that the antibody 
is recognising PARP11.  
 
Figure 5.11 Infection of Ifnar1-/- MEF with PARP11-amiR WNV. The Ifnar1-/- MEF were 
infected with PARP11-amiR, GFP amiR, and WT West Nile viruses at MOI =1 or mock uninfected. 
At 48 hpi cells were lysed in NP40-containing lysis buffer and subjected to western blot 
electrophoresis. Blots were probed with anti-PARP11, mAb, anti-WNV-E mAb (4G2) and anti-
GAPDH mAbs. Predicted sizes are 30 kDa, 37 kDa and 42 kDa for PARP11, GAPDH and E-
protein respectively. 
 
5.3.6 Viral Growth Kinetics 
To determine the role of ATF3, IRF7 and PARP11 in WNV infection, the replication efficiency of 
ATF3-amiR WNV, PARP11-amiR WNV and IRF7-amiR WNV compared with GFP-amiR WNV 
was evaluated in WT MEFs and Ifnar1-/- MEF. Both WT MEF and Ifnar1-/- MEF were infected at 
MOI =1 with respective viruses. At 0, 24, 48 and 72 hpi, virus culture fluid was collected and titres 
determined for each time point by immunoplaque assay on Vero cells. Three independent 
experiments were performed for each cell lines and virus. Results revealed that ATF3-amiR WNV, 
PARP11-amiR WNV and IRF7-amiR WNV replicated better than GFP-amiR WNV in both WT 
MEF and Ifnar1-/- MEF (Figure 5.12). Despite that there was no difference in replication at 0 hpi 
and 24 hpi, ATF3-amiR WNV replicated significantly higher than GFP-amiR WNV in WT MEF at 
48 hpi and 72 hpi (Figure 5.12 A). Infection of Ifnar1-/- MEF with ATF3-amiR WNV replicated 
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significantly higher than GFP-amiR WNV at 0 hpi, 24 hpi and 48hpi in, with no difference at 72 
hpi. This implied that by 48 hpi, all Ifnar1-/- MEF cells are infected thus limiting further rounds of 
infection. Infecting WT MEF with PARP11-amiR WNV revealed that PARP11-amiR WNV 
replicated significantly better than GFP-amiR WNV at 48 hpi and 72 hpi. When Ifnar1-/- MEF were 
infected with PARP11-amiR WNV at MOI =1, PARP11-amiR WNV replicated better than GFP-
amiR WNV at 0 hpi and 24 hpi and no difference in replication was observed at 48 hpi and 72 hpi.  
Furthermore, when WT MEF were infected with IRF7-amiR WNV, the virus replicated better at 0 
hpi and 72 hpi while infection of Ifnar1-/- MEF with the same virus showed that replication 
improved only at 72 hpi. 
 
Figure 5.12 In vivo selected amiR-encoding viruses replicate better than GFP-amiR WNV in 
WT MEF and Ifnar1-/- MEF. Viral growth kinetics of ATF3-amiR WNV, IRF7-amiR WNV, 
PARP11-amiR WNV and GFP-amiR WNV on WT MEF and Ifnar1-/- MEF. Cells were infected at 
MOI =1 for up to 72 hours post infection. Virus titres shown are log10 transformed mean values and 
represented as pfu/mL ± SEM, as determined by immunoplaque assay on Vero cells. Three 
independent experiments were performed for each cell line. Significant differences between the 
means are differentiated using two-way ANOVA with Dunnett’s multiple comparison test where *p 
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< 0.05, **p <0.005, ***p < 0.001, ****p < 0.0001. The results represent the means of three 
independent infection experiments and errors bars show standard error of the mean.  
 
 
5.3.7 Increased virulence of ISG targeting amiR-encoding West Nile Viruses  
To further investigate the role of ATF3-amiR WNV, IRF7-amiR WNV and PARP11-amiR WNV in 
West Nile virus infection, the generated recombinant WNVNSW2011 viruses encoding corresponding 
individual amiRs were examined in vivo. To determine virulence of amiR-encoding viruses, 40 
four-week-old CD-1 mice were infected with 106 pfu of respective viruses via the intraperitoneal 
route and monitored for 21 days post infection. Each day, each animal’s clinical score was 
determined and recorded. Mice that succumbed to encephalitis were culled and brains harvested for 
further analysis. At the end of the animal experiment, a survival curve was generated to determine 
percentage survival of mice infected with recombinant viruses in comparison to GFP-amiR WNV 
control. Results revealed that infection with each of ISG-targeting amiR-encoding virus caused 
100% mortality in mice and each virus was more virulent than GFP-amiR WNV (Figure 5.13).  By 
8 dpi and 9 dpi all mice infected with ATF3-amiR WNV and PARP11-amiR, and IRF7-amiR WNV 
had succumbed to WNV respectively compared to mice infected GFP-amiR WNV, which had 6/10 
(60%) mice survive until 21 dpi  
 
Figure 5.13 Percentage survival of in vivo selected ISG-targeting amiR encoding virus. Four-
week-old CD-1 mice were challenged with106 pfu of ATF3-amiR WNV, IRF7-amiR WNV or 
PARP11-amiR WNV p1-Vero generated virus stocks. Each virus group contained 10 mice, which 
were monitored for 21 days and at the survival curve generated. Analysis was performed using 
Mantel-Cox log-rank test ***p < 0.001 (IRF7-amiR WNV vs GFP-amiR WNV), ****p < 0.0001 
(PARP11 and ATF3-amiR WNV vs GFP-amiR WNV).  
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5.3.8 Increased progression of clinical signs in mice infected with ATF3-amiR, IRF7-amiR 
and PARP11-amiR West Nile viruses 
Mice infected with ATF3-amiR WNV, IRF7-amiR WNV and PARP11-amiR WNV presented an 
increase in progression and severity of observed clinical signs, such as ruffled fur and/or general 
loss of condition, loss weight, change in breathing, twitching, anti-social behaviour, severely 
hunched posture, paralysis among others (Figure 5.14).  
 
Figure 5.14 Increased progression of clinical signs in mice infected with ATF3-amiR, IRF7-
amiR and PARP11-amiR West Nile viruses. Four groups of mice were infected with (A) ATF3-
amiR WNV, (B) IRF7-amiR WNV, (C) PARP11-amiR WNV and (D) GFP-amiR WNV and each 
group monitored daily for signs of encephalitis. Clinical scores for each group were recorded each 
day for 21 days. For the clinical score 0 denoted Normal feeding and appearance. Clinical score 1: 
denoted slightly ruffled fur and/or general loss of condition respectively. Clinical score 2: denoted 
increase in general loss of behaviour, appearance, breathing changes, twitching and anti-social 
behaviour. Clinical score 3 denoted first signs of encephalitis such as severely hunched posture, 
partial paralysis and or full paralysis while clinical score 4 denoted death.  
 
5.3.9 Viraemia 
To determine viraemia, mice were tail bled for the first seven days to obtain sera for immunoplaque 
assay on C6/36 mosquito cells. Mice infected with ATF3-amiR WNV, IRF7-amiR WNV and 
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PARP11-amiR WNV all showed a trend for increased viraemia compared to mice infected with the 
control virus, GFP-amiR WNV. The differences were only significant for mice infected with ATF3-
amiR WNV at 1 dpi, 3 dpi and 4 dpi (Figure 5.15). Viraemia lasted until 4 dpi and by 5 dpi, there 
was no viraemia detectable. 
 
 
Figure 5.15 Increased viraemia in mice infected with ISG-targeting amiR encoding West Nile 
viruses. To determine viraemia, mice were tail bled from 1 dpi to 7 dpi. Serum virus titre was 
determined by C6/36 immunoplaque assay using WNV-E-16 antibody. Obtained titres were log 
transformed and plotted using GraphPad prism version 8. Error bars represent Standard Error of the 
mean log transformed virus titre per group. Analysis performed using 2-way ANOVA with 
Dunnett’s multiple comparison against GFP-amiR WNV control *p < 0.05 and **p <0.005. The 
limit of detection is 40 pfu/mL, equivalent to 1.602 log 10.  
 
5.4 Discussion  
5.4.1 Selection of ATF3 as important antiviral factor in peripheral and CNS dissemination of 
West Nile Virus infection  
ATF3 is induced by stress, such as inhibition of protein synthesis or infection, in infected cells 
[312, 313]. Four out of six mouse spleens that were analysed by deep sequencing showed that 
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ATF3-amiR WNV was selected and enriched when mice were infected with ISG-targeting amiR 
encoding WNV library mixed with scrambled amiR control. Furthermore, one mouse brain out of 
five brains showed selection and enrichment of ATF3-amiR WNV, suggesting that ATF3 is 
important in WNV infection. To assess the role of ATF3 as an important antiviral against WNV, in 
vitro characterisation was performed. Viral growth kinetics on WT MEF and Ifnar1-/- MEF cells 
revealed that ATF3-amiR WNV replicated better than GFP-amiR WNV in WT MEF and Ifnar1-/- 
MEF cells. Furthermore ATF3-amiR targeting murine Atf3 expression significantly knockdown 
expression of Atf3 in Ifnar1-/- MEF infected with ATF3-amiR WNV. Lastly, infection of Vero cells 
with ATF3-amiR WNV at MOI =1 and subsequent northern blot analysis on cellular RNA showed 
that ATF3-amiR is processed into a function mature ATF3 micro RNA by the host cell machinery. 
Therefore, it is the ATF3-amiR (siRNA) that blocks translation of Atf3 mRNA into a functional 
Atf3 protein. This could explain the low expression of Atf3 in Ifnar1-/- MEF cells. 
Having shown this, 4-week old CD-1 mixed sex mice were infected with 106 pfu of ATF3-amiR 
WNV and monitored for a period of 21 days, recording clinical score every day. Mice infected with 
ATF3-amiR WNV showed increased progression of clinical signs and symptoms characterised by, 
increased progression of encephalitic signs and by day nine post infection, all mice had succumbed 
to ATF3-amiR WNV. Furthermore, mice infected with ATF3-amiR WNV exhibited significant 
increase in viraemia at 1 dpi and 3 dpi. Perhaps increased viraemia could have contributed to the 
severity of infection and disease outcome.  
5.4.2 ATF3 roles in immune response 
ATF3 is a member of the ATF/cyclic AMP response element binding family of transcription 
factors, an adaptive response element in stress regulated by stress signal. Some of the stress signals 
in vivo include: ischemia,	 wounding, neural damage, toxicity, and seizure while in vitro stress 
signals may include: change in serum factors, cytokines, genotoxic agents, cell death-inducing 
agents among others [314]. ATF3 is usually expressed at low levels in neurons but in the event of 
neural damage, ATF3 expression is up regulated [315]. ATF3 expression is induced during neuron 
injury with prolonged ATF3 expression believed to facilitate axonal renewal and recovery in the 
nervous system [316]. ATF3 consists of 181 amino acids with a molecular mass of 22- 24 k Da 
[317-319]. ATF3 expression is induced by LR ligands to negatively modulates TLR signalling early 
in infection or stress related events [319, 320]. Micro-array studies have shown that ATF3 enables 
affected cells to cope with extracellular changes while most healthy tissues/ cells express basal 
levels of ATF3 [315, 318, 321, 322]. Two major roles of ATF3 have been postulated such as ATF3 
mediates cellular response to stress and regulates cellular proliferation with different studies 
suggesting that ATF3 could serve as a pro-apoptotic gene or anti apoptotic gene depending on the 
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promoter [323-325]. In addition, a recent study suggests that ATF3 represses cell cycle progression. 
Network system analysis postulated that ATF3 is an essential member of the NF-κB family of 
transcription factors that regulates expression of pro inflammatory cytokines such as IL-1β, IL-6, 
IL-12, TNFα and CCL4 [326]. Furthermore, research has shown that ATF3 expression stimulates 
cell death and cell cycle machinery. Although there is not much literature concerning the role of 
ATF3 in virus infection, ATF3 is shown to facilitate ER stress response, referred to as unfold 
protein response [327, 328]. Unfold protein response results from mismatched folded proteins in the 
lumen of the ER. ATF3 attempts to reinstate normal ER protein folding and processing through 
hindering translation of new protein and transportation of new protein into the ER. Therefore, ATF3 
stimulates transport of unfolded protein from the ER to cytoplasm for destruction and recruits 
molecular markers that ensure proper protein folding. In the event that ER stresses remain, 
apoptosis is induced [315]. Based on this literature, there is a possibility that ATF3 is involved 
regulation of immune response during WNV infection. Future research should aim at understanding 
whether ATF3 is involved in ER response or control of apoptosis during WNV infection. This will 
further elucidate the role of ATF3 in WNV infection. 
5.4.3 Enrichment of IRF7-amiR WNV in vivo 
During WNV infection, specific viral motifs such as ssRNAs, dsRNAs are sensed by TLR3 and 
TLR7 in endosome or MDA5 and RIG-I in cytoplasm. As a result, this activates transcription of 
IRF-3 and IRF-7, induction of IFN response and subsequent activation of ISGs [213]. Furthermore, 
infection of Irf7 deficient (Irf7-/-) mice with WNV results into increased viraemia, elevated virus 
burden in peripheral organs and CNS as well as higher mortality rate than in mice infected with 
WT-WNV [210].  Furthermore, when Irf7-/- primary macrophages were infected with WNV, IFN-α 
gene expression and protein production significantly reduced. This highlighted that IRF7 is an 
important antiviral host gene against WNV infection. Selection and enrichment of IRF7-amiR 
WNV in one mouse could be attributed to the fact that IRF7 is a known antiviral host gene against 
WNV. Furthermore, when mice were infected with IRF7-amiR WNV, higher mortality rate, 
viraemia and viral burden in the CNS was observed compared to the control group. However, it 
should be noted that the input virus used to infect mice contained more IRF7-amiR WNV variants 
at a percentage of 1.74%. This might have provided IRF7-amiR WNV greater advantage over other 
amiR-encoding variants in the library. It would be very informative to perform this in vivo RNAi 
screening a number of times to show whether IRF7-amiR WNV is still selected. The fact that only 
10 mice were infected with the p1-Vero virus library, warranties the need for experiments.   
Furthermore, it was only IRF7-2-amiR WNV that was selected in vivo although two amiR targeting 
IRF7 were present in the library. Therefore, another research question would be to understand why 
IRF7-20amiR WNV was selected and enriched in mice brains over IRF7-1-amiR WNV. It is 
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important to determine the effectiveness of the other IRF7-amiR. Future work would have to 
examine the ability both of IRF7-amiR West Nile viruses to knockdown its targets and enhance 
replication. Lastly, another way to test the virulence of IRF7-amiR WNV in mice would be to infect 
mice via intracranial route in order to assess the effects of IRF7-amiR WNV on the brain. This 
would bypass the need for peripheral infection and define effects of IRF7-amiR WNV on WNV 
replication in the different parts of the brain. 
5.4.4 Selection and enrichment of PARP11-amiR WNV in vivo 
From the literature, PARP11 belongs to the Poly ADP-ribosyltransferase poly (ADP-ribose) 
polymerase family. This family consists of 17 members, each with a unique structure and cellular 
functions such as PARP 1, 2, 3, 4, 5a, 5b, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 [329]. Members in 
PARP family act as catalysts that transfer of ADP-Ribose from nicotinamide adenine dinucleotide 
(NAD+) to target proteins to either form mono (ADP-ribosyl)ation (MARylation) or poly (ADP-
ribosyl)ation (PARylation) of proteins. The ADP-ribosylation is a crucial stage in many biological 
processes such cell signalling, DNA repair, gene regulation and apoptosis [330-332]. Research has 
shown that PARP1 activates NF-κβ during inflammatory disorders, regulation of oxidative, 
genotoxic and metabolic stress responses, which are often reported during cancers, inflammatory- 
related diseases and metabolic disorders. Therefore, PARP1 inhibitors are beneficial in controlling 
these conditions [333, 334]. Moreover, PARPs are utilised in generating oncology therapeutics, 
with the first licenced drug being against ovarian cancers being a PARP inhibitor [335, 336].  
Current research has shown that PARPs are linked to IFN-I signalling and priming of antiviral 
defence to protect cells from invading pathogens [337]. For instance, PARP1 and PARP10 are 
linked to activation of NF-κβ [334, 338]. In addition, PARP9 controls histone methylation to 
increase interferon signalling and expression of interferon-stimulated genes [339]. A recent study 
showed that PARP11 mono-ADP-ribosylates ubiquitin E3 ligase β-transducin repeat-containing 
protein (β-TrCP) to facilitate IFNAR1 ubiquitination and breakdown [340]. As a result knockdown 
of PARP11 expression blocked IFNAR-I binding, exposed ubiquitin sites and stimulated β-TrCP 
ubiquitination while over expression of PARP11 enhanced IFNAR-I binding [340]. 
Although precise mode of action of PARP11 in controlling West Nile virus infection is still 
unknown, infection of mice with PARP11-amiR WNV resulted into increased viraemia, mortality 
and progression of clinical signs, as all mice succumbed to encephalitis by day eight post infection. 
Selection and enrichment of PARP11-amiR WNV in one mouse implies that PARP11 is crucial in 
WNV replication in brain.  Furthermore, basing on the input virus used to infect mice, PARP11 was 
represented at 0.18% versus the more than 97% enrichment observed in the brain. It is possible that 
the selection of PARP11 could have resulted from the role of PARP11 in WNV infection. It would 
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be very informative to perform this in vivo RNAi screening a number of times (for instance two 
more experiments) to show whether PARP11-amiR WNV is still selected. The fact that only 10 
mice were infected with p1-Vero virus libraries, warranties the need for more in vivo RNAi 
screening experiments. Furthermore, it was only PARP11-2-amiR WNV that was selected in vivo 
although two amiRs targeting PARP11 were present in the library. Therefore, another research 
question would be to understand why PARP11-2 amiR WNV was selected and enriched in vivo 
over PARP11-1-amiR WNV. It is important to determine the effectiveness of the other PARP11-
amiR. Future work would have to examine the ability both of PARP11-amiR West Nile viruses to 
knockdown its targets and enhance replication. Lastly, since PARP11-amiR WNV is selected in the 
brain, infection of mice via intracranial would provide evidence in regards to effects of PARP11-
amiR WNV on the brain.  
 
5.4.5 Interaction between in vivo selected amiR-encoding viruses  
To determine the interaction of enriched amiR-encoding viruses and the respective biological 
pathways targeted, gene ontology bioinformatics analyses should be performed. This would 
decipher the interactions between ATF3, PARP11 and IRF7 enriched in the brains. Furthermore, 
gene ontology would show whether the selected and enriched amiR-encoding viruses in mouse 
spleens were targeting similar genes or biological pathways such as those associated with apoptosis 
and stress response. Gene ontology would also reveal whether most of the enriched amiR-encoding 
viruses in the spleens targeted genes and biological pathways that are important in the control of 
virus infections. 
The enrichment of some genes such as PARP11, IRF7, Fbxo39 and MAPK8 in mouse spleens or 
brains, down-regulated enrichment of ATF3 while enrichment of ATF3 down-regulated IRF7, 
PARP11 among other genes.  This could have been caused by (i) knockdown of either one of these 
expression of these proteins affects the same biological pathway (ii) knockdown of one host gene is 
a drawback of the system that when one virus’s replication is enhanced by knockdown of any one 
of the antiviral pathways, this virus is enriched and outcompetes the other making the identification 
of additional antiviral proteins difficult. 
Therefore, data presented in this chapter reveals two new antiviral host genes as Atf3 and Parp11 
that influence West Nile virus infection in vivo. These new antiviral host genes could be utilised to 
generate effective antivirals although more studies are still required to understand the precise 
mechanism by which PARP11, IRF7 and ATF3 control West Nile virus infection.  
Studies in this chapter screened and identified ATF3 as a major antiviral factor against West Nile 
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virus infection in peripheral and CNS infection using an in vivo RNAi screening technique. These 
studies characterised ATF3-amiR WNV, IRF7-amiR WNV and PARP11-amiR WNV both in vitro 
and in vivo and showed that infection all three viruses resulted into increased virulence in mice. 
However, further studies are desirable to understand the precise mechanism of action by which all 
these amiR-encoding viruses control West Nile virus infection.  
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Chapter 6: General Discussion and Conclusion 
The strategy of this project was divided into three distinct stages: (i) generation of plasmid and 
virus libraries, (ii) in vitro and in vivo RNAi screening using generated virus libraries and (iii) in 
vitro and in vivo characterisation of selected and enriched amiR encoding viruses. Preliminary data 
generated by Setoh et al. (unpublished), revealed that deletion of nucleotides 15-89 (Δ15-89) at the 
start of the 3′ UTR was an optimal site for inserting pre-amiR hairpins that target specific mouse 
genes without attenuating the subsequent recombinant viruses. Furthermore, when WT MEF cells 
were infected with Δ15-89 WNV or WT-WNVNSW2011, there was no significant difference in 
replication between the two viruses and Δ15-89 WNV replication and viral burden in mice was 
comparable with WT-WNVNSW2011 (Setoh et al. unpublished). As a result, this (Δ15-89) region was 
used for subsequent generation of amiR-encoding plasmid and virus libraries.  
6.1 Generation of plasmid and virus libraries 
Having identified an optimal site for inserting pre-amiR hairpins, the next step was to generate a 
small amiR-encoding plasmid library by cloning. Each plasmid was designed to encode a unique 
amiR sequence, which targets a specific mouse gene. Consequently 204 ISG-targeting amiR-
encoding plasmids were generated and combined to form an ISG-targeting amiR plasmid library. 
The generated plasmid libraries were subsequently used to generate p0 and p1 virus libraries 
through CPER. Generated virus libraries were confirmed to contain diverse amiR-encoding viruses 
by deep sequencing and were used as tools for both in vitro and in vivo RNAi screening.  
In addition, a scrambled amiR-encoding virus library was generated as a negative control for 
subsequent experiments. Ultimately this scrambled library containing over 6000 individual amiR 
sequences did not prove to be a useful control. Initially it was envisaged as a control to ensure that 
selection was not occurring stochastically and none of scrambled amiR encoding viruses were 
selected or provided replicative advantage in vitro or in vivo. However, the library was so large 
compared to the ISG-targeting amiR library that it was impossible for in vitro or in vivo screening 
to use an inoculum of the scrambled library that included a reasonable number of virus particles 
containing individual sequences. Ultimately, better controls were provided by the GFP-amiR-WNV 
and miR-124 amiR West Nile viruses, which were present at approximately the same frequency in 
the p1-Vero inoculum as the tested ISG-targeting amiR-encoding viruses. In any future studies a 
limited number, for example ten to twenty non-targeting amiR-encoding viruses could be included 
at similar frequencies to the test amiRs. 
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6.2 In vitro RNAi screening revealed IFITM3 as an antiviral factor 
Passaging of the ISG-amiR virus library in WT MEF and Ifnar1-/- MEF revealed selection and 
enrichment of IFITM3-amiR WNV. Mechanistic studies showed that amiR-mediated knockdown of 
Ifitm3 improved infectivity of secreted virions and virulence in cell culture and mice respectively. 
The natural extension of this work would be to infect Ifitm3-/- MEF cells and mice with WT-
WNVNSW2011 and GFP-amiR WNV to determine whether a similar phenomenon would be observed 
in regards to infectivity. There is a substantial body of literature that suggests this will be the case. 
For instance, when Ifitm3-/- mice were infected with WNV were more vulnerable to virus infection 
characterised by increased virus accumulation in peripheral organs and CNS [311]. Similarly, when 
Ifitm3-/- MEF cells were infected with IAV, WNV or ZIKV, increased cytopathic effects, virus titres 
were observed [296, 310, 311]. Therefore, work presented here is consistent with literature that 
IFITM3 incorporation reduces the infectivity of virions in cells [273, 274]. 
IFITM3 can act to reduce viral fusion with the host cell either when it is incorporated into the virus 
envelope, or when it is localised in the endosomal membrane in various viral infection such as IAV 
and HIV [302, 341]. With the experimental strategy used here, the observed effect of the IFITM3 
amiR in enhancing viral replication is presumably through lowering of virus-associated IFITM3, 
since when cells are first infected by virus their levels of IFITM3 will be normal. The delay in 
achieving knockdown of the amiR target after infection of a cell means that the difference in 
replication of WNV in WT versus Ifitm3-/- cells or mice is anticipated to be more profound than the 
difference in replication of control versus IFITM3-amiR-expressing WNV. 
A second factor which may limit the effectiveness of virus-expressed amiR against ISGs is that in 
culture with WT cells, type I IFN will be produced early in culture and induce ISGs expression in 
surrounding uninfected cells. The amiR in the infecting virus then has an uphill battle overcoming 
the pre-induced level of the target ISG. In the in vitro screening done here, this problem was 
overcome by using Ifnar1-/- MEF. However, this also has the disadvantage that some ISGs may 
need type I IFN-mediated induction in order for the effect of knockdown to be seen, if their basal 
level in Ifnar1-/- MEF is too low for function. Consequently, a combination of screening in WT and 
Ifnar1-/- cells, as done here, is a good approach. This allows comparison between basal and induced 
level of ISG expression in terms of infection. In addition, the basal levels of ISG expression could 
be normalised so as to determine the exact levels of ISG expression induced. 
To further validate how IFITM3 reduces virion infectivity the Ifitm3-/- cells and mice should be 
infectivity with GFP-amiR WNV alongside with WT-WNVNSW2011 and determine if similar 
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phenomenon is observed in terms of infectivity.  It is anticipated that infection with GFP-amiR 
WNV despite being a control virus, would result into increased cytopathic effects in cells and 
increased viraemia in mice.  
In all three experiments IFITM3 amiR-encoding virus dominated the pool of sequenced WNV, and 
in all cases it was the same single amiR, although two amiRs targeting IFITM3 are present in the 
library. The effectiveness of the other IFITM3-amiR, and why it was not also amplified, is an 
important question. In future work, the second IFITM3-amiR WNV should be prepared, and 
examined for its ability to knockdown its target and enhance replication.  Furthermore, IFITM3-
amiR sequence was imported into Blastn and found to target only mus musculus (mouse) species. 
There were no other matches found for this particular IFITM3-amiR sequence. This validated that 
this IFITM3-amiR did not have any predicted off targets. Thus, highlighting that the shown 
mechanistic activities such as knockdown of ifitm3 expression in cells, generation of mature 
functional amiRs were indeed as a result of IFITM3-amiR WNV.  However, there is need to test 
other IFITMs-amiR West Nile viruses to determine whether they result into similar phenomenon as 
IFITM3 clone 2 that was selected and enriched in vitro. 
It would also be very insightful and enlightening to assess whether IFITM3-amiR WNV along with 
other in vivo selected and enriched amiR encoding viruses affect sfRNA production and general 
function of sfRNA in vitro. It is anticipated that all selected and enriched amiR-encoding viruses 
should alter sfRNA production and general function in regards to pathogenesis since the Δ15-89 
site of insertion of pre-amiR hairpins is before the start of sfRNA structures as shown in Figure 1.4. 
 
6.3 In vivo RNAi screening  
In chapter 5, mice were infected with ISG-targeting amiR virus library mixed with 200 pfu of  p1-
Vero scrambled amiR WNV library to determine which amiR-encoding viruses were selected and 
enriched both in spleen and brain. This resulted in selection and enrichment of predominantly 
ATF3-amiR WNV in spleens, with 4/6 spleens showing ATF3-amiR WNV as the most enriched. 
Furthermore, in vivo RNAi screening in brains showed the selection and enrichment of three 
distinct amiR-encoding viruses, ATF3-amiR WNV, IRF7-amiR WNV and PARP11-amiR WNV in 
three different mouse brains. This was an unexpected observation but an assumption was made that 
the selected amiR-encoding viruses could be involved in similar biological pathways. In addition, 
the control library utilised in this screening was considered inadequate as 200 pfu of p1-Vero 
scrambled amiR WNV library could have been an ineffective control. Therefore to provide an 
adequate control for this experment p1-Vero ISG targeting amiR WNV library : p1-Vero scrambled 
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amiR WNV library needed to be mixed in ratio of 1:1. This was not possible since the scrambled 
library contained more than 6000 individual amiR variants, as the control library was very large 
compared to the ISG- targeting virus library. Therefore it would be enlightening to repeat this 
experiment while using equal ratio of p1-Vero ISG targeting amiR WNV library : p1-Vero 
scrambled amiR WNV library. This would determine whether the enriched amiR encoding viruses 
would still selected and enriched in the spleens and brains in presence of an equal amount of 
scrambled amiR-encoding viruses. 
The gene ontology data analysis would highlight the role of first line of defence in intracellular 
response to West Nile virus infection. With the use of gene ontology software and databases, it 
would be revealed whether most of the selected and enriched amiR-encoding viruses in mouse 
spleens target similar biological pathways. Furthermore, gene ontology data analysis of genes 
targeted by amiRs that were selected and enriched in vivo and in vitro would elucidate whether 
IFITM3, ATF3 PARP11 and IRF7 belong to interconnected networks. Gene ontology would 
determine whether the enrichment of viruses encoding those amiRs that deplete host mRNAs whose 
products restrict virus replication enhanced amplification and dissemination of virus in mouse 
spleen and brains. From this analysis, further experiments geared towards determining the definite 
mechanisms of action of enriched genes would be designed.  
Characterisation of in vivo selected amiR-encoding viruses revealed that all the three viruses were 
more infectious than control virus both in vitro and in vivo. However more mechanistic studies are 
still required to elucidate the role of ATF3, IRF7 and PARP11 in WNV infection. Mechanistic 
investigations such as using RNA sequencing (RNAseq) analysis will help identify cellular 
pathway(s) controlled by the selected host genes. By infecting Atf3-/-, Irf7-/- and Parp11-/- cells and 
mice with WT-WNV cellular pathway(s) controlled by the selected host genes would be identified. 
As a result, more specific mechanistic studies aimed at defining precise mode of action of selected 
genes will be designed. 
Deep sequence data were only obtained for three brains, but the fact that all three gave a different 
dominant amiR is of interest, and may point to some stochastic effects in viral entry into the brain. 
This result could be obtained if virus entry into the brain is relatively infrequent event early on in 
infection, and the first replicating virus in the brain has a significant "head start" and can come to 
dominate. If this is the case, such an effect may limit the analysis here, as there would not be a fair 
competition between similar numbers of starting viruses, within the brain. This would need to be 
assessed by infecting a larger number of mice with amiR-encoding virus libraries and analysing 
selection and enrichment in the brain. An approach to examining whether viral entry into the brain 
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is infrequent and involves minimal invading virions would be to infect mice with just 105 pfu of the 
scrambled amiR library, to see if non-targeting amiR-encoding viruses can also come to dominate. 
These studies used an amiR library that was specific for ISGs, and a large proportion of the targeted 
genes will be antiviral. A significant fraction may be involved in limiting WNV replication. 
Furthermore, there may be many that have a selective advantage compared to wild type virus, but 
are not picked up due to the dominance of a single amiR-containing virus. The lack of IFITM3-
amiR WNV enrichment after in vivo screening could have been influenced by tissue specificity or 
tropism and difference between in vivo and in vitro settings. During in vivo setting, each virus is 
faced with a robust system that ranges from host genetic factors, physical state (weight and general 
well being), which each virus must subdue to cause infection whereas this might not be the case 
during in vitro screening. The difference in tropism between in vitro and in vivo settings could 
explain the lack of enrichment of IFITM3 in vivo.  
 
Indeed, when tested as individual viruses, those with amiRs targeting IFITM3, ATF3, PARP11 and 
IRF7 all provided some indication of improved replication in vivo compared to control virus. It may 
be that following the dynamics of virus types through the earlier stages of infection before a single 
virus dominates would provide a more comprehensive analysis of the antiviral target genes. For 
example, deep sequencing of virus from spleens from day 1 or 2 rather than day 4, would provide 
more insight in what happens earlier on in the spleens. Furthermore, deep sequencing viruses from 
blood at the time when viraemia is at its peak would expound on the trend of enrichment in the 
earlier stages of virus infection. However, virus titres recovered from sera are usually very low and 
would necessitate a number of passaging in cells such as C6/36 to be able to obtain amplicons for 
deep sequencing. Comparison of the early dynamics of viruses encoding ISG-targeting amiRs 
against a panel of control non-targeting amiRs may pick up a larger number of important anti-viral 
genes. 
6.4 Conclusion 
This project designed and generated a tool for in vitro and in vivo RNAi screening studies and 
subsequently identified host factors that control West Nile virus infection both in vitro and in vivo.  
This project was as pilot study for a bigger whole mouse genome screening using WNV termed as 
WNV ultramiR that is underway. For the larger project that is currently underway, the scrambled 
amiR-encoding virus library is an adequate control as this new amiR library referred to as ultramiR 
contains over 93,000 amiR sequences targeting the whole human genome. The changes that have 
been made is commercially purchasing a bar coded library containing all the desired amiR 
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sequence. This has eliminated any errors that could result from generating and preparing the library 
in-house. With what has been learnt from this pilot study is that with in vivo screening, it is not 
clear-cut process and therefore different individual passages and experiments need to be performed 
to clearly confirm that the enriched amiR-encoding viruses are indeed necessary for West Nile virus 
infection. Unlike in this thesis where one animal experiment was done for each in vivo screening.  
Furthermore, it would be insightful to combine a selected panel of enriched amiR encoding viruses 
with scrambled amiR-encoding viruses and performing an in vivo RNAi screen to determine 
whether the enriched amiR-encoding viruses are still preferentially selected to the scrambled amiR-
encoding viruses. This project optimised conditions for subsequent in vivo screening using ultramiR 
WNV libraries to identify additional new host factors that control WNV virulence in vivo.  
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Appendices 
Appendix 1 
 
Three 96 well  plates were ordered from Integrated  DNA technologies (IDT), with each well  
containing a unique primer sequence, either forward (Fw) or Reverse (Rev) in 10 µM concentration.  
Table showing mutagenesis primers ordered from IDT and their respective wells. 
Forward and Reverse Primer Mix  
 
Well  
Sequence 
Name 
Sequence 
1 A1 
Fw Adar-2 
ATTTAATGTCATACAATTCTTGTAGGGTGAACACCGTGAGAGCGGAGCCTACGG
CTGCAC 
1 B1 
Fw Atf2-1 
ATTTAATGTCATACAATAAAGACACTTTGTAGCTGGTGAGAGCGGAGCCTACGG
CTGCAC 
1 C1 
Fw Atf2-2 
ATTTAATGTCATACAATTGACACTGTCATTACGTGCTGAGAGCGGAGCCTACGG
CTGCAC 
1 D1 
Fw Atf3-1 
ATTTAATGTCATACAATTTGAGTGGGATTAAACACTGAAGAGCGGAGCCTACG
GCTGCAC 
1 E1 
Fw Atf3-2 
ATTTAATGTCATACAATTCAAGGTAGACACTTCTGCCTAGAGCGGAGCCTACGG
CTGCAC 
1 F1 
Fw B2m-1 
ATTTAATGTCATACAATTTGGATTTCAATGTGAGGCGGAGAGCGGAGCCTACGG
CTGCAC 
1 G1 
Fw B2m-2 
ATTTAATGTCATACAATTTATTGCTCAGCTATCTAGGAAGAGCGGAGCCTACGG
CTGCAC 
1 H1 
Fw Birc6-
1 ATTTAATGTCATACAATTAACAGTCTTTCTAACTGCGGAGAGCGGAGCCTACGG
CTGCAC 
1 A2 
Fw Birc6-
2 ATTTAATGTCATACAATTCTATGATGACACTGCACCGGAGAGCGGAGCCTACGG
CTGCAC 
1 B2 
Fw Brd4-1 
ATTTAATGTCATACAATTAATCTTATAGTAATCAGGGAAGAGCGGAGCCTACGG
CTGCAC 
1 C2 
Fw Brd4-2 
ATTTAATGTCATACAATTTAAGCTATAGCTCGCTGGGAAGAGCGGAGCCTACGG
CTGCAC 
1 D2 
Fw Cdkl4-
1 ATTTAATGTCATACAATTATAGCTTTCTTAAACATCTTAGAGCGGAGCCTACGG
CTGCAC 
1 E2 
Fw Cdkl4-
2 ATTTAATGTCATACAATTTTAGAACACTTCTGCTTCTAAGAGCGGAGCCTACGG
CTGCAC 
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1 F2 
Fw 
Clec4d-1 ATTTAATGTCATACAATTACATCTGTCTTATTCTGGTAAGAGCGGAGCCTACGG
CTGCAC 
1 G2 
Fw 
Clec4d-2 ATTTAATGTCATACAATTTAACAGTGGTCTATGACCCAAGAGCGGAGCCTACGG
CTGCAC 
1 H2 
Fw 
Clec4e-1 ATTTAATGTCATACAATAATAATTTCACTTTGAACCTAAGAGCGGAGCCTACGG
CTGCAC 
1 A3 
Fw 
Clec4e-2 ATTTAATGTCATACAATTTTGTTAGAGAATTGATCTGTAGAGCGGAGCCTACGG
CTGCAC 
1 B3 
Fw 
Cmpk2-1 ATTTAATGTCATACAATTACAATAACAGGAAAGTTGGTAGAGCGGAGCCTACG
GCTGCAC 
1 C3 
Fw 
Cmpk2-2 ATTTAATGTCATACAATAACTAGGTCAAGTACTGCCCGAGAGCGGAGCCTACG
GCTGCAC 
1 D3 
Fw Cpeb3-
1 ATTTAATGTCATACAATTATAACATTAAGAACTTGGGGAGAGCGGAGCCTACG
GCTGCAC 
1 E3 
Fw Cpeb3-
2 ATTTAATGTCATACAATTCCATCTGCATCTTGTCGGGGAGAGCGGAGCCTACGG
CTGCAC 
1 F3 
Fw 
Cxcl10-1 ATTTAATGTCATACAATATAGCTTACAGTACAGAGCTAAGAGCGGAGCCTACG
GCTGCAC 
1 G3 
Fw 
Cxcl10-2 ATTTAATGTCATACAATTTGATGACACAAGTTCTTCCAAGAGCGGAGCCTACGG
CTGCAC 
1 H3 
Fw Cytip-
1 ATTTAATGTCATACAATTTGTCTTCCATCGTGAGCTGGAGAGCGGAGCCTACGG
CTGCAC 
1 A4 
Fw Cytip-
2 ATTTAATGTCATACAATTCCACAGTAACAACCTTCCTTAGAGCGGAGCCTACGG
CTGCAC 
1 B4 
Fw Daxx-1 
ATTTAATGTCATACAATTTAATGTACACATAGATCTTAAGAGCGGAGCCTACGG
CTGCAC 
1 C4 
Fw Daxx-2 
ATTTAATGTCATACAATTACAATGATGCTGTCATCGGTAGAGCGGAGCCTACGG
CTGCAC 
1 D4 
Fw 
Ddx58-1 ATTTAATGTCATACAATTTAGTGTCTCGGATCTGTCTGAGAGCGGAGCCTACGG
CTGCAC 
1 E4 
Fw 
Ddx58-2 ATTTAATGTCATACAATTAGCTGTCAACTATAGTCTTTAGAGCGGAGCCTACGG
CTGCAC 
1 F4 
Fw 
Ddx60-1 ATTTAATGTCATACAATTAAGCTGGAGTAGTCAGCCTTAGAGCGGAGCCTACGG
CTGCAC 
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1 G4 
Fw 
Ddx60-2 ATTTAATGTCATACAATTAATGAAATGTCGTATCGGGAAGAGCGGAGCCTACG
GCTGCAC 
1 H4 
Fw Dhx9-
1 ATTTAATGTCATACAATTTGTACTTCTTGTTCTTCCTTAGAGCGGAGCCTACGGC
TGCAC 
1 A5 
Fw Dhx9-
2 ATTTAATGTCATACAATTCACACATGAATTTCTGTCTGAGAGCGGAGCCTACGG
CTGCAC 
1 B5 
Fw Dtx3l-
1 ATTTAATGTCATACAATTACTCTATGAACTCTAGTCTAAGAGCGGAGCCTACGG
CTGCAC 
1 C5 
Fw Dtx3l-
2 ATTTAATGTCATACAATTAAACAACTAATGTATTGCTAAGAGCGGAGCCTACGG
CTGCAC 
1 D5 
Fw 
Eif2ak2-1 ATTTAATGTCATACAATTTTGAGGACTTCTCTAACCTGAGAGCGGAGCCTACGG
CTGCAC 
1 E5 
Fw 
Eif2ak2-2 ATTTAATGTCATACAATTTGTACTTCGTGCTCCGCCTTAGAGCGGAGCCTACGG
CTGCAC 
1 F5 
Fw Fa2h-1 
ATTTAATGTCATACAATTTGAATACTCTCTTGTGAGTGAGAGCGGAGCCTACGG
CTGCAC 
1 G5 
Fw Fa2h-2 
ATTTAATGTCATACAATTAGTACAGCTGGTATCTGGGGAGAGCGGAGCCTACGG
CTGCAC 
1 H5 
Fw 
Fbxo39-1 ATTTAATGTCATACAATTTATTGTTGAACTCGAACGTTAGAGCGGAGCCTACGG
CTGCAC 
1 A6 
Fw 
Fbxo39-2 ATTTAATGTCATACAATTTGTTCTCGCTCAAGGTCTCGAGAGCGGAGCCTACGG
CTGCAC 
1 B6 
Fw Gbp2-
1 ATTTAATGTCATACAATTTGTAGATGAAGGTGCTGCTGAGAGCGGAGCCTACGG
CTGCAC 
1 C6 
Fw Gbp2-
2 ATTTAATGTCATACAATTGTTTCAACAACATCTGCCTTAGAGCGGAGCCTACGG
CTGCAC 
1 D6 
Fw Gbp3-
1 ATTTAATGTCATACAATTTGGTTTGTATCTTTAACCTTAGAGCGGAGCCTACGGC
TGCAC 
1 E6 
Fw Gbp3-
2 ATTTAATGTCATACAATTTTATCTGTAGTGTACAACTGAGAGCGGAGCCTACGG
CTGCAC 
1 F6 
Fw Gbp6-
1 ATTTAATGTCATACAATTTTCTGTCTTAGTAGCTCCTGAGAGCGGAGCCTACGG
CTGCAC 
1 G6 
Fw Gbp6-
2 ATTTAATGTCATACAATTTCTGTGACATAGTGCAGCTGAGAGCGGAGCCTACGG
CTGCAC 
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1 H6 
Fw Gcc-1 
ATTTAATGTCATACAATTTAAAGAACAGAATTAACCAAAGAGCGGAGCCTACG
GCTGCAC 
1 A7 
Fw Gcc-2 
ATTTAATGTCATACAATTATACTTGTCCTTCAGCTCTGAGAGCGGAGCCTACGG
CTGCAC 
1 B7 
Fw Gvin-1 
ATTTAATGTCATACAATTTCTCTTCTAGGTTTGATCTGAGAGCGGAGCCTACGG
CTGCAC 
1 C7 
Fw Gvin-2 
ATTTAATGTCATACAATTTAATTACATCACTGAAGCGGAGAGCGGAGCCTACGG
CTGCAC 
1 D7 
Fw Ifi35-1 
ATTTAATGTCATACAATTTAGAAACTACAAACTTGGGCAGAGCGGAGCCTACG
GCTGCAC 
1 E7 
Fw Ifi35-2 
ATTTAATGTCATACAATTATACAGAGAAATCTAGTCTCAGAGCGGAGCCTACGG
CTGCAC 
1 F7 
Fw Ifi44-1 
ATTTAATGTCATACAATTATTGATCCAACACAGTTCTAAGAGCGGAGCCTACGG
CTGCAC 
1 G7 
Fw Ifi44-2 
ATTTAATGTCATACAATTAATATAGCACTCTAAAGGGAAGAGCGGAGCCTACG
GCTGCAC 
1 H7 
Fw Ifih1-1 
ATTTAATGTCATACAATTTATACATCATCTTCTCTCGGAGAGCGGAGCCTACGG
CTGCAC 
1 A8 
Fw Ifih1-2 
ATTTAATGTCATACAATTAAGATTTGACAACTTCTGGAAGAGCGGAGCCTACGG
CTGCAC 
1 B8 
Fw Ifit1-1 
ATTTAATGTCATACAATTATATTAACGTCACAGAGGTGAGAGCGGAGCCTACGG
CTGCAC 
1 C8 
Fw Ifit1-2 
ATTTAATGTCATACAATTTCTCCTAAATCCTGAAGCTTAGAGCGGAGCCTACGG
CTGCAC 
1 D8 
Fw Ifit3-1 
ATTTAATGTCATACAATTTCTGCATGAACTCCATCGTTAGAGCGGAGCCTACGG
CTGCAC 
1 E8 
Fw Ifit3-2 
ATTTAATGTCATACAATTTGTCTCACCTTGTCAACGTAAGAGCGGAGCCTACGG
CTGCAC 
1 F8 
Fw Ifitm3-
1 ATTTAATGTCATACAATTTGATTCTTTCGTAGTTTGGGAGAGCGGAGCCTACGG
CTGCAC 
1 G8 
Fw Ifitm3-
2 ATTTAATGTCATACAATTAAATGAGTGTTACACCTGCGAGAGCGGAGCCTACGG
CTGCAC 
1 H8 
Fw Ifna1-1 
ATTTAATGTCATACAATTTCTCTCTCAGGTACACAGTGAGAGCGGAGCCTACGG
CTGCAC 
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1 A9 
Fw Ifna1-2 
ATTTAATGTCATACAATTTTGATGTGAAGATGTTCAGGAGAGCGGAGCCTACGG
CTGCAC 
1 B9 
Fw Ifna4-1 
ATTTAATGTCATACAATTTGTGGGTCTTGTAGATGCTGAGAGCGGAGCCTACGG
CTGCAC 
1 C9 
Fw Ifna4-2 
ATTTAATGTCATACAATTTATCCACCTTCTCCAAGGGGAGAGCGGAGCCTACGG
CTGCAC 
1 D9 
Fw Ifnb1-1 
ATTTAATGTCATACAATTACAACAATAGTCTCATTCCAAGAGCGGAGCCTACGG
CTGCAC 
1 A1 
Rev Adar-
2 ATTGTATGACATTAAATTCTTGGCGGGGGAACACCGGTAGAGCAGAGTCTCTGA
TCTTGA 
1 B1 
Rev Atf2-1 
ATTGTATGACATTAAATAAAGATCCTTGGTAGCTGGGTAGAGCAGAGTCTCTGA
TCTTGA 
1 C1 
Rev Atf2-2 
ATTGTATGACATTAAATTGACATGGTCCTTACGTGCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 D1 
Rev Atf3-1 
ATTGTATGACATTAAATTTGAGGTGGAGTAAACACTTCAGAGCAGAGTCTCTGA
TCTTGA 
1 E1 
Rev Atf3-2 
ATTGTATGACATTAAATTCAAGTGAGATACTTCTGCTGAGAGCAGAGTCTCTGA
TCTTGA 
1 F1 
Rev B2m-
1 ATTGTATGACATTAAATTTGGAGGTCACTGTGAGGCTTAGAGCAGAGTCTCTGA
TCTTGA 
1 G1 
Rev B2m-
2 ATTGTATGACATTAAATTTATTTTTCATCTATCTAGTCAGAGCAGAGTCTCTGAT
CTTGA 
1 H1 
Rev Birc6-
1 ATTGTATGACATTAAATTAACATGCTTGCTAACTGCTTAGAGCAGAGTCTCTGA
TCTTGA 
1 A2 
Rev Birc6-
2 ATTGTATGACATTAAATTCTATTCTGATACTGCACCTTAGAGCAGAGTCTCTGAT
CTTGA 
1 B2 
Rev Brd4-
1 ATTGTATGACATTAAATTAATCGGATATTAATCAGGTCAGAGCAGAGTCTCTGA
TCTTGA 
1 C2 
Rev Brd4-
2 ATTGTATGACATTAAATTTAAGTGATATCTCGCTGGTCAGAGCAGAGTCTCTGA
TCTTGA 
1 D2 
Rev 
Cdkl4-1 ATTGTATGACATTAAATTATAGTGTTCGTAAACATCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 E2 
Rev 
Cdkl4-2 ATTGTATGACATTAAATTTTAGCCCACGTCTGCTTCGCAGAGCAGAGTCTCTGA
TCTTGA 
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1 F2 
Rev 
Clec4d-1 ATTGTATGACATTAAATTACATTGGTCGTATTCTGGGCAGAGCAGAGTCTCTGA
TCTTGA 
1 G2 
Rev 
Clec4d-2 ATTGTATGACATTAAATTTAACCTTGGGCTATGACCTCAGAGCAGAGTCTCTGA
TCTTGA 
1 H2 
Rev 
Clec4e-1 ATTGTATGACATTAAATAATAAGGTCATTTTGAACCGCAGAGCAGAGTCTCTGA
TCTTGA 
1 A3 
Rev 
Clec4e-2 ATTGTATGACATTAAATTTTGTGCGAGCATTGATCTTGAGAGCAGAGTCTCTGA
TCTTGA 
1 B3 
Rev 
Cmpk2-1 ATTGTATGACATTAAATTACAAGCACATGAAAGTTGTGAGAGCAGAGTCTCTGA
TCTTGA 
1 C3 
Rev 
Cmpk2-2 ATTGTATGACATTAAATAACTATTTCACGTACTGCCTTAGAGCAGAGTCTCTGA
TCTTGA 
1 D3 
Rev 
Cpeb3-1 ATTGTATGACATTAAATTATAATCTTACGAACTTGGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 E3 
Rev 
Cpeb3-2 ATTGTATGACATTAAATTCCATTGGCAGCTTGTCGGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 F3 
Rev 
Cxcl10-1 ATTGTATGACATTAAATATAGCGGACATTACAGAGCGCAGAGCAGAGTCTCTG
ATCTTGA 
1 G3 
Rev 
Cxcl10-2 ATTGTATGACATTAAATTTGATTCCACCAGTTCTTCTCAGAGCAGAGTCTCTGAT
CTTGA 
1 H3 
Rev Cytip-
1 ATTGTATGACATTAAATTTGTCGGCCAGCGTGAGCTTTAGAGCAGAGTCTCTGA
TCTTGA 
1 A4 
Rev Cytip-
2 ATTGTATGACATTAAATTCCACCTTAATAACCTTCCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 B4 
Rev Daxx-
1 ATTGTATGACATTAAATTTAATTGACATATAGATCTGCAGAGCAGAGTCTCTGA
TCTTGA 
1 C4 
Rev Daxx-
2 ATTGTATGACATTAAATTACAAGTATGTTGTCATCGTGAGAGCAGAGTCTCTGA
TCTTGA 
1 D4 
Rev 
Ddx58-1 ATTGTATGACATTAAATTTAGTTGCTCTGATCTGTCGTAGAGCAGAGTCTCTGAT
CTTGA 
1 E4 
Rev 
Ddx58-2 ATTGTATGACATTAAATTAGCTTGCAATTATAGTCTGGAGAGCAGAGTCTCTGA
TCTTGA 
1 F4 
Rev 
Ddx60-1 ATTGTATGACATTAAATTAAGCACGAGGAGTCAGCCGCAGAGCAGAGTCTCTG
ATCTTGA 
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1 G4 
Rev 
Ddx60-2 ATTGTATGACATTAAATTAATGTTATGGCGTATCGGCCAGAGCAGAGTCTCTGA
TCTTGA 
1 H4 
Rev Dhx9-
1 ATTGTATGACATTAAATTTGTATGTCTGGTTCTTCCGGAGAGCAGAGTCTCTGAT
CTTGA 
1 A5 
Rev Dhx9-
2 ATTGTATGACATTAAATTCACATCTGACTTTCTGTCGTAGAGCAGAGTCTCTGAT
CTTGA 
1 B5 
Rev Dtx3l-
1 ATTGTATGACATTAAATTACTCGCTGACCTCTAGTCGCAGAGCAGAGTCTCTGA
TCTTGA 
1 C5 
Rev Dtx3l-
2 ATTGTATGACATTAAATTAAACCCCTACTGTATTGCGCAGAGCAGAGTCTCTGA
TCTTGA 
1 D5 
Rev 
Eif2ak2-1 ATTGTATGACATTAAATTTTGATTACTGCTCTAACCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 E5 
Rev 
Eif2ak2-2 
ATTGTATGACATTAAATTTGTATGTCGGGCTCCGCCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 F5 
Rev Fa2h-
1 ATTGTATGACATTAAATTTGAAGCCTCGCTTGTGAGGTAGAGCAGAGTCTCTGA
TCTTGA 
1 G5 
Rev Fa2h-
2 ATTGTATGACATTAAATTAGTATCGCTTGTATCTGGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 H5 
Rev 
Fbxo39-1 ATTGTATGACATTAAATTTATTTGTGACCTCGAACGGGAGAGCAGAGTCTCTGA
TCTTGA 
1 A6 
Rev 
Fbxo39-2 ATTGTATGACATTAAATTTGTTTGCGCGCAAGGTCTTTAGAGCAGAGTCTCTGA
TCTTGA 
1 B6 
Rev Gbp2-
1 ATTGTATGACATTAAATTTGTATCTGACGGTGCTGCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 C6 
Rev Gbp2-
2 ATTGTATGACATTAAATTGTTTTCACACCATCTGCCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 D6 
Rev Gbp3-
1 ATTGTATGACATTAAATTTGGTGGGTAGCTTTAACCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 E6 
Rev Gbp3-
2 ATTGTATGACATTAAATTTTATTGGTATTGTACAACGTAGAGCAGAGTCTCTGA
TCTTGA 
1 F6 
Rev Gbp6-
1 ATTGTATGACATTAAATTTTCTTGCTTCGTAGCTCCGTAGAGCAGAGTCTCTGAT
CTTGA 
1 G6 
Rev Gbp6-
2 ATTGTATGACATTAAATTTCTGGTACAGAGTGCAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
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1 H6 
Rev Gcc-1 
ATTGTATGACATTAAATTTAAATCACATAATTAACCCCAGAGCAGAGTCTCTGA
TCTTGA 
1 A7 
Rev Gcc-2 
ATTGTATGACATTAAATTATACGGGTCTTTCAGCTCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 B7 
Rev Gvin-
1 ATTGTATGACATTAAATTTCTCGGCTATGTTTGATCGTAGAGCAGAGTCTCTGAT
CTTGA 
1 C7 
Rev Gvin-
2 ATTGTATGACATTAAATTTAATGCCATTACTGAAGCTTAGAGCAGAGTCTCTGA
TCTTGA 
1 D7 
Rev Ifi35-
1 ATTGTATGACATTAAATTTAGACCCTATAAACTTGGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 E7 
Rev Ifi35-
2 ATTGTATGACATTAAATTATACCTAGACATCTAGTCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 F7 
Rev Ifi44-
1 ATTGTATGACATTAAATTATTGCGCCACCACAGTTCGCAGAGCAGAGTCTCTGA
TCTTGA 
1 G7 
Rev Ifi44-
2 ATTGTATGACATTAAATTAATAGCGCATTCTAAAGGTCAGAGCAGAGTCTCTGA
TCTTGA 
1 H7 
Rev Ifih1-
1 ATTGTATGACATTAAATTTATATCTCAGCTTCTCTCTTAGAGCAGAGTCTCTGAT
CTTGA 
1 A8 
Rev Ifih1-
2 ATTGTATGACATTAAATTAAGAGGTGATAACTTCTGTCAGAGCAGAGTCTCTGA
TCTTGA 
1 B8 
Rev Ifit1-1 
ATTGTATGACATTAAATTATATGCACGGCACAGAGGGTAGAGCAGAGTCTCTG
ATCTTGA 
1 C8 
Rev Ifit1-2 
ATTGTATGACATTAAATTTCTCTGAAAGCCTGAAGCGGAGAGCAGAGTCTCTGA
TCTTGA 
1 D8 
Rev Ifit3-1 
ATTGTATGACATTAAATTTCTGTCTGACCTCCATCGGGAGAGCAGAGTCTCTGA
TCTTGA 
1 E8 
Rev Ifit3-2 
ATTGTATGACATTAAATTTGTCGTACCGTGTCAACGGCAGAGCAGAGTCTCTGA
TCTTGA 
1 F8 
Rev 
Ifitm3-1 ATTGTATGACATTAAATTTGATGTTTTTGTAGTTTGTTAGAGCAGAGTCTCTGAT
CTTGA 
1 G8 
Rev 
Ifitm3-2 ATTGTATGACATTAAATTAAATTCGTGGTACACCTGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 H8 
Rev Ifna1-
1 ATTGTATGACATTAAATTTCTCGTTCATGTACACAGGTAGAGCAGAGTCTCTGA
TCTTGA 
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1 A9 
Rev Ifna1-
2 ATTGTATGACATTAAATTTTGAGTTGACGATGTTCATTAGAGCAGAGTCTCTGA
TCTTGA 
1 B9 
Rev Ifna4-
1 ATTGTATGACATTAAATTTGTGTTTCTGGTAGATGCGTAGAGCAGAGTCTCTGA
TCTTGA 
1 C9 
Rev Ifna4-
2 ATTGTATGACATTAAATTTATCTCCCTGCTCCAAGGTTAGAGCAGAGTCTCTGA
TCTTGA 
1 D9 
Rev Ifnb1-
1 ATTGTATGACATTAAATTACAATCATATTCTCATTCTCAGAGCAGAGTCTCTGAT
CTTGA 
2 A1 Fw Ifnb1-2 
ATTTAATGTCATACAATTTCCTGAAGATCTCTGCTCGGAGAGCGGAGCCTACGG
CTGCAC 
2 B1 
Fw Ikbka-
1 
ATTTAATGTCATACAATTAACACTCTCTCAACAGTGTTAGAGCGGAGCCTACGG
CTGCAC 
2 C1 
Fw Ikbka-
2 
ATTTAATGTCATACAATTTTGTGACATCTTCTTCCCTGAGAGCGGAGCCTACGG
CTGCAC 
2 D1 
Fw Ikbkb-
1 
ATTTAATGTCATACAATTATACTATGGAAATACACCTTAGAGCGGAGCCTACGG
CTGCAC 
2 E1 
Fw Ikbkb-
2 
ATTTAATGTCATACAATTTGGACTAGCTGAAGTTCCTGAGAGCGGAGCCTACGG
CTGCAC 
2 F1 
Fw Ikbke-
1 
ATTTAATGTCATACAATTAGATGACTGAAATTTACCTTAGAGCGGAGCCTACGG
CTGCAC 
2 G1 
Fw Ikbke-
2 
ATTTAATGTCATACAATTAGACAGAAACAAACTTCTCAAGAGCGGAGCCTACG
GCTGCAC 
2 H1 Fw Il15-1 
ATTTAATGTCATACAATTATCTTACATCTATCCAGTTGAGAGCGGAGCCTACGG
CTGCAC 
2 A2 Fw Il15-2 
ATTTAATGTCATACAATTATCCATACAACTTTATTCCAAGAGCGGAGCCTACGG
CTGCAC 
2 B2 Fw Il6-1 
ATTTAATGTCATACAATTAGAGTTTCTGTATCTCTCTGAGAGCGGAGCCTACGG
CTGCAC 
2 C2 Fw Il6-2 
ATTTAATGTCATACAATTACATTCCAAGAAACCATCTGAGAGCGGAGCCTACGG
CTGCAC 
2 D2 Fw Irf1-1 
ATTTAATGTCATACAATTTATTGATCCAGATCAGCCCTAGAGCGGAGCCTACGG
CTGCAC 
2 E2 Fw Irf1-2 
ATTTAATGTCATACAATTTGTCTCCTAGTACAGAGCCAAGAGCGGAGCCTACGG
CTGCAC 
 148 
2 F2 Fw Irf2-1 
ATTTAATGTCATACAATTTTCTTTATGCTTCTGTCCTTAGAGCGGAGCCTACGGC
TGCAC 
2 G2 Fw Irf2-2 
ATTTAATGTCATACAATTACAACTATGATGTTCACCGTAGAGCGGAGCCTACGG
CTGCAC 
2 H2 Fw Irf3-1 
ATTTAATGTCATACAATTAGTTCTGAGACTCGCAGCCAAGAGCGGAGCCTACGG
CTGCAC 
2 A3 Fw Irf3-2 
ATTTAATGTCATACAATTTGTTCCTCAGCTAGCAGCTGAGAGCGGAGCCTACGG
CTGCAC 
2 B3 Fw Irf5-1 
ATTTAATGTCATACAATTAGAACAGCTGGAAGTCACGGAGAGCGGAGCCTACG
GCTGCAC 
2 C3 Fw Irf5-2 
ATTTAATGTCATACAATTTGAAGATGGTGTTGTCCCCAAGAGCGGAGCCTACGG
CTGCAC 
2 D3 Fw Irf7-1 
ATTTAATGTCATACAATTTCCTCGTAAACACGGTCTTGAGAGCGGAGCCTACGG
CTGCAC 
2 E3 Fw Irf7-2 
ATTTAATGTCATACAATTCTTCGTAGAGACTGTTGGTGAGAGCGGAGCCTACGG
CTGCAC 
2 F3 Fw Irf9-1 
ATTTAATGTCATACAATTATGTAAGTATACTGTAGCTGAGAGCGGAGCCTACGG
CTGCAC 
2 G3 Fw Irf9-2 
ATTTAATGTCATACAATTAAGTTTCAATTCTCCTCCGGAGAGCGGAGCCTACGG
CTGCAC 
2 H3 Fw Irgm-1 
ATTTAATGTCATACAATTATGTAAGTACACTGTAGCTGAGAGCGGAGCCTACGG
CTGCAC 
2 A4 Fw Irgm-2 
ATTTAATGTCATACAATTTCTCTTAAAGCTCTTTCGGTAGAGCGGAGCCTACGG
CTGCAC 
2 B4 
Fw 
Lgals3bp-1 
ATTTAATGTCATACAATTTGTCCTTGAAGAGGAAGCTGAGAGCGGAGCCTACGG
CTGCAC 
2 C4 
Fw 
Lgals3bp-2 
ATTTAATGTCATACAATTTAACCAAGCGCATGTCTCCAAGAGCGGAGCCTACGG
CTGCAC 
2 D4 
Fw 
Lgals8-1 
ATTTAATGTCATACAATTTTGCTTTGATAGTGCTTGTTAGAGCGGAGCCTACGG
CTGCAC 
2 E4 
Fw 
Lgals8-2 
ATTTAATGTCATACAATTTCCATACTCTGTAAATCCGAAGAGCGGAGCCTACGG
CTGCAC 
2 F4 Fw Lrp4-1 
ATTTAATGTCATACAATTTTCAGAGCATCTTCCTCCTGAGAGCGGAGCCTACGG
CTGCAC 
 149 
2 G4 Fw Lrp4-2 
ATTTAATGTCATACAATTTGTTGATTAGCACTTTGCGAAGAGCGGAGCCTACGG
CTGCAC 
2 H4 Fw Ly6e-1 
ATTTAATGTCATACAATTTAGACATCCTTGTCAGTGTGAGAGCGGAGCCTACGG
CTGCAC 
2 A5 Fw Ly6e-2 
ATTTAATGTCATACAATTAACATAGCGAGACCGTCTTAAGAGCGGAGCCTACGG
CTGCAC 
2 B5 
Fw 
Map3K8-1 
ATTTAATGTCATACAATTTAAACTTACACTAGAGTCGAAGAGCGGAGCCTACGG
CTGCAC 
2 C5 
Fw 
Map3K8-2 
ATTTAATGTCATACAATTTGACTAGTCACATTGGACTAAGAGCGGAGCCTACGG
CTGCAC 
2 D5 
Fw 
Map4k2-1 
ATTTAATGTCATACAATTTAACAATTCTCACACAGCGTAGAGCGGAGCCTACGG
CTGCAC 
2 E5 
Fw 
Map4k2-2 
ATTTAATGTCATACAATTTTGGTGTCAGGAATCTTGGTAGAGCGGAGCCTACGG
CTGCAC 
2 F5 
Fw 
Mapk8-1 
ATTTAATGTCATACAATTTCTTGATTGCAACATTTCTTAGAGCGGAGCCTACGG
CTGCAC 
2 G5 
Fw 
Mapk8-2 
ATTTAATGTCATACAATTTGTTGTCACGTTTGCTTCTGAGAGCGGAGCCTACGG
CTGCAC 
2 H5 
Fw Mbnl1-
1 
ATTTAATGTCATACAATTTAGTACCAACCTCTCACGTGAGAGCGGAGCCTACGG
CTGCAC 
2 A6 
Fw Mbnl1-
2 
ATTTAATGTCATACAATTCTTCTAAACTAAAGCAGCCTAGAGCGGAGCCTACGG
CTGCAC 
2 B6 
Fw Mitd1-
1 
ATTTAATGTCATACAATATCACTGTGACAACTCCTGGGAGAGCGGAGCCTACGG
CTGCAC 
2 C6 
Fw Mitd1-
2 
ATTTAATGTCATACAATAACTTCTGTAACTGTCTCGTGAGAGCGGAGCCTACGG
CTGCAC 
2 D6 Fw Mlkl-1 
ATTTAATGTCATACAATTATTCCAACACTTTCGGCCTGAGAGCGGAGCCTACGG
CTGCAC 
2 E6 Fw Mlkl-2 
ATTTAATGTCATACAATTTGAACTGGATCTCTCTGCTTAGAGCGGAGCCTACGG
CTGCAC 
2 F6 
Fw 
Mov10-1 
ATTTAATGTCATACAATTAGATGTGGAGTTCATAGCTTAGAGCGGAGCCTACGG
CTGCAC 
2 G6 
Fw 
Mov10-2 
ATTTAATGTCATACAATTCGTGGTTGTAAATCGTCCGCAGAGCGGAGCCTACGG
CTGCAC 
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2 H6 
Fw 
Myd88-1 
ATTTAATGTCATACAATTTTGTTTGTGGGACACTGCTTAGAGCGGAGCCTACGG
CTGCAC 
2 A7 
Fw 
Myd88-2 
ATTTAATGTCATACAATTAAGCCGATAGTCTGTCTGTTAGAGCGGAGCCTACGG
CTGCAC 
2 B7 
Fw 
Nfkbia-1 
ATTTAATGTCATACAATTAAATATACATCTTAGAAGTAAGAGCGGAGCCTACGG
CTGCAC 
2 C7 
Fw 
Nfkbia-2 
ATTTAATGTCATACAATTTGTACAAATATACAAGTCCAAGAGCGGAGCCTACGG
CTGCAC 
2 D7 Fw Nmi-1 
ATTTAATGTCATACAATTAGAACTGAACTCTACCTCGAAGAGCGGAGCCTACGG
CTGCAC 
2 E7 Fw Nmi-2 
ATTTAATGTCATACAATTTATTTATGTGCATTATGCGGAGAGCGGAGCCTACGG
CTGCAC 
2 F7 
Fw Oas1a-
1 
ATTTAATGTCATACAATTAAGTCTGGAGCTTCCTGGGTAGAGCGGAGCCTACGG
CTGCAC 
2 G7 
Fw Oas1a-
2 
ATTTAATGTCATACAATTTTGACATCAGCACCAAAGGTAGAGCGGAGCCTACGG
CTGCAC 
2 H7 Fw Oas2-1 
ATTTAATGTCATACAATTTCTCTGTTAGGTTTGAGGTTAGAGCGGAGCCTACGG
CTGCAC 
2 A8 Fw Oas2-2 
ATTTAATGTCATACAATTATAATGTCAACAGCTTCCTTAGAGCGGAGCCTACGG
CTGCAC 
2 B8 
Fw Oasl1-
1 
ATTTAATGTCATACAATTCTTCTTTCCACTCTCTGGTTAGAGCGGAGCCTACGGC
TGCAC 
2 C8 
Fw Oasl1-
2 
ATTTAATGTCATACAATTTGTCTCTCACATACTGCTGGAGAGCGGAGCCTACGG
CTGCAC 
2 D8 
Fw Oasl2-
1 
ATTTAATGTCATACAATTTGAAAGTGAAACTGCAGGGAAGAGCGGAGCCTACG
GCTGCAC 
2 E8 
Fw Oasl2-
2 
ATTTAATGTCATACAATTATTTCATTCTTAATCACGCAAGAGCGGAGCCTACGG
CTGCAC 
2 F8 
Fw p50 
(RelB)-1 
ATTTAATGTCATACAATAATCTCTGAGAATCTGTCCTGAGAGCGGAGCCTACGG
CTGCAC 
2 G8 
Fw p50 
(RelB)-2 
ATTTAATGTCATACAATTTTCGCTTCTTGTCCACACCGAGAGCGGAGCCTACGG
CTGCAC 
2 H8 
Fw p65 
(RelA)-1 
ATTTAATGTCATACAATTTGAAGGTCTCATAGGTCCTTAGAGCGGAGCCTACGG
CTGCAC 
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2 A9 
Fw p65 
(RelA)-2 
ATTTAATGTCATACAATTTGTTGGTCTGGATTCGCTGGAGAGCGGAGCCTACGG
CTGCAC 
2 B9 
Fw 
Papr14-2 
ATTTAATGTCATACAATTTGTTTCACAGCATCTTCTTTAGAGCGGAGCCTACGGC
TGCAC 
2 C9 
Fw 
Parp11-1 
ATTTAATGTCATACAATTTGAATGTTGGTATCCGGCTGAGAGCGGAGCCTACGG
CTGCAC 
2 D9 
Fw 
Parp11-2 
ATTTAATGTCATACAATTAACGGTGCGAAATCGAGCGGAGAGCGGAGCCTACG
GCTGCAC 
2 A1 
Rev Ifnb1-
2 ATTGTATGACATTAAATTTCCTTCAGAGCTCTGCTCTTAGAGCAGAGTCTCTGAT
CTTGA 
2 B1 
Rev Ikbka-
1 ATTGTATGACATTAAATTAACATGCTCGCAACAGTGGGAGAGCAGAGTCTCTGA
TCTTGA 
2 C1 
Rev Ikbka-
2 ATTGTATGACATTAAATTTTGTTCCATTTTCTTCCCGTAGAGCAGAGTCTCTGAT
CTTGA 
2 D1 
Rev Ikbkb-
1 ATTGTATGACATTAAATTATACGCTGGCAATACACCGGAGAGCAGAGTCTCTGA
TCTTGA 
2 E1 
Rev Ikbkb-
2 ATTGTATGACATTAAATTTGGATGAGCGGAAGTTCCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 F1 
Rev Ikbke-
1 ATTGTATGACATTAAATTAGATTCCTGCAATTTACCGGAGAGCAGAGTCTCTGA
TCTTGA 
2 G1 
Rev Ikbke-
2 ATTGTATGACATTAAATTAGACCTAAATAAACTTCTTCAGAGCAGAGTCTCTGA
TCTTGA 
2 H1 
Rev Il15-1 
ATTGTATGACATTAAATTATCTGCCATTTATCCAGTGTAGAGCAGAGTCTCTGA
TCTTGA 
2 A2 
Rev Il15-2 
ATTGTATGACATTAAATTATCCCGACACCTTTATTCTCAGAGCAGAGTCTCTGAT
CTTGA 
2 B2 
Rev Il6-1 
ATTGTATGACATTAAATTAGAGGGTCTTTATCTCTCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 C2 
Rev Il6-2 
ATTGTATGACATTAAATTACATGTCAATAAACCATCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 D2 
Rev Irf1-1 
ATTGTATGACATTAAATTTATTTCTCCCGATCAGCCTGAGAGCAGAGTCTCTGA
TCTTGA 
2 E2 
Rev Irf1-2 
ATTGTATGACATTAAATTTGTCGTCTATTACAGAGCTCAGAGCAGAGTCTCTGA
TCTTGA 
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2 F2 
Rev Irf2-1 
ATTGTATGACATTAAATTTTCTGGATGTTTCTGTCCGGAGAGCAGAGTCTCTGAT
CTTGA 
2 G2 
Rev Irf2-2 
ATTGTATGACATTAAATTACAATGATGCTGTTCACCTGAGAGCAGAGTCTCTGA
TCTTGA 
2 H2 
Rev Irf3-1 
ATTGTATGACATTAAATTAGTTTGGAGCCTCGCAGCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 A3 
Rev Irf3-2 
ATTGTATGACATTAAATTTGTTTTTCATCTAGCAGCGTAGAGCAGAGTCTCTGAT
CTTGA 
2 B3 
Rev Irf5-1 
ATTGTATGACATTAAATTAGAATCGCTTGAAGTCACTTAGAGCAGAGTCTCTGA
TCTTGA 
2 C3 
Rev Irf5-2 
ATTGTATGACATTAAATTTGAATCTGGGGTTGTCCCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 D3 
Rev Irf7-1 
ATTGTATGACATTAAATTTCCTTTTAACCACGGTCTGTAGAGCAGAGTCTCTGAT
CTTGA 
2 E3 
Rev Irf7-2 
ATTGTATGACATTAAATTCTTCTGAGATACTGTTGGGTAGAGCAGAGTCTCTGA
TCTTGA 
2 F3 Rev Irf9-1 
ATTGTATGACATTAAATTATGTCCGTAGACTGTAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 G3 Rev Irf9-2 
ATTGTATGACATTAAATTAAGTGGCAAGTCTCCTCCTTAGAGCAGAGTCTCTGA
TCTTGA 
2 H3 
Rev Irgm-
1 
ATTGTATGACATTAAATTATGTCCGTATACTGTAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 A4 
Rev Irgm-
2 
ATTGTATGACATTAAATTTCTCGGAAATCTCTTTCGTGAGAGCAGAGTCTCTGA
TCTTGA 
2 B4 
Rev 
Lgals3bp-1 
ATTGTATGACATTAAATTTGTCTGTGACGAGGAAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 C4 
Rev 
Lgals3bp-2 
ATTGTATGACATTAAATTTAACTCAGCTCATGTCTCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 D4 
Rev 
Lgals8-1 
ATTGTATGACATTAAATTTTGCGGTGAGAGTGCTTGGGAGAGCAGAGTCTCTGA
TCTTGA 
2 E4 
Rev 
Lgals8-2 
ATTGTATGACATTAAATTTCCAGCCTCGGTAAATCCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 F4 
Rev Lrp4-
1 
ATTGTATGACATTAAATTTTCATCGCAGCTTCCTCCGTAGAGCAGAGTCTCTGAT
CTTGA 
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2 G4 
Rev Lrp4-
2 
ATTGTATGACATTAAATTTGTTTCTTATCACTTTGCTCAGAGCAGAGTCTCTGAT
CTTGA 
2 H4 
Rev Ly6e-
1 
ATTGTATGACATTAAATTTAGATCTCCGTGTCAGTGGTAGAGCAGAGTCTCTGA
TCTTGA 
2 A5 
Rev Ly6e-
2 
ATTGTATGACATTAAATTAACAGCGCGCGACCGTCTGCAGAGCAGAGTCTCTGA
TCTTGA 
2 B5 
Rev 
Map3K8-1 
ATTGTATGACATTAAATTTAAATGTACCCTAGAGTCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 C5 
Rev 
Map3K8-2 
ATTGTATGACATTAAATTTGACGCGTCCCATTGGACGCAGAGCAGAGTCTCTGA
TCTTGA 
2 D5 
Rev 
Map4k2-1 
ATTGTATGACATTAAATTTAACCCTTCGCACACAGCTGAGAGCAGAGTCTCTGA
TCTTGA 
2 E5 
Rev 
Map4k2-2 
ATTGTATGACATTAAATTTTGGGTTCATGAATCTTGTGAGAGCAGAGTCTCTGA
TCTTGA 
2 F5 
Rev 
Mapk8-1 
ATTGTATGACATTAAATTTCTTTCTTGTAACATTTCGGAGAGCAGAGTCTCTGAT
CTTGA 
2 G5 
Rev 
Mapk8-2 
ATTGTATGACATTAAATTTGTTTGCACTTTTGCTTCGTAGAGCAGAGTCTCTGAT
CTTGA 
2 H5 
Rev 
Mbnl1-1 
ATTGTATGACATTAAATTTAGTCTCAATCTCTCACGGTAGAGCAGAGTCTCTGA
TCTTGA 
2 A6 
Rev 
Mbnl1-2 
ATTGTATGACATTAAATTCTTCGCAACGAAAGCAGCTGAGAGCAGAGTCTCTGA
TCTTGA 
2 B6 
Rev 
Mitd1-1 
ATTGTATGACATTAAATATCACGTTGATAACTCCTGTTAGAGCAGAGTCTCTGA
TCTTGA 
2 C6 
Rev 
Mitd1-2 
ATTGTATGACATTAAATAACTTTGGTACCTGTCTCGGTAGAGCAGAGTCTCTGA
TCTTGA 
2 D6 
Rev Mlkl-
1 
ATTGTATGACATTAAATTATTCTCACATTTTCGGCCGTAGAGCAGAGTCTCTGAT
CTTGA 
2 E6 
Rev Mlkl-
2 
ATTGTATGACATTAAATTTGAATGGGAGCTCTCTGCGGAGAGCAGAGTCTCTGA
TCTTGA 
2 F6 
Rev 
Mov10-1 
ATTGTATGACATTAAATTAGATCAGGACTTCATAGCCCAGAGCAGAGTCTCTGA
TCTTGA 
2 G6 
Rev 
Mov10-2 
ATTGTATGACATTAAATTCGTGCATGTTAATCGTCCCTAGAGCAGAGTCTCTGA
TCTTGA 
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2 H6 
Rev 
Myd88-1 
ATTGTATGACATTAAATTTTGTGGGTGTGACACTGCGGAGAGCAGAGTCTCTGA
TCTTGA 
2 A7 
Rev 
Myd88-2 
ATTGTATGACATTAAATTAAGCTTATATTCTGTCTGGGAGAGCAGAGTCTCTGA
TCTTGA 
2 B7 
Rev 
Nfkbia-1 
ATTGTATGACATTAAATTAAATCGACAGCTTAGAAGGCAGAGCAGAGTCTCTG
ATCTTGA 
2 C7 
Rev 
Nfkbia-2 
ATTGTATGACATTAAATTTGTATCAATCTACAAGTCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 D7 Rev Nmi-1 
ATTGTATGACATTAAATTAGAATGGAATTCTACCTCTCAGAGCAGAGTCTCTGA
TCTTGA 
2 E7 Rev Nmi-2 
ATTGTATGACATTAAATTTATTGCTGTTCATTATGCTTAGAGCAGAGTCTCTGAT
CTTGA 
2 F7 
Rev 
Oas1a-1 
ATTGTATGACATTAAATTAAGTTGGGATCTTCCTGGTGAGAGCAGAGTCTCTGA
TCTTGA 
2 G7 
Rev 
Oas1a-2 
ATTGTATGACATTAAATTTTGATCTCATCACCAAAGTGAGAGCAGAGTCTCTGA
TCTTGA 
2 H7 
Rev Oas2-
1 
ATTGTATGACATTAAATTTCTCGTTTATGTTTGAGGGGAGAGCAGAGTCTCTGA
TCTTGA 
2 A8 
Rev Oas2-
2 
ATTGTATGACATTAAATTATAAGTTCACCAGCTTCCGGAGAGCAGAGTCTCTGA
TCTTGA 
2 B8 
Rev Oasl1-
1 
ATTGTATGACATTAAATTCTTCGGTCCCCTCTCTGGGGAGAGCAGAGTCTCTGA
TCTTGA 
2 C8 
Rev Oasl1-
2 
ATTGTATGACATTAAATTTGTCGTTCATATACTGCTTTAGAGCAGAGTCTCTGAT
CTTGA 
2 D8 
Rev Oasl2-
1 
ATTGTATGACATTAAATTTGAACTTGACACTGCAGGTCAGAGCAGAGTCTCTGA
TCTTGA 
2 E8 
Rev Oasl2-
2 
ATTGTATGACATTAAATTATTTTCTTCGTAATCACGTCAGAGCAGAGTCTCTGAT
CTTGA 
2 F8 
Rev p50 
(RelB)-1 
ATTGTATGACATTAAATAATCTTGGAGCATCTGTCCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 G8 
Rev p50 
(RelB)-2 
ATTGTATGACATTAAATTTTCGTGTCTGGTCCACACTTAGAGCAGAGTCTCTGAT
CTTGA 
2 H8 
Rev p65 
(RelA)-1 
ATTGTATGACATTAAATTTGAATTTCTTATAGGTCCGGAGAGCAGAGTCTCTGA
TCTTGA 
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2 A9 
Rev p65 
(RelA)-2 
ATTGTATGACATTAAATTTGTTTTTCTTGATTCGCTTTAGAGCAGAGTCTCTGAT
CTTGA 
2 B9 
Rev 
Papr14-2 
ATTGTATGACATTAAATTTGTTGTACATCATCTTCTGGAGAGCAGAGTCTCTGAT
CTTGA 
2 C9 
Rev 
Parp11-1 
ATTGTATGACATTAAATTTGAAGTTTGTTATCCGGCGTAGAGCAGAGTCTCTGA
TCTTGA 
2 D9 
Rev 
Parp11-2 
ATTGTATGACATTAAATTAACGTGGCGCAATCGAGCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 A1 
Fw 
Parp12-1 
ATTTAATGTCATACAATTTGGAAGCTACAACTCTTCCGAGAGCGGAGCCTACGG
CTGCAC 
3 B1 
Fw 
Parp12-2 
ATTTAATGTCATACAATTTGTGATCAGTCTTCAAGTTGAGAGCGGAGCCTACGG
CTGCAC 
3 C1 
Fw 
Parp14-1 
ATTTAATGTCATACAATTTGTTGATCAAGTTCTTTGGGAGAGCGGAGCCTACGG
CTGCAC 
3 D1 
Fw Parp9-
1 
ATTTAATGTCATACAATTAGCTGACTCTCATTGCTCTTAGAGCGGAGCCTACGG
CTGCAC 
3 E1 
Fw Parp9-
2 
ATTTAATGTCATACAATTTGTCTTGGAAATAAAGCCGGAGAGCGGAGCCTACGG
CTGCAC 
3 F1 Fw Plec-1 
ATTTAATGTCATACAATTACAGGTCACTGATGTGCCTCAGAGCGGAGCCTACGG
CTGCAC 
3 G1 Fw Plec-2 
ATTTAATGTCATACAATTAGCTTGCTCACAATGCGCTGAGAGCGGAGCCTACGG
CTGCAC 
3 H1 
Fw 
Ppm1k-1 
ATTTAATGTCATACAATTAAACTAGACTGACTTCTCTGAGAGCGGAGCCTACGG
CTGCAC 
3 A2 
Fw 
Ppm1k-2 
ATTTAATGTCATACAATTAGAGCAATAATAGTATTCCGAGAGCGGAGCCTACGG
CTGCAC 
3 B2 
Fw 
Ppp3cb-1 
ATTTAATGTCATACAATTTCTTCAGAACATCAACCCTGAGAGCGGAGCCTACGG
CTGCAC 
3 C2 
Fw 
Ppp3cb-2 
ATTTAATGTCATACAATTTAAATCTATCTAATCTCCTAAGAGCGGAGCCTACGG
CTGCAC 
3 D2 
Fw 
Rnasel-1 
ATTTAATGTCATACAATTAATCTTGGTCCATCTGACTTAGAGCGGAGCCTACGG
CTGCAC 
3 E2 
Fw 
Rnasel-2 
ATTTAATGTCATACAATTTTCTGTTCGTTCTCTCCGTCAGAGCGGAGCCTACGGC
TGCAC 
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3 F2 Fw Rsad-1 
ATTTAATGTCATACAATTTAACCTGCTCATCGAAGCTGAGAGCGGAGCCTACGG
CTGCAC 
3 G2 Fw Rsad-2 
ATTTAATGTCATACAATTATTCTAATAACAACAGTCCGAGAGCGGAGCCTACGG
CTGCAC 
3 H2 Fw Rtp4-1 
ATTTAATGTCATACAATTTCTTGAAATGTCTGCTCCCAAGAGCGGAGCCTACGG
CTGCAC 
3 A3 Fw Rtp4-2 
ATTTAATGTCATACAATTTTATTTAATCAACATAGCTTAGAGCGGAGCCTACGG
CTGCAC 
3 B3 
Fw 
Samd9l-1 
ATTTAATGTCATACAATTTGGTGGTCTTAACCAGTCTGAGAGCGGAGCCTACGG
CTGCAC 
3 C3 
Fw 
Samd9l-2 
ATTTAATGTCATACAATTTCTCTGGAATCTTGATTGTGAGAGCGGAGCCTACGG
CTGCAC 
3 D3 
Fw Sfxn2-
1 
ATTTAATGTCATACAATTTGTTCACAAACTACAGACTGAGAGCGGAGCCTACGG
CTGCAC 
3 E3 
Fw Sfxn2-
2 
ATTTAATGTCATACAATTAGAACTGGAGCATGAAGCCCAGAGCGGAGCCTACG
GCTGCAC 
3 F3 
Fw 
Sh3bgrl-1 
ATTTAATGTCATACAATTATACACGGATCACCATCCTGAGAGCGGAGCCTACGG
CTGCAC 
3 G3 
Fw 
Sh3bgrl-2 
ATTTAATGTCATACAATTAACATATGAACATAACCTGTAGAGCGGAGCCTACGG
CTGCAC 
3 H3 Fw Stat1-1 
ATTTAATGTCATACAATTTTACTGTCCAGCTCCTTCTGAGAGCGGAGCCTACGG
CTGCAC 
3 A4 Fw Stat1-2 
ATTTAATGTCATACAATTTTAAAGTCATATTCATCTTGAGAGCGGAGCCTACGG
CTGCAC 
3 B4 Fw Stat2-1 
ATTTAATGTCATACAATTTCTGGTCTTCAATCCAGGTAAGAGCGGAGCCTACGG
CTGCAC 
3 C4 Fw Stat2-2 
ATTTAATGTCATACAATTTCTGCAACATCTCCCACTGCAGAGCGGAGCCTACGG
CTGCAC 
3 D4 Fw Stat3-1 
ATTTAATGTCATACAATTTAAGTTTCTGAACAGCTCCAAGAGCGGAGCCTACGG
CTGCAC 
3 E4 Fw Stat3-2 
ATTTAATGTCATACAATTTGAAATCAAAGTCGTCCTGGAGAGCGGAGCCTACGG
CTGCAC 
3 F4 Fw Tap1-1 
ATTTAATGTCATACAATTTTAGAGGAAGAAGAAACCGAAGAGCGGAGCCTACG
GCTGCAC 
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3 G4 Fw Tap1-2 
ATTTAATGTCATACAATTTCTCCATGAATCTCATTCTCAGAGCGGAGCCTACGG
CTGCAC 
3 H4 
Fw Tapbp-
1 
ATTTAATGTCATACAATTAGCTTTGGGTCAAGATCTGGAGAGCGGAGCCTACGG
CTGCAC 
3 A5 
Fw Tapbp-
2 
ATTTAATGTCATACAATATAGTGAACTCCATGCTGCTTAGAGCGGAGCCTACGG
CTGCAC 
3 B5 Fw Tbk1-1 
ATTTAATGTCATACAATTCTCATTTGAACATCCACTGGAGAGCGGAGCCTACGG
CTGCAC 
3 C5 Fw Tbk1-2 
ATTTAATGTCATACAATTTGATTTGAGGAAACAATCTTAGAGCGGAGCCTACGG
CTGCAC 
3 D5 
Fw 
Ticam1-1 
ATTTAATGTCATACAATTTGAGCTGGTAGATCTCCCGGAGAGCGGAGCCTACGG
CTGCAC 
3 E5 
Fw 
Ticam1-2 
ATTTAATGTCATACAATTTGATATCTGAACTGCACCGAAGAGCGGAGCCTACGG
CTGCAC 
3 F5 Fw Tlr3-1 
ATTTAATGTCATACAATTTAGATAAGAGGAACACCCTTAGAGCGGAGCCTACG
GCTGCAC 
3 G5 Fw Tlr3-2 
ATTTAATGTCATACAATTAAAGTCGAACTTAATCTCTTAGAGCGGAGCCTACGG
CTGCAC 
3 H5 Fw Tlr7-1 
ATTTAATGTCATACAATTTTACTTTAACTTCACAAGGTAGAGCGGAGCCTACGG
CTGCAC 
3 A6 Fw Tlr7-2 
ATTTAATGTCATACAATTAGAGTGGTTCTATAGATGGAAGAGCGGAGCCTACGG
CTGCAC 
3 B6 Fw Tlr9-1 
ATTTAATGTCATACAATTATAGCTCAAGTTCAGCTCCTAGAGCGGAGCCTACGG
CTGCAC 
3 C6 Fw Tlr9-2 
ATTTAATGTCATACAATTTAGCATCTAGAACCAGGATGAGAGCGGAGCCTACG
GCTGCAC 
3 D6 
Fw 
Tmem140-
1 
ATTTAATGTCATACAATTATCTTCTGCTGTTGCAGGGAAGAGCGGAGCCTACGG
CTGCAC 
3 E6 
Fw 
Tmem140-
2 
ATTTAATGTCATACAATTTCTAGTTTGACACTTTGCCAAGAGCGGAGCCTACGG
CTGCAC 
3 F6 
Fw Tor3a-
1 
ATTTAATGTCATACAATTACGTGTCCACATACTTGGGGAGAGCGGAGCCTACGG
CTGCAC 
3 G6 
Fw Tor3a-
2 
ATTTAATGTCATACAATTAAGCCTGTCAAGTTGTTGGAAGAGCGGAGCCTACGG
CTGCAC 
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3 H6 
Fw Trex1-
1 
ATTTAATGTCATACAATTATGTGAGTCTGTCGGTGCTTAGAGCGGAGCCTACGG
CTGCAC 
3 A7 
Fw Trex1-
2 
ATTTAATGTCATACAATTAGGTTGGTTGTTCCAGTGGTAGAGCGGAGCCTACGG
CTGCAC 
3 B7 
Fw 
Trim21-1 
ATTTAATGTCATACAATTAGAGGGTGATATCTGCCGTGAGAGCGGAGCCTACGG
CTGCAC 
3 C7 
Fw 
Trim21-2 
ATTTAATGTCATACAATTTAGTTATGTGCTCCCAGCTTAGAGCGGAGCCTACGG
CTGCAC 
3 D7 
Fw 
Trim25-1 
ATTTAATGTCATACAATTTTAACTTGCGCAAGGAGCTGAGAGCGGAGCCTACGG
CTGCAC 
3 E7 
Fw 
Trim25-2 
ATTTAATGTCATACAATTTCATTTCCATATACTCCTGTAGAGCGGAGCCTACGG
CTGCAC 
3 F7 
Fw 
Wwoxv-1 
ATTTAATGTCATACAATATCTCTAAAGAATTGCTTGTGAGAGCGGAGCCTACGG
CTGCAC 
3 G7 
Fw 
Wwoxv-2 
ATTTAATGTCATACAATTATCAGGTTATTCTAAGGTTGAGAGCGGAGCCTACGG
CTGCAC 
3 H7 
Fw 
Zc3hav1-1 
ATTTAATGTCATACAATTTAGTGAACTTCATCTCTCCAAGAGCGGAGCCTACGG
CTGCAC 
3 A8 
Fw 
Zc3hav1-2 
ATTTAATGTCATACAATTATTCGTCTGAATCATCCCTTAGAGCGGAGCCTACGG
CTGCAC 
3 B8 
Fw 
Zfp182-1 
ATTTAATGTCATACAATTTGTTTATCTTGATGTTGCCTAGAGCGGAGCCTACGGC
TGCAC 
3 C8 
Fw 
Zfp182-2 
ATTTAATGTCATACAATTTGTCTACCATAGTATTTCCAAGAGCGGAGCCTACGG
CTGCAC 
3 D8 
Fw Isg15-
1 
ATTTAATGTCATACAATTGCTTGATCACTGTGCACTGGAGAGCGGAGCCTACGG
CTGCAC 
3 E8 
Fw Isg15-
2 
ATTTAATGTCATACAATTTAAGCGTGTCTACAGTCTGCAGAGCGGAGCCTACGG
CTGCAC 
3 F8 Fw Ifi27-1 
ATTTAATGTCATACAATTTGAGCTGATAGAAGTGTCATAGAGCGGAGCCTACGG
CTGCAC 
3 G8 Fw Ifi27-2 
ATTTAATGTCATACAATTTGATGTGGAGAGTCCAAGGAAGAGCGGAGCCTACG
GCTGCAC 
3 H8 
Fw Usp18-
1 
ATTTAATGTCATACAATTATTTCAGACTGTTCCTTGGTAGAGCGGAGCCTACGG
CTGCAC 
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3 A9 
Fw Usp18-
2 
ATTTAATGTCATACAATATGTTCATCATGAACACTTGAAGAGCGGAGCCTACGG
CTGCAC 
3 B9 
Fw 
Parp10-1 
ATTTAATGTCATACAATTTAAGGACTTTGTAGAGCAGGAGAGCGGAGCCTACG
GCTGCAC 
3 C9 
Fw 
Parp10-2 
ATTTAATGTCATACAATTTGGAGACTCACTGTCTCCTCAGAGCGGAGCCTACGG
CTGCAC 
3 D9 
Fw miR-
124 
ATTTAATGTCATACAATTAAGGCACGCGGTGAATGCCAAGAGCGGAGCCTACG
GCTGCAC 
3 A1 
Rev 
Parp12-1 
ATTGTATGACATTAAATTTGGACTCTATAACTCTTCTTAGAGCAGAGTCTCTGAT
CTTGA 
3 B1 
Rev 
Parp12-2 
ATTGTATGACATTAAATTTGTGCGCAGGCTTCAAGTGTAGAGCAGAGTCTCTGA
TCTTGA 
3 C1 
Rev 
Parp14-1 
ATTGTATGACATTAAATTTGTTTCTCACGTTCTTTGTTAGAGCAGAGTCTCTGAT
CTTGA 
3 D1 
Rev Parp9-
1 
ATTGTATGACATTAAATTAGCTTCCTCGCATTGCTCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 E1 
Rev Parp9-
2 
ATTGTATGACATTAAATTTGTCGGGGACATAAAGCCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 F1 Rev Plec-1 
ATTGTATGACATTAAATTACAGTGCACGGATGTGCCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 G1 Rev Plec-2 
ATTGTATGACATTAAATTAGCTGTCTCCCAATGCGCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 H1 
Rev 
Ppm1k-1 
ATTGTATGACATTAAATTAAACGCGACGGACTTCTCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 A2 
Rev 
Ppm1k-2 
ATTGTATGACATTAAATTAGAGTCATACTAGTATTCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 B2 
Rev 
Ppp3cb-1 
ATTGTATGACATTAAATTTCTTTCGAATATCAACCCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 C2 
Rev 
Ppp3cb-2 
ATTGTATGACATTAAATTTAAAGTTATTTAATCTCCGCAGAGCAGAGTCTCTGA
TCTTGA 
3 D2 
Rev 
Rnasel-1 
ATTGTATGACATTAAATTAATCGGGGTTCATCTGACGGAGAGCAGAGTCTCTGA
TCTTGA 
3 E2 
Rev 
Rnasel-2 
ATTGTATGACATTAAATTTTCTTGTCGGTCTCTCCGGTAGAGCAGAGTCTCTGAT
CTTGA 
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3 F2 
Rev Rsad-
1 
ATTGTATGACATTAAATTTAACTGGCTTATCGAAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 G2 
Rev Rsad-
2 
ATTGTATGACATTAAATTATTCGCATACCAACAGTCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 H2 
Rev Rtp4-
1 
ATTGTATGACATTAAATTTCTTTCAATTTCTGCTCCTCAGAGCAGAGTCTCTGAT
CTTGA 
3 A3 
Rev Rtp4-
2 
ATTGTATGACATTAAATTTTATGGAATTAACATAGCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 B3 
Rev 
Samd9l-1 
ATTGTATGACATTAAATTTGGTTTTCTGAACCAGTCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 C3 
Rev 
Samd9l-2 
ATTGTATGACATTAAATTTCTCGTGAAGCTTGATTGGTAGAGCAGAGTCTCTGA
TCTTGA 
3 D3 
Rev 
Sfxn2-1 
ATTGTATGACATTAAATTTGTTTCCAACCTACAGACGTAGAGCAGAGTCTCTGA
TCTTGA 
3 E3 
Rev 
Sfxn2-2 
ATTGTATGACATTAAATTAGAATGGGATCATGAAGCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 F3 
Rev 
Sh3bgrl-1 
ATTGTATGACATTAAATTATACCTGGAGCACCATCCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 G3 
Rev 
Sh3bgrl-2 
ATTGTATGACATTAAATTAACAGCTGACCATAACCTTGAGAGCAGAGTCTCTGA
TCTTGA 
3 H3 
Rev Stat1-
1 ATTGTATGACATTAAATTTTACGTTCCCGCTCCTTCGTAGAGCAGAGTCTCTGAT
CTTGA 
3 A4 
Rev Stat1-
2 ATTGTATGACATTAAATTTTAACTTCAGATTCATCTGTAGAGCAGAGTCTCTGAT
CTTGA 
3 B4 
Rev Stat2-
1 
ATTGTATGACATTAAATTTCTGTGCTTTAATCCAGGGCAGAGCAGAGTCTCTGA
TCTTGA 
3 C4 
Rev Stat2-
2 
ATTGTATGACATTAAATTTCTGTCACAGCTCCCACTTTAGAGCAGAGTCTCTGAT
CTTGA 
3 D4 
Rev Stat3-
1 ATTGTATGACATTAAATTTAAGGGTCTTAACAGCTCTCAGAGCAGAGTCTCTGA
TCTTGA 
3 E4 
Rev Stat3-
2 
ATTGTATGACATTAAATTTGAACGCAACGTCGTCCTTTAGAGCAGAGTCTCTGA
TCTTGA 
3 F4 
Rev Tap1-
1 
ATTGTATGACATTAAATTTTAGCTGAATAAGAAACCTCAGAGCAGAGTCTCTGA
TCTTGA 
 161 
3 G4 
Rev Tap1-
2 
ATTGTATGACATTAAATTTCTCTCTGACTCTCATTCGTAGAGCAGAGTCTCTGAT
CTTGA 
3 H4 
Rev 
Tapbp-1 
ATTGTATGACATTAAATTAGCTGGGGGGCAAGATCTTTAGAGCAGAGTCTCTGA
TCTTGA 
3 A5 
Rev 
Tapbp-2 
ATTGTATGACATTAAATATAGTTCACTTCATGCTGCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 B5 
Rev Tbk1-
1 
ATTGTATGACATTAAATTCTCAGGTGACCATCCACTTTAGAGCAGAGTCTCTGA
TCTTGA 
3 C5 
Rev Tbk1-
2 
ATTGTATGACATTAAATTTGATGGGAGTAAACAATCGGAGAGCAGAGTCTCTG
ATCTTGA 
3 D5 
Rev 
Ticam1-1 
ATTGTATGACATTAAATTTGAGTGGGTCGATCTCCCTTAGAGCAGAGTCTCTGA
TCTTGA 
3 E5 
Rev 
Ticam1-2 
ATTGTATGACATTAAATTTGATCGCTGCACTGCACCTCAGAGCAGAGTCTCTGA
TCTTGA 
3 F5 Rev Tlr3-1 
ATTGTATGACATTAAATTTAGAGCAGATGAACACCCGGAGAGCAGAGTCTCTG
ATCTTGA 
3 G5 Rev Tlr3-2 
ATTGTATGACATTAAATTAAAGGTGAATTTAATCTCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 H5 Rev Tlr7-1 
ATTGTATGACATTAAATTTTACGGTAATTTCACAAGTGAGAGCAGAGTCTCTGA
TCTTGA 
3 A6 Rev Tlr7-2 
ATTGTATGACATTAAATTAGAGGTGTTTTATAGATGTCAGAGCAGAGTCTCTGA
TCTTGA 
3 B6 Rev Tlr9-1 
ATTGTATGACATTAAATTATAGTGCAATTTCAGCTCTGAGAGCAGAGTCTCTGA
TCTTGA 
3 C6 Rev Tlr9-2 
ATTGTATGACATTAAATTTAGCCGCTATAACCAGGAGTAGAGCAGAGTCTCTGA
TCTTGA 
3 D6 
Rev 
Tmem140-
1 
ATTGTATGACATTAAATTATCTGTTGCGGTTGCAGGTCAGAGCAGAGTCTCTGA
TCTTGA 
3 E6 
Rev 
Tmem140-
2 
ATTGTATGACATTAAATTTCTATGTTGCCACTTTGCTCAGAGCAGAGTCTCTGAT
CTTGA 
3 F6 
Rev 
Tor3a-1 
ATTGTATGACATTAAATTACGTTGCCATATACTTGGTTAGAGCAGAGTCTCTGA
TCTTGA 
3 G6 
Rev 
Tor3a-2 
ATTGTATGACATTAAATTAAGCTGGTCCAGTTGTTGTCAGAGCAGAGTCTCTGA
TCTTGA 
 162 
3 H6 
Rev 
Trex1-1 
ATTGTATGACATTAAATTATGTTCGTCGGTCGGTGCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 A7 
Rev 
Trex1-2 
ATTGTATGACATTAAATTAGGTGTGTTTTTCCAGTGTGAGAGCAGAGTCTCTGA
TCTTGA 
3 B7 
Rev 
Trim21-1 
ATTGTATGACATTAAATTAGAGTTTGAGATCTGCCGGTAGAGCAGAGTCTCTGA
TCTTGA 
3 C7 
Rev 
Trim21-2 
ATTGTATGACATTAAATTTAGTGCTGTTCTCCCAGCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 D7 
Rev 
Trim25-1 
ATTGTATGACATTAAATTTTAATGTGCTCAAGGAGCGTAGAGCAGAGTCTCTGA
TCTTGA 
3 E7 
Rev 
Trim25-2 
ATTGTATGACATTAAATTTCATGGCCAGATACTCCTTGAGAGCAGAGTCTCTGA
TCTTGA 
3 F7 
Rev 
Wwoxv-1 
ATTGTATGACATTAAATATCTCGCAAGCATTGCTTGGTAGAGCAGAGTCTCTGA
TCTTGA 
3 G7 
Rev 
Wwoxv-2 
ATTGTATGACATTAAATTATCATTTTAGTCTAAGGTGTAGAGCAGAGTCTCTGA
TCTTGA 
3 H7 
Rev 
Zc3hav1-1 
ATTGTATGACATTAAATTTAGTTCACTGCATCTCTCTCAGAGCAGAGTCTCTGAT
CTTGA 
3 A8 
Rev 
Zc3hav1-2 
ATTGTATGACATTAAATTATTCTGCTGCATCATCCCGGAGAGCAGAGTCTCTGA
TCTTGA 
3 B8 
Rev 
Zfp182-1 
ATTGTATGACATTAAATTTGTTGCTCTGGATGTTGCTGAGAGCAGAGTCTCTGA
TCTTGA 
3 C8 
Rev 
Zfp182-2 
ATTGTATGACATTAAATTTGTCGCCCAGAGTATTTCTCAGAGCAGAGTCTCTGA
TCTTGA 
3 D8 
Rev Isg15-
1 
ATTGTATGACATTAAATTGAATTCTCATTGTGCACTTTAGAGCAGAGTCTCTGAT
CTTGA 
3 E8 
Rev Isg15-
2 
ATTGTATGACATTAAATTTAAGTTTGTTTACAGTCTTTAGAGCAGAGTCTCTGAT
CTTGA 
3 F8 
Rev Ifi27-
1 
ATTGTATGACATTAAATTTAAGTGGATCGAAGTGTCCGAGAGCAGAGTCTCTGA
TCTTGA 
3 G8 
Rev Ifi27-
2 
ATTGTATGACATTAAATTTAATTGGGATAGTCCAAGTCAGAGCAGAGTCTCTGA
TCTTGA 
3 H8 
Rev 
Usp18-1 
ATTGTATGACATTAAATTAAATTCGACGGTTCCTTGTGAGAGCAGAGTCTCTGA
TCTTGA 
 163 
3 A9 
Rev 
Usp18-2 
ATTGTATGACATTAAATATAATTCTCAGGAACACTTTCAGAGCAGAGTCTCTGA
TCTTGA 
3 B9 
Rev 
Parp10-1 
ATTGTATGACATTAAATTTAAGTCCTTGGTAGAGCATTAGAGCAGAGTCTCTGA
TCTTGA 
3 C9 
Rev 
Parp10-2 
ATTGTATGACATTAAATTTAAATCCTCCCTGTCTCCGTAGAGCAGAGTCTCTGAT
CTTGA 
3 D9 
Rev miR-
124 
ATTGTATGACATTAAATCAAGGTCCGCTGTGAACACGGAGAGCAGAGTCTCTG
ATCTTGA 
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Appendix 2 
Salmon transcript workflow used to analyse deep sequencing results 
 
 
 
 
 
 
 
 
 
 
 
 
Upload reference in fasta format 
 
Choose Salmon transcript tool for RNA seq Data
and Double click it 
 
Select Reference file (fasta format)
Select size of the transcript 
(19 Kmer in this case)
Assign one fastq to Pair 1 Assign another fastq to Pair 2
If you have two fastq for each sample, 
select pair ended
Click execute  
Upload sequence data set in fastq format 
Open analysis file using Excel     Download Salmon analysis file  
 165 
Appendix 3 
In vitro RNAi screening results computed into percentage enrichment of amiR-encoding 
viruses  
WT MEF Experiment 1 
  Percentage 
Name 
PLASMID 
LIB P0-293T 
P1-
VERO P2-WT P3-WT P4-WT 
Adar-1 0.00 0.00 0.00 0.00 0.00 0.00 
Adar-2 0.66 0.16 0.09 0.09 0.00 0.00 
Atf2-1 0.41 0.18 0.10 0.39 0.00 0.00 
Atf2-2 1.19 0.48 0.50 0.44 0.00 0.00 
Atf3-1 0.58 0.46 0.37 0.22 0.00 0.00 
Atf3-2 1.95 2.44 3.41 4.22 0.02 0.00 
B2m-1 0.69 0.22 0.15 0.30 0.00 0.00 
B2m-2 0.37 0.41 0.42 0.25 0.00 0.00 
Birc6-1 0.49 0.28 0.27 0.64 0.00 0.00 
Birc6-2 0.51 0.35 0.24 0.21 0.00 0.00 
Brd4-1 0.45 1.25 1.73 1.79 0.02 0.00 
Brd4-2 0.62 0.54 0.54 0.55 0.00 0.00 
Cdkl4-1 0.63 0.67 0.56 0.37 0.00 0.00 
Cdkl4-2 0.60 0.34 0.21 0.17 0.00 0.00 
Clec4d-1 0.49 0.41 0.25 0.26 0.00 0.00 
Clec4d-2 0.61 0.48 0.41 0.30 0.00 0.00 
Clec4e-1 0.48 0.85 0.95 0.78 0.01 0.00 
Clec4e-2 0.52 0.30 0.16 0.10 0.00 0.00 
Cmpk2-1 1.56 0.69 0.44 0.41 0.00 0.00 
Cmpk2-2 0.72 0.13 0.08 0.08 0.00 0.00 
Cpeb3-1 0.01 0.08 0.12 0.09 0.00 0.00 
Cpeb3-2 0.74 0.22 0.20 0.16 0.00 0.00 
Cxcl10-1 0.56 0.66 0.77 0.58 0.00 0.00 
Cxcl10-2 0.57 0.46 0.33 0.16 0.00 0.01 
Cytip-1 0.62 0.38 0.20 0.25 0.00 0.00 
Cytip-2 0.64 0.66 0.67 0.41 0.00 0.00 
 166 
Daxx-1 0.41 1.16 1.42 0.71 0.00 0.00 
Daxx-2 0.85 0.22 0.10 0.56 0.00 0.00 
Ddx58-1 0.55 0.50 0.53 1.49 0.00 0.00 
Ddx58-2 0.53 0.60 0.57 0.39 0.00 0.00 
Ddx60-1 0.66 0.20 0.10 0.11 0.00 0.00 
Ddx60-2 0.88 0.26 0.15 0.12 0.00 0.00 
Dhx9-1 0.73 0.77 0.59 0.54 0.00 0.00 
Dhx9-2 0.46 0.28 0.27 0.72 0.00 0.00 
Dtx3l-1 0.69 0.84 0.76 1.15 0.01 0.00 
Dtx3l-2 0.52 0.45 0.44 0.90 0.00 0.00 
EGFP 0.49 0.02 0.02 0.03 0.00 0.00 
Eif2ak2-1 0.53 0.56 0.48 0.29 0.00 0.00 
Eif2ak2-2 0.49 0.27 0.29 0.68 0.00 0.00 
Fa2h-1 0.75 0.44 0.25 0.19 0.00 0.00 
Fa2h-2 0.68 0.26 0.16 0.14 0.00 0.00 
Fbxo39-1 0.59 0.97 1.10 1.42 0.00 0.00 
Fbxo39-2 0.63 0.25 0.15 0.12 0.01 0.01 
Gbp2-1 0.78 0.30 0.20 0.17 0.00 0.00 
Gbp2-2 0.53 1.77 2.29 4.39 0.01 0.00 
Gbp3-1 0.52 0.54 0.45 0.23 0.00 0.00 
Gbp3-2 0.62 0.76 0.72 0.63 0.01 0.00 
Gbp6-1 0.00 1.17 1.43 1.37 0.00 0.00 
Gbp6-2 0.13 0.00 0.00 0.00 0.00 0.00 
Gcc-1 0.63 0.21 0.16 0.09 0.00 0.00 
Gcc-2 0.51 0.79 0.88 0.62 0.01 0.01 
Gvin-1 0.49 0.71 0.66 0.85 0.00 0.00 
Gvin-2 0.39 0.72 0.71 0.54 0.00 0.00 
Ifi27-1 0.52 1.24 1.18 1.74 0.00 0.00 
Ifi27-2 0.61 1.38 1.82 1.42 0.01 0.00 
Ifi35-1 0.39 0.21 0.10 0.16 0.00 0.00 
Ifi35-2 0.45 2.14 2.54 1.76 0.02 0.00 
Ifi44-1 0.41 0.84 0.76 0.55 0.00 0.00 
Ifi44-2 0.46 0.50 0.61 0.35 0.00 0.00 
Ifih1-1 0.51 0.21 0.12 0.07 0.01 0.00 
 167 
Ifih1-2 0.68 1.01 1.32 0.76 0.01 0.00 
Ifit1-1 0.86 0.15 0.12 0.14 0.00 0.00 
Ifit1-2 0.45 0.48 0.40 0.60 0.00 0.00 
Ifit3-1 0.47 0.47 0.34 0.57 0.00 0.00 
Ifit3-2 0.58 0.44 0.30 0.44 0.00 0.00 
Ifitm3-1 0.61 0.60 0.58 0.33 0.01 0.00 
Ifitm3-2 0.90 0.61 0.92 1.75 96.71 90.19 
Ifna1-1 0.48 0.66 0.54 0.32 0.02 0.01 
Ifna1-2 0.65 0.36 0.37 0.25 0.00 0.00 
Ifna4-1 0.29 0.65 0.56 1.25 0.00 0.00 
Ifna4-2 0.48 0.29 0.26 0.23 0.00 0.00 
Ifnb1-1 0.90 0.49 0.34 0.20 0.00 0.00 
Ifnb1-2 0.39 0.30 0.49 0.28 0.01 0.00 
Ikbka-1 0.55 0.16 0.12 0.10 0.00 0.00 
Ikbka-2 0.53 0.34 0.22 0.18 0.00 0.00 
Ikbkb-1 0.48 0.51 0.36 0.35 0.00 0.00 
Ikbkb-2 0.61 0.70 0.59 0.94 0.00 0.00 
Ikbke-1 1.25 0.56 0.49 0.23 0.01 0.00 
Ikbke-2 0.61 0.68 0.59 0.30 0.00 0.00 
Il15-1 0.55 0.57 0.36 0.23 0.00 0.00 
Il15-2 0.56 0.70 0.58 0.25 0.00 0.00 
Il6-1 0.78 0.60 0.59 0.41 0.00 0.00 
Il6-2 0.52 0.62 0.58 0.48 0.01 0.00 
Irf1-1 0.69 0.23 0.14 0.69 0.00 0.00 
Irf1-2 0.51 0.26 0.17 0.12 0.00 0.00 
Irf2-1 0.56 0.49 0.50 0.36 0.00 0.00 
Irf2-2 0.67 0.50 0.34 0.67 0.00 0.00 
Irf3-1 0.57 0.24 0.24 0.16 0.00 0.00 
Irf3-2 0.68 0.42 0.32 0.24 0.00 0.00 
Irf5-1 0.62 0.30 0.22 0.13 0.00 0.00 
Irf5-2 0.61 0.16 0.05 0.37 0.00 0.00 
Irf7-1 0.36 0.81 0.57 1.29 1.71 7.57 
Irf7-2 0.57 1.36 1.97 2.49 0.01 0.00 
Irf9-1 0.44 0.28 0.27 0.28 0.00 0.00 
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Irf9-2 0.51 0.27 0.20 0.15 0.00 0.00 
Irgm-1 0.54 0.27 0.19 0.36 0.00 0.00 
Irgm-2 0.58 0.81 1.05 0.68 0.01 0.00 
Isg15-1 0.54 1.02 1.40 0.94 0.01 0.00 
Isg15-2 0.53 0.24 0.22 0.14 0.00 0.00 
Lgals3bp-1 0.58 0.64 0.72 0.63 0.00 0.00 
Lgals3bp-2 0.71 0.31 0.25 0.13 0.00 0.01 
Lgals8-1 0.80 0.60 0.50 1.02 0.01 0.00 
Lgals8-2 0.45 0.13 0.10 0.06 0.00 0.00 
Lrp4-1 0.65 0.21 0.08 0.07 0.00 0.00 
Lrp4-2 0.51 0.53 0.50 1.02 0.00 0.00 
Ly6e-1 0.45 0.21 0.13 0.13 0.02 0.01 
Ly6e-2 0.37 0.44 0.44 0.47 0.00 0.01 
Map3K8-1 0.49 0.63 0.59 0.50 0.00 0.00 
Map3K8-2 0.52 0.50 0.31 0.44 0.01 0.01 
Map4k2-1 0.45 0.60 0.44 0.50 0.78 1.74 
Map4k2-2 0.44 0.35 0.21 0.13 0.00 0.00 
Mapk8-1 0.54 0.64 0.54 0.31 0.00 0.00 
Mapk8-2 0.62 0.61 0.59 0.34 0.00 0.00 
Mbnl1-1 0.44 0.34 0.30 0.31 0.00 0.00 
Mbnl1-2 0.50 0.29 0.19 0.08 0.00 0.00 
miR-124 0.58 0.24 0.15 0.11 0.00 0.04 
Mitd1-1 0.66 0.14 0.10 0.07 0.02 0.01 
Mitd1-2 0.35 0.30 0.26 0.21 0.00 0.00 
Mlkl-1 0.31 0.33 0.39 0.77 0.00 0.00 
Mlkl-2 0.33 1.33 2.29 1.90 0.00 0.00 
Mov10-1 0.46 0.78 0.93 1.41 0.00 0.00 
Mov10-2 0.32 0.53 0.38 0.25 0.00 0.00 
Myd88-1 0.35 0.56 0.49 0.29 0.00 0.00 
Myd88-2 0.52 0.23 0.20 0.96 0.01 0.01 
Nfkbia-1 0.33 0.51 0.49 0.26 0.01 0.01 
Nfkbia-2 0.45 0.27 0.18 0.10 0.00 0.00 
Nmi-1 0.53 0.78 0.84 1.62 0.01 0.00 
Nmi-2 0.53 2.74 4.58 2.55 0.01 0.00 
 169 
Oas1a-1 0.41 0.22 0.16 0.46 0.00 0.00 
Oas1a-2 0.47 0.26 0.19 0.11 0.00 0.00 
Oas2-1 0.50 0.26 0.12 0.53 0.00 0.00 
Oas2-2 0.94 0.28 0.17 0.09 0.00 0.00 
Oasl1-1 0.41 0.71 0.84 1.35 0.00 0.00 
Oasl1-2 0.22 0.57 0.43 0.27 0.00 0.00 
Oasl2-1 0.59 0.51 0.40 0.34 0.00 0.00 
Oasl2-2 0.23 0.52 0.34 0.18 0.00 0.00 
p50 0.50 0.53 0.53 0.34 0.01 0.00 
p50 0.26 0.40 0.31 0.27 0.00 0.00 
p65 0.35 0.38 0.26 0.18 0.00 0.00 
p65 0.30 0.18 0.11 0.15 0.00 0.00 
Papr14-2 0.34 0.57 0.47 0.27 0.00 0.00 
Parp10-1 0.25 0.13 0.12 0.08 0.00 0.00 
Parp10-2 0.42 0.78 0.85 1.12 0.00 0.00 
Parp11-1 0.34 0.04 0.02 0.03 0.00 0.00 
Parp11-2 0.38 0.27 0.18 0.20 0.00 0.00 
Parp12-1 0.24 0.12 0.08 0.04 0.03 0.04 
Parp12-2 0.33 0.42 0.39 0.32 0.00 0.00 
Parp14-1 0.13 0.48 0.43 0.22 0.01 0.00 
Parp9-1 0.35 0.06 0.06 0.03 0.00 0.00 
Parp9-2 0.37 0.28 0.29 0.30 0.00 0.00 
Plec-1 0.37 0.12 0.05 0.06 0.00 0.00 
Plec-2 0.26 0.12 0.04 0.04 0.00 0.00 
Ppm1k-1 0.38 0.24 0.22 0.13 0.00 0.00 
Ppm1k-2 0.22 0.38 0.29 0.14 0.02 0.01 
Ppp3cb-1 0.37 0.23 0.12 0.11 0.00 0.00 
Ppp3cb-2 0.47 0.48 0.43 0.25 0.00 0.00 
Rnasel-1 0.33 0.74 0.90 1.05 0.00 0.00 
Rnasel-2 0.30 0.24 0.20 0.19 0.00 0.00 
Rsad-1 1.00 0.45 0.36 0.25 0.00 0.00 
Rsad-2 0.26 0.36 0.28 0.19 0.01 0.00 
Rtp4-1 0.33 0.57 0.60 0.36 0.00 0.00 
Rtp4-2 1.14 1.09 1.35 0.59 0.01 0.00 
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Samd9l-1 0.32 0.26 0.20 0.13 0.00 0.00 
Samd9l-2 0.33 0.18 0.11 0.07 0.01 0.00 
Sfxn2-1 0.31 0.27 0.20 0.17 0.00 0.00 
Sfxn2-2 1.22 0.20 0.11 0.06 0.00 0.00 
Sh3bgrl-1 0.25 0.60 0.46 0.50 0.01 0.00 
Sh3bgrl-2 0.30 0.10 0.07 0.05 0.00 0.00 
Stat1-1 0.50 0.21 0.15 0.12 0.00 0.00 
Stat1-2 0.32 1.87 1.45 0.87 0.01 0.00 
Stat2-1 0.29 0.50 0.46 0.50 0.01 0.00 
Stat2-2 0.25 0.23 0.21 0.34 0.00 0.00 
Stat3-1 0.31 0.45 0.46 0.24 0.01 0.01 
Stat3-2 0.35 0.89 0.64 0.52 0.00 0.00 
Tap1-1 0.26 0.26 0.22 0.12 0.00 0.00 
Tap1-2 0.21 0.86 0.95 0.54 0.00 0.00 
Tapbp-1 0.21 0.85 1.13 1.71 0.06 0.01 
Tapbp-2 0.28 0.25 0.20 0.31 0.00 0.00 
Tbk1-1 0.32 0.64 0.80 0.77 0.01 0.00 
Tbk1-2 0.19 0.91 0.99 0.47 0.00 0.00 
Ticam1-1 0.27 0.05 0.03 0.03 0.00 0.00 
Ticam1-2 0.28 0.21 0.18 0.09 0.00 0.00 
Tlr3-1 0.32 0.06 0.02 0.03 0.00 0.00 
Tlr3-2 0.38 1.11 1.80 2.20 0.01 0.00 
Tlr7-1 0.34 0.61 0.83 0.46 0.01 0.00 
Tlr7-2 0.32 0.25 0.16 0.20 0.00 0.00 
Tlr9-1 0.29 0.11 0.10 0.21 0.02 0.01 
Tlr9-2 0.32 0.17 0.12 0.11 0.00 0.00 
Tmem140-1 0.30 0.14 0.08 0.09 0.00 0.00 
Tmem140-2 0.28 0.33 0.30 0.79 0.00 0.05 
Tor3a-1 0.25 0.21 0.21 0.38 0.00 0.00 
Tor3a-2 0.26 0.28 0.26 0.16 0.00 0.00 
Trex1-1 0.26 0.10 0.03 0.08 0.00 0.00 
Trex1-2 0.28 0.16 0.09 0.06 0.00 0.00 
Trim21-1 0.34 0.41 0.56 0.55 0.00 0.00 
Trim21-2 0.34 0.34 0.28 0.20 0.00 0.00 
 171 
Trim25-1 0.38 0.14 0.10 0.17 0.00 0.00 
Trim25-2 0.30 0.35 0.32 0.24 0.00 0.00 
Usp18-1 0.57 0.36 0.40 0.21 0.00 0.00 
Usp18-2 0.31 0.34 0.53 0.55 0.00 0.00 
Wwoxv-1 0.15 0.12 0.11 0.07 0.03 0.03 
Wwoxv-2 0.29 0.22 0.22 0.16 0.00 0.00 
Zc3hav1-1 0.20 0.18 0.13 0.07 0.01 0.00 
Zc3hav1-2 0.17 0.38 0.39 0.30 0.00 0.00 
Zfp182-1 0.00 0.13 0.04 0.05 0.00 0.00 
Zfp182-2 0.36 0.75 1.12 0.82 0.01 0.01 
Total 100 100 100 100 100 100 
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WT MEF Experiment 2 
  Percentage 
Name 
PLASMID 
LIB P0-293T P1-VERO P2-WT P3-WT P4-WT 
Adar-1 0.00 0.00 0.00 0.00 0.00 0.00 
Adar-2 0.66 0.16 0.09 0.16 0.00 0.00 
Atf2-1 0.41 0.18 0.10 0.30 0.00 0.00 
Atf2-2 1.19 0.48 0.50 1.02 0.02 0.00 
Atf3-1 0.58 0.46 0.37 0.22 0.00 0.00 
Atf3-2 1.95 2.44 3.41 5.07 0.07 0.01 
B2m-1 0.69 0.22 0.15 0.21 0.01 0.00 
B2m-2 0.37 0.41 0.42 0.23 0.00 0.00 
Birc6-1 0.49 0.28 0.27 0.18 0.01 0.00 
Birc6-2 0.51 0.35 0.24 0.20 0.01 0.00 
Brd4-1 0.45 1.25 1.73 0.80 0.03 0.00 
Brd4-2 0.62 0.54 0.54 0.67 0.00 0.00 
Cdkl4-1 0.63 0.67 0.56 0.32 0.00 0.00 
Cdkl4-2 0.60 0.34 0.21 0.22 0.00 0.00 
Clec4d-1 0.49 0.41 0.25 0.17 0.00 0.00 
Clec4d-2 0.61 0.48 0.41 0.26 0.00 0.00 
Clec4e-1 0.48 0.85 0.95 0.44 0.05 0.00 
Clec4e-2 0.52 0.30 0.16 0.08 0.00 0.00 
Cmpk2-1 1.56 0.69 0.44 0.25 0.01 0.00 
Cmpk2-2 0.72 0.13 0.08 0.20 0.00 0.00 
Cpeb3-1 0.01 0.08 0.12 0.09 0.00 0.00 
Cpeb3-2 0.74 0.22 0.20 0.79 0.01 0.00 
Cxcl10-1 0.56 0.66 0.77 0.57 0.01 0.00 
Cxcl10-2 0.57 0.46 0.33 0.15 0.01 0.01 
Cytip-1 0.62 0.38 0.20 0.22 0.00 0.00 
Cytip-2 0.64 0.66 0.67 0.45 0.03 0.00 
Daxx-1 0.41 1.16 1.42 0.65 0.01 0.00 
Daxx-2 0.85 0.22 0.10 0.10 0.00 0.00 
Ddx58-1 0.55 0.50 0.53 0.54 0.01 0.00 
 173 
Ddx58-2 0.53 0.60 0.57 0.47 0.01 0.00 
Ddx60-1 0.66 0.20 0.10 0.09 0.00 0.00 
Ddx60-2 0.88 0.26 0.15 0.11 0.01 0.00 
Dhx9-1 0.73 0.77 0.59 0.83 0.02 0.00 
Dhx9-2 0.46 0.28 0.27 0.15 0.01 0.00 
Dtx3l-1 0.69 0.84 0.76 0.84 0.01 0.00 
Dtx3l-2 0.52 0.45 0.44 0.29 0.01 0.00 
EGFP 0.49 0.02 0.02 0.02 0.00 0.00 
Eif2ak2-1 0.53 0.56 0.48 0.24 0.00 0.00 
Eif2ak2-2 0.49 0.27 0.29 1.21 0.00 0.00 
Fa2h-1 0.75 0.44 0.25 0.40 0.00 0.00 
Fa2h-2 0.68 0.26 0.16 0.71 0.01 0.00 
Fbxo39-1 0.59 0.97 1.10 1.37 0.10 0.00 
Fbxo39-2 0.63 0.25 0.15 0.14 0.11 0.01 
Gbp2-1 0.78 0.30 0.20 0.17 0.00 0.00 
Gbp2-2 0.53 1.77 2.29 2.10 0.19 0.01 
Gbp3-1 0.52 0.54 0.45 0.23 0.00 0.00 
Gbp3-2 0.62 0.76 0.72 0.42 0.02 0.00 
Gbp6-1 0.00 1.17 1.43 1.65 0.01 0.00 
Gbp6-2 0.13 0.00 0.00 0.00 0.00 0.00 
Gcc-1 0.63 0.21 0.16 0.10 0.00 0.00 
Gcc-2 0.51 0.79 0.88 0.92 0.03 0.01 
Gvin-1 0.49 0.71 0.66 0.37 0.00 0.00 
Gvin-2 0.39 0.72 0.71 0.56 0.01 0.00 
Ifi27-1 0.52 1.24 1.18 0.57 0.01 0.00 
Ifi27-2 0.61 1.38 1.82 1.28 0.04 0.00 
Ifi35-1 0.39 0.21 0.10 0.06 0.00 0.00 
Ifi35-2 0.45 2.14 2.54 1.82 0.02 0.00 
Ifi44-1 0.41 0.84 0.76 0.70 0.03 0.00 
Ifi44-2 0.46 0.50 0.61 0.64 0.00 0.00 
Ifih1-1 0.51 0.21 0.12 0.07 0.01 0.00 
Ifih1-2 0.68 1.01 1.32 1.16 0.04 0.00 
Ifit1-1 0.86 0.15 0.12 0.14 0.00 0.00 
Ifit1-2 0.45 0.48 0.40 0.33 0.00 0.00 
 174 
Ifit3-1 0.47 0.47 0.34 0.27 0.00 0.00 
Ifit3-2 0.58 0.44 0.30 0.28 0.01 0.00 
Ifitm3-1 0.61 0.60 0.58 0.55 0.02 0.01 
Ifitm3-2 0.90 0.61 0.92 2.13 96.54 99.26 
Ifna1-1 0.48 0.66 0.54 0.39 0.01 0.01 
Ifna1-2 0.65 0.36 0.37 0.26 0.03 0.00 
Ifna4-1 0.29 0.65 0.56 0.97 0.01 0.00 
Ifna4-2 0.48 0.29 0.26 0.21 0.00 0.00 
Ifnb1-1 0.90 0.49 0.34 1.02 0.02 0.00 
Ifnb1-2 0.39 0.30 0.49 0.72 0.01 0.00 
Ikbka-1 0.55 0.16 0.12 1.13 0.00 0.00 
Ikbka-2 0.53 0.34 0.22 0.18 0.01 0.00 
Ikbkb-1 0.48 0.51 0.36 0.22 0.01 0.00 
Ikbkb-2 0.61 0.70 0.59 0.72 0.01 0.00 
Ikbke-1 1.25 0.56 0.49 0.22 0.00 0.00 
Ikbke-2 0.61 0.68 0.59 0.30 0.02 0.00 
Il15-1 0.55 0.57 0.36 0.25 0.01 0.00 
Il15-2 0.56 0.70 0.58 0.26 0.01 0.00 
Il6-1 0.78 0.60 0.59 0.79 0.00 0.00 
Il6-2 0.52 0.62 0.58 0.31 0.04 0.00 
Irf1-1 0.69 0.23 0.14 0.15 0.00 0.00 
Irf1-2 0.51 0.26 0.17 0.20 0.00 0.00 
Irf2-1 0.56 0.49 0.50 0.28 0.01 0.00 
Irf2-2 0.67 0.50 0.34 0.21 0.02 0.00 
Irf3-1 0.57 0.24 0.24 0.16 0.00 0.00 
Irf3-2 0.68 0.42 0.32 0.28 0.01 0.00 
Irf5-1 0.62 0.30 0.22 0.13 0.00 0.00 
Irf5-2 0.61 0.16 0.05 0.13 0.00 0.00 
Irf7-1 0.36 0.81 0.57 1.14 0.02 0.01 
Irf7-2 0.57 1.36 1.97 1.86 0.21 0.02 
Irf9-1 0.44 0.28 0.27 0.15 0.00 0.00 
Irf9-2 0.51 0.27 0.20 0.13 0.00 0.00 
Irgm-1 0.54 0.27 0.19 0.19 0.02 0.00 
Irgm-2 0.58 0.81 1.05 1.13 0.03 0.00 
 175 
Isg15-1 0.54 1.02 1.40 2.63 0.03 0.00 
Isg15-2 0.53 0.24 0.22 0.18 0.00 0.00 
Lgals3bp-1 0.58 0.64 0.72 0.55 0.01 0.00 
Lgals3bp-2 0.71 0.31 0.25 0.11 0.03 0.01 
Lgals8-1 0.80 0.60 0.50 0.41 0.02 0.00 
Lgals8-2 0.45 0.13 0.10 0.06 0.00 0.00 
Lrp4-1 0.65 0.21 0.08 0.07 0.00 0.00 
Lrp4-2 0.51 0.53 0.50 0.74 0.01 0.00 
Ly6e-1 0.45 0.21 0.13 0.09 0.03 0.01 
Ly6e-2 0.37 0.44 0.44 1.18 0.01 0.00 
Map3K8-1 0.49 0.63 0.59 0.36 0.01 0.00 
Map3K8-2 0.52 0.50 0.31 0.53 0.02 0.02 
Map4k2-1 0.45 0.60 0.44 0.39 0.02 0.00 
Map4k2-2 0.44 0.35 0.21 0.27 0.00 0.00 
Mapk8-1 0.54 0.64 0.54 0.56 0.01 0.00 
Mapk8-2 0.62 0.61 0.59 0.40 0.01 0.00 
Mbnl1-1 0.44 0.34 0.30 0.53 0.00 0.00 
Mbnl1-2 0.50 0.29 0.19 0.10 0.00 0.00 
miR-124 0.58 0.24 0.15 0.34 0.00 0.04 
Mitd1-1 0.66 0.14 0.10 0.09 0.02 0.02 
Mitd1-2 0.35 0.30 0.26 0.21 0.00 0.00 
Mlkl-1 0.31 0.33 0.39 0.75 0.02 0.00 
Mlkl-2 0.33 1.33 2.29 2.31 0.08 0.01 
Mov10-1 0.46 0.78 0.93 1.55 0.02 0.00 
Mov10-2 0.32 0.53 0.38 0.27 0.01 0.00 
Myd88-1 0.35 0.56 0.49 1.02 0.03 0.00 
Myd88-2 0.52 0.23 0.20 0.48 0.02 0.00 
Nfkbia-1 0.33 0.51 0.49 0.27 0.01 0.01 
Nfkbia-2 0.45 0.27 0.18 0.08 0.00 0.00 
Nmi-1 0.53 0.78 0.84 0.69 0.04 0.00 
Nmi-2 0.53 2.74 4.58 2.91 0.09 0.00 
Oas1a-1 0.41 0.22 0.16 0.13 0.00 0.00 
Oas1a-2 0.47 0.26 0.19 0.20 0.00 0.00 
Oas2-1 0.50 0.26 0.12 0.12 0.00 0.00 
 176 
Oas2-2 0.94 0.28 0.17 0.09 0.00 0.00 
Oasl1-1 0.41 0.71 0.84 1.51 0.02 0.01 
Oasl1-2 0.22 0.57 0.43 0.61 0.01 0.00 
Oasl2-1 0.59 0.51 0.40 0.35 0.02 0.00 
Oasl2-2 0.23 0.52 0.34 0.18 0.01 0.00 
p50 0.50 0.53 0.53 0.39 0.01 0.00 
p50 0.26 0.40 0.31 0.16 0.00 0.00 
p65 0.35 0.38 0.26 0.14 0.00 0.00 
p65 0.30 0.18 0.11 0.09 0.00 0.00 
Papr14-2 0.34 0.57 0.47 0.27 0.01 0.00 
Parp10-1 0.25 0.13 0.12 0.07 0.00 0.00 
Parp10-2 0.42 0.78 0.85 0.50 0.02 0.00 
Parp11-1 0.34 0.04 0.02 0.20 0.00 0.00 
Parp11-2 0.38 0.27 0.18 0.24 0.00 0.00 
Parp12-1 0.24 0.12 0.08 0.05 0.03 0.05 
Parp12-2 0.33 0.42 0.39 0.34 0.00 0.00 
Parp14-1 0.13 0.48 0.43 0.22 0.01 0.00 
Parp9-1 0.35 0.06 0.06 0.13 0.00 0.00 
Parp9-2 0.37 0.28 0.29 0.90 0.00 0.00 
Plec-1 0.37 0.12 0.05 0.06 0.00 0.00 
Plec-2 0.26 0.12 0.04 0.03 0.00 0.00 
Ppm1k-1 0.38 0.24 0.22 0.14 0.03 0.01 
Ppm1k-2 0.22 0.38 0.29 0.12 0.03 0.01 
Ppp3cb-1 0.37 0.23 0.12 0.12 0.00 0.00 
Ppp3cb-2 0.47 0.48 0.43 0.27 0.03 0.00 
Rnasel-1 0.33 0.74 0.90 0.89 0.03 0.00 
Rnasel-2 0.30 0.24 0.20 0.33 0.01 0.00 
Rsad-1 1.00 0.45 0.36 0.24 0.00 0.00 
Rsad-2 0.26 0.36 0.28 0.21 0.02 0.01 
Rtp4-1 0.33 0.57 0.60 0.34 0.05 0.00 
Rtp4-2 1.14 1.09 1.35 0.60 0.03 0.00 
Samd9l-1 0.32 0.26 0.20 0.43 0.00 0.00 
Samd9l-2 0.33 0.18 0.11 0.06 0.01 0.01 
Sfxn2-1 0.31 0.27 0.20 0.16 0.00 0.00 
 177 
Sfxn2-2 1.22 0.20 0.11 0.28 0.01 0.00 
Sh3bgrl-1 0.25 0.60 0.46 0.63 0.03 0.00 
Sh3bgrl-2 0.30 0.10 0.07 0.04 0.00 0.00 
Stat1-1 0.50 0.21 0.15 0.30 0.00 0.00 
Stat1-2 0.32 1.87 1.45 0.80 0.03 0.00 
Stat2-1 0.29 0.50 0.46 0.35 0.01 0.00 
Stat2-2 0.25 0.23 0.21 0.14 0.00 0.00 
Stat3-1 0.31 0.45 0.46 0.25 0.01 0.01 
Stat3-2 0.35 0.89 0.64 0.37 0.01 0.00 
Tap1-1 0.26 0.26 0.22 0.12 0.00 0.00 
Tap1-2 0.21 0.86 0.95 0.51 0.02 0.00 
Tapbp-1 0.21 0.85 1.13 0.71 0.50 0.09 
Tapbp-2 0.28 0.25 0.20 1.08 0.00 0.00 
Tbk1-1 0.32 0.64 0.80 0.67 0.01 0.00 
Tbk1-2 0.19 0.91 0.99 0.69 0.03 0.00 
Ticam1-1 0.27 0.05 0.03 0.03 0.00 0.00 
Ticam1-2 0.28 0.21 0.18 0.42 0.01 0.00 
Tlr3-1 0.32 0.06 0.02 0.02 0.00 0.00 
Tlr3-2 0.38 1.11 1.80 3.75 0.09 0.00 
Tlr7-1 0.34 0.61 0.83 0.40 0.00 0.00 
Tlr7-2 0.32 0.25 0.16 0.08 0.00 0.00 
Tlr9-1 0.29 0.11 0.10 0.05 0.02 0.01 
Tlr9-2 0.32 0.17 0.12 0.11 0.00 0.00 
Tmem140-1 0.30 0.14 0.08 0.07 0.00 0.00 
Tmem140-2 0.28 0.33 0.30 0.17 0.01 0.07 
Tor3a-1 0.25 0.21 0.21 0.19 0.00 0.00 
Tor3a-2 0.26 0.28 0.26 0.15 0.00 0.00 
Trex1-1 0.26 0.10 0.03 0.07 0.00 0.00 
Trex1-2 0.28 0.16 0.09 0.05 0.00 0.00 
Trim21-1 0.34 0.41 0.56 0.53 0.03 0.00 
Trim21-2 0.34 0.34 0.28 0.22 0.01 0.00 
Trim25-1 0.38 0.14 0.10 0.10 0.02 0.00 
Trim25-2 0.30 0.35 0.32 0.52 0.01 0.00 
Usp18-1 0.57 0.36 0.40 0.50 0.02 0.00 
 178 
Usp18-2 0.31 0.34 0.53 0.25 0.01 0.00 
Wwoxv-1 0.15 0.12 0.11 0.05 0.04 0.02 
Wwoxv-2 0.29 0.22 0.22 0.11 0.01 0.00 
Zc3hav1-1 0.20 0.18 0.13 0.06 0.00 0.01 
Zc3hav1-2 0.17 0.38 0.39 1.05 0.00 0.00 
Zfp182-1 0.00 0.13 0.04 0.03 0.00 0.00 
Zfp182-2 0.36 0.75 1.12 1.02 0.01 0.01 
Total 100 100 100 100 100 100 
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WT MEF Experiment 3 
  Percentage 
Name 
PLASMID 
LIB P0-293T P1-VERO P2-WT P3-WT P4-WT 
Adar-1 0.00 0.00 0.00 0.00 0.00 0.00 
Adar-2 0.66 0.16 0.09 0.08 0.00 0.00 
Atf2-1 0.41 0.18 0.10 0.06 0.00 0.00 
Atf2-2 1.19 0.48 0.50 1.24 0.00 0.00 
Atf3-1 0.58 0.46 0.37 0.23 0.00 0.00 
Atf3-2 1.95 2.44 3.41 4.39 0.03 0.01 
B2m-1 0.69 0.22 0.15 0.21 0.00 0.00 
B2m-2 0.37 0.41 0.42 0.26 0.00 0.00 
Birc6-1 0.49 0.28 0.27 0.17 0.00 0.00 
Birc6-2 0.51 0.35 0.24 0.22 0.00 0.00 
Brd4-1 0.45 1.25 1.73 1.66 0.01 0.00 
Brd4-2 0.62 0.54 0.54 1.39 0.00 0.00 
Cdkl4-1 0.63 0.67 0.56 0.22 0.01 0.00 
Cdkl4-2 0.60 0.34 0.21 0.45 0.00 0.00 
Clec4d-1 0.49 0.41 0.25 0.17 0.00 0.00 
Clec4d-2 0.61 0.48 0.41 0.26 0.00 0.00 
Clec4e-1 0.48 0.85 0.95 0.51 0.00 0.00 
Clec4e-2 0.52 0.30 0.16 0.09 0.00 0.00 
Cmpk2-1 1.56 0.69 0.44 0.19 0.00 0.00 
Cmpk2-2 0.72 0.13 0.08 0.09 0.00 0.00 
Cpeb3-1 0.01 0.08 0.12 0.05 0.00 0.00 
Cpeb3-2 0.74 0.22 0.20 0.63 0.00 0.00 
Cxcl10-1 0.56 0.66 0.77 0.98 0.00 0.00 
Cxcl10-2 0.57 0.46 0.33 0.15 0.00 0.01 
Cytip-1 0.62 0.38 0.20 0.31 0.00 0.00 
Cytip-2 0.64 0.66 0.67 0.39 0.00 0.00 
Daxx-1 0.41 1.16 1.42 0.74 0.00 0.00 
Daxx-2 0.85 0.22 0.10 0.07 0.00 0.00 
Ddx58-1 0.55 0.50 0.53 0.49 0.00 0.00 
 180 
Ddx58-2 0.53 0.60 0.57 0.30 0.00 0.00 
Ddx60-1 0.66 0.20 0.10 0.09 0.00 0.00 
Ddx60-2 0.88 0.26 0.15 0.08 0.00 0.00 
Dhx9-1 0.73 0.77 0.59 0.38 0.00 0.00 
Dhx9-2 0.46 0.28 0.27 0.17 0.00 0.00 
Dtx3l-1 0.69 0.84 0.76 0.53 0.00 0.00 
Dtx3l-2 0.52 0.45 0.44 0.69 0.00 0.00 
EGFP 0.49 0.02 0.02 0.08 0.00 0.00 
Eif2ak2-1 0.53 0.56 0.48 0.46 0.00 0.00 
Eif2ak2-2 0.49 0.27 0.29 0.38 0.00 0.00 
Fa2h-1 0.75 0.44 0.25 0.16 0.00 0.00 
Fa2h-2 0.68 0.26 0.16 0.14 0.00 0.00 
Fbxo39-1 0.59 0.97 1.10 1.59 0.01 0.00 
Fbxo39-2 0.63 0.25 0.15 0.38 0.01 0.00 
Gbp2-1 0.78 0.30 0.20 0.13 0.00 0.00 
Gbp2-2 0.53 1.77 2.29 3.92 0.03 0.01 
Gbp3-1 0.52 0.54 0.45 0.22 0.00 0.00 
Gbp3-2 0.62 0.76 0.72 0.42 0.01 0.00 
Gbp6-1 0.00 1.17 1.43 3.03 0.00 0.00 
Gbp6-2 0.13 0.00 0.00 0.00 0.00 0.00 
Gcc-1 0.63 0.21 0.16 0.50 0.00 0.00 
Gcc-2 0.51 0.79 0.88 0.60 0.01 0.01 
Gvin-1 0.49 0.71 0.66 0.37 0.00 0.00 
Gvin-2 0.39 0.72 0.71 0.49 0.00 0.00 
Ifi27-1 0.52 1.24 1.18 0.56 0.01 0.00 
Ifi27-2 0.61 1.38 1.82 2.81 0.01 0.00 
Ifi35-1 0.39 0.21 0.10 0.23 0.00 0.00 
Ifi35-2 0.45 2.14 2.54 2.36 0.02 0.00 
Ifi44-1 0.41 0.84 0.76 1.12 0.01 0.00 
Ifi44-2 0.46 0.50 0.61 0.90 0.00 0.00 
Ifih1-1 0.51 0.21 0.12 0.08 0.00 0.00 
Ifih1-2 0.68 1.01 1.32 1.51 0.03 0.01 
Ifit1-1 0.86 0.15 0.12 0.81 0.00 0.00 
Ifit1-2 0.45 0.48 0.40 0.28 0.00 0.00 
 181 
Ifit3-1 0.47 0.47 0.34 0.23 0.00 0.00 
Ifit3-2 0.58 0.44 0.30 0.22 0.00 0.00 
Ifitm3-1 0.61 0.60 0.58 0.32 0.00 0.00 
Ifitm3-2 0.90 0.61 0.92 1.08 98.94 99.48 
Ifna1-1 0.48 0.66 0.54 0.71 0.01 0.00 
Ifna1-2 0.65 0.36 0.37 0.79 0.00 0.00 
Ifna4-1 0.29 0.65 0.56 0.66 0.00 0.00 
Ifna4-2 0.48 0.29 0.26 0.17 0.00 0.00 
Ifnb1-1 0.90 0.49 0.34 0.16 0.01 0.00 
Ifnb1-2 0.39 0.30 0.49 0.23 0.01 0.00 
Ikbka-1 0.55 0.16 0.12 0.09 0.01 0.00 
Ikbka-2 0.53 0.34 0.22 0.40 0.00 0.00 
Ikbkb-1 0.48 0.51 0.36 0.21 0.00 0.00 
Ikbkb-2 0.61 0.70 0.59 1.18 0.00 0.00 
Ikbke-1 1.25 0.56 0.49 0.23 0.00 0.00 
Ikbke-2 0.61 0.68 0.59 0.33 0.00 0.00 
Il15-1 0.55 0.57 0.36 0.23 0.00 0.00 
Il15-2 0.56 0.70 0.58 0.53 0.00 0.00 
Il6-1 0.78 0.60 0.59 0.27 0.00 0.00 
Il6-2 0.52 0.62 0.58 0.77 0.00 0.00 
Irf1-1 0.69 0.23 0.14 0.35 0.00 0.00 
Irf1-2 0.51 0.26 0.17 0.11 0.00 0.00 
Irf2-1 0.56 0.49 0.50 0.36 0.00 0.00 
Irf2-2 0.67 0.50 0.34 0.31 0.00 0.00 
Irf3-1 0.57 0.24 0.24 0.13 0.00 0.00 
Irf3-2 0.68 0.42 0.32 0.19 0.00 0.00 
Irf5-1 0.62 0.30 0.22 0.10 0.00 0.00 
Irf5-2 0.61 0.16 0.05 0.20 0.00 0.00 
Irf7-1 0.36 0.81 0.57 0.97 0.00 0.01 
Irf7-2 0.57 1.36 1.97 2.46 0.01 0.00 
Irf9-1 0.44 0.28 0.27 0.18 0.01 0.00 
Irf9-2 0.51 0.27 0.20 0.12 0.00 0.00 
Irgm-1 0.54 0.27 0.19 0.13 0.00 0.00 
Irgm-2 0.58 0.81 1.05 1.16 0.01 0.00 
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Isg15-1 0.54 1.02 1.40 1.16 0.01 0.00 
Isg15-2 0.53 0.24 0.22 0.43 0.00 0.00 
Lgals3bp-1 0.58 0.64 0.72 0.44 0.00 0.00 
Lgals3bp-2 0.71 0.31 0.25 0.12 0.01 0.00 
Lgals8-1 0.80 0.60 0.50 0.76 0.00 0.00 
Lgals8-2 0.45 0.13 0.10 0.07 0.00 0.00 
Lrp4-1 0.65 0.21 0.08 0.17 0.00 0.00 
Lrp4-2 0.51 0.53 0.50 0.56 0.00 0.00 
Ly6e-1 0.45 0.21 0.13 0.24 0.02 0.02 
Ly6e-2 0.37 0.44 0.44 1.20 0.00 0.00 
Map3K8-1 0.49 0.63 0.59 0.28 0.00 0.00 
Map3K8-2 0.52 0.50 0.31 0.23 0.01 0.01 
Map4k2-1 0.45 0.60 0.44 0.30 0.01 0.00 
Map4k2-2 0.44 0.35 0.21 0.33 0.00 0.00 
Mapk8-1 0.54 0.64 0.54 0.33 0.00 0.00 
Mapk8-2 0.62 0.61 0.59 0.62 0.00 0.00 
Mbnl1-1 0.44 0.34 0.30 0.34 0.00 0.00 
Mbnl1-2 0.50 0.29 0.19 0.09 0.00 0.00 
miR-124 0.58 0.24 0.15 0.25 0.00 0.03 
Mitd1-1 0.66 0.14 0.10 0.08 0.02 0.01 
Mitd1-2 0.35 0.30 0.26 0.34 0.00 0.00 
Mlkl-1 0.31 0.33 0.39 0.99 0.00 0.00 
Mlkl-2 0.33 1.33 2.29 1.74 0.05 0.02 
Mov10-1 0.46 0.78 0.93 0.50 0.01 0.00 
Mov10-2 0.32 0.53 0.38 0.28 0.00 0.00 
Myd88-1 0.35 0.56 0.49 0.31 0.00 0.00 
Myd88-2 0.52 0.23 0.20 0.12 0.01 0.00 
Nfkbia-1 0.33 0.51 0.49 0.38 0.01 0.01 
Nfkbia-2 0.45 0.27 0.18 0.09 0.00 0.00 
Nmi-1 0.53 0.78 0.84 1.46 0.01 0.00 
Nmi-2 0.53 2.74 4.58 3.86 0.03 0.00 
Oas1a-1 0.41 0.22 0.16 0.10 0.00 0.00 
Oas1a-2 0.47 0.26 0.19 0.10 0.00 0.00 
Oas2-1 0.50 0.26 0.12 0.29 0.00 0.00 
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Oas2-2 0.94 0.28 0.17 0.09 0.00 0.00 
Oasl1-1 0.41 0.71 0.84 1.17 0.00 0.00 
Oasl1-2 0.22 0.57 0.43 0.29 0.00 0.00 
Oasl2-1 0.59 0.51 0.40 0.28 0.00 0.00 
Oasl2-2 0.23 0.52 0.34 0.18 0.00 0.00 
p50 0.50 0.53 0.53 0.34 0.00 0.00 
p50 0.26 0.40 0.31 0.31 0.00 0.00 
p65 0.35 0.38 0.26 0.29 0.00 0.00 
p65 0.30 0.18 0.11 0.08 0.00 0.00 
Papr14-2 0.34 0.57 0.47 0.26 0.00 0.00 
Parp10-1 0.25 0.13 0.12 0.10 0.00 0.00 
Parp10-2 0.42 0.78 0.85 0.88 0.00 0.00 
Parp11-1 0.34 0.04 0.02 0.04 0.00 0.00 
Parp11-2 0.38 0.27 0.18 0.18 0.00 0.00 
Parp12-1 0.24 0.12 0.08 0.03 0.03 0.03 
Parp12-2 0.33 0.42 0.39 0.33 0.00 0.00 
Parp14-1 0.13 0.48 0.43 0.22 0.01 0.01 
Parp9-1 0.35 0.06 0.06 0.04 0.00 0.00 
Parp9-2 0.37 0.28 0.29 0.20 0.00 0.00 
Plec-1 0.37 0.12 0.05 0.05 0.00 0.00 
Plec-2 0.26 0.12 0.04 0.04 0.00 0.00 
Ppm1k-1 0.38 0.24 0.22 0.22 0.01 0.00 
Ppm1k-2 0.22 0.38 0.29 0.34 0.01 0.01 
Ppp3cb-1 0.37 0.23 0.12 0.11 0.00 0.00 
Ppp3cb-2 0.47 0.48 0.43 0.35 0.00 0.00 
Rnasel-1 0.33 0.74 0.90 0.63 0.01 0.00 
Rnasel-2 0.30 0.24 0.20 0.53 0.00 0.00 
Rsad-1 1.00 0.45 0.36 0.26 0.00 0.00 
Rsad-2 0.26 0.36 0.28 0.21 0.01 0.01 
Rtp4-1 0.33 0.57 0.60 0.87 0.00 0.00 
Rtp4-2 1.14 1.09 1.35 0.86 0.00 0.00 
Samd9l-1 0.32 0.26 0.20 0.13 0.00 0.00 
Samd9l-2 0.33 0.18 0.11 0.06 0.01 0.00 
Sfxn2-1 0.31 0.27 0.20 0.14 0.00 0.00 
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Sfxn2-2 1.22 0.20 0.11 0.06 0.00 0.00 
Sh3bgrl-1 0.25 0.60 0.46 0.34 0.00 0.00 
Sh3bgrl-2 0.30 0.10 0.07 0.04 0.00 0.00 
Stat1-1 0.50 0.21 0.15 0.10 0.00 0.00 
Stat1-2 0.32 1.87 1.45 1.07 0.01 0.00 
Stat2-1 0.29 0.50 0.46 0.45 0.00 0.00 
Stat2-2 0.25 0.23 0.21 0.53 0.00 0.00 
Stat3-1 0.31 0.45 0.46 0.21 0.01 0.01 
Stat3-2 0.35 0.89 0.64 0.61 0.00 0.00 
Tap1-1 0.26 0.26 0.22 0.24 0.00 0.00 
Tap1-2 0.21 0.86 0.95 0.74 0.00 0.00 
Tapbp-1 0.21 0.85 1.13 0.95 0.21 0.03 
Tapbp-2 0.28 0.25 0.20 0.16 0.00 0.00 
Tbk1-1 0.32 0.64 0.80 0.80 0.01 0.00 
Tbk1-2 0.19 0.91 0.99 0.49 0.01 0.00 
Ticam1-1 0.27 0.05 0.03 0.02 0.00 0.00 
Ticam1-2 0.28 0.21 0.18 0.10 0.00 0.00 
Tlr3-1 0.32 0.06 0.02 0.03 0.00 0.00 
Tlr3-2 0.38 1.11 1.80 1.38 0.02 0.00 
Tlr7-1 0.34 0.61 0.83 0.37 0.00 0.00 
Tlr7-2 0.32 0.25 0.16 0.11 0.00 0.00 
Tlr9-1 0.29 0.11 0.10 0.06 0.01 0.01 
Tlr9-2 0.32 0.17 0.12 0.11 0.00 0.00 
Tmem140-1 0.30 0.14 0.08 0.06 0.00 0.00 
Tmem140-2 0.28 0.33 0.30 0.47 0.00 0.04 
Tor3a-1 0.25 0.21 0.21 0.17 0.00 0.00 
Tor3a-2 0.26 0.28 0.26 0.14 0.00 0.00 
Trex1-1 0.26 0.10 0.03 0.09 0.00 0.00 
Trex1-2 0.28 0.16 0.09 0.06 0.00 0.00 
Trim21-1 0.34 0.41 0.56 0.98 0.00 0.00 
Trim21-2 0.34 0.34 0.28 0.33 0.00 0.00 
Trim25-1 0.38 0.14 0.10 0.08 0.00 0.00 
Trim25-2 0.30 0.35 0.32 0.26 0.00 0.00 
Usp18-1 0.57 0.36 0.40 0.21 0.00 0.00 
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Usp18-2 0.31 0.34 0.53 0.22 0.00 0.00 
Wwoxv-1 0.15 0.12 0.11 0.05 0.02 0.02 
Wwoxv-2 0.29 0.22 0.22 0.32 0.00 0.00 
Zc3hav1-1 0.20 0.18 0.13 0.05 0.00 0.00 
Zc3hav1-2 0.17 0.38 0.39 0.78 0.00 0.00 
Zfp182-1 0.00 0.13 0.04 0.04 0.00 0.00 
Zfp182-2 0.36 0.75 1.12 0.95 0.01 0.01 
Total  100 100 100 100 100 100 
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Ifnar1-/- MEF Experiment 1 
  Percentage 
Name Plasmid lib P0-293T P1-Vero 
P2- 
Ifnar1-/- 
P3-  
Ifnar1-/- 
P4- 
Ifnar1-/- 
Adar-1 0.00 0.00 0.00 0.00 0.00 0.00 
Adar-2 0.66 0.16 0.09 0.12 0.02 0.00 
Atf2-1 0.41 0.18 0.10 0.11 0.02 0.00 
Atf2-2 1.19 0.48 0.50 0.93 0.12 0.01 
Atf3-1 0.58 0.46 0.37 0.35 0.04 0.00 
Atf3-2 1.95 2.44 3.41 4.79 1.31 0.21 
B2m-1 0.69 0.22 0.15 0.40 0.04 0.01 
B2m-2 0.37 0.41 0.42 0.55 0.13 0.01 
Birc6-1 0.49 0.28 0.27 0.14 0.07 0.00 
Birc6-2 0.51 0.35 0.24 0.35 0.04 0.00 
Brd4-1 0.45 1.25 1.73 1.44 0.31 0.04 
Brd4-2 0.62 0.54 0.54 0.86 0.15 0.03 
Cdkl4-1 0.63 0.67 0.56 0.26 0.06 0.01 
Cdkl4-2 0.60 0.34 0.21 0.18 0.05 0.01 
Clec4d-1 0.49 0.41 0.25 0.23 0.04 0.00 
Clec4d-2 0.61 0.48 0.41 0.38 0.12 0.02 
Clec4e-1 0.48 0.85 0.95 0.65 0.12 0.01 
Clec4e-2 0.52 0.30 0.16 0.08 0.01 0.00 
Cmpk2-1 1.56 0.69 0.44 0.22 0.04 0.00 
Cmpk2-2 0.72 0.13 0.08 0.10 0.03 0.01 
Cpeb3-1 0.01 0.08 0.12 0.12 0.02 0.00 
Cpeb3-2 0.74 0.22 0.20 0.27 0.04 0.01 
Cxcl10-1 0.56 0.66 0.77 0.81 0.13 0.01 
Cxcl10-2 0.57 0.46 0.33 0.20 0.06 0.01 
Cytip-1 0.62 0.38 0.20 0.41 0.09 0.01 
Cytip-2 0.64 0.66 0.67 1.07 0.27 0.04 
Daxx-1 0.41 1.16 1.42 1.03 0.31 0.02 
Daxx-2 0.85 0.22 0.10 0.13 0.01 0.00 
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Ddx58-1 0.55 0.50 0.53 0.64 0.11 0.01 
Ddx58-2 0.53 0.60 0.57 0.26 0.08 0.01 
Ddx60-1 0.66 0.20 0.10 0.09 0.01 0.00 
Ddx60-2 0.88 0.26 0.15 0.23 0.02 0.00 
Dhx9-1 0.73 0.77 0.59 0.43 0.05 0.00 
Dhx9-2 0.46 0.28 0.27 0.25 0.04 0.00 
Dtx3l-1 0.69 0.84 0.76 0.54 0.10 0.01 
Dtx3l-2 0.52 0.45 0.44 0.40 0.19 0.02 
EGFP 0.49 0.02 0.02 0.00 0.00 0.00 
Eif2ak2-1 0.53 0.56 0.48 0.31 0.09 0.00 
Eif2ak2-2 0.49 0.27 0.29 0.62 0.06 0.01 
Fa2h-1 0.75 0.44 0.25 0.18 0.03 0.00 
Fa2h-2 0.68 0.26 0.16 0.09 0.02 0.00 
Fbxo39-1 0.59 0.97 1.10 1.66 0.57 0.08 
Fbxo39-2 0.63 0.25 0.15 0.19 0.04 0.01 
Gbp2-1 0.78 0.30 0.20 0.13 0.03 0.00 
Gbp2-2 0.53 1.77 2.29 2.94 1.13 0.17 
Gbp3-1 0.52 0.54 0.45 0.22 0.06 0.01 
Gbp3-2 0.62 0.76 0.72 0.58 0.15 0.01 
Gbp6-1 0.00 1.17 1.43 1.72 0.38 0.03 
Gbp6-2 0.13 0.00 0.00 0.00 0.00 0.00 
Gcc-1 0.63 0.21 0.16 0.10 0.01 0.00 
Gcc-2 0.51 0.79 0.88 0.68 0.26 0.02 
Gvin-1 0.49 0.71 0.66 0.48 0.10 0.01 
Gvin-2 0.39 0.72 0.71 0.41 0.16 0.01 
Ifi27-1 0.52 1.24 1.18 0.84 0.23 0.02 
Ifi27-2 0.61 1.38 1.82 1.60 0.40 0.04 
Ifi35-1 0.39 0.21 0.10 0.09 0.01 0.00 
Ifi35-2 0.45 2.14 2.54 1.09 0.47 0.03 
Ifi44-1 0.41 0.84 0.76 0.83 0.13 0.02 
Ifi44-2 0.46 0.50 0.61 0.56 0.11 0.02 
Ifih1-1 0.51 0.21 0.12 0.10 0.02 0.00 
Ifih1-2 0.68 1.01 1.32 1.47 0.48 0.06 
Ifit1-1 0.86 0.15 0.12 0.17 0.04 0.01 
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Ifit1-2 0.45 0.48 0.40 0.52 0.09 0.00 
Ifit3-1 0.47 0.47 0.34 0.33 0.07 0.01 
Ifit3-2 0.58 0.44 0.30 0.30 0.04 0.00 
Ifitm3-1 0.61 0.60 0.58 0.27 0.11 0.02 
Ifitm3-2 0.90 0.61 0.92 4.61 74.66 96.50 
Ifna1-1 0.48 0.66 0.54 0.45 0.34 0.05 
Ifna1-2 0.65 0.36 0.37 0.36 0.09 0.02 
Ifna4-1 0.29 0.65 0.56 0.75 0.11 0.01 
Ifna4-2 0.48 0.29 0.26 0.37 0.06 0.01 
Ifnb1-1 0.90 0.49 0.34 0.20 0.03 0.00 
Ifnb1-2 0.39 0.30 0.49 0.46 0.18 0.02 
Ikbka-1 0.55 0.16 0.12 0.18 0.02 0.00 
Ikbka-2 0.53 0.34 0.22 0.22 0.04 0.00 
Ikbkb-1 0.48 0.51 0.36 0.33 0.04 0.00 
Ikbkb-2 0.61 0.70 0.59 0.71 0.15 0.01 
Ikbke-1 1.25 0.56 0.49 0.20 0.12 0.01 
Ikbke-2 0.61 0.68 0.59 0.55 0.13 0.01 
Il15-1 0.55 0.57 0.36 0.22 0.05 0.00 
Il15-2 0.56 0.70 0.58 0.22 0.07 0.01 
Il6-1 0.78 0.60 0.59 0.47 0.07 0.00 
Il6-2 0.52 0.62 0.58 0.37 0.06 0.01 
Irf1-1 0.69 0.23 0.14 0.15 0.02 0.01 
Irf1-2 0.51 0.26 0.17 0.14 0.01 0.00 
Irf2-1 0.56 0.49 0.50 0.37 0.09 0.01 
Irf2-2 0.67 0.50 0.34 0.20 0.04 0.00 
Irf3-1 0.57 0.24 0.24 0.32 0.07 0.01 
Irf3-2 0.68 0.42 0.32 0.25 0.05 0.00 
Irf5-1 0.62 0.30 0.22 0.08 0.03 0.00 
Irf5-2 0.61 0.16 0.05 0.04 0.00 0.00 
Irf7-1 0.36 0.81 0.57 0.95 0.22 0.05 
Irf7-2 0.57 1.36 1.97 3.00 0.67 0.11 
Irf9-1 0.44 0.28 0.27 0.23 0.13 0.01 
Irf9-2 0.51 0.27 0.20 0.29 0.07 0.01 
Irgm-1 0.54 0.27 0.19 0.22 0.04 0.00 
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Irgm-2 0.58 0.81 1.05 1.18 0.35 0.04 
Isg15-1 0.54 1.02 1.40 1.29 0.35 0.04 
Isg15-2 0.53 0.24 0.22 0.21 0.02 0.01 
Lgals3bp-1 0.58 0.64 0.72 0.78 0.21 0.02 
Lgals3bp-2 0.71 0.31 0.25 0.24 0.03 0.00 
Lgals8-1 0.80 0.60 0.50 0.43 0.11 0.01 
Lgals8-2 0.45 0.13 0.10 0.06 0.01 0.00 
Lrp4-1 0.65 0.21 0.08 0.08 0.04 0.01 
Lrp4-2 0.51 0.53 0.50 0.41 0.16 0.01 
Ly6e-1 0.45 0.21 0.13 0.06 0.03 0.02 
Ly6e-2 0.37 0.44 0.44 1.16 0.15 0.03 
Map3K8-1 0.49 0.63 0.59 0.53 0.12 0.01 
Map3K8-2 0.52 0.50 0.31 0.38 0.19 0.05 
Map4k2-1 0.45 0.60 0.44 0.36 0.11 0.02 
Map4k2-2 0.44 0.35 0.21 0.08 0.02 0.00 
Mapk8-1 0.54 0.64 0.54 0.59 0.11 0.01 
Mapk8-2 0.62 0.61 0.59 0.54 0.14 0.02 
Mbnl1-1 0.44 0.34 0.30 0.23 0.08 0.00 
Mbnl1-2 0.50 0.29 0.19 0.11 0.04 0.01 
miR-124 0.58 0.24 0.15 0.07 0.05 0.03 
Mitd1-1 0.66 0.14 0.10 0.11 0.03 0.02 
Mitd1-2 0.35 0.30 0.26 0.30 0.02 0.01 
Mlkl-1 0.31 0.33 0.39 0.77 0.16 0.03 
Mlkl-2 0.33 1.33 2.29 2.50 0.92 0.19 
Mov10-1 0.46 0.78 0.93 1.03 0.32 0.04 
Mov10-2 0.32 0.53 0.38 0.34 0.05 0.01 
Myd88-1 0.35 0.56 0.49 0.42 0.14 0.01 
Myd88-2 0.52 0.23 0.20 0.24 0.02 0.01 
Nfkbia-1 0.33 0.51 0.49 0.33 0.48 0.09 
Nfkbia-2 0.45 0.27 0.18 0.12 0.02 0.00 
Nmi-1 0.53 0.78 0.84 1.01 0.27 0.03 
Nmi-2 0.53 2.74 4.58 3.24 0.89 0.12 
Oas1a-1 0.41 0.22 0.16 0.15 0.03 0.01 
Oas1a-2 0.47 0.26 0.19 0.09 0.00 0.00 
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Oas2-1 0.50 0.26 0.12 0.21 0.03 0.01 
Oas2-2 0.94 0.28 0.17 0.04 0.03 0.00 
Oasl1-1 0.41 0.71 0.84 1.10 0.28 0.05 
Oasl1-2 0.22 0.57 0.43 0.34 0.07 0.01 
Oasl2-1 0.59 0.51 0.40 0.48 0.10 0.01 
Oasl2-2 0.23 0.52 0.34 0.32 0.04 0.00 
p50 0.50 0.53 0.53 0.43 0.11 0.01 
p50 0.26 0.40 0.31 0.30 0.06 0.01 
p65 0.35 0.38 0.26 0.17 0.03 0.00 
p65 0.30 0.18 0.11 0.07 0.01 0.00 
Papr14-2 0.34 0.57 0.47 0.21 0.05 0.01 
Parp10-1 0.25 0.13 0.12 0.09 0.03 0.00 
Parp10-2 0.42 0.78 0.85 0.85 0.22 0.02 
Parp11-1 0.34 0.04 0.02 0.05 0.01 0.00 
Parp11-2 0.38 0.27 0.18 0.23 0.04 0.01 
Parp12-1 0.24 0.12 0.08 0.06 0.02 0.02 
Parp12-2 0.33 0.42 0.39 0.39 0.09 0.01 
Parp14-1 0.13 0.48 0.43 0.23 0.06 0.01 
Parp9-1 0.35 0.06 0.06 0.06 0.02 0.01 
Parp9-2 0.37 0.28 0.29 0.32 0.08 0.02 
Plec-1 0.37 0.12 0.05 0.01 0.01 0.00 
Plec-2 0.26 0.12 0.04 0.02 0.01 0.00 
Ppm1k-1 0.38 0.24 0.22 0.13 0.10 0.01 
Ppm1k-2 0.22 0.38 0.29 0.15 0.09 0.02 
Ppp3cb-1 0.37 0.23 0.12 0.21 0.01 0.00 
Ppp3cb-2 0.47 0.48 0.43 0.27 0.08 0.01 
Rnasel-1 0.33 0.74 0.90 0.85 0.28 0.04 
Rnasel-2 0.30 0.24 0.20 0.35 0.03 0.00 
Rsad-1 1.00 0.45 0.36 0.21 0.10 0.01 
Rsad-2 0.26 0.36 0.28 0.16 0.03 0.01 
Rtp4-1 0.33 0.57 0.60 0.53 0.15 0.01 
Rtp4-2 1.14 1.09 1.35 0.91 0.32 0.05 
Samd9l-1 0.32 0.26 0.20 0.20 0.02 0.00 
Samd9l-2 0.33 0.18 0.11 0.06 0.04 0.01 
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Sfxn2-1 0.31 0.27 0.20 0.30 0.05 0.01 
Sfxn2-2 1.22 0.20 0.11 0.13 0.01 0.00 
Sh3bgrl-1 0.25 0.60 0.46 0.57 0.13 0.01 
Sh3bgrl-2 0.30 0.10 0.07 0.05 0.00 0.00 
Stat1-1 0.50 0.21 0.15 0.17 0.04 0.00 
Stat1-2 0.32 1.87 1.45 0.96 0.21 0.02 
Stat2-1 0.29 0.50 0.46 0.56 0.07 0.01 
Stat2-2 0.25 0.23 0.21 0.19 0.03 0.00 
Stat3-1 0.31 0.45 0.46 0.43 0.12 0.02 
Stat3-2 0.35 0.89 0.64 0.73 0.11 0.01 
Tap1-1 0.26 0.26 0.22 0.28 0.07 0.00 
Tap1-2 0.21 0.86 0.95 0.75 0.12 0.01 
Tapbp-1 0.21 0.85 1.13 1.33 0.76 0.25 
Tapbp-2 0.28 0.25 0.20 0.25 0.04 0.00 
Tbk1-1 0.32 0.64 0.80 1.08 0.18 0.02 
Tbk1-2 0.19 0.91 0.99 0.74 0.13 0.01 
Ticam1-1 0.27 0.05 0.03 0.02 0.01 0.00 
Ticam1-2 0.28 0.21 0.18 0.07 0.06 0.00 
Tlr3-1 0.32 0.06 0.02 0.01 0.01 0.00 
Tlr3-2 0.38 1.11 1.80 1.97 0.73 0.11 
Tlr7-1 0.34 0.61 0.83 0.59 0.13 0.01 
Tlr7-2 0.32 0.25 0.16 0.12 0.00 0.00 
Tlr9-1 0.29 0.11 0.10 0.05 0.04 0.01 
Tlr9-2 0.32 0.17 0.12 0.14 0.05 0.00 
Tmem140-1 0.30 0.14 0.08 0.12 0.01 0.00 
Tmem140-2 0.28 0.33 0.30 0.25 0.09 0.04 
Tor3a-1 0.25 0.21 0.21 0.27 0.06 0.01 
Tor3a-2 0.26 0.28 0.26 0.12 0.06 0.01 
Trex1-1 0.26 0.10 0.03 0.12 0.01 0.00 
Trex1-2 0.28 0.16 0.09 0.03 0.01 0.00 
Trim21-1 0.34 0.41 0.56 0.55 0.15 0.01 
Trim21-2 0.34 0.34 0.28 0.15 0.08 0.00 
Trim25-1 0.38 0.14 0.10 0.14 0.02 0.00 
Trim25-2 0.30 0.35 0.32 0.22 0.09 0.02 
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Usp18-1 0.57 0.36 0.40 0.46 0.08 0.01 
Usp18-2 0.31 0.34 0.53 0.32 0.15 0.02 
Wwoxv-1 0.15 0.12 0.11 0.15 0.05 0.02 
Wwoxv-2 0.29 0.22 0.22 0.23 0.06 0.00 
Zc3hav1-1 0.20 0.18 0.13 0.04 0.02 0.01 
Zc3hav1-2 0.17 0.38 0.39 0.47 0.14 0.01 
Zfp182-1 0.00 0.13 0.04 0.00 0.03 0.00 
Zfp182-2 0.36 0.75 1.12 1.03 0.26 0.04 
Total 100 100 100 100 100 100 
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Ifnar1-/- MEF Experiment 2 
  Percentage 
  
PLASMID 
LIB P0-293T 
P1-
VERO 
P2- 
Ifnar1-/- P3- Ifnar1-/- 
P4- 
Ifnar1-/- 
Adar-1 0.00 0.00 0.00 0.00 0.00 0.00 
Adar-2 0.66 0.16 0.09 0.08 0.01 0.00 
Atf2-1 0.41 0.18 0.10 0.10 0.03 0.01 
Atf2-2 1.19 0.48 0.50 0.78 0.35 0.09 
Atf3-1 0.58 0.46 0.37 0.32 0.04 0.01 
Atf3-2 1.95 2.44 3.41 4.44 1.19 0.55 
B2m-1 0.69 0.22 0.15 0.29 0.01 0.01 
B2m-2 0.37 0.41 0.42 0.37 0.07 0.02 
Birc6-1 0.49 0.28 0.27 0.24 0.08 0.02 
Birc6-2 0.51 0.35 0.24 0.33 0.03 0.02 
Brd4-1 0.45 1.25 1.73 1.22 0.56 0.16 
Brd4-2 0.62 0.54 0.54 0.77 0.17 0.14 
Cdkl4-1 0.63 0.67 0.56 0.30 0.07 0.00 
Cdkl4-2 0.60 0.34 0.21 0.27 0.01 0.01 
Clec4d-1 0.49 0.41 0.25 0.30 0.08 0.01 
Clec4d-2 0.61 0.48 0.41 0.31 0.07 0.03 
Clec4e-1 0.48 0.85 0.95 0.81 0.31 0.05 
Clec4e-2 0.52 0.30 0.16 0.06 0.09 0.01 
Cmpk2-1 1.56 0.69 0.44 0.21 0.03 0.00 
Cmpk2-2 0.72 0.13 0.08 0.09 0.03 0.01 
Cpeb3-1 0.01 0.08 0.12 0.09 0.04 0.01 
Cpeb3-2 0.74 0.22 0.20 0.24 0.03 0.02 
Cxcl10-1 0.56 0.66 0.77 0.67 0.28 0.07 
Cxcl10-2 0.57 0.46 0.33 0.22 0.28 0.05 
Cytip-1 0.62 0.38 0.20 0.27 0.02 0.01 
Cytip-2 0.64 0.66 0.67 0.55 0.13 0.16 
Daxx-1 0.41 1.16 1.42 0.99 0.55 0.12 
Daxx-2 0.85 0.22 0.10 0.07 0.02 0.00 
Ddx58-1 0.55 0.50 0.53 0.51 0.23 0.04 
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Ddx58-2 0.53 0.60 0.57 0.40 0.14 0.02 
Ddx60-1 0.66 0.20 0.10 0.13 0.01 0.01 
Ddx60-2 0.88 0.26 0.15 0.07 0.10 0.02 
Dhx9-1 0.73 0.77 0.59 0.33 0.17 0.03 
Dhx9-2 0.46 0.28 0.27 0.16 0.16 0.01 
Dtx3l-1 0.69 0.84 0.76 0.66 0.13 0.06 
Dtx3l-2 0.52 0.45 0.44 0.21 0.23 0.04 
EGFP 0.49 0.02 0.02 0.02 0.02 0.01 
Eif2ak2-1 0.53 0.56 0.48 0.36 0.04 0.01 
Eif2ak2-2 0.49 0.27 0.29 0.50 0.02 0.05 
Fa2h-1 0.75 0.44 0.25 0.11 0.03 0.01 
Fa2h-2 0.68 0.26 0.16 0.19 0.02 0.01 
Fbxo39-1 0.59 0.97 1.10 2.12 0.34 0.22 
Fbxo39-2 0.63 0.25 0.15 0.12 0.21 0.02 
Gbp2-1 0.78 0.30 0.20 0.15 0.09 0.01 
Gbp2-2 0.53 1.77 2.29 2.80 1.61 0.50 
Gbp3-1 0.52 0.54 0.45 0.41 0.07 0.02 
Gbp3-2 0.62 0.76 0.72 0.50 0.16 0.04 
Gbp6-1 0.00 1.17 1.43 1.46 0.30 0.16 
Gbp6-2 0.13 0.00 0.00 0.00 0.00 0.00 
Gcc-1 0.63 0.21 0.16 0.10 0.06 0.01 
Gcc-2 0.51 0.79 0.88 0.71 0.24 0.06 
Gvin-1 0.49 0.71 0.66 0.56 0.21 0.04 
Gvin-2 0.39 0.72 0.71 0.60 0.28 0.05 
Ifi27-1 0.52 1.24 1.18 0.77 0.32 0.05 
Ifi27-2 0.61 1.38 1.82 1.51 0.30 0.09 
Ifi35-1 0.39 0.21 0.10 0.05 0.05 0.01 
Ifi35-2 0.45 2.14 2.54 1.64 0.53 0.11 
Ifi44-1 0.41 0.84 0.76 0.81 0.37 0.10 
Ifi44-2 0.46 0.50 0.61 0.67 0.12 0.08 
Ifih1-1 0.51 0.21 0.12 0.05 0.04 0.01 
Ifih1-2 0.68 1.01 1.32 1.29 0.30 0.17 
Ifit1-1 0.86 0.15 0.12 0.22 0.01 0.01 
Ifit1-2 0.45 0.48 0.40 0.54 0.34 0.06 
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Ifit3-1 0.47 0.47 0.34 0.44 0.05 0.02 
Ifit3-2 0.58 0.44 0.30 0.27 0.02 0.00 
Ifitm3-1 0.61 0.60 0.58 0.37 0.11 0.03 
Ifitm3-2 0.90 0.61 0.92 4.17 66.33 89.55 
Ifna1-1 0.48 0.66 0.54 0.41 0.22 0.07 
Ifna1-2 0.65 0.36 0.37 0.36 0.12 0.06 
Ifna4-1 0.29 0.65 0.56 0.51 0.10 0.05 
Ifna4-2 0.48 0.29 0.26 0.26 0.10 0.02 
Ifnb1-1 0.90 0.49 0.34 0.27 0.11 0.01 
Ifnb1-2 0.39 0.30 0.49 0.48 0.16 0.07 
Ikbka-1 0.55 0.16 0.12 0.13 0.02 0.00 
Ikbka-2 0.53 0.34 0.22 0.19 0.01 0.01 
Ikbkb-1 0.48 0.51 0.36 0.34 0.09 0.02 
Ikbkb-2 0.61 0.70 0.59 0.78 0.14 0.05 
Ikbke-1 1.25 0.56 0.49 0.30 0.08 0.01 
Ikbke-2 0.61 0.68 0.59 0.56 0.08 0.02 
Il15-1 0.55 0.57 0.36 0.21 0.12 0.03 
Il15-2 0.56 0.70 0.58 0.40 0.14 0.03 
Il6-1 0.78 0.60 0.59 0.40 0.08 0.02 
Il6-2 0.52 0.62 0.58 0.41 0.25 0.04 
Irf1-1 0.69 0.23 0.14 0.22 0.04 0.02 
Irf1-2 0.51 0.26 0.17 0.11 0.02 0.00 
Irf2-1 0.56 0.49 0.50 0.48 0.06 0.05 
Irf2-2 0.67 0.50 0.34 0.24 0.05 0.01 
Irf3-1 0.57 0.24 0.24 0.18 0.09 0.03 
Irf3-2 0.68 0.42 0.32 0.27 0.07 0.03 
Irf5-1 0.62 0.30 0.22 0.06 0.03 0.01 
Irf5-2 0.61 0.16 0.05 0.05 0.01 0.00 
Irf7-1 0.36 0.81 0.57 1.06 0.06 0.13 
Irf7-2 0.57 1.36 1.97 2.49 0.93 0.43 
Irf9-1 0.44 0.28 0.27 0.23 0.07 0.01 
Irf9-2 0.51 0.27 0.20 0.19 0.05 0.01 
Irgm-1 0.54 0.27 0.19 0.31 0.22 0.01 
Irgm-2 0.58 0.81 1.05 1.19 0.39 0.16 
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Isg15-1 0.54 1.02 1.40 1.35 0.66 0.18 
Isg15-2 0.53 0.24 0.22 0.18 0.04 0.01 
Lgals3bp-1 0.58 0.64 0.72 0.69 0.15 0.09 
Lgals3bp-2 0.71 0.31 0.25 0.13 0.06 0.01 
Lgals8-1 0.80 0.60 0.50 0.59 0.11 0.04 
Lgals8-2 0.45 0.13 0.10 0.07 0.03 0.01 
Lrp4-1 0.65 0.21 0.08 0.05 0.15 0.02 
Lrp4-2 0.51 0.53 0.50 0.44 0.08 0.02 
Ly6e-1 0.45 0.21 0.13 0.07 0.04 0.02 
Ly6e-2 0.37 0.44 0.44 0.81 0.53 0.07 
Map3K8-1 0.49 0.63 0.59 0.73 0.07 0.03 
Map3K8-2 0.52 0.50 0.31 0.29 0.62 0.12 
Map4k2-1 0.45 0.60 0.44 0.37 0.14 0.03 
Map4k2-2 0.44 0.35 0.21 0.11 0.05 0.01 
Mapk8-1 0.54 0.64 0.54 0.32 0.10 0.03 
Mapk8-2 0.62 0.61 0.59 0.43 0.15 0.04 
Mbnl1-1 0.44 0.34 0.30 0.25 0.03 0.01 
Mbnl1-2 0.50 0.29 0.19 0.16 0.02 0.01 
miR-124 0.58 0.24 0.15 0.12 0.05 0.02 
Mitd1-1 0.66 0.14 0.10 0.04 0.03 0.02 
Mitd1-2 0.35 0.30 0.26 0.38 0.03 0.02 
Mlkl-1 0.31 0.33 0.39 0.64 0.07 0.06 
Mlkl-2 0.33 1.33 2.29 2.58 1.40 0.47 
Mov10-1 0.46 0.78 0.93 1.08 0.60 0.14 
Mov10-2 0.32 0.53 0.38 0.48 0.02 0.02 
Myd88-1 0.35 0.56 0.49 0.35 0.08 0.03 
Myd88-2 0.52 0.23 0.20 0.15 0.06 0.01 
Nfkbia-1 0.33 0.51 0.49 0.22 0.33 0.14 
Nfkbia-2 0.45 0.27 0.18 0.13 0.05 0.01 
Nmi-1 0.53 0.78 0.84 0.98 0.17 0.08 
Nmi-2 0.53 2.74 4.58 3.67 1.68 0.34 
Oas1a-1 0.41 0.22 0.16 0.11 0.03 0.01 
Oas1a-2 0.47 0.26 0.19 0.06 0.05 0.01 
Oas2-1 0.50 0.26 0.12 0.17 0.03 0.01 
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Oas2-2 0.94 0.28 0.17 0.13 0.03 0.00 
Oasl1-1 0.41 0.71 0.84 1.09 0.09 0.14 
Oasl1-2 0.22 0.57 0.43 0.26 0.13 0.03 
Oasl2-1 0.59 0.51 0.40 0.35 0.08 0.03 
Oasl2-2 0.23 0.52 0.34 0.22 0.01 0.01 
p50 0.50 0.53 0.53 0.59 0.14 0.03 
p50 0.26 0.40 0.31 0.22 0.09 0.02 
p65 0.35 0.38 0.26 0.28 0.03 0.01 
p65 0.30 0.18 0.11 0.10 0.01 0.00 
Papr14-2 0.34 0.57 0.47 0.38 0.15 0.02 
Parp10-1 0.25 0.13 0.12 0.19 0.02 0.03 
Parp10-2 0.42 0.78 0.85 0.78 0.29 0.06 
Parp11-1 0.34 0.04 0.02 0.03 0.02 0.00 
Parp11-2 0.38 0.27 0.18 0.42 0.01 0.03 
Parp12-1 0.24 0.12 0.08 0.07 0.03 0.03 
Parp12-2 0.33 0.42 0.39 0.55 0.09 0.04 
Parp14-1 0.13 0.48 0.43 0.37 0.04 0.01 
Parp9-1 0.35 0.06 0.06 0.10 0.13 0.01 
Parp9-2 0.37 0.28 0.29 0.41 0.05 0.04 
Plec-1 0.37 0.12 0.05 0.05 0.01 0.01 
Plec-2 0.26 0.12 0.04 0.04 0.01 0.00 
Ppm1k-1 0.38 0.24 0.22 0.22 0.15 0.03 
Ppm1k-2 0.22 0.38 0.29 0.12 0.02 0.01 
Ppp3cb-1 0.37 0.23 0.12 0.33 0.02 0.01 
Ppp3cb-2 0.47 0.48 0.43 0.34 0.02 0.01 
Rnasel-1 0.33 0.74 0.90 0.74 0.17 0.07 
Rnasel-2 0.30 0.24 0.20 0.22 0.02 0.02 
Rsad-1 1.00 0.45 0.36 0.39 0.11 0.02 
Rsad-2 0.26 0.36 0.28 0.20 0.05 0.02 
Rtp4-1 0.33 0.57 0.60 0.75 0.45 0.06 
Rtp4-2 1.14 1.09 1.35 1.04 0.47 0.15 
Samd9l-1 0.32 0.26 0.20 0.21 0.02 0.02 
Samd9l-2 0.33 0.18 0.11 0.04 0.03 0.01 
Sfxn2-1 0.31 0.27 0.20 0.32 0.06 0.02 
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Sfxn2-2 1.22 0.20 0.11 0.10 0.05 0.01 
Sh3bgrl-1 0.25 0.60 0.46 0.76 0.10 0.05 
Sh3bgrl-2 0.30 0.10 0.07 0.04 0.03 0.01 
Stat1-1 0.50 0.21 0.15 0.15 0.02 0.01 
Stat1-2 0.32 1.87 1.45 1.06 0.32 0.06 
Stat2-1 0.29 0.50 0.46 0.51 0.06 0.03 
Stat2-2 0.25 0.23 0.21 0.15 0.05 0.01 
Stat3-1 0.31 0.45 0.46 0.32 0.09 0.02 
Stat3-2 0.35 0.89 0.64 0.57 0.07 0.03 
Tap1-1 0.26 0.26 0.22 0.23 0.03 0.02 
Tap1-2 0.21 0.86 0.95 0.69 0.28 0.04 
Tapbp-1 0.21 0.85 1.13 1.42 1.77 0.63 
Tapbp-2 0.28 0.25 0.20 0.21 0.05 0.03 
Tbk1-1 0.32 0.64 0.80 0.55 0.47 0.13 
Tbk1-2 0.19 0.91 0.99 0.56 0.14 0.03 
Ticam1-1 0.27 0.05 0.03 0.01 0.00 0.00 
Ticam1-2 0.28 0.21 0.18 0.18 0.04 0.02 
Tlr3-1 0.32 0.06 0.02 0.02 0.01 0.01 
Tlr3-2 0.38 1.11 1.80 2.24 1.03 0.22 
Tlr7-1 0.34 0.61 0.83 0.96 0.23 0.07 
Tlr7-2 0.32 0.25 0.16 0.10 0.03 0.00 
Tlr9-1 0.29 0.11 0.10 0.09 0.04 0.02 
Tlr9-2 0.32 0.17 0.12 0.10 0.02 0.01 
Tmem140-1 0.30 0.14 0.08 0.10 0.04 0.02 
Tmem140-2 0.28 0.33 0.30 0.29 0.13 0.04 
Tor3a-1 0.25 0.21 0.21 0.35 0.07 0.06 
Tor3a-2 0.26 0.28 0.26 0.23 0.08 0.02 
Trex1-1 0.26 0.10 0.03 0.06 0.00 0.00 
Trex1-2 0.28 0.16 0.09 0.04 0.01 0.01 
Trim21-1 0.34 0.41 0.56 0.68 0.25 0.11 
Trim21-2 0.34 0.34 0.28 0.30 0.06 0.01 
Trim25-1 0.38 0.14 0.10 0.08 0.02 0.01 
Trim25-2 0.30 0.35 0.32 0.41 0.15 0.03 
Usp18-1 0.57 0.36 0.40 0.49 0.09 0.05 
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Usp18-2 0.31 0.34 0.53 0.59 0.20 0.04 
Wwoxv-1 0.15 0.12 0.11 0.07 0.08 0.04 
Wwoxv-2 0.29 0.22 0.22 0.17 0.11 0.03 
Zc3hav1-1 0.20 0.18 0.13 0.08 0.02 0.00 
Zc3hav1-2 0.17 0.38 0.39 0.56 0.12 0.04 
Zfp182-1 0.00 0.13 0.04 0.02 0.01 0.00 
Zfp182-2 0.36 0.75 1.12 1.26 0.58 0.13 
Total 100 100 100 100 100 100 
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Appendix 4 
 
 
Figure 1: Infection of WTMEF cells with MOI=10 of respective viruses is not sufficient does 
not result into effective WNV infection. WT MEFs were infected with IFITM3-amiR WNV, 
GFP-amiR WNV, WT-WNV at MOI=10 or mock infected. At 48hpi, cell lysates were harvested in 
NP-40 lysis buffer and subjected to western blot analysis. Blots were probed with rabbit polyclonal 
anti-IFITM3, anti-WNV-E and mouse anti-GAPDH antibodies. Expected band sizes were 14 kDa,  
42 kDa and 37 kDa for  IFITM3, WNV-E and GAPDH respectively. 
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Appendix 5 
 
Figure 2: Less IFITM3 was incorporated into virions secreted at 72 hpi compared to 48 hpi. 
Ifnar1-/- MEFs were infected at MOI=1, 48 hpi, virus culture fluid was collected, cells washed with 
PBS and new DMEM to generate 72 hpi sample. At 48 hpi and 72 hpi, an equal amount (250 µL) of 
virus particles were immunoprecipitated from each sample by binding a fixed amount (5 µg) of 
purified anti-E monoclonal antibody (6B6C-1) as the capture antibody on Dynabead protein G 
(Invitrogen, USA). Immunoprecipitated WNV-E protein was thereafter subjected to western blot 
analysis. Blots were probed with rabbit polyclonal anti-IFITM3 and the expected band size was 14 
kDa. 
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Animal ethics approval certificates  
 
Mice - non genetically modified (CD1, Mix, Juvenile / Weaners / Pouch animal, )
5 Apr 2017 Initial approval 26 26
31 Dec 2017 Use in 2017 (from 2018 MAR; AEMAR41053) -16 10
19 Sep 2018 Mod #1 120 130
Description Amount Balance
Approval Details
Office of Research Ethics
Director
Nicole Shively
Animal Ethics Approval Certificate 18-Sep-2018
Please check all details below and inform the Animal Ethics Unit within 10 working days if anything is incorrect.
Activity Details
Chief Investigator: Dr Yin Xiang Setoh, Chemistry and Molecular Biosciences
Title: In vivo screening of host genes critical for controlling West Nile virus 
replication/pathogenesis
AEC Approval Number: SCMB/008/17
Previous AEC Number:
Approval Duration: 05-Apr-2017 to 05-Apr-2019
Funding Body:
Group: Molecular Biosciences
Other Staff/Students: Alberto Amarilla Ortiz, Faith Elizabeth Nanyonga, Kevin Wathen-Dunn
Summary
Subspecies Strain Class Gender Source Approved Remaining
Mice - non 
genetically 
modified
CD1 Juvenile / Weaners 
/ Pouch animal
Mix 146 130
Permits
Provisos
Location(s): St Lucia Bldg 75 - AIBN
Cumbrae-Stewart Building
Research Road
St Lucia Qld 4072 Australia
Animal Ethics Unit
Office of Research Ethics
The University of Queensland
+61 7 336 52925 (Enquiries)
+61 7 334 68710 (Enquiries)
+61 7 336 52713 (Coordinator)
animal.ethics@research.uq.edu.au
uq.edu.au/research
Page 1 of 2
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Appendix 7  
Percentage enrichment in spleens  
                
  Percentage enrichment in spleen 
NAME 
p1-
vero  1  2  3  4  5  6 
Adar-1 0 0.00 0.00 0.0 0 0.0 0.01 
Adar-2 0.1 0.0 0.01 0.0 0.0 1.8 0.0 
Atf2-1 0.1 0.0 0.01 0.0 0.0 0.1 0.0 
Atf2-2 0.5 0.0 0.01 0.0 0.0 0.0 0.0 
Atf3-1 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Atf3-2 3.4 18.3 76.87 46.8 97.3 0.2 0.1 
B2m-1 0.2 0.0 0.00 0.0 0.0 0.0 1.9 
B2m-2 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Birc6-1 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Birc6-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Brd4-1 1.7 0.0 0.00 9.5 0.0 0.0 0.0 
Brd4-2 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Cdkl4-1 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Cdkl4-2 0.2 0.1 0.01 0.0 0.0 0.0 0.0 
Clec4d-1 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Clec4d-2 0.4 2.0 0.05 0.0 0.0 0.0 0.0 
Clec4e-1 1.0 0.0 0.00 0.0 0.0 0.0 0.0 
Clec4e-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Cmpk2-1 0.4 0.0 0.01 0.0 0.0 0.0 0.0 
Cmpk2-2 0.1 0.0 0.01 0.0 0.0 0.0 0.0 
Cpeb3-1 0.1 0.0 1.16 0.0 0.0 0.0 0.0 
Cpeb3-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Cxcl10-1 0.8 0 0.00 0 0 0 0 
Cxcl10-2 0.3 0 0.00 0 0 0 0 
Cytip-1 0.2 0.0 0.00 0.0 0.1 0.0 0.0 
Cytip-2 0.7 0.0 0.01 0.0 0.0 0.0 0.0 
Daxx-1 1.4 0.0 0.00 0.0 0.0 0.0 0.1 
Daxx-2 0.1 0.00 0.00 0.0 5E-06 0.01 0 
Ddx58-1 0.5 0.0 0.00 4.1 0.0 0.0 3.7 
Ddx58-2 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Ddx60-1 0.1 0.00 0.00 0.00 0.00 0.00 0.00 
Ddx60-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Dhx9-1 0.6 0.1 0.01 0.0 0.0 0.2 0.0 
Dhx9-2 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Dtx3l-1 0.8 0.0 0.00 0.0 0.0 0.0 0.0 
Dtx3l-2 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
EGFP 0.0 0.0 0.00 0.0 0.0 0.0 0.0 
Eif2ak2-1 0.5 0.0 0.00 0.0 0.0 0.2 0.0 
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Eif2ak2-2 0.3 0.0 0.01 0.6 0.0 0.0 0.0 
Fa2h-1 0.2 0.0 0.01 0.0 0.0 0.0 0.0 
Fa2h-2 0.2 1.8 0.06 0.0 0.0 0.0 2.3 
Fbxo39-1 1.1 0.0 0.01 0.0 1.2 80.3 0.1 
Fbxo39-2 0.2 0.7 0.05 0.0 0.0 0.0 0.1 
Gbp2-1 0.2 0.0 0.00 14.64 0.0 0.0 0.1 
Gbp2-2 2.3 0.0 0.00 0.0 0.0 0.02 0.0 
Gbp3-1 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Gbp3-2 0.7 6.1 0.13 0.0 0.0 0.0 0.0 
Gbp6-1 1.4 0.00 0.00 0.0 0 0.0 0.0 
Gbp6-2 0.0 0.0 0.00 0.0 0.0 0.00 0.0 
Gcc-1 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Gcc-2 0.9 0.0 0.00 0.0 0.0 0.0 0.0 
Gvin-1 0.7 0.0 0.00 0.0 0.0 0.1 0.0 
Gvin-2 0.7 0.0 0.01 0.0 0.0 0.0 0.0 
Ifi27-1 1.2 0.0 0.03 0.2 0.0 0.0 0.0 
Ifi27-2 1.8 0.0 0.00 0.0 0.0 0.0 0.0 
Ifi35-1 0.1 0.0 0.03 0.0 0.0 0.0 0.0 
Ifi35-2 2.5 0.0 0.01 0.0 0.2 0.0 0.0 
Ifi44-1 0.8 0.0 0.00 0.0 0.0 0.0 0.0 
Ifi44-2 0.6 0.0 0.01 0.0 0.0 0.0 0.0 
Ifih1-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Ifih1-2 1.3 0.0 0.00 0.0 0.0 0.5 0.0 
Ifit1-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Ifit1-2 0.4 0.0 0.01 0.0 0.0 0.0 0.0 
Ifit3-1 0.3 0.0 0.00 0.1 0.0 0.1 0.0 
Ifit3-2 0.3 0.0 0.01 0.0 0.0 0.1 0.0 
Ifitm3-1 0.6 0.1 0.13 0.1 0.0 0.8 0.3 
Ifitm3-2 0.9 0.0 1.38 0.0 0.0 0.1 0.0 
Ifna1-1 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Ifna1-2 0.4 0.0 0.01 0.0 0.0 0.0 0.0 
Ifna4-1 0.6 0.0 0.00 0.0 0 0.0 1.84 
Ifna4-2 0.3 0.0 0.00 0.0 0.0 0 0.0 
Ifnb1-1 0.3 0 0.00 0 0 0.0 0.0 
Ifnb1-2 0.5 0.0 0.01 0.0 0.0 0.0 0.0 
Ikbka-1 0.1 0 0.00 0 0.0 0.0 0 
Ikbka-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Ikbkb-1 0.4 0.0 4.69 0.0 0.0 0.0 0.0 
Ikbkb-2 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Ikbke-1 0.5 0.0 0.01 0.0 0.0 0.0 4.4 
Ikbke-2 0.6 0.0 0.00 0.0 0.0 0.4 0.0 
Il15-1 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Il15-2 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Il6-1 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Il6-2 0.6 0.1 0.03 0.0 0.0 0.0 0.0 
Irf1-1 0.1 0.02 0.00 0.00 0.00 0.0 0.00 
Irf1-2 0.2 0.0 0.01 0.0 0.0 0.00 19.8 
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Irf2-1 0.5 0.0 0.00 0.0 0 0.0 0.0 
Irf2-2 0.3 0.0 0.00 0.0 0.0 0.0 0 
Irf3-1 0.2 0.0 0.00 0.0 0.0 0 0.0 
Irf3-2 0.3 0.0 0.51 0.0 0.0 0.1 0.0 
Irf5-1 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Irf5-2 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Irf7-1 0.6 3.6 0.12 0.0 0.0 0.0 0.0 
Irf7-2 2.0 0.0 0.0 0.01 0.0 0.0 0.0 
Irf9-1 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Irf9-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Irgm-1 0.2 0.0 0.00 0.0 0.0 0.0 0.2 
Irgm-2 1.1 0.0 0.00 0.0 0.0 0.0 0.0 
Isg15-1 1.4 0 0.00 0 0 0.0 0.0 
Isg15-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Lgals3bp-1 0.7 0.0 0.00 0.0 0.0 0.0 0.0 
Lgals3bp-2 0.2 0.0 0.06 0.0 0.0 0.0 0.0 
Lgals8-1 0.5 0.0 0.00 0.0 0.0 0.1 0.0 
Lgals8-2 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Lrp4-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Lrp4-2 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Ly6e-1 0.1 0.0 0.00 0.0 0.0 0.0 0.1 
Ly6e-2 0.4 0.0 0.00 0.0 0.0 12.9 0.0 
Map3K8-1 0.6 0.0 0.00 0.1 0.0 0.0 0.0 
Map3K8-2 0.3 0.0 0.02 0.0 0.0 0.0 0.0 
Map4k2-1 0.4 1.1 0.31 0.0 0.0 0.0 0.0 
Map4k2-2 0.2 0.1 5.05 0.0 0.0 0.0 0.0 
Mapk8-1 0.5 0.0 0.04 0.0 0.0 0.3 12.8 
Mapk8-2 0.6 0.0 0.00 0.0 0.0 0.0 0.0 
Mbnl1-1 0.3 0.0 0.01 0.0 0.0 0.1 0.0 
Mbnl1-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
miR-124 0.2 0.0 0.01 0.0 0.0 0.0 0.5 
Mitd1-1 0.1 0.0 0.00 0.0 0.0 0.1 0.0 
Mitd1-2 0.3 0.0 0.18 20.6 0.1 0.0 11.3 
Mlkl-1 0.4 0.0 0.01 0.0 0.0 0.0 0.0 
Mlkl-2 2.3 0.0 0.00 0.0 0.0 0.0 0.0 
Mov10-1 0.9 0.0 0.05 0.0 0.0 0.0 0.0 
Mov10-2 0.4 0.0 0.01 0.0 0.0 0.0 0.0 
Myd88-1 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Myd88-2 0.2 0.0 0.02 0.0 0.0 0.0 0.0 
Nfkbia-1 0.5 0 0.00 0 0 0.0 0.0 
Nfkbia-2 0.2 0.1 0.00 0.0 0.0 0 0.0 
Nmi-1 0.8 0.0 0.00 0.0 0.1 0.0 0.0 
Nmi-2 4.6 0.0 0.03 0.0 0.0 0.0 0.0 
Oas1a-1 0.2 0 0.00 0.0 0.0 0.0 0.00 
Oas1a-2 0.2 0.0 0.01 0.0 0.0 0.0 6.3 
Oas2-1 0.1 0.0 0.03 0.0 0.0 0.0 0.0 
Oas2-2 0.2 0.0 0.02 0.0 0.0 0.0 0.0 
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Oasl1-1 0.8 0.0 0.00 0.0 0.0 0.0 0.0 
Oasl1-2 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Oasl2-1 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Oasl2-2 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
p50 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
p50 0.3 0.0 0.01 0.0 0.0 0.0 0.0 
p65 0.3 0.0 0.00 0.0 0.0 0.0 0.2 
p65 0.1 0.0 0.01 0.0 0.0 0.1 0.0 
Papr14-2 0.5 34.5 0.00 0.0 0.0 0.0 0.0 
Parp10-1 0.1 0.0 0.69 0.0 0.0 0.0 0.0 
Parp10-2 0.9 0.0 0.00 0.0 0.0 0.00 0.0 
Parp11-1 0.0 0.0 0.00 0.0 0.0 0.0 0.0 
Parp11-2 0.2 0.0 0.00 0.1 0.0 0.0 0.0 
Parp12-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Parp12-2 0.4 0.0 0.09 0.0 0.0 0.0 0.0 
Parp14-1 0.4 0.0 0.00 0.0 0.0 0.0 0.0 
Parp9-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Parp9-2 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Plec-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Plec-2 0.0 0 0.00 0 0 0.0 0 
Ppm1k-1 0.2 0.0 0.00 0.0 0.0 0.01 0.0 
Ppm1k-2 0.3 0.0 0.13 0.0 0.0 0.0 0.0 
Ppp3cb-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Ppp3cb-2 0.4 0.0 0.03 0.0 0.0 0.0 0.0 
Rnasel-1 0.9 0.0 0.00 0.0 0.0 0.0 0.0 
Rnasel-2 0.2 0.0 0.00 0.0 0.0 0.0 0.0 
Rsad-1 0.4 15.8 0.00 0.0 0.0 0.0 0.0 
Rsad-2 0.3 14.75 0.37 0.01 0.01 0.0 0.01 
Rtp4-1 0.6 0.0 0.31 0.0 0.0 0.03 0.0 
Rtp4-2 1.4 0.0 0.00 0.0 0.00 0.0 0 
Samd9l-1 0.2 0.0 0.01 0.0 0.0 0.05 0.0 
Samd9l-2 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Sfxn2-1 0.2 0.0 0.01 0.0 0.0 0.0 0.0 
Sfxn2-2 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Sh3bgrl-1 0.5 0.0 0.00 0.0 0.0 0.1 0.0 
Sh3bgrl-2 0.1 0.0 0.00 1.5 0.0 0.0 0.0 
Stat1-1 0.2 0.0 0.00 0.0 0.0 0.1 0.0 
Stat1-2 1.4 0.0 0.00 0.0 0.0 0.0 0.0 
Stat2-1 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Stat2-2 0.2 0.0 0.00 0.0 0.0 0.0 0.1 
Stat3-1 0.5 0.0 0.00 0.0 0.0 0.0 0.0 
Stat3-2 0.6 0.0 0.00 0.0 0.00 0.0 0.0 
Tap1-1 0.2 0.0 0.03 0.0 0.0 0.0 0.0 
Tap1-2 1.0 0.0 0.00 0.0 0.01 0.0 0.0 
Tapbp-1 1.1 0.00 0.01 0.00 0.00 0.0 0.00 
Tapbp-2 0.2 0.00 0.00 0.01 0.00 0.00 0.00 
Tbk1-1 0.8 0.0 0.01 0.0 0.0 0.00 0.0 
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Tbk1-2 1.0 0.01 0.00 0.00 0.00 0.0 0.00 
Ticam1-1 0.0 0.00 0.00 0.00 0.00 0.00 0.00 
Ticam1-2 0.2 0.0 0.00 0.0 0.01 0.01 32.8 
Tlr3-1 0.0 0.0 0.14 0.0 0.0 0.1 0.0 
Tlr3-2 1.8 0.0 0.00 0.0 0.0 0.0 0.0 
Tlr7-1 0.8 0.0 0.01 0.0 0.0 0.0 0.0 
Tlr7-2 0.2 0.0 0.08 0.0 0.0 0.0 0.0 
Tlr9-1 0.1 0 0.04 0 0 0.0 0.0 
Tlr9-2 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Tmem140-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Tmem140-2 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Tor3a-1 0.2 0.0 0.00 0.0 0 0.0 0.0 
Tor3a-2 0.3 0.0 0.01 0.0 0.4 0.0 0.0 
Trex1-1 0.0 5E-03 0.01 2E-03 0E+00 0.0 4E-03 
Trex1-2 0.1 0.0 0.01 0.0 0 4E-02 0 
Trim21-1 0.6 0.0 0.00 0.0 0.0 0.00 0.0 
Trim21-2 0.3 0.0 0.00 0.0 0.0 0.0 0.0 
Trim25-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Trim25-2 0.3 0.0 6.47 0.0 0.0 0.0 0.0 
Usp18-1 0.4 0.0 0.00 0.9 0.0 0.0 0.0 
Usp18-2 0.5 0.0 0.04 0.0 0.0 0.0 0.0 
Wwoxv-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Wwoxv-2 0.2 0 0.00 0.0 0 0.0 0.0 
Zc3hav1-1 0.1 0.0 0.00 0.0 0.0 0.0 0.0 
Zc3hav1-2 0.4 0.0 0.05 0.0 0.0 0.0 0.0 
Zfp182-1 0.0 0.0 0.00 0.00 0.0 0.0 0.0 
Zfp182-2 1.1 0.0 0.0 0.0 0.0 0.0 0.0 
EGFP 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
miR-124 0.2 0.0 0.0 0.0 0.0 0.0 0.0 
TOTAL 100 100 100 100 100 100 100 
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Appendix 8 
Percentage enrichment of amiR-encoding encoding viruses in the mouse brains A comparison 
was made between p1-Vero (inoculum used to infect mice) vs viruses enriched in the brains 
  Percentage 
Name P1-vero Brain 2 Brain 3 Brain 4 
Adar-1 0 0 0 0 
Adar-2 0.1 0.0 0.0 0.0 
Atf2-1 0.1 0.0 0.0 0.0 
Atf2-2 0.5 0.0 0.0 0.0 
Atf3-1 0.4 0.0 0.0 0.0 
Atf3-2 3.4 0.4 99.4 0.1 
B2m-1 0.2 0.0 0.0 0.0 
B2m-2 0.4 0.0 0.0 0.0 
Birc6-1 0.3 0.0 0.0 0.0 
Birc6-2 0.2 0.0 0.0 0.0 
Brd4-1 1.7 0.0 0.0 0.0 
Brd4-2 0.5 0.0 0.0 0.0 
Cdkl4-1 0.6 0.0 0.0 0.0 
Cdkl4-2 0.2 0 0 0.0 
Clec4d-1 0.3 0.0 0 0.0 
Clec4d-2 0.4 0.0 0.0 0.0 
Clec4e-1 1.0 0.0 0.0 0.0 
Clec4e-2 0.2 0.0 0.0 0.0 
Cmpk2-1 0.4 0.0 0.0 0.0 
Cmpk2-2 0.1 0.0 0.0 0.0 
Cpeb3-1 0.1 0.0 0.0 0.0 
Cpeb3-2 0.2 0.0 0 0.0 
Cxcl10-1 0.8 0 0 0 
Cxcl10-2 0.3 0 0 0 
Cytip-1 0.2 0 0 0.0 
Cytip-2 0.7 0.0 0.0 0.0 
Daxx-1 1.4 0.0 0.0 0.0 
Daxx-2 0.1 0.0 0 0 
Ddx58-1 0.5 0.0 0.0 0.0 
Ddx58-2 0.6 0.0 0.0 0.0 
Ddx60-1 0.1 0 0 0.00 
Ddx60-2 0.2 0.0 0.0 0.0 
Dhx9-1 0.6 0.0 0.0 0.0 
Dhx9-2 0.3 0.0 0.0 0.0 
Dtx3l-1 0.8 0.0 0.0 0.0 
Dtx3l-2 0.4 0.0 0.0 0.0 
EGFP 0.0 0.0 0 0.0 
Eif2ak2-1 0.5 0.0 0.0 0.0 
Eif2ak2-2 0.3 0.0 0.0 0.0 
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Fa2h-1 0.2 0.0 0.0 0.0 
Fa2h-2 0.2 0.0 0.0 0.0 
Fbxo39-1 1.1 0.0 0.0 0.0 
Fbxo39-2 0.2 0.0 0.0 0.0 
Gbp2-1 0.2 0.0 0.0 0 
Gbp2-2 2.3 0.0 0 0.0 
Gbp3-1 0.4 0.0 0.0 0.0 
Gbp3-2 0.7 0.0 0.0 0.0 
Gbp6-1 1.4 0 0 0 
Gbp6-2 0.0 0.0 0 0.0 
Gcc-1 0.2 0.0 0.0 0.0 
Gcc-2 0.9 0.0 0.0 0.0 
Gvin-1 0.7 0.0 0.0 0.0 
Gvin-2 0.7 0.0 0.0 0.0 
Ifi27-1 1.2 0.0 0.0 0.0 
Ifi27-2 1.8 0.0 0 0.0 
Ifi35-1 0.1 0.0 0.0 0.0 
Ifi35-2 2.5 0.0 0.0 0.0 
Ifi44-1 0.8 0.0 0.0 0.0 
Ifi44-2 0.6 0.0 0 0.0 
Ifih1-1 0.1 0.0 0.0 0.0 
Ifih1-2 1.3 0.0 0.0 0.0 
Ifit1-1 0.1 0.0 0.0 0.0 
Ifit1-2 0.4 0.0 0.0 0.0 
Ifit3-1 0.3 0.0 0.0 0.0 
Ifit3-2 0.3 0.0 0.0 0.0 
Ifitm3-1 0.6 0.0 0.0 0.0 
Ifitm3-2 0.9 0.0 0.0 0.0 
Ifna1-1 0.5 0.01 0 0.0 
Ifna1-2 0.4 0.0 0.0 0.0 
Ifna4-1 0.6 0.0 0.0 0 
Ifna4-2 0.3 0 0 0.0 
Ifnb1-1 0.3 0.0 0.0 0 
Ifnb1-2 0.5 0.00 0 0.0 
Ikbka-1 0.1 0.0 0.0 0 
Ikbka-2 0.2 0 0 0.0 
Ikbkb-1 0.4 0.0 0.0 0.0 
Ikbkb-2 0.6 0.0 0.0 0.0 
Ikbke-1 0.5 0.0 0.0 0.0 
Ikbke-2 0.6 0.0 0.0 0.0 
Il15-1 0.4 0.0 0.0 0.0 
Il15-2 0.6 0.0 0.0 0.0 
Il6-1 0.6 0.0 0.0 0.0 
Il6-2 0.6 0.0 0.0 0.0 
Irf1-1 0.1 0.0 0.0 0.00 
Irf1-2 0.2 0 0 0.0 
Irf2-1 0.5 0.0 0.0 0.0 
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Irf2-2 0.3 0.0 0.0 0 
Irf3-1 0.2 0 0 0.0 
Irf3-2 0.3 0.0 0.0 0.0 
Irf5-1 0.2 1.4 0.1 0.0 
Irf5-2 0.1 0.0 0.0 0.0 
Irf7-1 0.6 0.0 0.0 0.0 
Irf7-2 2.0 0.0 0.0 99.6 
Irf9-1 0.3 0.0 0.0 0.0 
Irf9-2 0.2 0.0 0.0 0.0 
Irgm-1 0.2 0 0 0.0 
Irgm-2 1.1 0.0 0.0 0.0 
Isg15-1 1.4 0.0 0 0 
Isg15-2 0.2 0.0 0.0 0.0 
Lgals3bp-1 0.7 0.0 0.0 0.0 
Lgals3bp-2 0.2 0.0 0.0 0.0 
Lgals8-1 0.5 0.0 0.0 0.0 
Lgals8-2 0.1 0.0 0.0 0.0 
Lrp4-1 0.1 0.0 0.0 0.0 
Lrp4-2 0.5 0.0 0.0 0.0 
Ly6e-1 0.1 0.0 0.0 0.0 
Ly6e-2 0.4 0.0 0.0 0.0 
Map3K8-1 0.6 0.0 0.0 0.0 
Map3K8-2 0.3 0.0 0.0 0.0 
Map4k2-1 0.4 0.0 0.0 0.0 
Map4k2-2 0.2 0.0 0 0.0 
Mapk8-1 0.5 0.0 0.0 0.0 
Mapk8-2 0.6 0.0 0.0 0.0 
Mbnl1-1 0.3 0.0 0.0 0.0 
Mbnl1-2 0.2 0.0 0.0 0.0 
miR-124 0.2 0.0 0.0 0.0 
Mitd1-1 0.1 0.0 0.0 0.0 
Mitd1-2 0.3 0.0 0.0 0.0 
Mlkl-1 0.4 0.0 0.0 0.0 
Mlkl-2 2.3 0.0 0.0 0.0 
Mov10-1 0.9 0.0 0.0 0.0 
Mov10-2 0.4 0.0 0.0 0.0 
Myd88-1 0.5 0.0 0.0 0.0 
Myd88-2 0.2 0 0 0.0 
Nfkbia-1 0.5 0.0 0.0 0 
Nfkbia-2 0.2 0.0 0.0 0.0 
Nmi-1 0.8 0.0 0.0 0.0 
Nmi-2 4.6 0.0 0 0.0 
Oas1a-1 0.2 0.0 0 0 
Oas1a-2 0.2 0.0 0.0 0.0 
Oas2-1 0.1 0.0 0.0 0.0 
Oas2-2 0.2 0.0 0.0 0.0 
Oasl1-1 0.8 0.00 0 0.0 
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Oasl1-2 0.4 0.0 0.0 0.0 
Oasl2-1 0.4 0.0 0.0 0.0 
Oasl2-2 0.3 0.0 0.0 0.0 
p50 0.5 0.0 0.2 0.0 
p50 0.3 0.0 0.0 0.1 
p65 0.3 0.0 0.0 0.0 
p65 0.1 0 0.0 0.0 
Papr14-2 0.5 0 0 0.0 
Parp10-1 0.1 0 0.0 0 
Parp10-2 0.9 0 0.0 0.0 
Parp11-1 0.0 0.0 0.0 0.0 
Parp11-2 0.2 97.9 0 0.0 
Parp12-1 0.1 0.0 0.0 0.0 
Parp12-2 0.4 0.0 0.0 0.0 
Parp14-1 0.4 0.0 0.0 0.0 
Parp9-1 0.1 0 0.0 0.0 
Parp9-2 0.3 0.0 0 0.0 
Plec-1 0.1 0.0 0 0.0 
Plec-2 0.0 0.0 0.0 0 
Ppm1k-1 0.2 0 0.0 0.0 
Ppm1k-2 0.3 0.0 0.0 0.0 
Ppp3cb-1 0.1 0.0 0.0 0.0 
Ppp3cb-2 0.4 0.0 0 0.0 
Rnasel-1 0.9 0.0 0.0 0.0 
Rnasel-2 0.2 0 0.0 0.0 
Rsad-1 0.4 0 0 0.0 
Rsad-2 0.3 0.0 0.0 0.00 
Rtp4-1 0.6 0.0 0 0.0 
Rtp4-2 1.4 0.0 0.0 0 
Samd9l-1 0.2 0.0 0.0 0.0 
Samd9l-2 0.1 0 0 0.0 
Sfxn2-1 0.2 0.0 0.0 0.0 
Sfxn2-2 0.1 0.0 0.0 0.0 
Sh3bgrl-1 0.5 0.0 0 0.0 
Sh3bgrl-2 0.1 0.0 0.0 0.0 
Stat1-1 0.2 0.0 0.0 0.0 
Stat1-2 1.4 0.0 0.0 0.0 
Stat2-1 0.5 0.0 0.0 0.0 
Stat2-2 0.2 0.00 0.0 0.0 
Stat3-1 0.5 0.0 0 0.0 
Stat3-2 0.6 0.0 0 0 
Tap1-1 0.2 0.0 0 0.0 
Tap1-2 1.0 0.0 0.00 0 
Tapbp-1 1.1 0.0 0.00 0.00 
Tapbp-2 0.2 0.0 0 0.00 
Tbk1-1 0.8 0.0 0.02 0.0 
Tbk1-2 1.0 0.0 0.00 0.00 
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Ticam1-1 0.0 0.0 0 0.00 
Ticam1-2 0.2 0.0 0.0 0 
Tlr3-1 0.0 0 0 0.0 
Tlr3-2 1.8 0.00 0.0 0.0 
Tlr7-1 0.8 0.00 0.0 0.0 
Tlr7-2 0.2 0 0 0.0 
Tlr9-1 0.1 0.00 0.0 0 
Tlr9-2 0.1 0.00 0.0 0.0 
Tmem140-1 0.1 0 0.0 0.0 
Tmem140-2 0.3 0.0 0 0.0 
Tor3a-1 0.2 2E-07 0 0 
Tor3a-2 0.3 0.0 6E-09 0.0 
Trex1-1 0.0 0.0 0 4E-03 
Trex1-2 0.1 0 0.0 0 
Trim21-1 0.6 0.0 0.0 0.0 
Trim21-2 0.3 0.0 0.0 0.0 
Trim25-1 0.1 0.0 0.0 0.0 
Trim25-2 0.3 0.0 0.0 0.0 
Usp18-1 0.4 0.0 0.0 0.0 
Usp18-2 0.5 0E+00 0.0 0.0 
Wwoxv-1 0.1 0.0 0 0.0 
Wwoxv-2 0.2 0.0 0.0 0 
Zc3hav1-1 0.1 0.0 0.0 0.0 
Zc3hav1-2 0.4 0.0 0.0 0.0 
Zfp182-1 0.0 0.0 0 0.0 
Zfp182-2 1.1 0.0 0 0 
EGFP 0.0 0.0 0 0 
miR-124 0.2 0.0 0 0 
TOTAL 100 100 100 100 
